<SEC-DOCUMENT>0001193125-12-345451.txt : 20120809
<SEC-HEADER>0001193125-12-345451.hdr.sgml : 20120809
<ACCEPTANCE-DATETIME>20120809070114
ACCESSION NUMBER:		0001193125-12-345451
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20120630
FILED AS OF DATE:		20120809
DATE AS OF CHANGE:		20120809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CURIS INC
		CENTRAL INDEX KEY:			0001108205
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043505116
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30347
		FILM NUMBER:		121018460

	BUSINESS ADDRESS:	
		STREET 1:		4 MAGUIRE ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-503-6500

	MAIL ADDRESS:	
		STREET 1:		4 MAGUIRE ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d351853d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 10-Q
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Mark one) </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE QUARTERLY PERIOD ENDED June&nbsp;30, 2012 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OR </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number: 000-30347 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>CURIS, INC.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Its Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3505116</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporation or Organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4 Maguire Road</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lexington, Massachusetts</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02421</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s Telephone Number, Including Area Code: (617)&nbsp;503-6500 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every
interactive data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August&nbsp;2, 2012, there were 79,622,590 shares of the registrant&#146;s common stock outstanding. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>CURIS, INC. AND SUBSIDIARIES QUARTERLY REPORT ON FORM 10-Q
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART I. FINANCIAL INFORMATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_1">Unaudited Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_2">Condensed Consolidated Balance Sheets as of June 30, 2012 and December&nbsp;31, 2011</A></FONT></P></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_3">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June
 30, 2012 and 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_4">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2012 and
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_5">Notes to Condensed Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_6">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_7">Quantitative and Qualitative Disclosures About Market Risk</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_8">Controls and Procedures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#tx351853_9">PART&nbsp;II. OTHER INFORMATION </A></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_10">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_11">Exhibits</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx351853_12">SIGNATURE </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_1"></A>Item&nbsp;1. FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_2"></A>CURIS, INC. AND SUBSIDIARIES </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,089,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,119,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,616,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,597,845</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">397,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">743,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,421,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,503,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">428,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">455,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term investment &#150; restricted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">194,282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,982,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,982,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,029,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,180,065</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,429,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,364,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,062,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,422,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,491,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,786,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,304,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,361,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,396</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,974,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,304,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; Equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.01 par value &#150; 125,000,000 shares authorized; 80,581,596 shares issued and 79,533,889 shares outstanding at
June&nbsp;30, 2012; and 78,165,360 shares issued and 77,117,653 shares outstanding at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">805,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">781,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">779,848,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">772,039,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Treasury stock (at cost, 1,047,707 shares)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(891,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(891,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(732,748,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(732,087,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,054,892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,875,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,029,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,180,065</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to unaudited condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_3"></A>CURIS, INC. AND SUBSIDIARIES </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">REVENUES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">226,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">252,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">523,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,351,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">392,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,707,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">526,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">COSTS AND EXPENSES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of royalty revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,500,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,144,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,742,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,202,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,264,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,867,782</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,065,663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,275,131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,777,679</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,011,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,934,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,477,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,426,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,618,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(226,410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,951,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">OTHER INCOME/(EXPENSE):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(495,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(320,440</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(487,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,821,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(460,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(295,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(434,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,762,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,886,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,914,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(660,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,714,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per common share (basic and diluted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average common shares (basic and diluted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,052,517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,378,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78,304,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,103,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,899,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,931,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(654,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,725,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to unaudited condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_4"></A>CURIS, INC. AND SUBSIDIARIES </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM OPERATING ACTIVITIES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(660,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,714,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,030,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,039,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock to licensees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">964,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">487,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,821,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest (income)/expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(99,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net gain on sale of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(36,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(276,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">468,486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(273,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(117,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,362,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,887,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by/(used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,701,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,826,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM INVESTING ACTIVITIES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30,163,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,611,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,250,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,097,814</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(246,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from sale of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decrease in restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">219,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used in)/provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,905,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,496,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM FINANCING ACTIVITIES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock under the Company&#146;s share-based compensation plans and warrant
exercises</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,174,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,295,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,174,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,295,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NET DECREASE IN CASH AND CASH EQUIVALENTS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,030,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,034,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,119,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,826,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH AND CASH EQUIVALENTS, END OF PERIOD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,089,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,791,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to unaudited condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_5"></A>CURIS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Nature of Business</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Curis, Inc. (the &#147;Company&#148; or &#147;Curis&#148;) is a drug discovery and development company
that is committed to leveraging its innovative signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. Curis is building upon its past experiences in targeting signaling pathways, including the
Hedgehog signaling pathway, in its efforts to develop network-targeted cancer therapies. Curis conducts research and development programs both internally and through strategic collaborations. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company operates in a single reportable segment, which is the research and development of innovative cancer
therapeutics. The Company expects that any successful products would be used in the health care industry and would be regulated in the United States, or the U.S., by the U.S. Food and Drug Administration, or FDA, and in overseas markets by similar
regulatory agencies. In January 2012, the Erivedge&#153; capsule was approved by the FDA and became commercially available in February 2012 (see Note 4). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to: development by its competitors of new or better technological innovations; dependence on
key personnel; its ability to protect proprietary technology; its ability to successfully advance discovery, preclinical and clinical stage drug candidates in its internally funded programs; unproven technologies and drug development approaches;
reliance on corporate collaborators and licensees to successfully research, develop and commercialize products based on its technologies; its ability to comply with FDA regulations and approval requirements; its ability to execute on its business
strategies; and its ability to obtain adequate financing to fund its operations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s future
operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its research and development pipeline. The results of the
Company&#146;s operations will vary significantly from year to year and quarter to quarter and depend on, among other factors, the timing of its entry into new collaborations, if any, the timing of the receipt of payments from new or existing
collaborators and the cost and outcome of any preclinical development or clinical trials then being conducted. The Company anticipates that existing capital resources at June&nbsp;30, 2012 should enable the Company to maintain its current and
planned operations into the first half of 2014. The Company&#146;s ability to continue funding its planned operations into and beyond the first half of 2014 is dependent upon, among other things, the success of its collaborations with Genentech
Inc., or Genentech, and Debiopharm S.A., or Debiopharm, and receipt of additional cash payments under these collaborations, its ability to control expenses and its ability to raise additional funds through equity or debt financings, new
collaborations or other sources of financing. The Company may not be able to successfully enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly
uncertain. As a result, the Company cannot assure that it will attain any further revenue under any collaborations or licensing arrangements. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay
spending on its research and/or development programs. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Basis of Presentation</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying condensed consolidated financial statements of the Company have been prepared in
accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by generally accepted accounting principles, or GAAP, in the U.S. for complete
financial statements and should be read in conjunction with the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2011, as filed with the Securities and Exchange Commission on February&nbsp;29, 2012. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the opinion of the Company, the unaudited financial statements contain all adjustments (all of which were considered
normal and recurring) necessary for a fair statement of the Company&#146;s financial position at June&nbsp;30, 2012 and the results of operations and cash flows for the six-month periods ended June&nbsp;30, 2012 and 2011. The preparation of the
Company&#146;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date.
Such estimates include revenue recognition, the collectibility of receivables, the carrying value of property and equipment and intangible assets, management assumptions used in its calculations of stock-based compensation expense, and the value of
certain investments and liabilities, including the value of its warrant liability. Actual results may differ from such estimates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These interim results are not necessarily indicative of results to be
expected for a full year or subsequent interim periods.</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Revenue Recognition</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s business strategy includes entering into collaborative license and development
agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&#146;s product candidates. The terms of these agreements may provide for the Company&#146;s licensees and collaborators to agree to
make non-refundable license fee payments, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales if any products are successfully
commercialized. For a complete discussion of the Company&#146;s revenue recognition policy, see Note 2(c) included in its annual report on Form 10-K, as previously filed with the Securities and Exchange Commission on February&nbsp;29, 2012.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Collaboration Agreements</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech June 2003 Collaboration </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2012, the FDA approved Genentech&#146;s New Drug Application for the Erivedge capsule for the treatment of adults with basal cell carcinoma that has spread to other parts of the body or that
has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is being developed and commercialized by F. Hoffmann-La Roche Ltd, or Roche, and Genentech, a member of the Roche Group,
under a collaboration agreement between the Company and Genentech. As a result of the FDA's approval of Erivedge in this indication, the Company earned a $10,000,000 milestone payment from Genentech and is also entitled to receive royalties on
future sales of the product. In May 2012, Roche announced that it has submitted an application for marketing registration for Erivedge to Australia&#146;s Therapeutic Goods Administration, or TGA, and as a result, the Company earned an additional
$4,000,000 milestone payment. The Company is eligible to receive up to an aggregate of $115,000,000 in contingent cash payments under the collaboration for the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming
the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. As of June&nbsp;30, 2012, the Company has received $46,000,000 in the aggregate since the inception of the agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognized $4,000,000 and $14,000,000 in milestone payments as license revenue in its Condensed Consolidated
Statement of Operations for the three and six months ended June&nbsp;30, 2012, respectively, as the Company does not have any further substantive performance obligations under the collaboration. The Company did not recognize license revenue under
this collaboration during the three and six months ended June&nbsp;20, 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the receipt of
milestone payments from Genentech, the Company recorded research and development expenses of $650,000 and $2,114,000 during the three and six months ended June&nbsp;30, 2012, respectively, which represents the Company&#146;s obligations to
university licensors. Research and development expenses of $650,000 recorded during the three months ended June&nbsp;30, 2012 include $550,000 for obligations the Company incurred in connection with Roche&#146;s application to the TGA for marketing
registration for Erivedge in Australia and the related $4,000,000 milestone that the Company received. The remaining $100,000 in research and development expense recorded during the three months ended June&nbsp;30, 2012 represents an immaterial
out-of-period expense associated with Roche's 2009 investigational new drug filing in Australia. The Company also recorded research and development expenses of $500,000 during the six months ended June&nbsp;30, 2012, related to the Company&#146;s
receipt of the $10,000,000 milestone payment associated with the FDA&#146;s U.S. approval of Erivedge in January 2012. The remaining expense of $964,000 recognized during the six months ended June&nbsp;30, 2012 represents the fair value of a
one-time issuance of an aggregate of 200,000 shares of the Company&#146;s common stock in March 2012 to two university licensors in connection with the FDA-approval of Erivedge. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company also recognized $252,750 and $523,372 in royalty revenue from Genentech&#146;s net sales of Erivedge during
the three and six months ended June&nbsp;30, 2012, respectively. The Company recorded cost of royalty revenues within the costs and expenses section of its Condensed Consolidated Statements of Operations of $12,637 and $126,168 during these same
periods. Cost of royalty revenues include $12,637 and $26,168 for the three and six months ended June&nbsp;30, 2012, respectively, which represents 5% of the royalties earned by the Company with respect to Erivedge that the Company is obligated to
pay to two university licensors. Cost of royalty revenues for the six months ended June&nbsp;30, 2012 also includes a one-time cash payment of $100,000 paid to a university licensor upon the first commercial sale of Erivedge. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Leukemia&nbsp;&amp; Lymphoma Society Agreement </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In November 2011, the Company entered into an agreement with The Leukemia&nbsp;&amp; Lymphoma Society, or LLS, under which LLS will support the Company&#146;s ongoing development of CUDC-907 for patients
with B-cell lymphoma and multiple myeloma. Under the agreement, LLS will fund approximately 50% of the direct costs of the development of CUDC-907, up to $4,000,000. Under certain conditions associated with the successful partnering and/or
commercialization of CUDC-907 in these indications, the Company may be obligated to make payments to LLS up to a maximum of $10,000,000. As of June&nbsp;30, 2012, the Company has not received any payments or recorded any revenue under this agreement
to date and expects that the first milestone could be achieved in the second half of 2012 as CUDC-907 nears the filing of an investigational new drug application, or IND. Additional milestones would be earned as the Company progresses CUDC-907 into
a phase Ia clinical trial. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Fair Value Measurements</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company discloses fair value measurements based on a framework outlined by GAAP which requires
expanded disclosures regarding fair value measurements. GAAP also defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&nbsp;independent, (ii)&nbsp;knowledgeable, (iii)&nbsp;able to transact, and
(iv)&nbsp;willing to transact. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Financial Accounting Standards Board, or FASB, Codification Topic 820,
<I>Fair Value Measurements and Disclosures, </I>requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information
generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The
cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value hierarchy which requires an
entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quoted prices in active markets for identical assets or liabilities.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level 2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level 3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company's warrant liability was
valued using a probability-weighted Black-Scholes model, discussed further in Note 6, and is therefore classified as Level&nbsp;3.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the fair value hierarchy, the following table shows the
fair value as of June 30, 2012 and December&nbsp;31, 2011 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair market value. No
financial assets or liabilities are measured at fair value on a nonrecurring basis at June&nbsp;30, 2012 and December&nbsp;31, 2011. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>(Level 1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other<BR>Observable<BR>Inputs&nbsp;(Level&nbsp;2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unobservable<BR>Inputs&nbsp;(Level&nbsp;3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As of June&nbsp;30, 2012:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,832,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,832,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Municipal bonds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,145,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,145,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate commercial paper, stock, bonds and notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,423,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,192,698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,616,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets at fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,255,515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,337,698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,593,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,304,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,304,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities at fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,304,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,304,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As of December&nbsp;31, 2011:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,366,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,366,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Municipal bonds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,375,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,375,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US government obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,808,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,808,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate commercial paper, stock, bonds and notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,365,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,423,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,789,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets at fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,107,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,232,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,339,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,361,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,361,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities at fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,361,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,361,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table rolls forward the fair value of the Company&#146;s warrant liability, the fair
value of which is determined by Level&nbsp;3 inputs for the six months ended June&nbsp;30, 2011 and 2012: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,604,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,821,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at June&nbsp;30, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,426,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,361,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants exercised </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(543,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">487,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at June&nbsp;30, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,304,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Investments</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amortized cost, unrealized gains and fair value of marketable securities available-for-sale as of
June&nbsp;30, 2012, with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amortized<BR>Cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized<BR>Gain</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate bonds, notes and stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,608,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,616,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,608,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,616,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amortized cost, unrealized gains and fair value of marketable securities
available-for-sale as of December&nbsp;31, 2011, with maturity dates ranging between one and twelve months and with a weighted average maturity of 3.7 months are as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amortized<BR>Cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized<BR>Gain</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,808,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,808,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate bonds, notes and stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,787,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,789,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,596,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,597,845</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Common Stock and Warrant Liability</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;27, 2010, the Company completed a registered direct offering of 6,449,288 units with
each unit consisting of (i)&nbsp;one share of the Company&#146;s common stock and (ii)&nbsp;one warrant to purchase 0.25&nbsp;of one share of common stock at a purchase price of $2.52 per unit. The Company received net proceeds from the sale of the
units, after deducting offering expenses, of approximately $14,942,000. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, the
Company issued warrants to purchase an aggregate of 1,612,322 shares of common stock. As of June&nbsp;30, 2012, warrants to purchase 214,004 shares of the Company&#146;s common stock have been exercised. The warrants have an initial exercise price
of $3.55 per share and a five-year term. The warrants contain antidilution adjustment provisions that will result in a decrease in the price and an increase in the number of shares of common stock issuable upon exercise of such warrants in the event
of certain issuances of common stock by the Company at prices below $3.55 per share. The warrants also included a cash-settlement option in the event of a change of control that expired on January&nbsp;27, 2012. Due to the terms, the warrants are
classified as a liability and, therefore, the fair value of the warrants was recorded as a liability in the Consolidated Balance Sheets as of June&nbsp;30, 2012 and December&nbsp;31, 2011. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has estimated the fair value of the warrants using a Black-Scholes option pricing model under various
probability-weighted outcomes which take into consideration the protective, but limited, cash-settlement feature of the warrants, with updated assumptions at each reporting date. The Company estimated that the fair value of the warrants at
June&nbsp;30, 2012 was $4,304,922, using the following assumptions: expected volatility of 75.4%, risk free interest rate of 0.4%, expected life of 2.6 years, and no dividends. The Company estimated that the fair value of the warrants at
June&nbsp;30, 2011 was $3,426,592 using this same model with the following assumptions assigned to the varying outcomes: expected volatility of 80%, risk free interest rates ranging from 0.8% to 1.1%, expected lives of three to four years, and no
dividends. The warrants are revalued at each reporting period and the resulting change in fair value of the warrant liability is recognized in the Consolidated Statement of Operations. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recorded other expense of approximately $495,341 and $487,400 for the three and six months ended June&nbsp;30,
2012, respectively, due to changes in fair value of the warrant liability. During the six months ended June&nbsp;30, 2012, as a result of the exercise of warrants to purchase 212,500 shares of the Company&#146;s common stock, the warrant liability
decreased $543,646 with an offsetting increase to additional paid-in-capital. The Company recorded other expense of approximately $320,440 and $1,821,850 for the three and six months ended June&nbsp;30, 2011, respectively, as a result of a change in
the fair value of the warrant liability that was primarily due to an increase in the Company&#146;s stock price during the prior year periods. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Accrued Liabilities</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued liabilities consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">787,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,065,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Professional fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,518</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">166,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,062,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,422,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Related Party Transaction</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective on February&nbsp;24, 2012, the Company entered into a Drug Development Partnership and License Agreement for CU-906 and CU-908 (the &#147;license agreement&#148;) with Guangzhou BeBetter
Medicine Technology Company Ltd., a company organized under the laws of the People&#146;s Republic of China (&#147;GBMT&#148;). Dr.&nbsp;Changgeng Qian, the Company&#146;s former Senior Vice President, Discovery and Preclinical Development, is the
founder, owner, and legal representative of GBMT. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the license agreement, the Company has granted
to GBMT an exclusive royalty-free license, with the right to grant sublicenses subject to certain conditions, to develop, manufacture, market and sell any product containing CU-906 or CU-908 in China, Macau, Taiwan and Hong Kong, or the GBMT
territory. The Company does not intend to internally develop these compounds. In addition, the Company has granted to GBMT a non-exclusive, royalty-free manufacturing license, with the right to grant sublicenses subject to certain conditions, to
manufacture CU-906 or CU-908 or any product containing CU-906 or CU-908 outside of the GBMT Territory solely to import the compounds or products into the GBMT territory. Pursuant to the terms of the license agreement, the Company has retained
rights, including the right to grant sublicenses, to develop, manufacture, market and sell any product containing CU-906 or CU-908 worldwide excluding the GBMT Territory. The Company also has certain specified rights to any GBMT technology developed
under the license agreement as well as certain specified rights to GBMT&#146;s interest in joint technology developed under the license agreement. Furthermore, the Company has a right of first negotiation to obtain a license to CU-906 or CU-908 for
the GBMT Territory from GBMT. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has agreed to transfer to GBMT know how, information and materials
necessary for GBMT to continue the development of products in accordance with the development plan outlined in the license agreement and has agreed not to assert certain Company patents against GMBT, its affiliates or sublicensee so that such party
may manufacture, market and sell any product containing CU-906 or CU-908 in the GBMT territory. Furthermore, the Company will provide GBMT with up to $400,000 in financial support for specified CU-908 pre-clinical activities related to enabling the
filing by the Company of an IND with the FDA, provided that GMBT completes such CU-908 IND-enabling activities in accordance with specified criteria and delivers a U.S. IND package for CU-908 to the Company within prescribed timeframes as specified
in the license agreement. All costs incurred under this agreement will be expensed as incurred. As of June&nbsp;30, 2012, the Company had not incurred any expenses under this agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GBMT will assume all future development responsibility and incur all future costs related to the development, registration
and commercialization of products in the GMBT Territory under the license agreement. Pursuant to the terms of the license agreement, GBMT has agreed to undertake reasonable commercial efforts, and to use qualified third party service providers
approved by the Company, to implement the development plan in the timeframes described in the license agreement in order to develop, register and commercialize the products in the GBMT Territory and will be solely responsible for all the costs
relating thereto. The Company and GBMT must agree to any changes to the development plan and such revised development plan is subject to review and approval by the joint steering committee. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless terminated earlier in accordance with the terms of the license agreement, the license agreement will expire on the
later of (i)&nbsp;the expiration of the last-to-expire valid claim of the Company patents and the Company non-assert patents relating to the products, and (ii)&nbsp;such time as none of GBMT, its affiliates and sublicensees is commercializing any
compound or product in the GBMT Territory. Pursuant to the license agreement, either party can terminate the license agreement upon notice under prescribed circumstances, and the license agreement specifies the consequences to each party for such
early termination. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The license agreement also sets forth customary terms regarding each
party&#146;s intellectual property ownership rights, representations and warranties, indemnification obligations, confidentiality rights and obligations, and patent prosecution, maintenance, enforcement and defense rights and obligations.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Severance Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;16, 2012, the Company and Dr.&nbsp;Qian entered into a severance agreement that became binding and effective on February&nbsp;24, 2012. The severance agreement provides that
Dr.&nbsp;Qian, in exchange for his execution and nonrevocation of a general release of claims in favor of the Company as set forth in the severance agreement, will be provided certain severance benefits, including a lump-sum payment equivalent to
one-half times his base annual salary rate in effect as of his termination date to be paid in August 2012. As a result, the Company had accrued $137,500 related to Dr.&nbsp;Qian&#146;s severance in the accrued liabilities section of the
Company&#146;s Condensed Consolidated Balance Sheets as of June&nbsp;30, 2012. The severance agreement also provides for the engagement of Dr.&nbsp;Qian as a consultant pursuant to the terms of a consulting agreement. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Accounting for Stock-Based Compensation</U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2012, the Company had two shareholder-approved, share-based compensation plans: the
2010 Stock Incentive Plan and the 2010 Employee Stock Purchase Plan. These plans were adopted by the board of directors in April 2010 and approved by shareholders in June 2010. In the first quarter of 2010, the Company&#146;s 2000 Stock Incentive
Plan expired in accordance with its terms and its 2000 Director Stock Option Plan had no available shares remaining under the plan. No additional awards will be made under these plans, although all outstanding awards under these plans will remain in
effect until they are exercised or they expire in accordance with their terms. For a complete discussion of the Company&#146;s share-based compensation plans, see Note 5 included in the Company&#146;s Annual Report on Form 10-K for the year ended
December&nbsp;31, 2011, as previously filed with the Securities and Exchange Commission on February&nbsp;29, 2012. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the six months ended June&nbsp;30, 2012, the Company&#146;s board of directors granted options to purchase 1,182,000 shares of the Company&#146;s common stock to officers and employees of the
Company under the 2010 Stock Incentive Plan. These options vest over a four-year period and bear exercise prices that are equal to the closing market price of the Company&#146;s common stock on the NASDAQ Global Market on the grant date. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the six months ended June&nbsp;30, 2012, the Company&#146;s board of directors also granted options to its
non-employee directors to purchase 470,000 shares of common stock under the 2010 Stock Incentive Plan. These options will vest monthly over a one-year period and bear exercise prices that are equal to the closing market price of the Company&#146;s
common stock on the NASDAQ Global Market on the grant date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Employee and Director Grants</U> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the fair value of stock options, the Company uses the Black-Scholes option pricing model. The Company
calculated the Black-Scholes value of employee and director options awarded during the six months ended June&nbsp;30, 2012 and 2011 based on the assumptions noted in the following table: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected life (years) &#150; employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected life (years) &#150; directors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0-1.2%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4-2.5%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74-76%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73-74%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">None</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">None</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expected volatility is based on the annualized daily historical volatility of the Company&#146;s
stock price through the grant date for a time period consistent with the expected term of a grant. Management believes that the historical volatility of the Company&#146;s stock price best represents the volatility of the stock price. The risk-free
rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company does not anticipate declaring dividends in the foreseeable future. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The stock price volatility and expected terms utilized in the calculation involve management&#146;s best estimates at that time, both of which impact the fair value of the option calculated under the
Black-Scholes methodology and, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected
to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from
those estimated by management, additional adjustments to compensation expense may be required in future periods. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate intrinsic value of employee options outstanding at June&nbsp;30, 2012 was $30,021,000, of which $24,464,000
related to exercisable options. The weighted average grant-date fair values of stock options granted during the six months ended June&nbsp;30, 2012 and 2011 were $2.99 and $1.43, respectively. As of June&nbsp;30, 2012, there was approximately
$5,765,000, net of the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding under the Company&#146;s 2000 and 2010 Stock Incentive Plans that is expected to be recognized as
expense over a weighted average period of 2.5 years. The intrinsic values of employee stock options exercised during the six months ended June&nbsp;30, 2012 and 2011 were $5,779,000 and $826,000, respectively. The total fair values of vested stock
options for the six months ended June&nbsp;30, 2012 and 2011 were $1,228,000 and $1,050,000, respectively. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company recorded $833,497 and $1,649,725 in compensation expense for the three and six months ended June&nbsp;30, 2012, respectively, and $348,742 and $1,011,738 in compensation expense for the three and six months ended June&nbsp;30, 2011,
respectively, related to employee and director stock option grants. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Non-Employee Grants</U> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has periodically granted stock options and unrestricted stock awards to consultants for services, pursuant to
the Company&#146;s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled. The Company recognized
expense related to non-employee stock options of $174,245 and $380,693, for the three and six months ended June&nbsp;30, 2012, respectively, and expense of $13,104 and $27,820 for the three and six months ended June&nbsp;30, 2011, respectively.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Total Stock-Based Compensation Expense </U> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the three and six months ended June&nbsp;30, 2012 and 2011, the Company recorded employee and non-employee stock-based
compensation expense to the following line items in its Costs and Expenses section of the Consolidated Statements of Operations, including expense related to its 2010 Employee Stock Purchase Plan: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Six Months Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">365,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">178,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">765,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">343,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">641,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,265,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">695,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,007,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">361,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,030,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,039,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below summarizes options outstanding and exercisable at June&nbsp;30, 2012: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options Outstanding</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise Price Range</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Life&nbsp;(in&nbsp;years)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price<BR>per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price<BR>per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">$ 0.79 - $ 1.39</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,735,809</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,567,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp; 1.43 - &nbsp;&nbsp; 2.15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,628,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,063,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp; 2.27 - &nbsp;&nbsp; 3.76</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,432,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,555,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp; 3.98 - &nbsp;&nbsp; 4.52</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,204,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">758,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp; 4.56 - &nbsp;&nbsp; 5.60</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">720,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">712,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,721,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,656,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Loss Per Common Share </U> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company applies ASC Topic 260&#151;<I>Earnings&nbsp;per Share</I>, which establishes standards for
computing and presenting earnings per share. Basic and diluted loss per common share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common
share for the three and six months ended June&nbsp;30, 2012 and 2011, as the effect of the potential common stock equivalents is antidilutive due to the Company&#146;s net loss position for these periods. Antidilutive securities consist of stock
options and warrants outstanding as of the respective reporting period as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the<BR>Three and<BR>Six Months<BR>Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the<BR>Three and<BR>Six Months<BR>Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,721,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,828,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,398,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,610,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total antidilutive securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,120,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,439,045</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>


 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;<A NAME="tx351853_6"></A>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following discussion of our financial condition and results of operations should be read in conjunction with the condensed
consolidated financial statements and the related notes appearing elsewhere in this report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a drug discovery and development company that is committed to leveraging our innovative signaling pathway drug technologies in
seeking to develop next generation network-targeted cancer therapies. We are building upon our experience in modulating signaling pathways, including the Hedgehog signaling pathway, in our effort to develop network-targeted cancer therapies. We
conduct our research and development programs both internally and through strategic collaborations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Hedgehog Pathway
Inhibitor Program (Erivedge&#153;) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Erivedge&#153; (vismodegib) capsule.</I> Our most advanced program is our
Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., or Genentech, a member of the Roche Group. Pursuant to this collaboration, Genentech and Roche are responsible for clinical development, and Genentech (in the U.S.), Roche
(outside the U.S., excluding Japan) and Chugai Pharmaceuticals (in Japan) are responsible for commercialization of Erivedge. The lead drug candidate being developed under this program is Erivedge, a first-in-class orally-administered small molecule
Hedgehog pathway inhibitor, which is also referred to as vismodegib. Erivedge is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in
regulating proper growth and development in the early stages of life and becomes less active in adults. However, mutations in the pathway that reactivate Hedgehog signaling are seen in certain cancers, including basal cell carcinoma, or BCC.
Abnormal signaling in the Hedgehog pathway is implicated in over 90% of BCC cases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, the U.S. Food and Drug
Administration, or FDA, approved Genentech&#146;s new drug application, or NDA, for the Erivedge&#153; capsule for the treatment of adults with BCC that has spread to other parts of the body or that has come back after surgery or that their
healthcare provider decides cannot be treated with surgery or radiation. Erivedge is being developed and commercialized by Roche and Genentech. As a result of the FDA&#146;s approval of Erivedge in this indication, we earned a $10,000,000 payment
from Genentech and we are also entitled to receive royalties on future net sales of the product. During the three months ended March&nbsp;31, 2012, we recognized the $10,000,000 milestone payment as license revenue. In addition, we recorded research
and development expenses related to the FDA&#146;s approval of Erivedge of $1,464,000 during the three months ended March&nbsp;31, 2012 which represents our obligations to university licensors. Of this amount, $964,000 represents the fair value of a
one-time issuance of an aggregate of 200,000 shares of our common stock to two university licensors in connection with the FDA-approval of Erivedge. The remaining $500,000 represents sublicense fees we paid to these same licensors upon our receipt
of the $10,000,000 milestone payment in the first quarter of 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May 2012, we earned a $4,000,000 milestone payment in
connection with Roche&#146;s filing in Australia which we recognized as license revenue during the three months ended June&nbsp;30, 2012. In addition, we recorded research and development expenses for this period of $650,000 which represents our
obligations to university licensors. Of this amount, $450,000 represents cash milestones specific to the Australian territory and the remaining $200,000 represents sublicense fees totaling 5% of the $4,000,000 milestone payment that we received.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also recognized $523,000 of royalty revenue from Genentech&#146;s net sales of Erivedge during the first half of 2012,
including $253,000 during the second quarter. We recorded cost of royalty revenues of $126,000 during this same period, including a $100,000 one-time cash payment paid to a university licensor upon the first commercial sale of Erivedge and $26,000
paid to two university licensors, which represents 5% of the royalties that we earned with respect to Erivedge during the first half of 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the fourth quarter of 2011, Roche submitted a Marketing Authorization Application, or MAA, for Erivedge to the European Medicines Agency, or EMA, for which we earned a $6,000,000 milestone payment.
Roche has indicated that it anticipates potential EMA approval for Erivedge during the second half of 2012 or the first half of 2013. Roche has also filed new drug applications in 2012 for marketing registration with Australian, Canadian, Israeli,
Mexican and Swiss health agencies seeking approval for Erivedge in advanced BCC. Erivedge&#146;s FDA approval and Roche&#146;s regulatory submissions in regards to Erivedge in Europe, Australia, Canada and Switzerland are based on positive clinical
data from ERIVANCE BCC/SHH4476g, a pivotal phase II study of Erivedge in patients with advanced BCC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will receive additional milestone payments if Erivedge receives EMA marketing
authorization or approval in Australia and will be obligated to make payments to university licensors that total 5% of each of these milestone payments that we receive. We are also entitled to a royalty on net sales of Erivedge that ranges from the
mid-to-high single digits, which escalates within this range with increasing product sales. The royalties that we recorded during the first half of 2012, for example, were calculated at 5% of Erivedge net sales reported by Roche. In certain
specified circumstances, the royalty rate applicable to Erivedge may be decreased to a low-to-mid single digit royalty, including when a competing product that binds to the same molecular target as Erivedge is approved by the applicable regulatory
authority and is being sold in such country by a third party for use in the same indication as Erivedge. We are obligated to make payments to university licensors on royalties that we earn in all territories other than Australia in an amount that is
equal to 5% of the royalty payments that we receive from Genentech for a period of 10 years from the first commercial sale of Erivedge, which occurred in February 2012. For royalties that we earn from Roche&#146;s potential future sales of Erivedge
in Australia, we will be obligated to make payments to university licensors in an amount that is equal to 2% of Roche&#146;s direct net sales in Australia until expiration of the patent in April 2019, after which the amount will decrease to 5% of
the royalty payments that we receive from Genentech for the remainder of the period ending 10 years from the first commercial sale of Erivedge, or February 2022. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Genentech is also conducting a separate phase II clinical trial of Erivedge in patients with operable nodular BCC, which is a less severe form of the disease and accounts for a significant percentage of
the approximately two million BCCs diagnosed annually in the U.S. This phase II trial is the first study to assess the ability of Erivedge to provide complete histological clearance of tumor, an important first step in determining the efficacy of
Erivedge in less severe forms of BCC, where BCC lesions are generally treated surgically. This trial is designed to test Erivedge as a single-agent therapy in approximately 75 patients with operable nodular BCC in a US-based, open label,
three-cohort clinical trial. Patients in the first and second cohorts receive a 150 mg daily oral dose of Erivedge for 12 weeks, while patients in the third cohort receive 16 weeks of daily dosing, with two eight-week dosing cycles surrounding a
four-week period in which patients will not receive Erivedge. The primary outcome measure for the first and third cohorts is <B>t</B>he rate of complete histological clearance of the target nodular BCC lesions at the time of tumor excision (which
may occur up to 12 or 20 weeks, respectively, following initiation of treatment) while the primary outcome measure for the second cohort is the rate of durable complete clearance of target nodular BCC lesions at the time of excision (which may occur
up to 36 weeks following initiation of treatment).<B> </B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Data from the first cohort were published in April 2012 in the
<I>Journal of Investigative Dermatology </I>and were also presented at the annual meeting of the Society for Investigative Dermatology in May 2012. This first cohort evaluated the safety and efficacy of 12 weeks of daily 150 mg dosing of Erivedge in
24 patients with newly diagnosed nodular, operable BCC. Patients then underwent Mohs surgery with independent pathology review. Pathologically confirmed complete clearance was reported in 10 (42%)&nbsp;patients and clinical complete and partial
responses were reported for 23 (96%)&nbsp;patients. The most frequent adverse events were similar to those observed in previous studies with Erivedge and included muscle spasms (79%), ageusia/dysgeusia (79%), alopecia (38%), fatigue (21%)&nbsp;and
nausea (21%). Most adverse events were Grade 1-2; seven patients (29%)&nbsp;reported Grade 3 adverse events, including four patients with muscle spasm. No serious adverse events were reported. Eight (33%)&nbsp;patients discontinued the study,
including two (8%)&nbsp;due to adverse events. Cohort two is fully enrolled and accrual to cohort three is ongoing with full study results expected in first half of 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to the BCC clinical trials being conducted directly by Genentech and Roche, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech
and either third-party investigators or the U.S. National Cancer Institute, or NCI. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Network-Targeted Cancer Programs
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our internal drug development efforts are focused on our network-targeted cancer programs, in which we are seeking to
design single novel small molecule drug candidates that inhibit multiple signaling pathways that are believed to play roles in cancer cell proliferation. We refer to this approach as cancer network disruption. We believe that our approach of
targeting multiple nodes in cancer signaling pathway networks may provide a better therapeutic effect than many of the cancer drugs currently marketed or in development which are designed to disrupt only one target. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CUDC-101. </I>Our lead candidate from these programs is CUDC-101, a first-in-class small molecule compound designed to simultaneously
target epidermal growth factor receptor, or EGFR, human epidermal growth factor receptor 2, or HER2, and histone deacetylase, or HDAC, all of which are validated cancer targets. A significant amount of our capital resources are focused on the
ongoing clinical and preclinical development of this molecule. To date, we have completed a phase I dose escalation clinical trial of CUDC-101 in 25 patients with advanced, refractory solid tumors and a phase I expansion trial that tested CUDC-101
in 46 patients with specific tumor types, including breast, gastric, head and neck, liver and non-small cell lung cancers. The phase I expansion trial was designed as an open-label study in which patients were
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">
treated with CUDC-101 at the maximum tolerated dose, which was determined in the phase I dose escalation study to be 275 milligrams per meter</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">. The primary objectives of this study were to compare the safety and
tolerability of CUDC-101 in subjects with these specific advanced solid tumors when the drug was administered via one-hour intravenous infusion either on a five days per week schedule (one week on/one week off) or on a three days per week schedule
(three weeks on/one week off). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2011, we initiated a phase I clinical trial of CUDC-101 in patients with locally advanced
head and neck cancer patients whose cancer is human papilloma virus, or HPV, negative. In April 2012, we amended the protocol for this trial to allow enrollment of patients with HPV positive head and neck cancer patients and a prior smoking history.
We have treated five patients in this trial as of August&nbsp;3, 2012. The primary objectives of this study are to evaluate the safety and tolerability of CUDC-101 when administered in combination with the current standard-of-care of cisplatin, a
chemotherapeutic drug, and radiation.&nbsp;Upon determination of the maximum tolerated dose and assuming the otherwise successful completion of this phase I trial, we intend to conduct a randomized phase II two-arm clinical trial in which head and
neck cancer patients will receive cisplatin and radiation plus or minus CUDC-101.&nbsp;The phase II study would seek to evaluate whether the addition of CUDC-101 can improve the efficacy of cisplatin and radiation therapy in this patient
population.&nbsp;We currently estimate initiating this phase II study in the first half of 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also working on
advancing an oral formulation of CUDC-101 into clinical development. We believe that an oral formulation has the potential to make CUDC-101 more competitive in certain cancers where there are investigational or commercially available molecules that
are orally administered. Pending the successful completion of ongoing formulation and preclinical development work, we intend to file an investigational new drug application, or IND, with the FDA and begin a phase I study of an oral formulation of
CUDC-101 in the second half of 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CUDC-907</I>. In 2011, we selected development candidate CUDC-907, an orally
bioavailable, network-targeted small molecule that is designed to inhibit phosphatidylinositol-3-kinase, or PI3K, and HDAC. Our scientists are developing CUDC-907 based on published and internally generated data demonstrating that HDAC and PI3K
inhibitors have synergistic interaction in certain preclinical cancer models, and based on published observations of clinical activity of such agents in hematological cancers. We believe that CUDC-907 with its synergistic mechanism of cancer
signaling network disruption has demonstrated potent preclinical antitumor activity in a variety of hematological tumor models including non-Hodgkin&#146;s lymphoma and multiple myeloma which has the potential to translate into clinical advantages
over single targeted agents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2011, we entered into an agreement with The Leukemia&nbsp;&amp; Lymphoma Society, or
LLS, under which LLS will provide a portion of the funding for the development of CUDC-907 if we succeed in advancing this development candidate into a clinical trial for patients with B-cell lymphoma and multiple myeloma. Pending the successful
completion of ongoing formulation and preclinical development work, we expect to file an IND with the FDA and begin a phase I study of CUDC-907 during the second half of 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Hsp90 Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Debio 0932. </I>Our heat shock protein 90, or
Hsp90, program is being developed by Debiopharm S.A., a Swiss pharmaceutical development company, under an August 2009 license agreement between Curis and Debiopharm. In April 2010, Debiopharm recruited the first patient in a phase I clinical trial
to evaluate the safety of Debio 0932 in patients with advanced solid tumors. In 2011, Debiopharm successfully advanced Debio 0932 through the dose escalation portion of this phase I study. Debiopharm presented data from this study at the annual
meeting of the American Society of Clinical Oncology in June 2012. Debio 0932 was tested in 50 patients in this portion of the study, including 22 patients that received Debio 0932 every other day and 28 patients that received daily dosing of Debio
0932. Debio 0932 was generally well tolerated in this study, with mostly adverse events classified as Grade 1 or 2, or mild to moderate, with no apparent dose or schedule relationship. In addition, no ocular or cardiac toxicities were observed and
no consistent changes in hematology or biochemistry parameters were observed. The most common adverse events included asthenia, constipation, decreased appetite, diarrhea, nausea, and vomiting. Anti-tumor activity was assessed in 45 of the 50
patients enrolled in this study, with 2 patients achieving partial responses in this study, including one patient with breast cancer and one patient with Kras-mutated lung cancer. Stable disease was observed in 12 patients and disease progression
was observed in the remaining 31 patients. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recommended dose for further study was determined by Debiopharm to be 1000mg
daily and Debiopharm advanced Debio 0932 into the phase Ib expansion portion of the study in the beginning of 2012 at this 1000 mg daily dosing level. The primary objectives of the phase Ib portion of the study are to further assess the safety
profile, pharmacokinetics and pharmacodynamics of Debio 0932 and to make a preliminary assessment of anti-tumor activity. Debiopharm expects that approximately 30 patients with advanced solid tumors will be treated in this portion of the study,
including patients with non-small cell lung cancer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debiopharm has also indicated that it plans to initiate a combination phase I/II study in
patients with non-small cell lung cancer, or NSCLC, in the second half of 2012. The objectives of the study are to determine the recommended phase II dose of Debio 0932 in combination with various chemotherapy regimes used in the first or second
line treatment of patients with NSCLC and then to evaluate the efficacy of these combinations. We are eligible to receive our next milestone payment under our license agreement with Debiopharm if and when Debiopharm treats its fifth patient in a
phase II clinical trial, assuming that Debiopharm advances Debio 0932 into phase II clinical testing. We currently anticipate that phase II testing could commence in 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Liquidity </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our inception, we have funded our operations
primarily through license fees, contingent cash payments, research and development funding from our corporate collaborators, the private and public placement of our equity securities, debt financings and the monetization of certain royalty rights.
We have never been profitable on an annual basis and have an accumulated deficit of $732,748,000 as of June&nbsp;30, 2012. We expect to continue to incur significant costs and expenses as we seek to advance our research and development programs. We
expect that we will incur significant operating losses for the next several years as we devote substantially all of our resources to our research and development programs. Although Genentech recently received FDA approval to market Erivedge in the
U.S., the amount of future sales and resulting royalty revenue payable to us are highly uncertain. We will need to generate significant revenues to achieve profitability and do not expect to achieve profitability in the foreseeable future, if at
all. We anticipate that existing capital resources as of June&nbsp;30, 2012 should enable us to maintain current and planned operations into the first half of 2014. We believe that near term key drivers to our success will include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech&#146;s ability to successfully scale up the commercialization of Erivedge in advanced basal cell carcinoma the US;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech&#146;s and/or Roche&#146;s receipt of approval to commercialize Erivedge in advanced basal cell carcinoma in Europe and other territories
including in Australia, Canada, Israel, Mexico and Switzerland in advanced BCC as well as its ability to successfully launch and commercialize Erivedge in these markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">positive results in Genentech&#146;s ongoing phase II clinical trial in patients with operable basal cell carcinoma; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully plan, finance and complete current and planned clinical trials for CUDC-101 and advance CUDC-101 into phase II clinical
testing in head and neck cancers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully complete the preclinical development and advance an oral formulation of CUDC-101 and/or CUDC-907 into clinical testing;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debiopharm&#146;s ability to advance Debio 0932 into later stages of clinical development; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully enter into one or more material licenses or collaboration agreements for our proprietary drug candidates.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the longer term, a key driver to our success will be our ability, and the ability of any current or
future collaborator or licensee, to successfully commercialize drugs other than Erivedge based upon our proprietary technologies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Collaboration Agreements </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently a party to a June 2003 collaboration with Genentech relating to our Hedgehog pathway inhibitor technologies, and an
August 2009 license agreement with Debiopharm relating to our Hsp90 inhibitor technology. Our past and current collaborations have generally provided for research, development and commercialization programs to be wholly or majority-funded by our
collaborators and provide us with the opportunity to receive additional contingent cash payments if specified development and regulatory approval objectives are achieved, as well as royalty payments upon the successful commercialization of any
products based upon the collaborations. We are currently not receiving any research funding and we do not expect to receive such funding in the future from Genentech or Debiopharm under our current agreements with these parties. Under our
collaborations with Genentech, we currently expect to incur only costs related to the maintenance of licenses, including sublicense payments due upon milestone payments and any royalties we receive, as well as patent-related expenses. As a result of
our licensing agreements with various universities, we are also obligated to make payments to these university licensors when we receive certain payments from Genentech. As of June&nbsp;30, 2012, we have incurred expenses in an aggregate amount of
approximately $2,916,000 related to ongoing agreements, of which $2,876,000 relates to payments that we have or will receive from Genentech. As we receive additional milestone payments from Genentech upon European or Australian approval of Erivedge,
if achieved, we will be obligated to pay additional sublicense fees to these licensors, as well as fees related to any royalties received from the sale of Erivedge. In addition, we were obligated to issue 200,000 shares of our common stock to
certain licensees upon FDA approval of Erivedge that represented $964,000 in expense during the first quarter of 2012. We do not expect to incur any material costs in the foreseeable future related to our Hsp90 technologies under development by
Debiopharm under our August 2009 license agreement with Debiopharm. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Operations Overview </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General.</I>&nbsp;Our future operating results will largely depend on the magnitude of payments from our current and potential future
corporate collaborators and the progress of drug candidates currently in our research and development pipeline. The results of our operations will vary significantly from year to year and quarter to quarter and depend on, among other factors, the
timing of our entry into new collaborations, if any, the timing of the receipt of payments, if any, from new or existing collaborators and the cost and outcome of any preclinical development or clinical trials then being conducted. We anticipate
that existing capital resources as of June&nbsp;30, 2012 should enable us to maintain current and planned operations into the first half of 2014. Our ability to continue funding our planned operations into and beyond the first half of 2014 is
dependent on future contingent payments that we may receive from Debiopharm or Genentech upon the achievement of development and regulatory approval objectives, our ability to manage our expenses and our ability to raise additional funds through
additional corporate collaborations, equity or debt financings, or from other sources of financing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A discussion of certain
risks and uncertainties that could affect our liquidity, capital requirements and ability to raise additional funds is set forth under &#147;Part II, Item&nbsp;1A&#151;Risk Factors.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue.</I>&nbsp;We do not expect to generate any revenues from our direct sale of products for several years, if ever. Substantially
all of our revenues to date have been derived from license fees, research and development payments, and other amounts that we have received from our strategic collaborators and licensees. We expect to recognize royalty revenue in future quarters
from Genentech&#146;s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We could receive additional milestone payments from Genentech and Debiopharm, provided the respective programs meet contractually-specified development and regulatory objectives. For example, we earned a
$10,000,000 milestone payment from Genentech in January 2012 upon FDA approval of Erivedge and a $4,000,000 milestone payment upon Roche&#146;s submission with Australian health authorities seeking to commercialize Erivedge in advanced basal cell
carcinoma in Australia. Erivedge is currently being reviewed for potential marketing approval by the EMA in European territories as well as by Australian, Canadian and Swiss health authorities. We are eligible to receive additional milestone revenue
should Erivedge receive approval by the EMA and/or Australian health authorities, and we are also eligible to receive royalties on net sales of Erivedge in all territories where Erivedge is sold. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently receive no research funding for our programs under our collaborations with Genentech and Debiopharm and we do not expect to
receive such funding in the future under these collaborations. Accordingly, our only source of revenues and/or cash flows from operations for the foreseeable future will be up-front license payments and funded research and development that we may
receive under new collaboration agreements, if any, contingent cash payments for the achievement of clinical development and regulatory objectives, if any are met, under new collaborations or our existing collaborations with Genentech and Debiopharm
and royalty payments that are contingent upon the successful commercialization of any products based upon these collaborations. Our ability to enter into new collaborations and our receipt of additional payments under our existing collaborations
with Genentech and Debiopharm cannot be assured, nor can we predict the timing of any such arrangements or payments, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Royalty Revenues.</I>&nbsp;Cost of royalty revenues consists of all expenses incurred associated with royalty revenues that we record in the Revenues section of our consolidated statements of
operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development.</I>&nbsp;Research and development expense consists of costs incurred to discover,
research and develop our drug candidates. These expenses consist primarily of: (1)&nbsp;salaries and related expenses for personnel including stock-based compensation expense; (2)&nbsp;outside service costs including clinical research organizations,
medicinal chemistry; (3)&nbsp;sublicense payments; and (4)&nbsp;the costs of supplies and reagents, consulting, and occupancy and depreciation charges. We expense research and development costs as incurred. We are currently incurring research and
development expenses under our Hedgehog pathway inhibitor collaboration with Genentech related to the maintenance of third-party licenses to certain background technologies. In addition, we record research and development expense for payments that
we are obligated to make to certain third-party university licensors upon our earning payments from Genentech related to the achievement of clinical development and regulatory objectives under our Hedgehog pathway inhibitor collaboration </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development programs, both internal and under collaboration, are summarized
in the following table: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:65pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Product Candidate</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Primary&nbsp;Disease</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Collaborator/Licensee</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Status</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Hedgehog Pathway Inhibitor</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">-&nbsp;&nbsp;&nbsp;Erivedge (vismodegib)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advanced BCC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA approved;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory
submissions pending in EU, Australia, Canada, Israel, Mexico, and Switzerland</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Erivedge (vismodegib)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operable Nodular BCC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase II</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Network-targeted Cancer Programs</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">-&nbsp;&nbsp;&nbsp;&nbsp;CUDC-101 intravenous formulation (EGFR, HER2, HDAC inhibitor)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal development</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase I expansion</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">-&nbsp;&nbsp;&nbsp;&nbsp;CUDC-101 intravenous formulation (EGFR, HER2, HDAC inhibitor)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Locally advanced head and neck cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal development</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase I in combination with cisplatin and radiotherapy</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">-&nbsp;&nbsp;&nbsp;&nbsp;CUDC-101 oral formulation (EGFR, HER2, HDAC inhibitor)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal development</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development candidate</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">-&nbsp;&nbsp;&nbsp;&nbsp;CUDC-907 (PI3K, HDAC inhibitor)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal development</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development candidate</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">-&nbsp;&nbsp;&nbsp;&nbsp;Debio 0932 (formerly CUDC-305) (Hsp90 inhibitor)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debiopharm</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase Ib</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the chart above, &#147;Phase II&#148; means that Genentech is currently treating human patients in a
phase II clinical trial, the primary objective of which is a therapeutic response in the patient population. &#147;Phase I expansion&#148; means that we have completed treating human patients with specific tumor types in an extension of our phase I
dose escalation trial, at the maximum tolerated dose from such trial, the principal purpose of which is to evaluate the safety and tolerability of the compound being tested, and that we are currently compiling final study data for future
presentation at a medical conference. &#147;Phase Ib&#148; means that Debiopharm is further assessing the safety profile, pharmacokinetics and pharmacodynamics of Debio 0932 at the recommended phase II dose level, and seeking to make a preliminary
assessment of anti-tumor activity in patients with advanced solid tumors. &#147;Phase I in combination with cisplatin and radiotherapy&#148; means that we are currently treating human patients in a phase I clinical trial with CUDC-101, cisplatin and
radiotherapy, the principal purpose of which is to evaluate the safety and tolerability of the compound being tested. "Development candidate" means that we have selected a single lead candidate for potential future clinical development and are
seeking to complete the relevant safety, toxicology, and other studies required to submit an IND application with the FDA seeking to commence a phase I clinical trial based on our testing in several preclinical models of human disease of various
compounds from a particular compound class. &#147;Preclinical&#148; means that we are seeking to obtain evidence of therapeutic efficacy and safety in preclinical models of human disease of one or more compounds within a particular class of drug
candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the early stages of development of these programs, our ability and that of our collaborators and
licensees to successfully complete preclinical studies and clinical trials of these drug candidates, and the timing of completion of such programs, is highly uncertain. There are numerous risks and uncertainties associated with developing drugs
which may affect our and our collaborators&#146; future results, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, quality of data, rate of progress and cost of clinical trials and other research and development activities undertaken by us or our
collaborators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of future preclinical studies and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and timing of regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and timing of establishing sales, marketing and distribution capabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of establishing clinical and commercial supplies of our drug candidates and any products that we may develop; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing technological and market developments; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and effectiveness of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot reasonably estimate or know the nature, timing and estimated costs of the efforts
necessary to complete the development of, or the period in which material net cash inflows are expected to commence from any of our drug candidates. Any failure to complete the development of our drug candidates in a timely manner could have a
material adverse effect on our operations, financial position and liquidity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A further discussion of some of the risks and
uncertainties associated with completing our research and development programs on schedule, or at all, and some consequences of failing to do so, are set forth under &#147;Part II, Item&nbsp;1A&#151;Risk Factors.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General and Administrative</I>.&nbsp;General and administrative expense consists primarily of salaries, stock-based compensation
expense and other related costs for personnel in executive, finance, accounting, business development, legal, information technology, corporate communications and human resource functions. Other costs include facility costs not otherwise included in
research and development expense, insurance, and professional fees for legal, patent and accounting services. Patent costs include certain patents covered under collaborations, a portion of which is reimbursed by collaborators and a portion of which
is borne by us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires that we make estimates and assumptions that affect the reported
amounts and disclosures in the financial statements. Such estimates and judgments include the assumptions underlying the valuation of our warrant liability, carrying value of property and equipment and intangible assets, revenue recognition, the
collectability of receivables and the value of certain investments and liabilities. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances, the results of which form the
basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes to the probabilities underlying the assumptions used in valuing our warrant liability could materially impact our
financial statements. Actual results may differ from these estimates under different assumptions or conditions. We set forth our critical accounting policies and estimates in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011,
which and there have been no material changes to such policies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Three-Month Periods Ended June&nbsp;30, 2012 and June&nbsp;30, 2011 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenues.&nbsp;</I>Total revenues are summarized as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>June 30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REVENUES:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subtotal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>License fees</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Royalty revenues from Genentech</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">253,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,352,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">393,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues increased by $3,959,000 to $4,352,000 for the three months ended June&nbsp;30, 2012 as
compared to $393,000 for the same period in the prior year, primarily related to an increase in our license fee revenues of $3,700,000 due to a $4,000,000 payment we received from Genentech in connection with Roche&#146;s NDA filing for marketing
registration in Australia in May 2012. We recognized license fee revenue of $300,000 under a separate collaboration during the three months ended June&nbsp;30, 2011. In addition, we recognized $253,000 of royalty revenues from the net sales of
Erivedge during the second quarter of 2012. Erivedge was approved by the FDA for commercial sale in January 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
potential future contingent payments under our collaboration agreements are tied to clinical and regulatory objective milestones as well as royalties on future net sales. Research and development revenues are limited to expenses that we incur under
our collaborations, primarily Genentech, for which our collaborators are obligated to reimburse us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Royalty
Revenues. </I>Cost of royalty revenues of $13,000 for the three months ended June&nbsp;30, 2012 represents the amount we are obligated to pay to two university licensors, which represents 5% of the royalties that we earned with respect to Erivedge
during the three months ended June&nbsp;30, 2012. We did not have cost of royalty revenues for the three months ended June&nbsp;30, 2011 as Erivedge was approved in January 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expenses.</I>&nbsp;Research and development expenses are summarized as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Three Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/</B></FONT>
<br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:125pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Research and Development Program</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hedgehog pathway inhibitor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CUDC-101</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,263,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,123,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CUDC-907</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,228,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">659,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debio 0932</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other network-targeted cancer programs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">948,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,108,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublicense fees incurred on development and regulatory milestones under our Genentech collaboration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">650,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other sublicense fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain on sale of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">179,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,144,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development expenses increased by $1,356,000, or 43%, to $4,500,000 for the three months
ended June&nbsp;30, 2012 as compared to $3,144,000 for the same period in the prior year. In the second quarter of 2012, we incurred sublicense fees of $650,000 in connection with Roche&#146;s regulatory filings in Australia and our receipt of the
related $4,000,000 milestone payment. In addition, spending on our CUDC-907 program also increased $569,000 over the prior year period primarily related to costs for IND-enabling toxicology studies. In addition, spending related to our CUDC-101
programs increased $140,000 over the prior year period, primarily related to expenses for outside services related formulation </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
studies, including the development of an oral formulation that were not incurred in the prior year period. Offsetting these increases, spending on our other network-targeted cancer programs
decreased $160,000 when compared to the prior year period as resources have been allocated to our development programs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation also increased $187,000 from the prior year period primarily related to the expense recognized on unvested
non-employee stock options that are marked-to-market at each reporting period, and which increased as our stock price increased over the prior year period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect that a majority of our research and development expenses for the foreseeable future will be incurred in support of our efforts to advance CUDC-101, CUDC-907 and our other targeted cancer
programs. In addition, we will be obligated to pay additional sublicense fees when we receive milestone payments upon the achievement of certain regulatory objectives as well as for royalty payments that we receive on Genentech or Roche&#146;s net
sales of Erivedge. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General and Administrative Expenses.</I>&nbsp;General and administrative expenses are summarized as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Three Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">645,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">536,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy and depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">351,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">524,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting and professional services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">246,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insurance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">642,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,265,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,868,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses increased by $397,000, or 21%, to $2,265,000 for the three months
ended June&nbsp;30, 2012 as compared to $1,868,000 for the prior year period. This increase was primarily due to an increase in stock-based compensation of $459,000 from the prior year period as a result of an increase in the number of, and
grant-date fair value of, options granted during 2012 compared to the prior year period. In addition, personnel costs increased $109,000 primarily due to the accrual of cash incentive payments for executive officers under our 2012 short-term
incentive program. Potential cash incentive payments under the 2012 plan could total $521,000 if targets are achieved, of which $381,000 would be recorded in general and administrative expense and $140,000 would be recorded in research and
development. No cash incentive payments were accrued during the second quarter of 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Offsetting these increases, legal
fees decreased $173,000 from the prior year period primarily due to decreased spending on patent costs, which includes fees related to foreign patent filings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Change in Fair Value of Warrant Liability. </I>In connection with our January 2010 registered direct offering, we issued warrants to purchase an aggregate of 1,612,322 shares of common stock which
became exercisable as of the closing of the transaction. The warrants have an initial exercise price of $3.55 per share and have a five year term, and the fair value of the warrants is recorded as a long-term liability. The fair value of the
warrants was estimated using a Black-Scholes option pricing model under various probability-weighted outcomes which take into consideration the protective, but limited, cash-settlement feature for the benefit of the warrant holder that expired on
January&nbsp;27, 2012. The warrants will be revalued each reporting period, with updated assumptions and the resulting gains and losses recorded as the change in fair value of warrant liability in the statement of operations. Expected volatilities
used in the models were based on our historical volatility commensurate with the term of the warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimated that the
fair value of the warrants at June&nbsp;30, 2012 was $4,305,000 using this model with the following assumptions: expected volatility of 75.4%, risk free interest rate of 0.4%, expected life of 2.6 years and no dividends. We estimated that the fair
value of the warrants at June&nbsp;30, 2011 was $3,427,000 using this same model with the following assumptions assigned to the varying outcomes: expected volatilities of 80%, risk free interest rates ranging from 0.8% to 1.1%, expected lives of
three to four years and no dividends. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>We recorded charges of $495,000 and $320,000 for the quarters ended
June&nbsp;30, 2012 and 2011, respectively, primarily related to the increase in our stock price during the respective periods. <I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Six-Month Periods Ended June&nbsp;30, 2012 and June&nbsp;30, 2011 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenues.</I>&nbsp;Total revenues are summarized as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REVENUES:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Research and development</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">158,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">182,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subtotal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">185,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">226,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>License fees</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subtotal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Royalty revenues from Genentech</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">523,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,708,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">526,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues increased by $14,182,000 to $14,708,000 for the six months ended June&nbsp;30, 2012 as
compared to $526,000 for the same period in 2011, primarily related to an increase in our license fee revenues of $14,000,000 due to payments we received from Genentech upon FDA approval of Erivedge in January 2012 and Roche&#146;s NDA filing in
Australia in May 2012. We recognized license fee revenues of $300,000 under a separate collaboration for the six months ended June&nbsp;30, 2011. In addition, we recognized $523,000 of royalty revenues from the net sales of Erivedge during the first
half of 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Royalty Revenues. </I>Cost of royalty revenues of $126,000 for the six months ended June&nbsp;30,
2012 includes a $100,000 one-time cash payment paid to a university licensor upon the first commercial sale of Erivedge and $26,000 paid to two university licensors, which represents 5% of the royalties that we earned with respect to Erivedge during
the first half of 2012. We did not have cost of royalty revenues for the six months ended June&nbsp;30, 2011 as Erivedge was approved in January 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expenses.</I>&nbsp;Research and development expenses are summarized as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Six Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/</B></FONT>
<br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:125pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Research and Development Program</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hedgehog pathway inhibitor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">97,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CUDC-101</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,530,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,217,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CUDC-907</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,163,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,355,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debio 0932</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other network-targeted cancer programs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,060,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,187,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublicense fees incurred on development and regulatory milestones under our Genentech collaboration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,114,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other sublicense fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain on sale of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(36,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">765,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">344,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">122</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,742,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,203,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development expenses increased by $3,539,000, or 57%, to $9,742,000 for the six months
ended June&nbsp;30, 2012 as compared to $6,203,000 for the same period in the prior year. We incurred sublicense fees of $2,114,000 to various university licensors in connection with Erivedge&#146;s FDA approval and our receipt of milestone payments
during the first half of 2012. Of this amount, $964,000 represents the fair value of a one-time issuance of an aggregate of 200,000 shares of our common stock to two university licensors in connection with the FDA-approval of Erivedge. The remaining
$1,150,000 represents sublicense fees we paid to these same licensors upon receipt of $14,000,000 in milestone payments, of which payments of $450,000 are specific to milestones achieved pursuant to Roche&#146;s NDA filing in Australia. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, spending on our CUDC-907 program also increased $808,000 over the prior year
period primarily related to costs for additional IND-enabling toxicology studies that were completed in the first half of 2012 as well as formulation development. Spending related to our CUDC-101 programs increased $313,000 over the prior year
period primarily related to expenses for outside services related to formulation studies, including the development of an oral formulation. These increases were offset by decreased spending on our CUDC-101 Phase Ib trial, as the last patient on
trial was treated in October 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation also increased $421,000 from the prior year period primarily
related to the expense recognized on unvested non-employee stock options that are marked-to-market at each reporting period, and which increased as our stock price increased over the prior year period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General and Administrative Expenses.</I>&nbsp;General and administrative expenses are summarized as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Increase/<BR>(Decrease)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,308,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,108,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy and depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">242,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,092,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,102,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting and professional services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">613,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">584,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insurance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">119,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">499,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">419,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,265,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">696,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,066,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses increased by $791,000, or 19%, to $5,066,000 for the six months ended
June&nbsp;30, 2012 as compared to $4,275,000 for the prior year period. This increase was primarily due to an increase in stock-based compensation of $569,000 from the prior year period as a result of an increase in the number of and grant-date fair
value of options granted during 2012 compared to the prior year period. In addition, personnel costs increased $200,000 primarily due to the accrual of cash incentive payments for executive officers under our 2012 short-term incentive program, for
which no such cash incentive payments were accrued during the second quarter of 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change in Fair Value of Warrant
Liability. </I>As a result of revaluing the warrants issued in January 2010, we recorded charges of $487,000 and $1,822,000 for the six months ended June&nbsp;30, 2012 and 2011, respectively, as a result of the increase in the fair value of the
warrants, primarily related to the increase in our stock price during this period. During the six months ended June&nbsp;30, 2012, warrants to purchase 212,500 shares of our common stock were exercised. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Sources of Liquidity </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
have financed our operations primarily through license fees, contingent cash payments and research and development funding from our collaborators and licensors, the private and public placement of our equity securities, debt financings and the
monetization of certain royalty rights. In the first quarter of 2012, we received a milestone payment of $10,000,000 based upon the FDA approval of Erivedge and, in May 2012, we earned a $4,000,000 milestone payment in connection with Roche&#146;s
filing in Australia. We also earned royalty revenues of $523,000 in connection with Genentech&#146;s net sales of Erivedge during the first half of 2012 and we will continue to receive royalties on any future Erivedge net sales. In addition, during
the fourth quarter of 2011, Roche submitted a MAA for Erivedge to the EMA for which we earned a $6,000,000 milestone payment. Roche has indicated that it anticipates potential EMA approval for Erivedge during the second half of 2012 or the first
half of 2013. Roche has also filed new drug applications in 2012 with Australian, Canadian and Swiss health agencies seeking approval for Erivedge in advanced BCC. We will receive additional milestone payments if Erivedge receives EMA marketing
authorization or approval in Australia, as well as royalties on future net sales in all territories where Erivedge is sold. We are currently not receiving any research funding and we do not expect to receive such funding in the future from Genentech
or Debiopharm under our current agreements with these parties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At June&nbsp;30, 2012, our principal sources of liquidity consisted of cash, cash
equivalents, and marketable securities of $44,706,000, excluding our restricted investment of $194,000. Our cash and cash equivalents are highly liquid investments with a maturity of three months or less at date of purchase and consist of
investments in money market funds with commercial banks and financial institutions, short-term commercial paper, and government obligations. We maintain cash balances with financial institutions in excess of insured limits. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cash Flows </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The use of
our cash flows for operations has primarily consisted of salaries and wages for our employees, facility and facility-related costs for our office and laboratory, fees paid in connection with preclinical studies, laboratory supplies, consulting fees
and legal fees. During 2008, we began incurring clinical costs associated with our phase I clinical trial of CUDC-101. We expect that costs associated with clinical studies will increase in future periods assuming that CUDC-101 advances into further
stages of clinical testing and other of our network-targeted cancer drug candidates, such as CUDC-907, reach clinical trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by operating activities of $2,701,000 for the six-month period ended June&nbsp;30, 2012 was primarily the result of the
receipt of $14,523,000 in milestone and royalty payments from Genentech during the period. We incurred operating and other expenses of $15,369,000 for the six months ended June&nbsp;30, 2012, of which $3,443,000 related to non-cash charges
consisting of stock-based compensation, changes in the fair value of our warrant liability, non-cash interest expense, the issuance of common stock to licensees and depreciation. In addition, changes in certain operating assets and liabilities
affected operating cash during the six-month period ended June&nbsp;30, 2012, including a decrease of $468,000 in prepaid expenses and other current assets, which was offset by an increase of $276,000 in our accounts receivable, primarily related to
royalties earned on the sale of Erivedge, and a decrease of $273,000 in our accounts payable and accrued liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net
cash used in operating activities of $8,827,000 for the six-month period ended June&nbsp;30, 2011 was primarily the result of our net loss for the period of $11,714,000. This decrease was offset by non-cash charges and credits totaling $2,990,000
consisting of stock-based compensation, changes in the fair value of our warrant liability, non-cash interest expense, depreciation and a gain on the sale of assets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect to continue to use cash in operations as we seek to advance our targeted cancer drug programs through preclinical testing and into clinical development. In addition, in the future we may owe
royalties and other contingent payments to our licensors based on the achievement of developmental milestones, product sales and other specified objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Investing activities used cash of $9,905,000 for the six-month period ended June&nbsp;30, 2012 and provided cash of $6,496,000 for the six-month period ended June&nbsp;30, 2011, resulting primarily from
net investment activity for the respective periods. During the six-month period ended June&nbsp;30, 2012, we reduced our long-term restricted investment resulting in an increase in our available cash for the period of $42,000. During the six-month
period ended June&nbsp;30, 2011, the restriction on our short-term investment for $219,000 ended resulting in an increase in our available cash for the period. This increase in cash was offset by purchases of research equipment totaling $246,000
during the six-month period ended June&nbsp;30, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financing activities provided cash of $4,174,000 and $1,296,000 for the
six-month period ended June&nbsp;30, 2012 and 2011, respectively, principally from the exercise of stock options and warrants and purchases of common stock under our employee stock purchase plan. We issued 2,216,236 shares of our common stock
related to these exercises and purchases during the six-month period ended June&nbsp;30, 2012 compared to 723,943 shares for the prior year period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Funding Requirements </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have incurred significant losses since our
inception. As of June&nbsp;30, 2012, we had an accumulated deficit of approximately $732,748,000. We will require substantial funds to continue our research and development programs and to fulfill our planned operating goals. In particular, our
currently planned operating and capital requirements include the need for working capital to support our research and development activities for CUDC-101, CUDC-907 and other small molecules that we are seeking to develop from our pipeline of
network-targeted cancer programs, and to fund our general and administrative costs and expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have historically derived
a substantial portion of our operating cash flow from the research funding portion of collaboration agreements with third parties. However, we have no current research funding revenue under collaboration agreements. Our ability to generate cash flow
to operate our business will depend, in part, on royalty payments from the commercial sale of Erivedge and the ability of Erivedge to be approved for commercial sale in other countries, which would result in us becoming eligible to receive
additional milestone payments as well as royalties on any future sales. We expect that our only source of cash flows from operations for the foreseeable future will be: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">up-front license payments and research and development funding that we may receive if we are able to successfully enter into new collaboration
agreements; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">contingent cash payments that we may receive for the achievement of development objectives under any new collaborations or our existing collaborations
with Genentech, Debiopharm and the LLS; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">royalty payments that are contingent upon the successful commercialization of products based upon these collaborations, including royalties on sales of
Erivedge in advanced BCC by Genentech, which is approved in the U.S. and is under review for approval in Europe, Australia, Canada and Switzerland by the respective health authorities in those countries. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be able to successfully enter into or continue any corporate collaborations and the timing, amount and likelihood of us
receiving payments under such collaborations is highly uncertain. For example, the amount of future royalty payments that we will receive as a result of Genentech&#146;s U.S. net sales of Erivedge, as well as potential future royalty payments that
we may receive on net sales of Erivedge in territories outside of the U.S., to the extent that Genentech successfully obtains marketing approval in such territories, is highly uncertain. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that existing cash, cash equivalents, marketable securities and working capital at June&nbsp;30, 2012, should enable us to
maintain current and planned operations into the first half of 2014. Our future capital requirements, however, may vary from what we currently expect. There are a number of factors that may adversely affect our planned future capital requirements
and accelerate our need for additional financing, many of which are outside our control, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unanticipated costs in our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing and cost of obtaining regulatory approvals for our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of payments, if any, from current and potential future collaborators; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing and amount of payments due to licensors of patent rights and technology used in our drug candidates, including the level of any royalty
payments from sales of Erivedge; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unplanned costs to prepare, file, prosecute, maintain and enforce patent claims and other patent-related costs, including litigation costs and
technology license fees; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unexpected losses in our cash investments or an inability to otherwise liquidate our cash investments due to unfavorable conditions in the capital
markets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may seek additional funding through public or private financings of debt or equity. The market
for emerging life science stocks in general, and the market for our common stock in particular, are highly volatile. Due to this and various other factors, including potentially adverse general market conditions and the early-stage status of our
internal development pipeline and the early stage of the commercial U.S. launch of Erivedge, additional funding may not be available to us on acceptable terms, if at all. In addition, the terms of any potential financing may be dilutive or otherwise
adversely affect other rights of our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also expect to seek additional funds through arrangements with
collaborators, licensees or other third parties. These arrangements would generally require us to relinquish or encumber rights to some of our technologies or drug candidates, and we may not be able to enter into such arrangements on acceptable
terms, if at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we anticipate receiving royalty payments in future periods from sales of Erivedge by Genentech, we
anticipate that we will require additional funding. If we are unable to obtain such additional funding on a timely basis, whether through payments under existing or future collaborations or license agreement or sales of debt or equity, we may be
required to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product candidates; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our
product candidates. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no off-balance sheet arrangements as of June&nbsp;30, 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_7"></A>ITEM&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our current cash balances in excess of operating requirements are invested in cash equivalents and short-term marketable securities, which consist of time deposits and investments in money market funds
with commercial banks and financial institutions, short-term commercial paper, and government obligations with an average maturity of less than one year. All marketable securities are considered available for sale. The primary objective of our cash
investment activities is to preserve principal while at the same time maximizing the income we receive from our invested cash without significantly increasing risk of loss. This objective may be adversely affected by the ongoing economic downturn
and volatile business environment and continued unpredictable and unstable market conditions. Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. While as of the date of this filing,
we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents or marketable securities since June&nbsp;30, 2012, no assurance can be given that further deterioration in conditions
of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or marketable securities or our ability to meet our financing objectives. Further dislocations in the credit market may adversely impact
the value and/or liquidity of marketable securities owned by us. Our investments are investment grade securities, and deposits are with investment grade financial institutions. We believe that the realization of losses due to changes in credit
spreads is unlikely as we currently have the ability to hold our investments for a sufficient period of time to recover the fair value of the investment and there is sufficient evidence to indicate that the fair value of the investment is
recoverable. We do not use derivative financial instruments in our investment portfolio. We do not believe that a 10% change in interest rate percentages would have a material impact on the fair value of our investment portfolio or our interest
income. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_8"></A>ITEM&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONTROLS AND PROCEDURES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Evaluation of Disclosure Controls&nbsp;&amp; Procedures </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June&nbsp;30, 2012. The term
&#147;disclosure controls and procedures,&#148; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1034, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information
required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#146;s
management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated,
can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls
and procedures as of June&nbsp;30, 2012, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Changes in Internal Control Over Financial Reporting </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended June&nbsp;30, 2012 that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_9"></A>PART II&#151;OTHER INFORMATION </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_10"></A>Item&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Factors </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should
carefully consider the following risk factors, in addition to other information included in this quarterly report on Form 10-Q and in other documents we file with the SEC, in evaluating Curis and our business. If any of the following risks occur,
our business, financial condition and operating results could be materially adversely affected. The following risk factors include material changes to, and restate and supersede, the risk factors previously disclosed in &#147;Part I, Item&nbsp;1A.
Risk Factors&#148; of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISKS RELATING TO THE
DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We are reliant on Genentech for the successful development and commercialization of
Erivedge. If Genentech does not successfully commercialize Erivedge for advanced BCC, or develop Erivedge for other indications, our future prospects and our ability to finance our operations may be substantially harmed. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, Erivedge was approved by the FDA as the first and only FDA-approved medicine for people with advanced forms of BCC.
Genentech and/or Roche have also filed and had accepted an MAA with the EMA as well as regulatory submissions with Australian, Canadian, Israeli, Mexican and Swiss regulatory authorities seeking regulatory approvals of Erivedge in these territories
for this same indication. Genentech and Roche are also conducting a phase II clinical trial of Erivedge in operable nodular BCC and Erivedge is currently being tested in other cancers under collaborative agreements between Genentech and either
third-party investigators or the NCI. Our near-term prospects substantially depend upon Genentech&#146;s ability to successfully develop and commercialize Erivedge in one or more indications and to demonstrate its safety and efficacy, as well as its
superiority over existing therapies and standards of care. Moreover, our ability to finance our company and to generate revenues will depend heavily on the ability of Genentech and Roche to: (i)&nbsp;successfully commercialize Erivedge in the
advanced BCC indication such that net sales are generated at a level for which we will derive meaningful royalties from Genentech, (ii)&nbsp;successfully file regulatory submissions for, and obtain approval to sell, Erivedge in Europe and/or other
territories for advanced BCC, and (iii)&nbsp;obtain favorable results in ongoing and planned clinical trials of Erivedge in other indications, including the ongoing clinical trial in operable BCC. The development and commercialization of Erivedge
could be unsuccessful if: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Erivedge for the treatment of advanced BCC is not accepted as safe, efficacious, cost-effective, less costly and preferable to current therapies in the
medical community and by third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech and/or Roche fails to apply the necessary financial resources and expertise to manufacturing, marketing and selling Erivedge for advanced BCC
and to regulatory approvals for this indication outside of the U.S.; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech and/or Roche does not develop and implement effective marketing, sales and distribution strategies and operations, for development and
commercialization of Erivedge for advanced BCC; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech and/or Roche does not develop, validate and maintain a commercially viable manufacturing process for Erivedge that is compliant with current
good manufacturing practices, or cGMP; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech and/or Roche does not successfully obtain third party reimbursement and generate commercial demand that results in sales of Erivedge for
advanced BCC in any geographic areas where requisite approvals have been, or may be, obtained; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or Genentech and/or Roche encounter any third party patent interference or patent infringement claims with respect to Erivedge;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech and/or Roche does not comply with any and all regulatory and legal requirements applicable to the sale of Erivedge for advanced BCC;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">new safety risks are identified after Erivedge is commercially marketed; and/or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Erivedge does not demonstrate acceptable safety and efficacy in current or future clinical trials, or otherwise does not meet applicable regulatory
standards for approval in indications other than advanced BCC. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The therapeutic efficacy of drug candidates being developed in our network-targeted cancer programs is
unproven in humans, and we may not be able to successfully develop and commercialize CUDC-101 or any other future drug candidates that we may select from these programs. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our drug candidates in our network-targeted cancer program, including CUDC-101, Debio 0932 and CUDC-907, are novel compounds and their potential benefit as therapeutic cancer drugs is unproven. These drug
candidates may not prove to be effective inhibitors of the cancer targets they are being designed to act against and may not demonstrate in patients any or all of the pharmacological benefits that we believe they may possess or that may have been
demonstrated in preclinical studies. Moreover, there is a risk that these drug candidates may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result of these and other risks described herein that are inherent
in the development of novel therapeutic agents, we may never successfully develop, enter into or maintain third party licensing or collaboration transactions with respect to, or successfully commercialize CUDC-101, CUDC-907 or Debio 0932, or any
other drug candidates from our network-targeted cancer programs, in which case we will not achieve profitability and the value of our stock may decline. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>We depend on third parties for the development of certain of our programs. If one or more of our collaborators fails or delays in developing or commercializing drug candidates based upon our
technologies, our business prospects and operating results would suffer and our stock price would likely decline. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
currently have a collaboration with Genentech pursuant to which we have granted to Genentech exclusive rights to develop and commercialize products based upon our Hedgehog pathway technologies. Genentech recently obtained FDA approval to
commercialize Erivedge, the sole compound being developed under this collaboration, in advanced BCC. Genentech and Roche are also seeking to obtain regulatory approval for this same indication in the EU, Australia, Canada, Israel, Mexico and
Switzerland and are also conducting, both alone and in collaboration, further studies of Erivedge for other indications. In addition, we entered into a license agreement with Debiopharm pursuant to which Debiopharm is testing Debio 0932 in a phase
Ib clinical trial in advanced solid tumors. Our collaboration agreement with Genentech and our license agreement with Debiopharm are our most significant collaborations, and these collaborations may not be scientifically or commercially successful
due to a number of factors, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech and Debiopharm each have significant discretion in determining the efforts and resources that they will apply to their respective
collaboration with us. The timing and amount of any cash payments related to royalties and the achievement of development objectives that we may receive under such collaborative arrangements will depend on, among other things, our collaboration
partners&#146; efforts, allocation of resources and successful development and commercialization of our drug candidates under their respective agreements with us. For example, our ability to obtain meaningful amounts of royalty income from sales of
Erivedge for advanced BCC will depend in large part upon the degree to which Genentech applies suitable financial and other resources to the manufacture, commercialization and sale of Erivedge for advanced BCC and to obtaining regulatory approvals
outside of the U.S. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our agreements with Genentech and Debiopharm each permits the other party wide discretion in deciding which drug candidates to advance through the
clinical trial process. It is possible for Genentech or Debiopharm to reject drug candidates at any point in the research, development and clinical trial process, without triggering a termination of the applicable agreement. In the event of any such
decision, our business and prospects may be adversely affected and we may not have the commercial rights or the resources necessary to advance such programs on our own. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted clinical development rights to Genentech and Debiopharm, respectively, under our agreements with each of them. If they fail to allocate
sufficient time, attention and resources to clinical trials of product candidates under these collaborations, or fail to comply with good clinical practices or other applicable regulatory requirements for such clinical trials, the successful
clinical development and commercialization of such product candidates is likely to be adversely affected, as will our ability to generate revenue from such collaborations. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech or Debiopharm may develop and commercialize, either alone or with others, products that are similar to or competitive with the drug
candidates that are the subject of its collaboration with us. For example, Genentech and Debiopharm each are developing several other programs in cancer. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech or Debiopharm may change the focus of its development and commercialization efforts or pursue higher-priority programs. Our ability to
successfully commercialize drug candidates under collaboration with Genentech or Debiopharm could be limited if Genentech or Debiopharm decreases or fails to increase spending related to such drug candidates. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Either Genentech or Debiopharm may enter into one or more transactions with third parties, including a merger, consolidation, reorganization, sale of
substantial assets, sale of substantial stock or change of control. For example, during the first quarter of 2009, Roche Holdings Ltd. completed its acquisition of Genentech. Any such transaction could divert the attention of our collaborative
partner&#146;s management and adversely affect its ability to retain and motivate key personnel who are important to the continued development of the programs under such collaboration. In addition, an acquirer could determine to reprioritize our
collaborator&#146;s development programs such that our collaborator ceases to diligently pursue the development of our programs, and/or terminates its collaboration with us. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech or Debiopharm may, under specified circumstances, terminate its collaboration with us on short notice and for circumstances outside of our
control, which could make it difficult for us to attract new collaborators or adversely affect how we are perceived in the scientific and financial communities. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both Genentech and Debiopharm have the first right to maintain or defend our intellectual property rights under their respective agreements and,
although we may have the right to assume the maintenance and defense of our intellectual property rights if our collaborators do not, our ability to do so may be compromised by our collaborators&#146; acts or omissions. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech or Debiopharm may utilize our intellectual property rights in such a way as to invite litigation that could jeopardize or invalidate our
intellectual property rights or expose us to potential liability. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Genentech or Debiopharm may not comply with all applicable regulatory requirements, or fail to report safety data in accordance with all applicable
regulatory requirements. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If either Genentech or Debiopharm were to breach or terminate its arrangement with us, the development and commercialization of the affected product
candidate could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue development and commercialization of the product candidate on our own. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Either Genentech or Debiopharm may not have sufficient resources necessary to advance clinical development of product candidates under our
collaborations with each of them or may not obtain the necessary regulatory approvals. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Genentech or
Debiopharm fails to successfully develop and commercialize our drug candidates under collaboration, we may not be able to develop and commercialize these candidates independently or successfully enter into one or more alternative collaborations, in
which event our financial condition, results of operations and stock price may be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For a further
discussion of risks relating specifically to our dependence on Genentech for the successful development and commercialization of Erivedge, see our separate risk factor: &#147;We are reliant on Genentech for the successful development and
commercialization of Erivedge. If Genentech does not successfully commercialize Erivedge for advanced BCC, or develop Erivedge for other indications, our future prospects and our ability to finance our operations will be substantially harmed.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We may not be successful in establishing additional strategic collaborations, which could adversely affect our ability to develop and
commercialize products. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current strategy is to seek corporate collaborators or licensees for the further development
and commercialization of one or more drug candidates under our network-targeted cancer drug programs, generally following our completion of at least phase I clinical testing. For example, while we are not presently seeking to enter into corporate
collaborations for CUDC-101, we are likely to seek to partner CUDC-101, CUDC-907 as well as other drug candidates from these programs in the future. We do not currently have the resources or capacity to advance these programs into later stage
clinical development (i.e., phase III) or commercialization. As such, our success will depend, in part, on our ability to enter into one or more such collaborations. We face significant competition in seeking appropriate collaborators and the
negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for CUDC-101, CUDC-907 or any future programs because our research and development
pipeline may be insufficient, our programs may be deemed to be at too early of a stage of development for collaborative effort and/or third parties may not view our drug candidates and programs as having the requisite potential to demonstrate safety
and efficacy or sufficient differentiability compared to existing or emerging treatments. Even if we are successful in our efforts to establish new collaborations, the terms that we agree upon may not be favorable to us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, if we fail to establish and maintain additional strategic partnerships related to our product candidates: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the development of certain of our current or future product candidates may be terminated or delayed; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our cash expenditures related to development of certain of our current or future product candidates would increase significantly and we may need to
seek additional financing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to hire additional employees or otherwise develop expertise, such as additional clinical, regulatory, sales and marketing expertise,
for which we have not budgeted; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we will bear all of the risk related to the development of any such product candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our future prospects may be adversely affected and our stock price could decline. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If preclinical studies and clinical trials of our drug candidates are not successful then our future profitability and success could be adversely
affected. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to obtain regulatory approval for the commercial sale of our drug candidates, we and any current or
potential future collaborators will be required to complete extensive preclinical studies as well as clinical trials in humans to demonstrate to the FDA and foreign regulatory authorities that our drug candidates are safe and effective for each
indication for which approval is sought. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development, including preclinical and clinical testing, is a long, expensive and
uncertain process. Preclinical testing and clinical trials of our drug candidates may not be successful. We and our collaborators could experience delays or failures in preclinical testing or clinical trials of any of our drug candidates for a
number of reasons including, for example: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preclinical studies or clinical trials may produce negative, inconsistent or inconclusive results, as occurred in Genentech&#146;s phase II clinical
trials of Erivedge in colorectal cancer and ovarian cancer, both of which were completed in 2010; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or any collaborators may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or terminate testing for
a particular drug candidate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results from preclinical studies and early clinical trials may not be statistically significant or predictive of results that will be obtained from
expanded, advanced clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter difficulties or delays in manufacturing sufficient quantities of the drug candidate used in any preclinical study or clinical trial;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing and completion of clinical trials of our drug candidates depend on, among other factors, the number of patients required to be enrolled in
the clinical trials and the rate at which those patients are enrolled, and any increase in the required number of patients, decrease in recruitment rates or difficulties retaining study participants may result in increased costs, program delays or
program termination; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our products under development may not be effective in treating any of our network-targeted cancer indications or may prove to have undesirable or
unintended side effects, toxicities or other characteristics that may prevent or limit their commercial use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">institutional review boards, regulators, including the FDA or its foreign equivalents, or any collaborators may hold, suspend or terminate our clinical
research or the clinical trials of our drug candidates for various reasons, including failure to achieve established success criteria, noncompliance with regulatory requirements or if, in their opinion, the participating subjects are being exposed
to unacceptable health risks; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, along with any of our current or potential future collaborators and subcontractors, may not employ, in any capacity, persons who have been debarred
under the FDA&#146;s Application Integrity Policy, or similar policy under foreign regulatory authorities, nor may we or any of our current or potential future collaborators or subcontractors use disqualified clinical investigators or institutions
to perform clinical trials of our drug candidates. Employment or use of such a debarred or disqualified person or institution may result in delays in FDA&#146;s or foreign equivalent&#146;s review or approval of our products, or the rejection of
data developed with the involvement of such person(s) or institution(s). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the preclinical studies and/or
clinical trials for any of our drug candidates that we and any collaborators pursue are not successful, then our ability to successfully develop and commercialize products on the basis of the respective technologies will be materially adversely
affected, our reputation and our ability to raise additional capital will be materially impaired and our stock price is likely to decline. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We expect to rely in part on third parties to conduct clinical trials of our internally-developed product
candidates, and if such third parties perform inadequately then we will not be able to successfully develop and commercialize drug candidates and grow our business. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have a limited internal group for overseeing our clinical trials. For the foreseeable future, we expect to rely in part on third parties such as consultants, contract research organizations and other
similar entities to complete IND-enabling preclinical studies, assist us in creating and submitting IND applications, enroll qualified subjects, conduct our clinical trials and provide services in connection with such clinical trials. Our reliance
on these third parties for clinical development activities will reduce our control over these activities. These third parties may not complete activities on schedule, or at all, or may not conduct our clinical trials in accordance with the clinical
trial protocol or design. In addition, the FDA and its foreign equivalents require us to comply with certain standards, referred to as good clinical practices, and applicable regulatory requirements, for conducting, recording and reporting the
results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties that we do not control does not
relieve us of these responsibilities and requirements. If any of the third party contractors on whom we rely do not comply with good clinical practices or other applicable regulatory requirements, we may not be able to use the data and reported
results from the applicable trial. Any failure by a third party to conduct our clinical trials as planned or in accordance with regulatory requirements could delay or otherwise adversely affect our efforts to obtain regulatory approvals for and
commercialize our drug candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we and our collaborative partners do not obtain necessary regulatory approvals, then our business
will be unsuccessful and the market price of our common stock could substantially decline. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our collaborators will
be required to obtain regulatory approval in order to successfully advance drug candidates through the clinic and prior to marketing and selling such products. The process of obtaining required regulatory approvals is expensive and the time required
for these approvals is uncertain and typically takes a number of years, depending on the type, complexity and novelty of the product. With respect to our internal programs, we have limited experience in filing and prosecuting applications to obtain
marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any regulatory approval to market a product may be subject to limitations on the approved indicated uses
for which we or our collaborative partners may market the product or to distribution and use restrictions or other requirements under a Risk Evaluation and Mitigation Strategy, or REMS. These limitations may restrict the size of the market for the
product and affect reimbursement by third-party payors. In addition, regulatory agencies may not grant approvals on a timely basis or may revoke or significantly modify previously granted approvals. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our collaborators are subject to numerous foreign regulatory requirements governing the manufacturing and marketing of potential
future products outside of the U.S. The approval procedure varies among countries, additional testing may be required in some jurisdictions, and the time required to obtain foreign approvals often differs from that required to obtain FDA approvals.
Moreover, approval by the FDA or a foreign equivalent does not ensure approval by regulatory authorities in other countries, and vice versa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, regulatory agencies may change existing requirements or adopt new requirements or policies. We and any collaborative partners may be slow to adapt or may not be able to adapt to these changes
or new requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of these factors, we and any collaborators may not successfully begin or complete clinical
trials and/or obtain regulatory approval to market and sell drug candidates in the time periods estimated, if at all. Moreover, if we or any collaborators incur costs and delays in development programs or fail to successfully develop and
commercialize products based upon our technologies, we may not become profitable and our stock price could decline. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Even if marketing
approval is obtained, any products we or any collaborators develop will be subject to ongoing regulatory oversight, which may affect the successful commercialization of such products. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we or any collaborators obtain regulatory approval of a drug candidate, the approval may be subject to limitations on the
approved indicated uses for which the product can be marketed, impose restrictions on how the product can be distributed and used pursuant to a REMS, or require costly post-marketing follow-up studies. After marketing approval for any product is
obtained, the manufacturer and the manufacturing facilities for that product will be subject to continual review and periodic inspections by the FDA, or foreign equivalent, and other regulatory agencies. The subsequent discovery of previously
unknown problems with the product, or with the manufacturer or facility, or a failure to comply with regulatory requirements, may result in restrictions on the product or manufacturer, including withdrawal of the product from the market, fines,
refusal to approve pending applications or supplements, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, refusal to permit the import or export of our products or those of our
collaborators, and criminal prosecution. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA&#146;s policies may change and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of our or our collaborators&#146; product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action,
either in the U.S. or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we or they may lose
any marketing approvals that have been obtained, which would adversely affect the amount of revenue generated from such products and adversely affect our ability to achieve or sustain profitability. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We and our current collaborators are, and any potential future collaborators will be, subject to governmental regulations in connection with the
research, development and commercialization of our drug candidates. We and our collaborators may not be able to comply with these regulations, which could subject us or such collaborators to penalties and result in the imposition of limitations on
our or such collaborators&#146; operations. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to regulations imposed by the FDA or foreign equivalents, we and
our current collaborators are, and any potential future collaborators will be, subject to regulation under, among other laws, the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Research
Conservation and Recovery Act, as well as regulations administered by the Nuclear Regulatory Commission, national restrictions on technology transfer, import, export and customs regulations and certain other local, state or federal regulations. From
time to time, other federal agencies and congressional committees have indicated an interest in implementing further regulation of pharmaceutical and biotechnology companies. We are not able to predict whether any such regulations will be adopted or
whether, if adopted, such regulations will apply to our business, or whether we or any collaborators would be able to comply with any applicable regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our business involves the use of hazardous materials and we must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development activities involve the controlled use of hazardous materials and chemicals. Although we believe that our
safety procedures for handling and disposing of such materials comply with all applicable laws and regulations, we cannot completely eliminate the risk of accidental contamination or injury caused by these materials. Violation of these laws and
regulations could lead to substantial fines and penalties. In the event of an accident, state or federal authorities may curtail our use of these materials and interrupt our business operations. In addition, we could become subject to potentially
material liabilities relating to the investigation and cleanup of any contamination, whether currently unknown or caused by future releases. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our business and operations would suffer in the event of system failures. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the implementation of security measures, our internal computer systems are vulnerable to damage from computer viruses,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our product
development programs. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability and the further
development of our product candidates may be delayed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we or any of our collaborators fail to achieve market acceptance for any approved
products, our future revenue and ability to achieve profitability may be adversely affected. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future products,
including those developed under collaborations with third parties, may not gain commercial acceptance among physicians, patients and third-party payors, even if necessary marketing approvals have been obtained. We believe that recommendations and
endorsements by physicians will be essential for market acceptance of any products we or our collaborators successfully develop. If we or our collaborators are not able to obtain market acceptance for such products, our expected revenues from sales
of these products would be adversely affected and our business may not be successful. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISKS RELATING TO OUR FINANCIAL
RESULTS AND NEED FOR FINANCING </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We have incurred substantial losses, expect to continue to incur substantial losses for the foreseeable
future and may never generate significant revenue or achieve profitability. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2012, we had an
accumulated deficit of approximately $732,748,000. We have incurred net losses of $9,859,000, $4,435,000 and $9,823,000 for the years ended December&nbsp;31, 2011, 2010, and 2009, respectively, and a net loss of $661,000 for the six months ended
June&nbsp;30, 2012. Other than Erivedge, which was approved by the FDA in January 2012 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
for the treatment of advanced forms of BCC, we have not successfully commercialized any products to date, either alone or in collaboration with others. We are entitled to royalties on net sales
of Erivedge by Genentech. If these royalties are not meaningful or we are not able to successfully commercialize any other products, we will not achieve sustainable profitability. All of our drug candidates other than Erivedge are in early stages of
development. For the foreseeable future, we will need to spend significant capital in an effort to develop and commercialize products and we expect to incur substantial operating losses. Our failure to become and remain profitable would, among other
things, depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our research and development programs or continue our operations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We will require substantial additional capital, which may be difficult to obtain. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require substantial funds to continue our research and development programs and to fulfill our planned operating goals. In
particular, our currently planned operating and capital requirements include the need for substantial working capital to support our research and development activities for CUDC-101, CUDC-907 and other small molecules that we are seeking to develop
from our pipeline of network-targeted cancer programs, and to fund our general and administrative costs and expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
historically derived a substantial portion of our operating cash flow from the research funding portion of collaboration agreements with third parties. However, we have no current research funding revenue under collaboration agreements. Our ability
to generate cash flow to operate our business will depend, in part, on royalty payments from the commercial sale of Erivedge and the ability of Erivedge to be approved for commercial sale in other countries, which would result in us becoming
eligible to receive additional milestone payments as well as royalties on any future sales. We expect that our only source of cash flows from operations for the foreseeable future will be: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">up-front license payments and research and development funding that we may receive if we are able to successfully enter into new collaboration
agreements for our technologies under development; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">contingent cash payments that we may receive for the achievement of development objectives under any new collaborations or our existing collaborations
with Genentech, Debiopharm and LLS; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">royalty payments that are contingent upon the successful commercialization of products based upon these collaborations, including royalties on sales of
Erivedge in advanced BCC by Genentech, which is approved in the U.S. and is under review for approval in Europe, Australia, Canada, Israel, Mexico and Switzerland by the respective health authorities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be able to successfully enter into or continue any corporate collaborations and the timing, amount and likelihood of us
receiving payments under such collaborations is highly uncertain. For example, the amount of future royalty payments that we will receive as a result of Genentech&#146;s U.S. net sales of Erivedge, as well as potential future royalty payments that
we may receive on net sales of Erivedge in territories outside of the U.S., to the extent that Genentech successfully obtains marketing approval in such territories, is highly uncertain. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that existing cash, cash equivalents, marketable securities and working capital at June 30, 2012 should enable us to
maintain current and planned operations into the first half of 2014. Our future capital requirements, however, may vary from what we currently expect. There are a number of factors that may affect our planned future capital requirements and
accelerate our need for additional working capital, many of which are outside our control, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unanticipated costs in our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing and cost of obtaining regulatory approvals for our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of payments, if any, from current and potential future collaborators, including the level of any royalty payments from
sales of Erivedge; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing and amount of payments due to licensors of patent rights and technology used in our drug candidates, including the level of any royalty
payments from sales of Erivedge; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unplanned costs to prepare, file, prosecute, maintain and enforce patent claims and other patent-related costs, including litigation costs and
technology license fees; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unexpected losses in our cash investments or an inability to otherwise liquidate our cash investments due to unfavorable conditions in the capital
markets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may seek additional funding through public or private financings of debt or equity. The market
for emerging life science stocks in general, and the market for our common stock in particular, are highly volatile. Due to this and various </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
other factors, including potentially adverse general market conditions and the early-stage status of our internal development pipeline and the early stage of the commercial U.S. launch of
Erivedge, additional funding may not be available to us on acceptable terms, if at all. In addition, the terms of any potential financing may be dilutive or otherwise adversely affect other rights of our stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also expect to seek additional funds through arrangements with collaborators, licensees or other third parties. These arrangements
would generally require us to relinquish or encumber rights to some of our technologies or drug candidates, and we may not be able to enter into such arrangements on acceptable terms, if at all. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we anticipate receiving royalty payments in future periods from sales of Erivedge by Genentech, we anticipate that we will require
additional funding. If we are unable to obtain such additional funding on a timely basis, whether through payments under existing or future collaborations or license agreement or sales of debt or equity, we may be required to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product candidates; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our
product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Raising additional capital may cause dilution to our existing stockholders, restrict our operations
or require us to relinquish rights to our technologies or product candidates. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may seek additional funding through
public or private financings of debt or equity. For example, in June 2011 we entered into an agreement with McNicoll, Lewis&nbsp;&amp; Vlak, LLC, or MLV, pursuant to which, from time to time, we may offer and sell up to $20 million of common stock
that was registered pursuant to our universal shelf registration statement through MLV pursuant to one or more &#147;at the market&#148; offerings. In addition, with our prior written approval, MLV may also sell these shares of common stock by any
other method permitted by law, including in privately negotiated transactions. The market for emerging life science stocks in general, and the market for our common stock in particular, are highly volatile. Due to this and various other factors,
including adverse general market conditions and the early-stage status of our development pipeline, additional funding may not be available to us on acceptable terms, if at all, and we may not be able to sell additional shares under the arrangement
with MLV at favorable prices, if at all. In addition, the terms of any financing may be dilutive or otherwise adversely affect other rights of our stockholders. We also expect to seek additional funds through arrangements with collaborators,
licensees or other third parties. These arrangements would generally require us to relinquish or encumber rights to some of our technologies or drug candidates. Moreover, we may not be able to enter into such arrangements on acceptable terms, if at
all. If we are unable to obtain additional funding on a timely basis, whether through sales of debt or equity or through third party collaboration or license arrangements, we may be required to curtail or terminate some or all of our development
programs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We may face fluctuations in our operating results from period to period, which may result in a decline in our stock price.
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operating results have fluctuated significantly from period to period in the past and may rise or fall significantly
from period to period in the future as a result of many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of research and development that we engage in; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a failure to successfully complete preclinical studies and clinical trials in a timely manner or at all, resulting in a delay in receiving, or a
failure to receive, the required regulatory approvals to commercialize our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of payments, if any, from current and potential future collaborators, including the level of any royalty payments from
sales of Erivedge; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the entry into, or termination of, collaboration agreements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, duration and effectiveness of our collaborative arrangements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs involved in prosecuting, maintaining and enforcing patent claims; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to operate without infringing upon the proprietary rights of others; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs to comply with changes in government regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs related to changes in management and reductions or additions of personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation costs; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs and accounting charges associated with financing or borrowing arrangements we may enter into from time to time; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general and industry-specific adverse economic conditions that may affect, among other things, our and our collaborators&#146; operations and financial
results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in accounting estimates, policies or principles, including changes in revenue recognition policies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the introduction of competitive products and technologies by third parties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to fluctuations in our operating results, quarterly comparisons of our financial results may not necessarily be meaningful, and
investors should not rely upon such results as an indication of our future performance. In addition, investors may react adversely if our reported operating results are less favorable than in a prior period or are less favorable than those
anticipated by investors or the financial community, which may result in a decline in our stock price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Unstable market and economic
conditions may have serious adverse consequences on our business, financial condition and stock price. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our general
business strategy and prospects may be adversely affected by the unfavorable economic conditions, volatile business environment and continued unpredictable and unstable market conditions, both domestically and abroad. If equity and credit markets
are unfavorable, it may make future debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth
strategy, financial performance and stock price and could require us to delay or abandon research and development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive
these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At June&nbsp;30, 2012, we had $44,706,000 of cash, cash equivalents and marketable securities consisting of cash, money market, commercial paper, corporate debt securities, and government obligations.
While as of the date of this filing, we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents or marketable securities since June&nbsp;30, 2012, no assurance can be given that
further deterioration in conditions of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or marketable securities or our ability to meet our financing objectives. Further dislocations in
the credit market may adversely impact the value and liquidity of marketable securities owned by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a possibility
that our stock price may decline due to the volatility of the stock market and the general economic downturn. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISKS RELATED
TO OUR BUSINESS, INDUSTRY, STRATEGY AND OPERATIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We and our collaborators may not achieve projected research and development goals
in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We set goals for, and make public statements regarding, the timing of certain accomplishments, such as the commencement and completion of preclinical studies, initiation and completion of clinical trials,
and other developments and milestones under our proprietary programs and those programs being developed under collaboration agreements. Genentech is a wholly-owned member of the Roche Group and Roche has also made public statements regarding its
expectations for the clinical development and potential regulatory approval of Erivedge in territories other than the U.S., and may in the future make additional statements about its goals and expectations for this collaboration with us. The actual
timing of these events can vary dramatically due to a number of factors including without limitation delays or failures in our and our current and potential future collaborators&#146; preclinical studies or clinical trials, the amount of time,
effort and resources committed to our programs by us and our current and potential future collaborators and the uncertainties inherent in the regulatory approval process. As a result, we can not be assured that our or our current and potential
future collaborators&#146; preclinical studies and clinical trials will advance or be completed in the time frames we or they announce or expect, that we or our current and potential future collaborators will make regulatory submissions or receive
regulatory approvals as planned or that we or our current and potential future collaborators will be able to adhere to our current schedule for the achievement of key milestones under any of our internal or collaborative programs. If we or any
collaborators fail to achieve one or more of these milestones as planned, our business could be materially adversely affected and the price of our common stock could decline. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We face substantial competition, which may result in our competitors discovering, developing or
commercializing products before or more successfully than we do. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our drug candidates face competition from existing and
new technologies and products being developed by biotechnology, medical device and pharmaceutical companies, as well as universities and other research institutions. For example, there are several Hedgehog pathway inhibitors presently in clinical
development by companies including Bristol-Myers Squibb, Infinity Pharmaceuticals, Millenium Pharmaceuticals, Novartis and Pfizer that may compete with Erivedge. Genentech and Roche are currently commercializing Erivedge in advanced BCC and also
conducting a phase II trial in less severe forms of BCC. In addition, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech and either third-party investigators or the NCI. We currently
believe that the nearest competitive molecule to Erivedge in clinical development is in phase II clinical testing in locally advanced and metastatic BCC. Competitors may discover, characterize and develop their Hedgehog pathway inhibitor drug
candidates and compete with us in the same cancer indications in which Erivedge is currently being studied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our
small molecule network-targeted cancer drug development candidates, which are focused primarily on validated cancer targets, face significant competition from marketed drugs and drugs under development that seek to inhibit the same targets as our
drug candidates. We expect competition to intensify in cancer generally and, specifically, in targeted approaches to develop potential cancer therapies as technical advances in the field are made and become more widely known. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our competitors have substantially greater capital resources, research and development staffs and facilities, and more extensive
experience than we have. As a result, efforts by other life science, medical device and pharmaceutical companies could render our programs or products uneconomical or result in therapies superior to those that we develop alone or with a
collaborator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For those programs that we have selected for internal development, we face competition from companies that are
more experienced in product development and commercialization, obtaining regulatory approvals and product manufacturing. Other smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large
and established companies. As a result, any of these companies may be more successful in obtaining collaboration agreements or other monetary support, approval and commercialization of their products and/or may develop competing products more
rapidly and/or at a lower cost. For those programs that are subject to a collaboration agreement, competitors may have greater expertise in discovery, research and development, manufacturing, preclinical and clinical testing, obtaining regulatory
approvals and marketing than our collaborators and, consequently, may discover, develop and commercialize products that render our products non-competitive or obsolete. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we are not able to compete effectively, then we may not be able, either alone or with others, to advance the development and commercialization of our drug candidates, which would adversely affect our
ability to grow our business and become profitable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The trend towards consolidation in the pharmaceutical and biotechnology industries may
adversely affect us. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a trend towards consolidation in the pharmaceutical and biotechnology industries. This
consolidation trend may result in the remaining companies in these industries having greater financial resources and technological capabilities, thus intensifying competition in these industries. This trend may also result in fewer potential
collaborators or licensees for our therapeutic drug candidates. Also, if a consolidating company is already doing business with our competitors, we may lose existing licensees or collaborators as a result of such consolidation. This trend may
adversely affect our ability to enter into agreements for the development and commercialization of our drug candidates, and as a result may harm our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>We could be exposed to significant monetary damages and business harm if we are unable to obtain or maintain adequate product liability insurance at acceptable costs or otherwise protect ourselves
against potential product liability claims. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product liability claims are inherent in the process of researching,
developing and commercializing human health care products and could expose us to significant liabilities and prevent or interfere with the development or commercialization of our drug candidates. Regardless of their merit or eventual outcome,
product liability claims would require us to spend significant time, money and other resources to defend such claims, could result in decreased demand for our future products or result in reputational harm and could result in the payment of a
significant damage award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we currently have product liability insurance for our clinical trials, this insurance is
subject to deductibles and coverage limitations and may not be adequate in scope to protect us in the event of a successful product liability claim. If any of our drug candidates advance in clinical trials and/or are approved for marketing, we may
seek additional insurance coverage. Product liability insurance is expensive and may be difficult to procure. As such, it is possible that we will not be able to obtain product liability insurance on acceptable terms, if at all, or that our product
liability insurance coverage will prove to be inadequate to protect us from all potential claims, which may harm our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we are not able to attract and retain key management and scientific personnel and advisors, we may not
successfully develop our drug candidates or achieve our other business objectives. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We depend upon our senior management,
including Daniel R. Passeri, our President and Chief Executive Officer, Maurizio Voi, our Chief Medical and Chief Development Officer, and Michael P. Gray, our Chief Operating Officer and Chief Financial Officer. The loss of the service of any of
the key members of our senior management may significantly delay or prevent the achievement of product development and other business objectives. Our officers all serve pursuant to &#147;at will&#148; employment arrangements and can terminate their
employment with us at any time. We do not maintain key man life insurance on any of these officers. Replacing key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with
the breadth of skills and experience required to research, develop and successfully commercialize products in our areas of core competency. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ability to operate successfully will depend on our ability to attract and retain qualified personnel, consultants and advisors. We face intense competition for qualified individuals from numerous
pharmaceutical and biotechnology companies, universities, governmental entities and other research institutions. We may be unable to attract and retain these individuals, and our failure to do so would have an adverse effect on our business.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We may seek to acquire complementary businesses and technologies or otherwise seek to expand our operations to grow our business, which
may divert management resources and adversely affect our financial condition and operating results. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may seek to expand
our operations, including without limitation through internal growth and/or the acquisition of businesses and technologies that we believe are a strategic complement to our business model. We may not be able to identify suitable acquisition
candidates or expansion strategies and successfully complete such acquisitions or successfully execute any such other expansion strategies. We may never realize the anticipated benefits of any efforts to expand our business. Furthermore, the
expansion of our business, either through internal growth or through acquisitions, poses significant risks to our existing operations, financial condition and operating results, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a diversion of management from our existing operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">increased operating complexity of our business, requiring greater personnel and resources; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant additional cash expenditures to expand our operations and acquire and integrate new businesses and technologies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">incurrence of debt, other liabilities and contingent liabilities; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">dilutive stock issuances. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Any business that we conduct in China will expose us to risks resulting from adverse changes in political, legal and economic policies of the Chinese
government, which could impede our preclinical efforts in China and materially and adversely affect the development of our network-targeted cancer programs. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently engage approximately 16 medicinal chemists in China pursuant to a contract research agreement with a medicinal chemistry provider in China. In addition, we have a subsidiary in China, Curis
Shanghai, which is currently licensed to conduct business but is not operational. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conducting business in China exposes us to
a variety of risks and uncertainties that are unique to China. The economy of China has been transitioning from a planned economy to a more market-oriented economy. Although in recent years the Chinese government has implemented measures emphasizing
the utilization of market forces for economic reform, the reduction of state ownership of productive assets and the establishment of sound corporate governance in business enterprises, a substantial portion of productive assets in China is still
owned by the Chinese government. In addition, the Chinese government continues to play a significant role in regulating industrial development. It also exercises significant control over China&#146;s economic growth through the allocation of
resources, controlling payment of foreign currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies. Efforts by the Chinese government to slow the pace of growth of the
Chinese economy could result in interruptions of our development efforts in China. If our research and development efforts in China are delayed due to such interruptions, we may not realize the reductions in costs anticipated from doing business in
China. We would also have to consider moving our chemistry and/or biology research that is currently conducted in China to U.S. or European providers, thereby potentially either increasing our overall costs for such services or reducing the total
number of chemists and or/biologists that we could engage. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Chinese legal system is a civil law system based on written statutes.
Unlike common law systems, it is a system in which decided legal cases have little precedential value. In 1979, the Chinese government began to promulgate a comprehensive system of laws and regulations governing economic matters in general.
Accordingly, we cannot predict the effect of future developments in the Chinese legal system, including the promulgation of new laws, changes to existing laws or the interpretation or enforcement thereof, or the preemption of local regulations by
national laws. Our business could be materially harmed by any changes in the political, legal or economic climate in China or the inability to enforce applicable Chinese laws and regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>If the estimates we make and the assumptions on which we rely in preparing our financial statements prove inaccurate, our actual results may vary significantly. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of
these financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges taken by us and related disclosure. Such estimates and judgments
include the carrying value of our property, equipment and intangible assets, revenue recognition, the value of certain liabilities, including the fair value of our warrant liability, and stock-based compensation expense. We base our estimates and
judgments on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. However, these estimates and judgments, or the assumptions underlying them, may change over time. Accordingly, our actual
financial results may vary significantly from the estimates contained in our financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For a further discussion
of the estimates and judgments that we make and the critical accounting policies that affect these estimates and judgments, see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Critical Accounting
Policies and Estimates&#148; elsewhere in this Quarterly Report on Form 10-Q. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our employees may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements and insider trading. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to the
risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply
with federal and state health-care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws or regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any such actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. In addition, during the course of our operations, our directors, executives
and employees may have access to material, nonpublic information regarding our business, our results of operations or potential transactions we are considering. Despite our adoption of an Insider Trading Policy, we may not be able to prevent a
director, executive or employee from trading in our common stock on the basis of, or while having access to, material, nonpublic information. If a director, executive or employee was to be investigated, or an action was to be brought against a
director, executive or employee for insider trading, it could have a negative impact on our reputation and our stock price. Such a claim, with or without merit, could also result in substantial expenditures of time and money, and divert attention of
our management team from other tasks important to the success of our business. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISKS RELATING TO OUR INTELLECTUAL PROPERTY
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We may not be able to obtain patent protection for our technologies and the patent protection we do obtain may not be sufficient to
stop our competitors from using similar technology. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The long-term success of our business depends in significant part on
our ability to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain patents to protect our technologies and discoveries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">protect trade secrets from disclosure to third-party competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">operate without infringing upon the proprietary rights of others; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">prevent others from infringing on our proprietary rights. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent positions of pharmaceutical and life science companies, including ours, are
generally uncertain and involve complex legal, scientific and factual questions. The laws, procedures and standards that the U.S. Patent and Trademark Office and various foreign intellectual property offices use to grant patents, and the standards
that courts use to interpret patents, are not always applied predictably or uniformly and have changed in significant ways and are expected to continue to change. Consequently, the level of protection, if any, that will be obtained and provided by
our patents if we attempt to enforce them, and they are challenged, is uncertain. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents may not issue from any of the
patent applications that we own or license. If patents do issue, the type and extent of patent claims issued to us may not be sufficient to protect our technology from exploitation by our competitors. In addition, issued patents that we own or
license may be challenged, invalidated or circumvented. Our patents also may not afford us protection against competitors with similar technology. Because patent applications in the U.S. and in many countries abroad are maintained in secrecy until
18 months after filing, it is possible that third parties have filed or maintained patent applications for technology used by us or covered by our pending patent applications without our knowledge. The U.S. Congress recently passed the Leahy-Smith
America Invents Act, or the America Invents Act, which was signed into law in September 2011. The America Invents Act reforms U.S. patent law in part by changing the standard for patent approval from a &#147;first to invent&#148; standard to a
&#147;first to file&#148; standard and developing a post-grant review system. This new legislation changes U.S. patent law in a way that may weaken our ability to obtain or maintain patent protection for future inventions in the U.S. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not have rights under patents that may cover one or more of our drug candidates. In some cases, these patents may be owned or
controlled by third-party competitors and may prevent or impair our ability to exploit our technology. As a result, we or our current or potential future collaborative partners may be required to obtain licenses under third-party patents to develop
and commercialize some of our drug candidates. If we are unable to secure licenses to such patented technology on acceptable terms, we or our collaborative partners may not be able to develop and commercialize the affected drug candidate or
candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We may become involved in expensive and unpredictable patent litigation or other intellectual property proceedings, which
could result in liability for damages or require us to cease our development and commercialization efforts. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are
substantial litigation and other adversarial opposition proceedings regarding patent and other intellectual property rights in the pharmaceutical and life science industries. We may become a party to patent litigation or other proceedings regarding
intellectual property rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Situations that may give rise to patent litigation or other disputes over the use of our
intellectual property include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">initiation of litigation or other proceedings against third parties to enforce our patent rights, to seek to invalidate the patents held by these third
parties or to obtain a judgment that our drug candidates do not infringe the third parties&#146; patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">participation in interference and/or derivation proceedings to determine the priority of invention if our competitors file U.S. patent applications
that claim technology also claimed by us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">initiation of opposition, reexamination, post grant review or inter partes review proceedings by third parties that seek to limit or eliminate the
scope of our patent protection; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">initiation of litigation by third parties claiming that our processes or drug candidates or the intended use of our drug candidates infringe their
patent or other intellectual property rights; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">initiation of litigation by us or third parties seeking to enforce contract rights relating to intellectual property that may be important to our
business. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The costs associated with any patent litigation or other proceeding, even if resolved favorably,
will likely be substantial and a distraction to management. Some of our competitors may be able to sustain the cost of such litigation or other proceedings more effectively than we can because of their substantially greater financial resources. If a
patent litigation or other intellectual property proceeding is resolved unfavorably, we or any collaborative partners may be enjoined from manufacturing or selling our future products without a license from the other party and be held liable for
significant damages. Moreover, we may not be able to obtain required licenses on commercially acceptable terms or any terms at all. In addition, we could be held liable for lost profits if we are found to have infringed a valid patent, or liable for
treble damages if we are found to have willfully infringed a valid patent. Litigation results are highly unpredictable and we or any collaborative partner may not prevail in any patent litigation or other proceeding in which we may become involved.
Any changes in, or unexpected interpretations of the patent laws may adversely affect our ability to enforce our patent position. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could damage our
ability to compete in the marketplace. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We face risks relating to the enforcement of our intellectual property rights in China that could
adversely affect our business. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our contract research agreement with a medicinal chemistry provider in China,
we currently engage approximately 16 medicinal chemists in China to perform drug discovery research. We seek to protect our intellectual property rights under this arrangement through, among other things, non-disclosure and assignment of invention
covenants. Implementation and enforcement of Chinese intellectual property-related laws has historically been inconsistent and damages assessed may fail to reflect the true value of the infringed technology and its market. Accordingly, intellectual
property rights and confidentiality protections in China may not be as effective as in the U.S. or other countries. Policing unauthorized use of proprietary technology is difficult and expensive, and we might need to resort to litigation to enforce
or defend patents issued to us or to determine the enforceability, scope and validity of our proprietary rights or those of others. The experience and capabilities of Chinese courts in handling intellectual property litigation varies, and outcomes
are unpredictable. Further, such litigation may require significant expenditure of cash and management efforts and could harm our business, financial condition and results of operations. An adverse determination in any such litigation will impair
our intellectual property rights and may harm our business, prospects and reputation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we are unable to keep our trade secrets
confidential, our technology and proprietary information may be used by others to compete against us. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely
significantly upon proprietary technology, information, processes and know-how that are not subject to patent protection. We seek to protect this information through confidentiality and intellectual property license or assignment provisions in
agreements with our employees, consultants and other third-party contractors, including our contract research agreement with a medicinal chemistry provider in China, as well as through other security measures. The confidentiality and intellectual
property provisions of our agreements and security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently developed by competitors.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, we could lose
license rights that are important to our business. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are party to agreements that provide for licenses to us of
intellectual property or sharing of rights to intellectual property that is important to our business, and we may enter into additional agreements in the future that provide licenses to us of valuable technology. These licenses impose, and future
licenses may impose, various commercialization, milestone and other obligations on us, including the obligation to terminate our use of patented subject matter under certain contingencies. If a licensor becomes entitled to, and exercises,
termination rights under a license, we would lose valuable rights and could lose our ability to develop our products. We may need to license other intellectual property to commercialize future products. Our business may suffer if any current or
future licenses terminate, if the licensors fail to abide by the terms of the license or fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid or if we are unable to enter into necessary
licenses on acceptable terms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of
their former employers. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were
previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims,
litigation could result in substantial costs and be a distraction to management. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISKS RELATING TO MANUFACTURING AND SALES
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We will depend on our collaborators and third-party manufacturers to produce most, if not all, of our products under development, and
if these third parties do not successfully formulate or manufacture these products, our business will be harmed. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
no manufacturing experience or manufacturing capabilities. In order to continue to develop drug candidates, apply for regulatory approvals, and commercialize our products under development, we or any collaborators must be able to manufacture
products in adequate clinical and commercial quantities, in compliance with regulatory requirements, including </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
those related to quality control and quality assurance, at acceptable costs and in a timely manner. The manufacture of our drug candidates may be complex, difficult to accomplish and difficult to
scale-up when large-scale production is required. Manufacture may be subject to delays, inefficiencies and poor or low yields of quality products. The cost of manufacturing some of our product candidates may make them prohibitively expensive.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that we or any collaborators seek to enter into manufacturing arrangements with third parties, we and such
collaborators will depend upon these third parties to perform their obligations in a timely and effective manner and in accordance with government regulations. Contract manufacturers may breach their manufacturing agreements because of factors
beyond our and our collaborators&#146; control or may terminate or fail to renew a manufacturing agreement based on their own business priorities at a time that is costly or inconvenient for us and our collaborators. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any contract manufacturers with whom we or our collaborators enter into manufacturing arrangements will be subject to ongoing periodic,
unannounced inspection by the FDA and corresponding state and foreign agencies or their designees to ensure strict compliance with current good manufacturing practices and other governmental regulations and corresponding foreign standards. Any
failure by our or our collaborators&#146; contract manufacturers, any collaborators, or us to comply with applicable regulations could result in sanctions being imposed, including fines, injunctions, civil penalties, failure of regulatory
authorities to grant marketing approval of drug candidates, delays, suspension or withdrawal of approvals, seizures or recalls of drug candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely
affect our business. If we or a collaborator need to change manufacturers, the FDA and corresponding foreign regulatory agencies must approve any new manufacturers in advance. This would involve testing and pre-approval inspections to ensure
compliance with FDA and foreign regulations and standards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If third-party manufacturers fail to perform their obligations,
our competitive position and ability to generate revenue may be adversely affected in a number of ways, including; </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we and any collaborators may not be able to initiate or continue certain preclinical and/or clinical trials of products that are under development;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we and any collaborators may be delayed in submitting applications for regulatory approvals for our drug candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we and any collaborators may not be able to meet commercial demands for any approved products. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Because we rely on a limited number of suppliers for the raw materials used in our product candidates, any delay or interruption in the supply of such
raw materials could lead to delays in the manufacture and supply of our product candidates. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on third parties to
supply certain raw materials necessary to produce our drug candidates, including CUDC-101, for preclinical studies and clinical trials. There are a small number of suppliers for certain raw materials that we use to manufacture our drug candidates.
Such suppliers may not sell these raw materials to us at the times we need them or on commercially reasonable terms, or delivery of these raw materials may be delayed or interrupted. Although we generally do not begin a preclinical study or clinical
trial unless we believe we have a sufficient supply of a drug candidate to complete such study or trial, any significant delay in the supply of raw materials for our drug candidates for an ongoing clinical trial due to the need to replace a
third-party supplier could considerably delay completion of certain preclinical studies and/or clinical trials. Moreover, if we were unable to purchase raw materials after regulatory approval had been obtained for our drug candidates, the commercial
launch of our drug candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our drug candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>We have no sales or marketing experience and, as such, plan to depend significantly on third parties who may not successfully market and sell any products we develop. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no sales, marketing or product distribution experience. If we receive required regulatory approvals, we plan to rely primarily on
sales, marketing and distribution arrangements with third parties, including our collaborative partners. For example, as part of our agreements with Genentech and Debiopharm, we have granted Genentech and Debiopharm the exclusive rights to
distribute certain products resulting from such collaborations, and Genentech is currently distributing Erivedge as part of its U.S. commercialization rights following FDA approval of Erivedge in February 2012. We may have to enter into additional
marketing arrangements in the future and we may not be able to enter into these additional arrangements on terms that are favorable to us, if at all. In addition, we may have limited or no control over the sales, marketing and distribution
activities of these third parties and sales through these third parties could be less profitable to us than direct sales. These third parties could sell competing products and may devote insufficient sales efforts to our products. Our future
revenues will be materially dependent upon the success of the efforts of these third parties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may seek to independently market products that are not already subject to marketing
agreements with other parties. If we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional risks, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to attract and build a significant and skilled marketing staff or sales force; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of establishing a marketing staff or sales force may not be justifiable in light of the revenues generated by any particular product; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our direct sales and marketing efforts may not be successful. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Even if we successfully commercialize any products under development, either alone or in collaboration, we face uncertainty with respect to pricing, third-party reimbursement and healthcare reform, all
of which could adversely affect the commercial success of our product candidates. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to collect significant
revenues from sales of our products, if commercialized successfully, may depend on our ability, and the ability of any current or potential future collaboration partners or customers, to obtain adequate levels of coverage and reimbursement for such
products from third-party payers such as: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">government health administration authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">private health insurers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">health maintenance organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pharmacy benefit management companies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other healthcare-related organizations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Third party payers are increasingly challenging the prices charged for medical products and services. For example, third-party payers may deny coverage or offer inadequate levels of reimbursement if they
determine that a prescribed product has not received appropriate clearances from the FDA, or foreign equivalent, or other government regulators, is not used in accordance with cost-effective treatment methods as determined by the third-party payer,
or is experimental, unnecessary or inappropriate. Prices could also be driven down by health maintenance organizations that control or significantly influence purchases of healthcare services and products. If third-party payers deny coverage or
offer inadequate levels of reimbursement, we or any collaborators may not be able to market our products effectively or we may be required to offer our products at prices lower than anticipated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals and initiatives to
change the health care system in ways that could affect our ability to sell our products profitably. Some of these proposed and implemented reforms could result in reduced reimbursement rates for our potential products, which would adversely affect
our business strategy, operations and financial results. For example, in March 2010, President Obama signed into law a legislative overhaul of the U.S. healthcare system, known as the Patient Protection and Affordable Care Act of 2010, as amended by
the Healthcare and Education Affordability Reconciliation Act of 2010, which we refer to as the PPACA. This legislation may have far reaching consequences for life science companies like us. As a result of this new legislation, substantial changes
could be made to the current system for paying for healthcare in the U.S., including changes made in order to extend medical benefits to those who currently lack insurance coverage. Extending coverage to a large population could substantially change
the structure of the health insurance system and the methodology for reimbursing medical services, drugs and devices. These structural changes could entail modifications to the existing system of private payors and government programs, such as
Medicare and Medicaid, creation of a government-sponsored healthcare insurance source, or some combination of both, as well as other changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement for prescribed drugs,
biopharmaceuticals and medical devices. If reimbursement for our approved product candidates, if any, is substantially less that we expect in the future, or rebate obligations associated with them are substantially increased, our business could be
materially and adversely impacted. Congress has also proposed a number of legislative initiatives, including possible repeal of the PPACA. At this time, it remains unclear whether there will be any changes made to the PPACA, whether to certain
provisions or its entirety. In addition, some details regarding the implementation of the PPACA are yet to be determined, and at this time, the full effect that the PPACA would have on our business remains unclear. In addition, the Medicare
Prescription Drug Improvement and Modernization Act of 2003, or MPDIMA, reformed the way Medicare will cover and reimburse for pharmaceutical products. This legislation could also decrease the coverage and price that we may receive for our approved
product candidates, if any. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost-containment measures that healthcare providers are instituting and the results of
healthcare reforms such as the PPACA and the MPDIMA may prevent us from maintaining prices for our approved product candidates that are sufficient for us to realize profits and may otherwise significantly harm our business, financial condition and
operating </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
results. In addition, to the extent that our approved product candidates, if any, are marketed outside of the U.S., foreign government pricing controls and other regulations may prevent us from
maintaining prices for such products that are sufficient for us to realize profits and may otherwise significantly harm our business, financial condition and operating results. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>RISKS RELATED TO OUR COMMON STOCK </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our stock price may fluctuate significantly and the
market price of our common stock could drop below the price paid. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading price of our common stock has been volatile
and is likely to continue to be volatile in the future. For example, our stock traded within a range of a high price of $5.65 and a low price of $1.97 per share for the period January&nbsp;1, 2011 through August&nbsp;2, 2012. The stock market,
particularly in recent years, has experienced significant volatility with respect to pharmaceutical and biotechnology company stocks. Prices for our stock will be determined in the marketplace and may be influenced by many factors, including:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements regarding new technologies by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">market conditions in the biotechnology and pharmaceutical sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">rumors relating to us or our collaborators or competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation or public concern about the safety of our potential products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or anticipated variations in our quarterly operating results and any subsequent restatement of such results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or anticipated changes to our research and development plans; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">deviations in our operating results from the estimates of securities analysts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entering into new collaboration agreements or termination of existing collaboration agreements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse results or delays in clinical trials being conducted by us or any collaborators; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any intellectual property or other lawsuits involving us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third-party sales of large blocks of our common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of our common stock by our executive officers, directors or significant stockholders; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">equity sales by us of our common stock to fund our operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the loss of any of our key scientific or management personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA or international regulatory actions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general economic and market conditions, including recent adverse changes in the domestic and international financial markets.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we cannot predict the individual effect that these factors may have on the price of our common stock,
these factors, either individually or in the aggregate, could result in significant variations in price during any given period of time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the past, securities class action litigation has often been instituted against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs
and divert our management&#146;s attention and resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The limited liquidity for our common stock could affect an investor&#146;s
ability to sell our shares at a satisfactory price and makes the trading price of our common stock more volatile. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
common stock is relatively illiquid. As of June&nbsp;30, 2012, we had approximately 79.5&nbsp;million shares of common stock outstanding. The average daily trading volume in our common stock during the prior 90 trading days ending on June&nbsp;30,
2012 was approximately 622,000 shares. A more active public market for our common stock may not develop, which would continue to adversely affect the trading price and liquidity of our common stock. Moreover, common stock with a thin trading market
may experience greater price fluctuation than the stock market as a whole. Without a large float, our common stock is less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our common stock may
be more volatile. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Future sales of shares of our common stock, including shares issued upon the exercise of currently
outstanding options and warrants or pursuant to our universal shelf registration statement could result in dilution to our stockholders and negatively affect our stock price. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of our outstanding common stock can be traded without restriction at any time. As such, sales of a substantial number of shares of
our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell such shares, could reduce the market price of our common stock. In addition, we
have a significant number of shares that are subject to outstanding options and warrants and in the future we may issue additional options, warrants or other derivative securities convertible into our common stock. The exercise of any such options,
warrants or other derivative securities, and the subsequent sale of the underlying common stock could cause a further decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and
at a price that we deem appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, as of June&nbsp;30, 2012, we have outstanding warrants to purchase
1,398,318 shares of our common stock that contain antidilution adjustment provisions that will result in a decrease in the price and an increase in the number of shares of common stock issuable upon exercise of such warrants in the event of certain
issuances of common stock by us at prices below $3.55 per share.&nbsp;For example, assuming that we issued and sold shares of common stock in a public offering at $3.00 per share, these warrants would become exercisable for an aggregate of 1,414,945
shares of our common stock, at an exercise price of $3.51 per share, which is equal to an aggregate of additional 16,627 shares as a result of the adjustment. To the extent that we are required to adjust the price and number of shares underlying
these warrants as a result of this antidilution clause, and thereafter such warrants are exercised, additional shares of our common stock will be issued that will be eligible for resale in the public market, which could result in added dilution to
our security holders and could also have an adverse effect on the market price of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have on file
with the SEC a &#147;universal&#148; shelf registration statement which allows us to offer and sell registered common stock, preferred stock and warrants from time to time pursuant to one or more offerings at prices and terms to be determined at the
time of sale. For example, in June 2011 we entered into an agreement with MLV pursuant to which, from time to time, we may offer and sell up to $20 million of the common stock that was registered on this shelf registration statement through MLV
pursuant to one or more &#147;at the market&#148; offerings. In addition, with our prior written approval, MLV may also sell these shares of common stock by any other method permitted by law, including in privately negotiated transactions. Sales of
substantial amounts of shares of our common stock or other securities under this registration statement could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compliance with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 requires our management to devote substantial time to compliance initiatives, and
if our independent registered public accounting firm is required to provide an attestation report on our internal controls but is unable to provide an unqualified attestation report, our stock price could be adversely affected. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we are required to furnish a report by our
management on the effectiveness of our internal control over financial reporting. The internal control report must contain (i)&nbsp;a statement of management&#146;s responsibility for establishing and maintaining adequate internal control over
financial reporting, (ii)&nbsp;a statement identifying the framework used by management to conduct the required evaluation of the effectiveness of our internal control over financial reporting and (iii)&nbsp;management&#146;s assessment of the
effectiveness of our internal control over financial reporting as of the end of our most recent fiscal year, including a statement as to whether or not internal control over financial reporting is effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our
internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, hire additional employees for our finance and audit functions, potentially engage outside
consultants and adopt a detailed work plan to (i)&nbsp;assess and document the adequacy of internal control over financial reporting, (ii)&nbsp;continue steps to improve control processes where appropriate, (iii)&nbsp;validate through testing that
controls are functioning as documented, and (iv)&nbsp;implement a continuous reporting and improvement process for internal control over financial reporting. In addition, in connection with the attestation process by our independent registered
public accounting firm, if required, we may encounter problems or delays in completing the implementation of any requested improvements and receiving a favorable attestation. If we cannot favorably assess the effectiveness of our internal control
over financial reporting, or if our independent registered public accounting firm is unable to provide an unqualified attestation report on our internal controls, investors could lose confidence in our financial information and our stock price could
decline. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If securities or industry analysts do not publish research or reports or publish unfavorable research or
reports about our business, our stock price and trading volume could decline. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading market for our common stock
will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. There are currently nine research analysts that publish research coverage related to Curis. These
securities and industry analysts may not maintain such coverage or we may fail to obtain research coverage by additional securities and industry analysts. If we do not maintain such existing coverage, and additional securities or industry analysts
do not commence coverage of our company, the trading price for our stock may be negatively impacted. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to
cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>We do not intend to pay dividends on our common stock, and any return to investors will come, if at all, only from potential increases in the price of our common stock. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the present time, we intend to use available funds to finance our operations. Accordingly, while payment of dividends rests within the
discretion of our board of directors, no common stock dividends have been declared or paid by us and we have no intention of paying any common stock dividends in the foreseeable future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Insiders have substantial influence over us and could delay or prevent a change in corporate control. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2012, we believe that our directors, executive officers and principal stockholders, together with their affiliates, owned, in the aggregate, approximately 24% of our outstanding common
stock. As a result, these stockholders, if acting together, will be able to exert influence over the management and affairs of our company and over matters requiring stockholder approval, including the election of directors and approval of
significant corporate transactions. This concentration of ownership could&nbsp;harm the market price of our common stock by: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delaying, deferring or preventing a change in control of our company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impeding a merger, consolidation, takeover or other business combination involving our company; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We have anti-takeover defenses that could delay or prevent an acquisition that our stockholders may consider favorable and the market price of our
common stock may be lower as a result. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions of our certificate of incorporation, our bylaws and Delaware law may
have the effect of deterring unsolicited takeovers or delaying or preventing changes in control of our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices.
In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interest. For example, we have divided our board of directors into three classes that serve staggered three-year
terms, we may issue shares of our authorized &#147;blank check&#148; preferred stock and our stockholders are limited in their ability to call special stockholder meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, we are subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation from engaging in a business
combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the
person became an interested stockholder, unless the business combination is approved in a prescribed manner. These provisions could discourage, delay or prevent a change in control transaction. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_11"></A>Item&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Exhibits.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">See exhibit index. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBITS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exhibits
filed herewith or incorporated by reference are set forth on the exhibit index attached hereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx351853_12"></A>SIGNATURE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CURIS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: August&nbsp;9, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;M<SMALL>ICHAEL</SMALL> P.
G<SMALL>RAY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Michael P. Gray</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B></B>Chief Operating Officer and Chief Financial Officer<B></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>(Principal
Financial and Accounting Officer)<B></B></FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;32.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of the Chief Financial Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furnished, not filed, herewith. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d351853dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Daniel R. Passeri, certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Curis, Inc.; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;9, 2012 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;D<SMALL>ANIEL</SMALL> R. P<SMALL>ASSERI</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel R. Passeri</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President
and Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d351853dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 31.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Michael P. Gray, certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Curis, Inc.; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;9, 2012 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;M<SMALL>ICHAEL</SMALL> P. G<SMALL>RAY</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael P. Gray</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief
Operating Officer and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Principal Financial and Accounting Officer)</FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d351853dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 32.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AS ADOPTED PURSUANT TO
906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Quarterly Report on Form 10-Q of Curis, Inc. (the
&#147;Company&#148;) for the quarter ended June&nbsp;30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Daniel R. Passeri, President and Chief Executive Officer of the Company,
hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, that: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;The Report fully complies with the
requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dated: August&nbsp;9, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;D<SMALL>ANIEL</SMALL> R. P<SMALL>ASSERI</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel R. Passeri</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President
and Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d351853dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 32.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AS ADOPTED PURSUANT TO
906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Quarterly Report on Form 10-Q of Curis, Inc. (the
&#147;Company&#148;) for the quarter ended June&nbsp;30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Michael P. Gray, Vice President of Finance and Chief Financial Officer
of the Company, hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, that: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;The Report fully
complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: August&nbsp;9, 2012 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;M<SMALL>ICHAEL</SMALL> P. G<SMALL>RAY</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael P. Gray</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief
Operating Officer and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Principal Financial and Accounting Officer)</FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>cris-20120630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<!--Merged instance document: F:\Production\LIVE RRD GCM Tagger Jobs\CURIS INC_1108205\8_08_2012\Preflight\Notes Only Package\cris-20120630.xml-->
<!--merged on: 8/8/2012 9:41:42 AM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cris="http://curis.com/20120630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="cris-20120630.xsd" />
  <!-- Context Section -->
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level3_Member_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level3_Member_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Zero_Point_Seven_Nine_Us_Dollars_To_One_Point_Three_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Two_Point_Two_Seven_Us_Dollars_To_Three_Point_Seven_Six_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Three_Point_Nine_Eight_Us_Dollars_To_Four_Point_Five_Two_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_One_Point_Four_Three_Us_Dollars_To_Two_Point_One_Five_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Four_Point_Five_Six_Us_Dollars_To_Five_Point_Six_Zero_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Zero_Point_Seven_Nine_Us_Dollars_To_One_Point_Three_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Two_Point_Two_Seven_Us_Dollars_To_Three_Point_Seven_Six_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Three_Point_Nine_Eight_Us_Dollars_To_Four_Point_Five_Two_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_One_Point_Four_Three_Us_Dollars_To_Two_Point_One_Five_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Four_Point_Five_Six_Us_Dollars_To_Five_Point_Six_Zero_Us_Dollars_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">cris:FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Director_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011_Director_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Non_Employee_Directors_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">cris:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_General_And_Administrative_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_General_And_Administrative_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2011_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2011_General_And_Administrative_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011_General_And_Administrative_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_Genentech_Inc_Member_University_Licensors_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:UniversityLicensorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Cash_And_Cash_Equivalents_Member_Fair_Value_Measurements_Recurring_Member_Fair_Value_Inputs_Level2_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31March2012_Genentech_Inc_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_University_Licensors_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:UniversityLicensorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_University_Licensors_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:UniversityLicensorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level3_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level3_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Warrant_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cris:SaleOfStockByOfferingClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member_Investments_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member_Investments_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Corporate_Bonds_Notes_And_Stock_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cris:CorporateBondsNotesAndStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Us_Government_Obligations_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cris:UsGovernmentObligationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Corporate_Bonds_Notes_And_Stock_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cris:CorporateBondsNotesAndStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_Warrant_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Warrant_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2011_Warrant_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2011_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011_Warrant_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_02Aug2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <instant>2012-08-02</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_Out_Of_Period_Adjustment_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">cris:OutOfPeriodAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_F_Hoffmann_La_Roche_Limited_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:FHoffmannLaRocheLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Genentech_Inc_Member_University_Licensors_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:UniversityLicensorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31March2012_Genentech_Inc_Member_University_Licensors_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:UniversityLicensorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012_Genentech_Inc_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_27Jan2010_Warrant_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cris:SaleOfStockByOfferingClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-01-27</instant>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_31Mar2012_Food_And_Drug_Administration_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011_Minimum_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011_Maximum_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_27Jan2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <instant>2010-01-27</instant>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Leukemia_And_Lymphoma_Society_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:LeukemiaAndLymphomaSocietyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_31Mar2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2012_Genentech_Inc_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Genentech_Inc_Member_University_Licensors_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:UniversityLicensorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2012_Genentech_Inc_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">cris:GenentechIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="Jan-01-2012_Jun-30-2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Plan">
    <measure>cris:Plan</measure>
  </unit>
  <unit id="USDPerUnit">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>cris:unit</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="University">
    <measure>cris:University</measure>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!-- Element Section -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:NatureOfOperations contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations--&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Nature of Business&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Curis, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Curis&amp;#8221;) is a drug discovery and development company
   that is committed to leveraging its innovative signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. Curis is building upon its past experiences in targeting signaling pathways, including the
   Hedgehog signaling pathway, in its efforts to develop network-targeted cancer therapies. Curis conducts research and development programs both internally and through strategic collaborations. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company operates in a single reportable segment, which is the research and development of innovative cancer
   therapeutics. The Company expects that any successful products would be used in the health care industry and would be regulated in the United States, or the U.S., by the U.S. Food and Drug Administration, or FDA, and in overseas markets by similar
   regulatory agencies. In January 2012, the Erivedge&amp;#8482; capsule was approved by the FDA and became commercially available in February 2012 (see Note 4). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The Company is subject to risks common to companies in the biotechnology industry including, but not limited to: development by its competitors of new or better technological innovations; dependence on
   key personnel; its ability to protect proprietary technology; its ability to successfully advance discovery, preclinical and clinical stage drug candidates in its internally funded programs; unproven technologies and drug development approaches;
   reliance on corporate collaborators and licensees to successfully research, develop and commercialize products based on its technologies; its ability to comply with FDA regulations and approval requirements; its ability to execute on its business
   strategies; and its ability to obtain adequate financing to fund its operations. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company&amp;#8217;s future
   operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its research and development pipeline. The results of the
   Company&amp;#8217;s operations will vary significantly from year to year and quarter to quarter and depend on, among other factors, the timing of its entry into new collaborations, if any, the timing of the receipt of payments from new or existing
   collaborators and the cost and outcome of any preclinical development or clinical trials then being conducted. The Company anticipates that existing capital resources at June&amp;#160;30, 2012 should enable the Company to maintain its current and
   planned operations into the first half of 2014. The Company&amp;#8217;s ability to continue funding its planned operations into and beyond the first half of 2014 is dependent upon, among other things, the success of its collaborations with Genentech
   Inc., or Genentech, and Debiopharm S.A., or Debiopharm, and receipt of additional cash payments under these collaborations, its ability to control expenses and its ability to raise additional funds through equity or debt financings, new
   collaborations or other sources of financing. The Company may not be able to successfully enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly
   uncertain. As a result, the Company cannot assure that it will attain any further revenue under any collaborations or licensing arrangements. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay
   spending on its research and/or development programs. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:NatureOfOperations>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The accompanying condensed consolidated financial statements of the Company have been prepared in
   accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by generally accepted accounting principles, or GAAP, in the U.S. for complete
   financial statements and should be read in conjunction with the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2011, as filed with the Securities and Exchange Commission on February&amp;#160;29, 2012. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In the opinion of the Company, the unaudited financial statements contain all adjustments (all of which were considered
   normal and recurring) necessary for a fair statement of the Company&amp;#8217;s financial position at June&amp;#160;30, 2012 and the results of operations and cash flows for the six-month periods ended June&amp;#160;30, 2012 and 2011. The preparation of the
   Company&amp;#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date.
   Such estimates include revenue recognition, the collectibility of receivables, the carrying value of property and equipment and intangible assets, management assumptions used in its calculations of stock-based compensation expense, and the value of
   certain investments and liabilities, including the value of its warrant liability. Actual results may differ from such estimates. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;These
   interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.&lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:SignificantAccountingPoliciesTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company&amp;#8217;s business strategy includes entering into collaborative license and development
   agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&amp;#8217;s product candidates. The terms of these agreements may provide for the Company&amp;#8217;s licensees and collaborators to agree to
   make non-refundable license fee payments, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales if any products are successfully
   commercialized. For a complete discussion of the Company&amp;#8217;s revenue recognition policy, see Note 2(c) included in its annual report on Form 10-K, as previously filed with the Securities and Exchange Commission on February&amp;#160;29, 2012.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:CollaborativeArrangementDisclosureTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Collaboration Agreements&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(a)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Genentech June 2003 Collaboration &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In January 2012, the FDA approved Genentech&amp;#8217;s New Drug Application for the Erivedge capsule for the treatment of adults with basal cell carcinoma that has spread to other parts of the body or that
   has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is being developed and commercialized by F. Hoffmann-La Roche Ltd, or Roche, and Genentech, a member of the Roche Group,
   under a collaboration agreement between the Company and Genentech. As a result of the FDA's approval of Erivedge in this indication, the Company earned a $10,000,000 milestone payment from Genentech and is also entitled to receive royalties on
   future sales of the product. In May 2012, Roche announced that it has submitted an application for marketing registration for Erivedge to Australia&amp;#8217;s Therapeutic Goods Administration, or TGA, and as a result, the Company earned an additional
   $4,000,000 milestone payment. The Company is eligible to receive up to an aggregate of $115,000,000 in contingent cash payments under the collaboration for the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming
   the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. As of June&amp;#160;30, 2012, the Company has received $46,000,000 in the aggregate since the inception of the agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company recognized $4,000,000 and $14,000,000 in milestone payments as license revenue in its Condensed Consolidated
   Statement of Operations for the three and six months ended June&amp;#160;30, 2012, respectively, as the Company does not have any further substantive performance obligations under the collaboration. The Company did not recognize license revenue under
   this collaboration during the three and six months ended June&amp;#160;20, 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection with the receipt of
   milestone payments from Genentech, the Company recorded research and development expenses of $650,000 and $2,114,000 during the three and six months ended June&amp;#160;30, 2012, respectively, which represents the Company&amp;#8217;s obligations to
   university licensors. Research and development expenses of $650,000 recorded during the three months ended June&amp;#160;30, 2012 include $550,000 for obligations the Company incurred in connection with Roche&amp;#8217;s application to the TGA for marketing
   registration for Erivedge in Australia and the related $4,000,000 milestone that the Company received. The remaining $100,000 in research and development expense recorded during the three months ended June&amp;#160;30, 2012 represents an immaterial
   out-of-period expense associated with Roche's 2009 investigational new drug filing in Australia. The Company also recorded research and development expenses of $500,000 during the six months ended June&amp;#160;30, 2012, related to the Company&amp;#8217;s
   receipt of the $10,000,000 milestone payment associated with the FDA&amp;#8217;s U.S. approval of Erivedge in January 2012. The remaining expense of $964,000 recognized during the six months ended June&amp;#160;30, 2012 represents the fair value of a
   one-time issuance of an aggregate of 200,000 shares of the Company&amp;#8217;s common stock in March 2012 to two university licensors in connection with the FDA-approval of Erivedge. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company also recognized $252,750 and $523,372 in royalty revenue from Genentech&amp;#8217;s net sales of Erivedge during
   the three and six months ended June&amp;#160;30, 2012, respectively. The Company recorded cost of royalty revenues within the costs and expenses section of its Condensed Consolidated Statements of Operations of $12,637 and $126,168 during these same
   periods. Cost of royalty revenues include $12,637 and $26,168 for the three and six months ended June&amp;#160;30, 2012, respectively, which represents 5% of the royalties earned by the Company with respect to Erivedge that the Company is obligated to
   pay to two university licensors. Cost of royalty revenues for the six months ended June&amp;#160;30, 2012 also includes a one-time cash payment of $100,000 paid to a university licensor upon the first commercial sale of Erivedge. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(b)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Leukemia&amp;#160;&amp;#038; Lymphoma Society Agreement &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In November 2011, the Company entered into an agreement with The Leukemia&amp;#160;&amp;#038; Lymphoma Society, or LLS, under which LLS will support the Company&amp;#8217;s ongoing development of CUDC-907 for patients
   with B-cell lymphoma and multiple myeloma. Under the agreement, LLS will fund approximately 50% of the direct costs of the development of CUDC-907, up to $4,000,000. Under certain conditions associated with the successful partnering and/or
   commercialization of CUDC-907 in these indications, the Company may be obligated to make payments to LLS up to a maximum of $10,000,000. As of June&amp;#160;30, 2012, the Company has not received any payments or recorded any revenue under this agreement
   to date and expects that the first milestone could be achieved in the second half of 2012 as CUDC-907 nears the filing of an investigational new drug application, or IND. Additional milestones would be earned as the Company progresses CUDC-907 into
   a phase Ia clinical trial. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:FairValueMeasurementInputsDisclosureTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Fair Value Measurements&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company discloses fair value measurements based on a framework outlined by GAAP which requires
   expanded disclosures regarding fair value measurements. GAAP also defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
   or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&amp;#160;independent, (ii)&amp;#160;knowledgeable, (iii)&amp;#160;able to transact, and
   (iv)&amp;#160;willing to transact. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Financial Accounting Standards Board, or FASB, Codification Topic 820,
   &lt;i&gt;Fair Value Measurements and Disclosures, &lt;/i&gt;requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information
   generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The
   cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value hierarchy which requires an
   entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="94%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td width="91%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Level&amp;#160;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="2"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
   observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="2"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company's warrant liability was
   valued using a probability-weighted Black-Scholes model, discussed further in Note 6, and is therefore classified as Level&amp;#160;3.&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In
   accordance with the fair value hierarchy, the following table shows the fair value as of June 30, 2012 and December&amp;#160;31, 2011 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the
   valuation techniques the Company used to determine their fair market value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at June&amp;#160;30, 2012 and December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="49%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;br /&gt;Active Markets&lt;br /&gt;(Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;Observable&lt;br /&gt;Inputs&amp;#160;(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unobservable&lt;br /&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;As of June&amp;#160;30, 2012:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,832,066&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,832,066&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Municipal bonds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,145,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,145,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Investments&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;16,423,449&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;16,192,698&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,616,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;24,255,515&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,337,698&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;42,593,213&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;As of December&amp;#160;31, 2011:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,366,747&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,366,747&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Municipal bonds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,375,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,375,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Investments&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;US government obligations&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,704&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,704&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:5.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,365,841&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,423,300&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,789,141&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15,107,588&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15,232,004&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;30,339,592&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following table rolls forward the fair value of the Company&amp;#8217;s warrant liability, the fair
   value of which is determined by Level&amp;#160;3 inputs for the six months ended June&amp;#160;30, 2011 and 2012: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="85%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,604,742&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Change in fair value &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,821,850&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at June&amp;#160;30, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,426,592&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:5.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants exercised &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(543,646&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Change in fair value &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;487,400&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at June&amp;#160;30, 2012&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <invest:InvestmentTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - invest:InvestmentTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Investments&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The amortized cost, unrealized gains and fair value of marketable securities available-for-sale as of
   June&amp;#160;30, 2012, with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="63%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amortized&lt;br /&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;br /&gt;Gain&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate bonds, notes and stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,608,962&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,185&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,616,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,608,962&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,185&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,616,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The amortized cost, unrealized gains and fair value of marketable securities
   available-for-sale as of December&amp;#160;31, 2011, with maturity dates ranging between one and twelve months and with a weighted average maturity of 3.7 months are as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="63%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amortized&lt;br /&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;br /&gt;Gain&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,641&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;63&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,704&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate bonds, notes and stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,787,778&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,363&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,789,141&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;22,596,419&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,426&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;22,597,845&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</invest:InvestmentTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <cris:CommonStockAndWarrantLiabilityTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - cris:CommonStockAndWarrantLiabilityTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Common Stock and Warrant Liability&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On January&amp;#160;27, 2010, the Company completed a registered direct offering of 6,449,288 units with
   each unit consisting of (i)&amp;#160;one share of the Company&amp;#8217;s common stock and (ii)&amp;#160;one warrant to purchase 0.25&amp;#160;of one share of common stock at a purchase price of $2.52 per unit. The Company received net proceeds from the sale of the
   units, after deducting offering expenses, of approximately $14,942,000. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection with this offering, the
   Company issued warrants to purchase an aggregate of 1,612,322 shares of common stock. As of June&amp;#160;30, 2012, warrants to purchase 214,004 shares of the Company&amp;#8217;s common stock have been exercised. The warrants have an initial exercise price
   of $3.55 per share and a five-year term. The warrants contain antidilution adjustment provisions that will result in a decrease in the price and an increase in the number of shares of common stock issuable upon exercise of such warrants in the event
   of certain issuances of common stock by the Company at prices below $3.55 per share. The warrants also included a cash-settlement option in the event of a change of control that expired on January&amp;#160;27, 2012. Due to the terms, the warrants are
   classified as a liability and, therefore, the fair value of the warrants was recorded as a liability in the Consolidated Balance Sheets as of June&amp;#160;30, 2012 and December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has estimated the fair value of the warrants using a Black-Scholes option pricing model under various
   probability-weighted outcomes which take into consideration the protective, but limited, cash-settlement feature of the warrants, with updated assumptions at each reporting date. The Company estimated that the fair value of the warrants at
   June&amp;#160;30, 2012 was $4,304,922, using the following assumptions: expected volatility of 75.4%, risk free interest rate of 0.4%, expected life of 2.6 years, and no dividends. The Company estimated that the fair value of the warrants at
   June&amp;#160;30, 2011 was $3,426,592 using this same model with the following assumptions assigned to the varying outcomes: expected volatility of 80%, risk free interest rates ranging from 0.8% to 1.1%, expected lives of three to four years, and no
   dividends. The warrants are revalued at each reporting period and the resulting change in fair value of the warrant liability is recognized in the Consolidated Statement of Operations. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company recorded other expense of approximately $495,341 and $487,400 for the three and six months ended June&amp;#160;30,
   2012, respectively, due to changes in fair value of the warrant liability. During the six months ended June&amp;#160;30, 2012, as a result of the exercise of warrants to purchase 212,500 shares of the Company&amp;#8217;s common stock, the warrant liability
   decreased $543,646 with an offsetting increase to additional paid-in-capital. The Company recorded other expense of approximately $320,440 and $1,821,850 for the three and six months ended June&amp;#160;30, 2011, respectively, as a result of a change in
   the fair value of the warrant liability that was primarily due to an increase in the Company&amp;#8217;s stock price during the prior year periods. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</cris:CommonStockAndWarrantLiabilityTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 8 - us-gaap:OtherLiabilitiesDisclosureTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Accrued Liabilities&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued liabilities consist of the following: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="74%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;787,483&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,065,570&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Professional fees&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;159,625&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;190,500&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;115,518&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;166,037&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,062,626&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,422,107&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:OtherLiabilitiesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 9 - us-gaap:RelatedPartyTransactionsDisclosureTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Related Party Transaction&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:6%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;License Agreement &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Effective on February&amp;#160;24, 2012, the Company entered into a Drug Development Partnership and License Agreement for CU-906 and CU-908 (the &amp;#8220;license agreement&amp;#8221;) with Guangzhou BeBetter
   Medicine Technology Company Ltd., a company organized under the laws of the People&amp;#8217;s Republic of China (&amp;#8220;GBMT&amp;#8221;). Dr.&amp;#160;Changgeng Qian, the Company&amp;#8217;s former Senior Vice President, Discovery and Preclinical Development, is the
   founder, owner, and legal representative of GBMT. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Pursuant to the license agreement, the Company has granted
   to GBMT an exclusive royalty-free license, with the right to grant sublicenses subject to certain conditions, to develop, manufacture, market and sell any product containing CU-906 or CU-908 in China, Macau, Taiwan and Hong Kong, or the GBMT
   territory. The Company does not intend to internally develop these compounds. In addition, the Company has granted to GBMT a non-exclusive, royalty-free manufacturing license, with the right to grant sublicenses subject to certain conditions, to
   manufacture CU-906 or CU-908 or any product containing CU-906 or CU-908 outside of the GBMT Territory solely to import the compounds or products into the GBMT territory. Pursuant to the terms of the license agreement, the Company has retained
   rights, including the right to grant sublicenses, to develop, manufacture, market and sell any product containing CU-906 or CU-908 worldwide excluding the GBMT Territory. The Company also has certain specified rights to any GBMT technology developed
   under the license agreement as well as certain specified rights to GBMT&amp;#8217;s interest in joint technology developed under the license agreement. Furthermore, the Company has a right of first negotiation to obtain a license to CU-906 or CU-908 for
   the GBMT Territory from GBMT. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has agreed to transfer to GBMT know how, information and materials
   necessary for GBMT to continue the development of products in accordance with the development plan outlined in the license agreement and has agreed not to assert certain Company patents against GMBT, its affiliates or sublicensee so that such party
   may manufacture, market and sell any product containing CU-906 or CU-908 in the GBMT territory. Furthermore, the Company will provide GBMT with up to $400,000 in financial support for specified CU-908 pre-clinical activities related to enabling the
   filing by the Company of an IND with the FDA, provided that GMBT completes such CU-908 IND-enabling activities in accordance with specified criteria and delivers a U.S. IND package for CU-908 to the Company within prescribed timeframes as specified
   in the license agreement. All costs incurred under this agreement will be expensed as incurred. As of June&amp;#160;30, 2012, the Company had not incurred any expenses under this agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;GBMT will assume all future development responsibility and incur all future costs related to the development, registration
   and commercialization of products in the GMBT Territory under the license agreement. Pursuant to the terms of the license agreement, GBMT has agreed to undertake reasonable commercial efforts, and to use qualified third party service providers
   approved by the Company, to implement the development plan in the timeframes described in the license agreement in order to develop, register and commercialize the products in the GBMT Territory and will be solely responsible for all the costs
   relating thereto. The Company and GBMT must agree to any changes to the development plan and such revised development plan is subject to review and approval by the joint steering committee. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Unless terminated earlier in accordance with the terms of the license agreement, the license agreement will expire on the
   later of (i)&amp;#160;the expiration of the last-to-expire valid claim of the Company patents and the Company non-assert patents relating to the products, and (ii)&amp;#160;such time as none of GBMT, its affiliates and sublicensees is commercializing any
   compound or product in the GBMT Territory. Pursuant to the license agreement, either party can terminate the license agreement upon notice under prescribed circumstances, and the license agreement specifies the consequences to each party for such
   early termination. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The
   license agreement also sets forth customary terms regarding each party&amp;#8217;s intellectual property ownership rights, representations and warranties, indemnification obligations, confidentiality rights and obligations, and patent prosecution,
   maintenance, enforcement and defense rights and obligations. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Severance Agreement &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On February&amp;#160;16, 2012, the Company and Dr.&amp;#160;Qian entered into a severance agreement that became binding and
   effective on February&amp;#160;24, 2012. The severance agreement provides that Dr.&amp;#160;Qian, in exchange for his execution and nonrevocation of a general release of claims in favor of the Company as set forth in the severance agreement, will be
   provided certain severance benefits, including a lump-sum payment equivalent to one-half times his base annual salary rate in effect as of his termination date to be paid in August 2012. As a result, the Company had accrued $137,500 related to
   Dr.&amp;#160;Qian&amp;#8217;s severance in the accrued liabilities section of the Company&amp;#8217;s Condensed Consolidated Balance Sheets as of June&amp;#160;30, 2012. The severance agreement also provides for the engagement of Dr.&amp;#160;Qian as a consultant
   pursuant to the terms of a consulting agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 10 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Accounting for Stock-Based Compensation&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As of June&amp;#160;30, 2012, the Company had two shareholder-approved, share-based compensation plans: the
   2010 Stock Incentive Plan and the 2010 Employee Stock Purchase Plan. These plans were adopted by the board of directors in April 2010 and approved by shareholders in June 2010. In the first quarter of 2010, the Company&amp;#8217;s 2000 Stock Incentive
   Plan expired in accordance with its terms and its 2000 Director Stock Option Plan had no available shares remaining under the plan. No additional awards will be made under these plans, although all outstanding awards under these plans will remain in
   effect until they are exercised or they expire in accordance with their terms. For a complete discussion of the Company&amp;#8217;s share-based compensation plans, see Note 5 included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended
   December&amp;#160;31, 2011, as previously filed with the Securities and Exchange Commission on February&amp;#160;29, 2012. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   During the six months ended June&amp;#160;30, 2012, the Company&amp;#8217;s board of directors granted options to purchase 1,182,000 shares of the Company&amp;#8217;s common stock to officers and employees of the
   Company under the 2010 Stock Incentive Plan. These options vest over a four-year period and bear exercise prices that are equal to the closing market price of the Company&amp;#8217;s common stock on the NASDAQ Global Market on the grant date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the six months ended June&amp;#160;30, 2012, the Company&amp;#8217;s board of directors also granted options to its
   non-employee directors to purchase 470,000 shares of common stock under the 2010 Stock Incentive Plan. These options will vest monthly over a one-year period and bear exercise prices that are equal to the closing market price of the Company&amp;#8217;s
   common stock on the NASDAQ Global Market on the grant date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Employee and Director Grants&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In determining the fair value of stock options, the Company uses the Black-Scholes option pricing model. The Company
   calculated the Black-Scholes value of employee and director options awarded during the six months ended June&amp;#160;30, 2012 and 2011 based on the assumptions noted in the following table: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="82%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="3" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Six Months Ended&lt;br /&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expected life (years) &amp;#8211; employees&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expected life (years) &amp;#8211; directors&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.0-1.2%&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.4-2.5%&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;74-76%&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;73-74%&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Dividends&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The expected volatility is based on the annualized daily historical volatility of the Company&amp;#8217;s
   stock price through the grant date for a time period consistent with the expected term of a grant. Management believes that the historical volatility of the Company&amp;#8217;s stock price best represents the volatility of the stock price. The risk-free
   rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company does not anticipate declaring dividends in the foreseeable future. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The stock price volatility and expected terms utilized in the calculation involve management&amp;#8217;s best estimates at that time, both of which impact the fair value of the option calculated under the
   Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected
   to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from
   those estimated by management, additional adjustments to compensation expense may be required in future periods. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The aggregate intrinsic value of employee options outstanding at June&amp;#160;30, 2012 was $30,021,000, of which $24,464,000
   related to exercisable options. The weighted average grant-date fair values of stock options granted during the six months ended June&amp;#160;30, 2012 and 2011 were $2.99 and $1.43, respectively. As of June&amp;#160;30, 2012, there was approximately
   $5,765,000, net of the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding under the Company&amp;#8217;s 2000 and 2010 Stock Incentive Plans that is expected to be recognized as
   expense over a weighted average period of 2.5 years. The intrinsic values of employee stock options exercised during the six months ended June&amp;#160;30, 2012 and 2011 were $5,779,000 and $826,000, respectively. The total fair values of vested stock
   options for the six months ended June&amp;#160;30, 2012 and 2011 were $1,228,000 and $1,050,000, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The
   Company recorded $833,497 and $1,649,725 in compensation expense for the three and six months ended June&amp;#160;30, 2012, respectively, and $348,742 and $1,011,738 in compensation expense for the three and six months ended June&amp;#160;30, 2011,
   respectively, related to employee and director stock option grants. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Non-Employee Grants&lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has periodically granted stock options and unrestricted stock awards to consultants for services, pursuant to
   the Company&amp;#8217;s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled. The Company recognized
   expense related to non-employee stock options of $174,245 and $380,693, for the three and six months ended June&amp;#160;30, 2012, respectively, and expense of $13,104 and $27,820 for the three and six months ended June&amp;#160;30, 2011, respectively.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Total Stock-Based Compensation Expense &lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;For the three and six months ended June&amp;#160;30, 2012 and 2011, the Company recorded employee and non-employee stock-based
   compensation expense to the following line items in its Costs and Expenses section of the Consolidated Statements of Operations, including expense related to its 2010 Employee Stock Purchase Plan: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="58%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For&amp;#160;the&amp;#160;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the Six Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;365,855&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;178,808&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;765,010&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;343,861&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;641,887&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;183,038&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,265,408&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;695,697&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,007,742&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;361,846&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,030,418&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,039,558&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The table below summarizes options outstanding and exercisable at June&amp;#160;30, 2012: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="56%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;
   &lt;p style="border-bottom:1px solid #000000;width:72pt"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Exercise Price Range&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Number of&lt;br /&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life&amp;#160;(in&amp;#160;years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&amp;#160;Price&lt;br /&gt;per&amp;#160;Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Number of&lt;br /&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&amp;#160;Price&lt;br /&gt;per&amp;#160;Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$ 0.79 - $ 1.39&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,735,809&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.97&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.18&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,567,519&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.19&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 1.43 - &amp;#160;&amp;#160; 2.15&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,628,568&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.63&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.73&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,063,310&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 2.27 - &amp;#160;&amp;#160; 3.76&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,432,733&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.03&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.75&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,555,446&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.52&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 3.98 - &amp;#160;&amp;#160; 4.52&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,204,614&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7.85&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.39&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;758,445&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.13&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 4.56 - &amp;#160;&amp;#160; 5.60&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;720,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.88&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.74&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;712,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.74&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,721,724&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.53&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.57&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,656,720&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.20&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:EarningsPerShareTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 11 - us-gaap:EarningsPerShareTextBlock--&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;u&gt;Loss Per Common Share &lt;/u&gt; &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company applies ASC Topic 260&amp;#8212;&lt;i&gt;Earnings&amp;#160;per Share&lt;/i&gt;, which establishes standards for
   computing and presenting earnings per share. Basic and diluted loss per common share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common
   share for the three and six months ended June&amp;#160;30, 2012 and 2011, as the effect of the potential common stock equivalents is antidilutive due to the Company&amp;#8217;s net loss position for these periods. Antidilutive securities consist of stock
   options and warrants outstanding as of the respective reporting period as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="74%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the&lt;br /&gt;Three and&lt;br /&gt;Six Months&lt;br /&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;br /&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the&lt;br /&gt;Three and&lt;br /&gt;Six Months&lt;br /&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;br /&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock options outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,721,724&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,828,227&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,398,318&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,610,818&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total antidilutive securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,120,042&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,439,045&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note Table: cris-20120630_note5_table1-->
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note5_table1 - us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="49%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;br /&gt;Active Markets&lt;br /&gt;(Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;Observable&lt;br /&gt;Inputs&amp;#160;(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unobservable&lt;br /&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;As of June&amp;#160;30, 2012:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,832,066&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,832,066&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Municipal bonds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,145,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,145,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Investments&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;16,423,449&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;16,192,698&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,616,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;24,255,515&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,337,698&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;42,593,213&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;As of December&amp;#160;31, 2011:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,366,747&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,366,747&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Municipal bonds&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,375,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,375,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Investments&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;US government obligations&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,704&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,704&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:5.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,365,841&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,423,300&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,789,141&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15,107,588&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15,232,004&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;30,339,592&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note5_table1-->
  <!-- Begin Block Tagged Note Table: cris-20120630_note5_table2-->
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note5_table2 - us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="85%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,604,742&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Change in fair value &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,821,850&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at June&amp;#160;30, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,426,592&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,361,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:5.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants exercised &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(543,646&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Change in fair value &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;487,400&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at June&amp;#160;30, 2012&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,304,922&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note5_table2-->
  <!-- Begin Block Tagged Note Table: cris-20120630_note6_table1-->
  <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note6_table1 - us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="63%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amortized&lt;br /&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;br /&gt;Gain&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate bonds, notes and stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,608,962&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,185&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,616,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,608,962&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,185&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,616,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The amortized cost, unrealized gains and fair value of marketable securities
   available-for-sale as of December&amp;#160;31, 2011, with maturity dates ranging between one and twelve months and with a weighted average maturity of 3.7 months are as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="63%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amortized&lt;br /&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;br /&gt;Gain&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,641&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;63&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,808,704&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate bonds, notes and stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,787,778&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,363&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,789,141&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;22,596,419&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,426&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;22,597,845&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note6_table1-->
  <!-- Begin Block Tagged Note Table: cris-20120630_note8_table1-->
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note8_table1 - us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="74%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;787,483&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,065,570&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Professional fees&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;159,625&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;190,500&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;115,518&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;166,037&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,062,626&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,422,107&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note8_table1-->
  <!-- Begin Block Tagged Note Table: cris-20120630_note10_table1-->
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note10_table1 - us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="82%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="3" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Six Months Ended&lt;br /&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expected life (years) &amp;#8211; employees&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expected life (years) &amp;#8211; directors&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.0-1.2%&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.4-2.5%&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;74-76%&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;73-74%&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Dividends&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note10_table1-->
  <!-- Begin Block Tagged Note Table: cris-20120630_note10_table2-->
  <cris:ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note10_table2 - cris:ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="58%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For&amp;#160;the&amp;#160;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the Six Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;365,855&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;178,808&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;765,010&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;343,861&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;641,887&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;183,038&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,265,408&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;695,697&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,007,742&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;361,846&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,030,418&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,039,558&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</cris:ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note10_table2-->
  <!-- Begin Block Tagged Note Table: cris-20120630_note10_table3-->
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note10_table3 - us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="56%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;
   &lt;p style="border-bottom:1px solid #000000;width:72pt"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Exercise Price Range&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Number of&lt;br /&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life&amp;#160;(in&amp;#160;years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&amp;#160;Price&lt;br /&gt;per&amp;#160;Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Number of&lt;br /&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&amp;#160;Price&lt;br /&gt;per&amp;#160;Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$ 0.79 - $ 1.39&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,735,809&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.97&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.18&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,567,519&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.19&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 1.43 - &amp;#160;&amp;#160; 2.15&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,628,568&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.63&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.73&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,063,310&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 2.27 - &amp;#160;&amp;#160; 3.76&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,432,733&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.03&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.75&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,555,446&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.52&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 3.98 - &amp;#160;&amp;#160; 4.52&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,204,614&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7.85&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.39&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;758,445&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.13&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160; 4.56 - &amp;#160;&amp;#160; 5.60&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;720,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.88&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.74&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;712,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.74&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,721,724&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.53&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.57&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,656,720&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.20&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note10_table3-->
  <!-- Begin Block Tagged Note Table: cris-20120630_note11_table1-->
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Jan-01-2012_Jun-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: cris-20120630_note11_table1 - us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="74%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the&lt;br /&gt;Three and&lt;br /&gt;Six Months&lt;br /&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;br /&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the&lt;br /&gt;Three and&lt;br /&gt;Six Months&lt;br /&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;June&amp;#160;30,&lt;br /&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock options outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,721,724&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,828,227&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,398,318&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,610,818&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total antidilutive securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,120,042&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,439,045&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <!-- End Block Tagged Note Table: cris-20120630_note11_table1-->
  <cris:AdditionalMilestoneRecognizedFromPartner contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">4000000</cris:AdditionalMilestoneRecognizedFromPartner>
  <cris:CashPaymentToUniversityLicensor contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member_University_Licensors_Member" unitRef="USD" decimals="0">100000</cris:CashPaymentToUniversityLicensor>
  <cris:ChangeInFairValueUponWarrantExercise contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-543646</cris:ChangeInFairValueUponWarrantExercise>
  <cris:CollaborationAgreementContingentConsiderationPotentialCashPayment contextRef="BalanceAsOf_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">115000000</cris:CollaborationAgreementContingentConsiderationPotentialCashPayment>
  <cris:CollaborationAgreementContingentConsiderationReceivedFromPartner contextRef="BalanceAsOf_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">46000000</cris:CollaborationAgreementContingentConsiderationReceivedFromPartner>
  <cris:CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber contextRef="ThreeMonthsEnded_31Mar2012" unitRef="University" decimals="INF">2</cris:CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber>
  <cris:ContingentObligations contextRef="SixMonthsEnded_30Jun2012_Leukemia_And_Lymphoma_Society_Member" unitRef="USD" decimals="0">10000000</cris:ContingentObligations>
  <cris:DirectOfferingPurchasePrice contextRef="BalanceAsOf_27Jan2010" unitRef="USDEPS" decimals="2">2.52</cris:DirectOfferingPurchasePrice>
  <cris:EstimatedRiskFreeInterestRate contextRef="SixMonthsEnded_30Jun2011_Maximum_Member" unitRef="Pure" decimals="INF">0.011</cris:EstimatedRiskFreeInterestRate>
  <cris:EstimatedRiskFreeInterestRate contextRef="SixMonthsEnded_30Jun2011_Minimum_Member" unitRef="Pure" decimals="INF">0.008</cris:EstimatedRiskFreeInterestRate>
  <cris:EstimatedRiskFreeInterestRate contextRef="Jan-01-2012_Jun-30-2012" unitRef="Pure" decimals="INF">0.004</cris:EstimatedRiskFreeInterestRate>
  <cris:ExpectedLivesOfWarrantsYears contextRef="SixMonthsEnded_30Jun2011_Maximum_Member">P4Y</cris:ExpectedLivesOfWarrantsYears>
  <cris:ExpectedLivesOfWarrantsYears contextRef="SixMonthsEnded_30Jun2011_Minimum_Member">P3Y</cris:ExpectedLivesOfWarrantsYears>
  <cris:ExpectedLivesOfWarrantsYears contextRef="Jan-01-2012_Jun-30-2012">P2Y7M6D</cris:ExpectedLivesOfWarrantsYears>
  <cris:IssuanceOfCommonStockToLicensees contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">964000</cris:IssuanceOfCommonStockToLicensees>
  <cris:MaximumFinancialSupportToRelatedParty contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="INF">400000</cris:MaximumFinancialSupportToRelatedParty>
  <cris:MilestonesRecognizedFromPartner contextRef="ThreeMonthsEnded_31Mar2012_Food_And_Drug_Administration_Member" unitRef="USD" decimals="0">10000000</cris:MilestonesRecognizedFromPartner>
  <cris:MilestonesRecognizedFromPartner contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">10000000</cris:MilestonesRecognizedFromPartner>
  <cris:MoneyMarketFundsFairValue contextRef="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member" unitRef="USD" decimals="0">5366747</cris:MoneyMarketFundsFairValue>
  <cris:MoneyMarketFundsFairValue contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member" unitRef="USD" decimals="0">5366747</cris:MoneyMarketFundsFairValue>
  <cris:MoneyMarketFundsFairValue contextRef="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member" unitRef="USD" decimals="0">7832066</cris:MoneyMarketFundsFairValue>
  <cris:MoneyMarketFundsFairValue contextRef="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member" unitRef="USD" decimals="0">7832066</cris:MoneyMarketFundsFairValue>
  <cris:PercentageOfContributionToFund contextRef="SixMonthsEnded_30Jun2012_Leukemia_And_Lymphoma_Society_Member" unitRef="Pure" decimals="2">0.50</cris:PercentageOfContributionToFund>
  <cris:PercentageOfSublicenseFeesPaidOnRoyaltiesEarned contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="Pure" decimals="2">0.05</cris:PercentageOfSublicenseFeesPaidOnRoyaltiesEarned>
  <cris:ProceedsFromContributionOfFund contextRef="SixMonthsEnded_30Jun2012_Leukemia_And_Lymphoma_Society_Member" unitRef="USD" decimals="0">4000000</cris:ProceedsFromContributionOfFund>
  <cris:ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">14942000</cris:ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts>
  <cris:RangeOfExpectedVolatilities contextRef="SixMonthsEnded_30Jun2011" unitRef="Pure" decimals="2">0.80</cris:RangeOfExpectedVolatilities>
  <cris:RangeOfExpectedVolatilities contextRef="Jan-01-2012_Jun-30-2012" unitRef="Pure" decimals="3">0.754</cris:RangeOfExpectedVolatilities>
  <cris:RegisteredDirectOfferingNumberOfCommonStockPerUnit contextRef="BalanceAsOf_27Jan2010" unitRef="USDPerUnit" decimals="INF">1</cris:RegisteredDirectOfferingNumberOfCommonStockPerUnit>
  <cris:RegisteredDirectOfferingNumberOfWarrantPerUnit contextRef="BalanceAsOf_27Jan2010" unitRef="USDPerUnit" decimals="INF">1</cris:RegisteredDirectOfferingNumberOfWarrantPerUnit>
  <cris:RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant contextRef="BalanceAsOf_27Jan2010_Warrant_Member" unitRef="Pure" decimals="2">0.25</cris:RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant>
  <cris:RegisteredDirectOfferingUnits contextRef="BalanceAsOf_27Jan2010" unitRef="Shares" decimals="INF">6449288</cris:RegisteredDirectOfferingUnits>
  <cris:ResearchAndDevelopmentRevenue contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">226405</cris:ResearchAndDevelopmentRevenue>
  <cris:ResearchAndDevelopmentRevenue contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">92867</cris:ResearchAndDevelopmentRevenue>
  <cris:ResearchAndDevelopmentRevenue contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">184454</cris:ResearchAndDevelopmentRevenue>
  <cris:ResearchAndDevelopmentRevenue contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">98824</cris:ResearchAndDevelopmentRevenue>
  <cris:RevenueRecognizedMilestonePaymentsLicenseRevenue contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">14000000</cris:RevenueRecognizedMilestonePaymentsLicenseRevenue>
  <cris:RevenueRecognizedMilestonePaymentsLicenseRevenue contextRef="ThreeMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">4000000</cris:RevenueRecognizedMilestonePaymentsLicenseRevenue>
  <cris:SeveranceAgreementToRelatedParty contextRef="Jan-01-2012_Jun-30-2012">The severance agreement provides that Dr.&amp;#160;Qian, in exchange for his execution and nonrevocation of a general release of claims in favor of the Company as set forth in the severance agreement, will be provided certain severance benefits, including a lump-sum payment equivalent to one-half times his base annual salary rate in effect as of his termination date to be paid out in August 2012.</cris:SeveranceAgreementToRelatedParty>
  <cris:ShareBasedCompensationPlans contextRef="Jan-01-2012_Jun-30-2012" unitRef="Plan" decimals="INF">2</cris:ShareBasedCompensationPlans>
  <cris:SharesIssuedToSublicensees contextRef="BalanceAsOf_31March2012_Genentech_Inc_Member_University_Licensors_Member" unitRef="Shares" decimals="INF">200000</cris:SharesIssuedToSublicensees>
  <cris:SharesIssuedToSublicensees contextRef="BalanceAsOf_30Jun2012_Genentech_Inc_Member_University_Licensors_Member" unitRef="Shares" decimals="INF">200000</cris:SharesIssuedToSublicensees>
  <cris:StockIssuedDuringPeriodDueToExerciseOfWarrants contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">214004</cris:StockIssuedDuringPeriodDueToExerciseOfWarrants>
  <cris:SublicenseFeesPaid contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">1150000</cris:SublicenseFeesPaid>
  <cris:SublicenseFeesPaid contextRef="ThreeMonthsEnded_30Jun2012_F_Hoffmann_La_Roche_Limited_Member" unitRef="USD" decimals="0">550000</cris:SublicenseFeesPaid>
  <cris:SublicenseFeesPaid contextRef="ThreeMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">650000</cris:SublicenseFeesPaid>
  <cris:SublicenseFeesPaid contextRef="ThreeMonthsEnded_30Jun2012_Out_Of_Period_Adjustment_Member" unitRef="USD" decimals="0">100000</cris:SublicenseFeesPaid>
  <cris:TermOfWarrantsYears contextRef="Jan-01-2012_Jun-30-2012">P5Y</cris:TermOfWarrantsYears>
  <dei:AmendmentFlag contextRef="Jan-01-2012_Jun-30-2012">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Jan-01-2012_Jun-30-2012">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Jan-01-2012_Jun-30-2012">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Jan-01-2012_Jun-30-2012">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Jan-01-2012_Jun-30-2012">2012-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Jan-01-2012_Jun-30-2012">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Jan-01-2012_Jun-30-2012">0001108205</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_02Aug2012" unitRef="Shares" decimals="INF">79622590</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="Jan-01-2012_Jun-30-2012">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Jan-01-2012_Jun-30-2012">CURIS INC</dei:EntityRegistrantName>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">2364437</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">2429316</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">42067</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">318306</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-120363</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">99171</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">1422107</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">1062626</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">190500</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">159625</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">1065570</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">787483</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">33965</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">39723</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">772039254</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">779848984</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">2887684</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">3362031</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="SixMonthsEnded_30Jun2011" unitRef="Shares" decimals="INF">13439045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="SixMonthsEnded_30Jun2011_Stock_Options_Member" unitRef="Shares" decimals="INF">11828227</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="SixMonthsEnded_30Jun2011_Warrant_Member" unitRef="Shares" decimals="INF">1610818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Jun2011" unitRef="Shares" decimals="INF">13439045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Jun2011_Stock_Options_Member" unitRef="Shares" decimals="INF">11828227</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Jun2011_Warrant_Member" unitRef="Shares" decimals="INF">1610818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Jan-01-2012_Jun-30-2012" unitRef="Shares" decimals="INF">12120042</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="SixMonthsEnded_30Jun2012_Stock_Options_Member" unitRef="Shares" decimals="INF">10721724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="SixMonthsEnded_30Jun2012_Warrant_Member" unitRef="Shares" decimals="INF">1398318</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Jun2012" unitRef="Shares" decimals="INF">12120042</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Jun2012_Stock_Options_Member" unitRef="Shares" decimals="INF">10721724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Jun2012_Warrant_Member" unitRef="Shares" decimals="INF">1398318</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">48180065</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">55029459</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">38503441</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">45421247</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">30339592</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">15107588</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">15232004</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">42593213</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">24255515</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">18337698</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">22596419</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="BalanceAsOf_31Dec2011_Corporate_Bonds_Notes_And_Stock_Member" unitRef="USD" decimals="0">18787778</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="BalanceAsOf_31Dec2011_Us_Government_Obligations_Member" unitRef="USD" decimals="0">3808641</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">32608962</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="BalanceAsOf_30Jun2012_Corporate_Bonds_Notes_And_Stock_Member" unitRef="USD" decimals="0">32608962</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">22597845</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="BalanceAsOf_31Dec2011_Corporate_Bonds_Notes_And_Stock_Member" unitRef="USD" decimals="0">18789141</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="BalanceAsOf_31Dec2011_Us_Government_Obligations_Member" unitRef="USD" decimals="0">3808704</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">32616147</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="BalanceAsOf_30Jun2012_Corporate_Bonds_Notes_And_Stock_Member" unitRef="USD" decimals="0">32616147</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">18789141</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">7365841</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">11423300</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">32616147</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">16423449</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">16192698</us-gaap:AvailableForSaleSecuritiesFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">1426</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="BalanceAsOf_31Dec2011_Corporate_Bonds_Notes_And_Stock_Member" unitRef="USD" decimals="0">1363</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="BalanceAsOf_31Dec2011_Us_Government_Obligations_Member" unitRef="USD" decimals="0">63</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">7185</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss contextRef="BalanceAsOf_30Jun2012_Corporate_Bonds_Notes_And_Stock_Member" unitRef="USD" decimals="0">7185</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGainLoss>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="0">7826549</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="0">6791800</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">15119730</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">12089655</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-1034749</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-3030075</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="BalanceAsOf_30Jun2012" unitRef="USDPerUnit" decimals="2">3.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">1612322</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="BalanceAsOf_30Jun2012_Warrant_Member" unitRef="Shares" decimals="INF">212500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" unitRef="USD" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_30Jun2012" unitRef="USD" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Jun2012" unitRef="USDEPS" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">78165360</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">80581596</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">77117653</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">79533889</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">781654</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">805816</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-11725873</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-4931189</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-654957</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">-2899231</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:CostsAndExpenses contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">10477680</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">5011832</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">14934236</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">6777679</us-gaap:CostsAndExpenses>
  <us-gaap:DepreciationAndAmortization contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">45089</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">60432</us-gaap:DepreciationAndAmortization>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">4361168</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level3_Member" unitRef="USD" decimals="0">4361168</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">4304922</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level3_Member" unitRef="USD" decimals="0">4304922</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:DirectOperatingCostRoyaltyExpense contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">126168</us-gaap:DirectOperatingCostRoyaltyExpense>
  <us-gaap:DirectOperatingCostRoyaltyExpense contextRef="SixMonthsEnded_30Jun2012_University_Licensors_Member" unitRef="USD" decimals="0">26168</us-gaap:DirectOperatingCostRoyaltyExpense>
  <us-gaap:DirectOperatingCostRoyaltyExpense contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">12637</us-gaap:DirectOperatingCostRoyaltyExpense>
  <us-gaap:DirectOperatingCostRoyaltyExpense contextRef="ThreeMonthsEnded_30Jun2012_University_Licensors_Member" unitRef="USD" decimals="0">12637</us-gaap:DirectOperatingCostRoyaltyExpense>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="SixMonthsEnded_30Jun2011" unitRef="USDEPS" decimals="2">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USDEPS" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Jan-01-2012_Jun-30-2012" unitRef="USDEPS" decimals="2">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USDEPS" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">1011738</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">348742</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">1649725</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">833497</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">5765000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Jan-01-2012_Jun-30-2012">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EquityFairValueDisclosure contextRef="BalanceAsOf_31March2012_Genentech_Inc_Member" unitRef="USD" decimals="0">964000</us-gaap:EquityFairValueDisclosure>
  <us-gaap:EquityFairValueDisclosure contextRef="BalanceAsOf_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">964000</us-gaap:EquityFairValueDisclosure>
  <us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue contextRef="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member" unitRef="USD" decimals="0">2375000</us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue>
  <us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level1_Member_Fair_Value_Measurements_Recurring_Member_Cash_And_Cash_Equivalents_Member" unitRef="USD" decimals="0">2375000</us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue>
  <us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue contextRef="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">2145000</us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue>
  <us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue contextRef="BalanceAsOf_30Jun2012_Cash_And_Cash_Equivalents_Member_Fair_Value_Measurements_Recurring_Member_Fair_Value_Inputs_Level2_Member" unitRef="USD" decimals="0">2145000</us-gaap:FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue>
  <us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue contextRef="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">3808704</us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue>
  <us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level2_Member_Fair_Value_Measurements_Recurring_Member_Investments_Member" unitRef="USD" decimals="0">3808704</us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-1821850</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-320440</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-487400</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">-495341</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">36446</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">4275131</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">1867782</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">5065663</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">2264586</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Goodwill contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">8982000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">8982000</us-gaap:Goodwill>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-117760</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-273295</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">7153</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">276239</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-22183</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-468486</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-219458</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-41632</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InvestmentIncomeInterest contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">58910</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">25341</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">53095</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">34994</us-gaap:InvestmentIncomeInterest>
  <us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">8304108</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">7974567</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">48180065</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">55029459</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">3786544</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">3491942</us-gaap:LiabilitiesCurrent>
  <us-gaap:LicensesRevenue contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">300000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">300000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">14000000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">4000000</us-gaap:LicensesRevenue>
  <us-gaap:MarketableSecuritiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">22597845</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">32616147</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">1295620</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">4174002</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">6496162</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-9905393</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-8826531</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">2701316</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-11714215</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-4914064</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-660715</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">-2886452</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-1762940</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-295099</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-434305</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">-460347</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-9951275</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">-4618965</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">-226410</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">-2426105</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">166037</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">115518</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">137500</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">2980</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">2980</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">156396</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">177703</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">25611178</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">30163823</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">246378</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">33652</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">743799</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">397139</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">1295620</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">4174002</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">32097814</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">20250450</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">36446</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">455730</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">428950</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">6202549</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">3144050</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">9742405</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member_University_Licensors_Member" unitRef="USD" decimals="0">2114000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">4500456</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Jun2012_Genentech_Inc_Member_University_Licensors_Member" unitRef="USD" decimals="0">650000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestrictedInvestmentsNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">235914</us-gaap:RestrictedInvestmentsNoncurrent>
  <us-gaap:RestrictedInvestmentsNoncurrent contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">194282</us-gaap:RestrictedInvestmentsNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">-732087642</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">-732748357</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Revenues contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">526405</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">392867</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">14707826</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">4351574</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">126168</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="ThreeMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">12637</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">523372</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="SixMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">523372</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">252750</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="ThreeMonthsEnded_30Jun2012_Genentech_Inc_Member" unitRef="USD" decimals="0">252750</us-gaap:RoyaltyRevenue>
  <us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">1039558</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2011_General_And_Administrative_Expense_Member" unitRef="USD" decimals="0">695697</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2011_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">343861</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">361846</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_30Jun2011_General_And_Administrative_Expense_Member" unitRef="USD" decimals="0">183038</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_30Jun2011_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">178808</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">2030418</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2012_General_And_Administrative_Expense_Member" unitRef="USD" decimals="0">1265408</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2012_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">765010</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">1007742</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_30Jun2012_General_And_Administrative_Expense_Member" unitRef="USD" decimals="0">641887</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_30Jun2012_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">365855</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Jan-01-2012_Jun-30-2012">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="SixMonthsEnded_30Jun2012_Non_Employee_Directors_Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate xsi:nil="true" contextRef="SixMonthsEnded_30Jun2011" unitRef="Pure" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate xsi:nil="true" contextRef="Jan-01-2012_Jun-30-2012" unitRef="Pure" />
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="SixMonthsEnded_30Jun2011">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="SixMonthsEnded_30Jun2011_Director_Member">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Jan-01-2012_Jun-30-2012">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="SixMonthsEnded_30Jun2012_Director_Member">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="SixMonthsEnded_30Jun2011" unitRef="Pure" decimals="INF">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Jan-01-2012_Jun-30-2012" unitRef="Pure" decimals="INF">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="SixMonthsEnded_30Jun2011" unitRef="Pure" decimals="INF">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Jan-01-2012_Jun-30-2012" unitRef="Pure" decimals="INF">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="SixMonthsEnded_30Jun2011" unitRef="Pure" decimals="INF">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Jan-01-2012_Jun-30-2012" unitRef="Pure" decimals="INF">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="SixMonthsEnded_30Jun2011" unitRef="Pure" decimals="INF">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Jan-01-2012_Jun-30-2012" unitRef="Pure" decimals="INF">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">24464000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">826000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">5779000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="Jan-01-2012_Jun-30-2012" unitRef="Shares" decimals="INF">1182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="SixMonthsEnded_30Jun2012_Non_Employee_Directors_Member" unitRef="Shares" decimals="INF">470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="SixMonthsEnded_30Jun2011" unitRef="USDEPS" decimals="2">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Jan-01-2012_Jun-30-2012" unitRef="USDEPS" decimals="2">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">30021000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">1050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">1228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="BalanceAsOf_30Jun2012" unitRef="USDEPS" decimals="2">2.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="BalanceAsOf_30Jun2012_Four_Point_Five_Six_Us_Dollars_To_Five_Point_Six_Zero_Us_Dollars_Member" unitRef="USDEPS" decimals="2">4.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="BalanceAsOf_30Jun2012_One_Point_Four_Three_Us_Dollars_To_Two_Point_One_Five_Us_Dollars_Member" unitRef="USDEPS" decimals="2">1.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="BalanceAsOf_30Jun2012_Three_Point_Nine_Eight_Us_Dollars_To_Four_Point_Five_Two_Us_Dollars_Member" unitRef="USDEPS" decimals="2">4.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="BalanceAsOf_30Jun2012_Two_Point_Two_Seven_Us_Dollars_To_Three_Point_Seven_Six_Us_Dollars_Member" unitRef="USDEPS" decimals="2">2.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="BalanceAsOf_30Jun2012_Zero_Point_Seven_Nine_Us_Dollars_To_One_Point_Three_Us_Dollars_Member" unitRef="USDEPS" decimals="2">1.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">7656720</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="BalanceAsOf_30Jun2012_Four_Point_Five_Six_Us_Dollars_To_Five_Point_Six_Zero_Us_Dollars_Member" unitRef="Shares" decimals="INF">712000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="BalanceAsOf_30Jun2012_One_Point_Four_Three_Us_Dollars_To_Two_Point_One_Five_Us_Dollars_Member" unitRef="Shares" decimals="INF">2063310</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="BalanceAsOf_30Jun2012_Three_Point_Nine_Eight_Us_Dollars_To_Four_Point_Five_Two_Us_Dollars_Member" unitRef="Shares" decimals="INF">758445</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="BalanceAsOf_30Jun2012_Two_Point_Two_Seven_Us_Dollars_To_Three_Point_Seven_Six_Us_Dollars_Member" unitRef="Shares" decimals="INF">1555446</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="BalanceAsOf_30Jun2012_Zero_Point_Seven_Nine_Us_Dollars_To_One_Point_Three_Us_Dollars_Member" unitRef="Shares" decimals="INF">2567519</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">10721724</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="BalanceAsOf_30Jun2012_Four_Point_Five_Six_Us_Dollars_To_Five_Point_Six_Zero_Us_Dollars_Member" unitRef="Shares" decimals="INF">720000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="BalanceAsOf_30Jun2012_One_Point_Four_Three_Us_Dollars_To_Two_Point_One_Five_Us_Dollars_Member" unitRef="Shares" decimals="INF">2628568</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="BalanceAsOf_30Jun2012_Three_Point_Nine_Eight_Us_Dollars_To_Four_Point_Five_Two_Us_Dollars_Member" unitRef="Shares" decimals="INF">2204614</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="BalanceAsOf_30Jun2012_Two_Point_Two_Seven_Us_Dollars_To_Three_Point_Seven_Six_Us_Dollars_Member" unitRef="Shares" decimals="INF">2432733</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="BalanceAsOf_30Jun2012_Zero_Point_Seven_Nine_Us_Dollars_To_One_Point_Three_Us_Dollars_Member" unitRef="Shares" decimals="INF">2735809</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="BalanceAsOf_30Jun2012" unitRef="USDEPS" decimals="2">2.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="BalanceAsOf_30Jun2012_Four_Point_Five_Six_Us_Dollars_To_Five_Point_Six_Zero_Us_Dollars_Member" unitRef="USDEPS" decimals="2">4.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="BalanceAsOf_30Jun2012_One_Point_Four_Three_Us_Dollars_To_Two_Point_One_Five_Us_Dollars_Member" unitRef="USDEPS" decimals="2">1.73</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="BalanceAsOf_30Jun2012_Three_Point_Nine_Eight_Us_Dollars_To_Four_Point_Five_Two_Us_Dollars_Member" unitRef="USDEPS" decimals="2">4.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="BalanceAsOf_30Jun2012_Two_Point_Two_Seven_Us_Dollars_To_Three_Point_Seven_Six_Us_Dollars_Member" unitRef="USDEPS" decimals="2">2.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="BalanceAsOf_30Jun2012_Zero_Point_Seven_Nine_Us_Dollars_To_One_Point_Three_Us_Dollars_Member" unitRef="USDEPS" decimals="2">1.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Jan-01-2012_Jun-30-2012">P5Y6M11D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="SixMonthsEnded_30Jun2012_Four_Point_Five_Six_Us_Dollars_To_Five_Point_Six_Zero_Us_Dollars_Member">P1Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="SixMonthsEnded_30Jun2012_One_Point_Four_Three_Us_Dollars_To_Two_Point_One_Five_Us_Dollars_Member">P5Y7M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="SixMonthsEnded_30Jun2012_Three_Point_Nine_Eight_Us_Dollars_To_Four_Point_Five_Two_Us_Dollars_Member">P7Y10M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="SixMonthsEnded_30Jun2012_Two_Point_Two_Seven_Us_Dollars_To_Three_Point_Seven_Six_Us_Dollars_Member">P5Y11D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="SixMonthsEnded_30Jun2012_Zero_Point_Seven_Nine_Us_Dollars_To_One_Point_Three_Us_Dollars_Member">P4Y11M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="0">27820</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="0">13104</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense contextRef="Jan-01-2012_Jun-30-2012" unitRef="USD" decimals="0">380693</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense contextRef="ThreeMonthsEnded_30Jun2012" unitRef="USD" decimals="0">174245</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">39875957</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">47054892</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockShares contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">1047707</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares contextRef="BalanceAsOf_30Jun2012" unitRef="Shares" decimals="INF">1047707</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">891274</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">891274</us-gaap:TreasuryStockValue>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="0">1604742</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="0">3426592</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">4361168</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_31Dec2011_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">4361168</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_31Dec2011_Fair_Value_Inputs_Level3_Member_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">4361168</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_30Jun2012" unitRef="USD" decimals="0">4304922</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_30Jun2012_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">4304922</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_30Jun2012_Fair_Value_Inputs_Level3_Member_Fair_Value_Measurements_Recurring_Member" unitRef="USD" decimals="0">4304922</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="SixMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">76103611</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="ThreeMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">76378369</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Jan-01-2012_Jun-30-2012" unitRef="Shares" decimals="0">78304441</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="ThreeMonthsEnded_30Jun2012" unitRef="Shares" decimals="0">79052517</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cris-20120630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 4.3.96.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Modified on: 8/8/2012 9:36:52 AM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://curis.com/20120630" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:cris="http://curis.com/20120630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://curis.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
        <link:definition>0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/role/InvestmentsDetails" id="InvestmentsDetails">
        <link:definition>0606 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/role/InvestmentsTables" id="InvestmentsTables">
        <link:definition>0506 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/role/Investments" id="Investments">
        <link:definition>0206 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/role/RelatedPartyTransactionDetails" id="RelatedPartyTransactionDetails">
        <link:definition>0609 - Disclosure - Related Party Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/role/CollaborationAgreementsDetails" id="CollaborationAgreementsDetails">
        <link:definition>0604 - Disclosure - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/role/RelatedPartyTransaction" id="RelatedPartyTransaction">
        <link:definition>0209 - Disclosure - Related Party Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/role/CollaborationAgreements" id="CollaborationAgreements">
        <link:definition>0204 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/BalanceSheets" id="BalanceSheets">
        <link:definition>0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>0605 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/NatureOfBusiness" id="NatureOfBusiness">
        <link:definition>0201 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>0202 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/RevenueRecognition" id="RevenueRecognition">
        <link:definition>0203 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>0205 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiability" id="CommonStockAndWarrantLiability">
        <link:definition>0207 - Disclosure - Common Stock and Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccruedLiabilities" id="AccruedLiabilities">
        <link:definition>0208 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensation" id="AccountingForStockBasedCompensation">
        <link:definition>0210 - Disclosure - Accounting for Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShare" id="IncomeLossPerCommonShare">
        <link:definition>0211 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>0505 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
        <link:definition>0508 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationTables" id="AccountingForStockBasedCompensationTables">
        <link:definition>0510 - Disclosure - Accounting for Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareTables" id="IncomeLossPerCommonShareTables">
        <link:definition>0511 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
        <link:definition>06051 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" id="CommonStockAndWarrantLiabilityDetails">
        <link:definition>0607 - Disclosure - Common Stock and Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
        <link:definition>0608 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" id="AccountingForStockBasedCompensationDetailsTextual">
        <link:definition>06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" id="AccountingForStockBasedCompensationDetails">
        <link:definition>0610 - Disclosure - Accounting for Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" id="AccountingForStockBasedCompensationDetails1">
        <link:definition>06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" id="AccountingForStockBasedCompensationDetails2">
        <link:definition>06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" id="IncomeLossPerCommonShareDetails">
        <link:definition>0611 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cris-20120630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cris-20120630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cris-20120630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cris-20120630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
  <!--<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />-->
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2012-01-31" schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2012-01-31" schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd" />
  <import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/invest/2012-01-31" schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd" />
  <element id="cris_CommonStockAndWarrantLiabilityAbstract" name="CommonStockAndWarrantLiabilityAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_CommonStockAndWarrantLiabilityTextBlock" name="CommonStockAndWarrantLiabilityTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts" name="ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cris_ResearchAndDevelopmentRevenue" name="ResearchAndDevelopmentRevenue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cris_NatureOfBusinessAbstract" name="NatureOfBusinessAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_RegisteredDirectOfferingUnits" name="RegisteredDirectOfferingUnits" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="cris_DirectOfferingPurchasePrice" name="DirectOfferingPurchasePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="cris_CommonStockAndWarrantLiabilityLineItems" name="CommonStockAndWarrantLiabilityLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="cris_ShareBasedCompensationPlans" name="ShareBasedCompensationPlans" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="cris_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="cris_CommonStockAndWarrantLiabilityTable" name="CommonStockAndWarrantLiabilityTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="cris_MoneyMarketFundsFairValue" name="MoneyMarketFundsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="cris_TermOfWarrantsYears" name="TermOfWarrantsYears" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" name="ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_RangeOfExpectedVolatilities" name="RangeOfExpectedVolatilities" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_EstimatedRiskFreeInterestRate" name="EstimatedRiskFreeInterestRate" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_CommonStockAndWarrantLiabilityTextualAbstract" name="CommonStockAndWarrantLiabilityTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" name="CommonStockAndWarrantLiabilityAdditionalTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_CurrentAccruedLiabilitiesAbstract" name="CurrentAccruedLiabilitiesAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" name="IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_AccountingForStockBasedCompensationTextualAbstract" name="AccountingForStockBasedCompensationTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" name="AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_AccountingForStockBasedCompensationAbstract" name="AccountingForStockBasedCompensationAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_SaleOfStockByOfferingClassAxis" name="SaleOfStockByOfferingClassAxis" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" />
  <element id="cris_SaleOfStockByOfferingClassDomain" name="SaleOfStockByOfferingClassDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_GenentechIncMember" name="GenentechIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_LeukemiaAndLymphomaSocietyMember" name="LeukemiaAndLymphomaSocietyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_CollaborationAgreementsTextualAbstract" name="CollaborationAgreementsTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" name="RevenueRecognizedMilestonePaymentsLicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cris_CashPaymentToUniversityLicensor" name="CashPaymentToUniversityLicensor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cris_UniversityLicensorsMember" name="UniversityLicensorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_RelatedPartyTransactionTextualAbstract" name="RelatedPartyTransactionTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_IssuanceOfCommonStockToLicensees" name="IssuanceOfCommonStockToLicensees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" name="CollaborationAgreementContingentConsiderationPotentialCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants" name="StockIssuedDuringPeriodDueToExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="cris_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_SublicenseFeesPaid" name="SublicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" name="PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_PercentageOfContributionToFund" name="PercentageOfContributionToFund" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_ContingentObligations" name="ContingentObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cris_ChangeInFairValueUponWarrantExercise" name="ChangeInFairValueUponWarrantExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cris_ExpectedLivesOfWarrantsYears" name="ExpectedLivesOfWarrantsYears" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_SharesIssuedToSublicensees" name="SharesIssuedToSublicensees" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="cris_ProceedsFromContributionOfFund" name="ProceedsFromContributionOfFund" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cris_MaximumFinancialSupportToRelatedParty" name="MaximumFinancialSupportToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="cris_SeveranceAgreementToRelatedParty" name="SeveranceAgreementToRelatedParty" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_MilestonesRecognizedFromPartner" name="MilestonesRecognizedFromPartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cris_AdditionalMilestoneRecognizedFromPartner" name="AdditionalMilestoneRecognizedFromPartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" name="CollaborationAgreementContingentConsiderationReceivedFromPartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" name="CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit" name="RegisteredDirectOfferingNumberOfCommonStockPerUnit" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" name="RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit" name="RegisteredDirectOfferingNumberOfWarrantPerUnit" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" name="ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" name="OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" name="TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" name="ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" name="FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_OutOfPeriodAdjustmentMember" name="OutOfPeriodAdjustmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_CorporateBondsNotesAndStockMember" name="CorporateBondsNotesAndStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_UsGovernmentObligationsMember" name="UsGovernmentObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_ResearchAndDevelopmentExpenseForMarketingRegistration" name="ResearchAndDevelopmentExpenseForMarketingRegistration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cris_PaymentAssociatedFda" name="PaymentAssociatedFda" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="cris_FoodAndDrugAdministrationMember" name="FoodAndDrugAdministrationMember" abstract="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cris_FHoffmannLaRocheLimitedMember" name="FHoffmannLaRocheLimitedMember" abstract="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cris-20120630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 4.3.96.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Modified on: 8/8/2012 9:36:37 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#BalanceSheets" roleURI="http://curis.com/2010-09-30/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#StatementsOfCashFlows" roleURI="http://curis.com/2010-09-30/role/StatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurementsDetails" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://curis.com/2010-09-30/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#BalanceSheetsParenthetical" roleURI="http://curis.com/2010-09-30/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#NatureOfBusiness" roleURI="http://curis.com/2010-09-30/role/NatureOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#BasisOfPresentation" roleURI="http://curis.com/2010-09-30/role/BasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#RevenueRecognition" roleURI="http://curis.com/2010-09-30/role/RevenueRecognition" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurements" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CommonStockAndWarrantLiability" roleURI="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiability" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccruedLiabilities" roleURI="http://curis.com/2010-09-30/role/AccruedLiabilities" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensation" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#IncomeLossPerCommonShare" roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShare" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurementsTables" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccruedLiabilitiesTables" roleURI="http://curis.com/2010-09-30/role/AccruedLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationTables" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#IncomeLossPerCommonShareTables" roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurementsDetails1" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails1" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CommonStockAndWarrantLiabilityDetails" roleURI="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccruedLiabilitiesDetails" roleURI="http://curis.com/2010-09-30/role/AccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails1" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails2" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetailsTextual" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#IncomeLossPerCommonShareDetails" roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CollaborationAgreements" roleURI="http://curis.com/role/CollaborationAgreements" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#RelatedPartyTransaction" roleURI="http://curis.com/role/RelatedPartyTransaction" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CollaborationAgreementsDetails" roleURI="http://curis.com/role/CollaborationAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#RelatedPartyTransactionDetails" roleURI="http://curis.com/role/RelatedPartyTransactionDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#Investments" roleURI="http://curis.com/role/Investments" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#InvestmentsTables" roleURI="http://curis.com/role/InvestmentsTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#InvestmentsDetails" roleURI="http://curis.com/role/InvestmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://curis.com/role/StatementsOfOperationsAndComprehensiveLoss" />
  <calculationLink xlink:role="http://curis.com/2010-09-30/role/BalanceSheets" xlink:type="extended" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_634255826889286504" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634255826889286504" xlink:to="us-gaap_AssetsCurrent_634647456620219225" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634647456620219225" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_634647456620219225" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634647456620219225" xlink:to="us-gaap_MarketableSecuritiesCurrent_634647456620219225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634647456620219225" xlink:to="us-gaap_AccountsReceivableNetCurrent_634647456620219225" order="60" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_634647456620219225" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_634647456620219225" order="80" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634255826889286504" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_634647456620219225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634255826889286504" xlink:to="us-gaap_Goodwill_634647456620219225" order="60" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634255826889286504" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent_634647456620219225" order="80" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_634255826889286504" xlink:to="us-gaap_OtherAssetsNoncurrent_634647456620219225" order="100" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_634255826889996504" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_634255826889996504" xlink:to="us-gaap_Liabilities_634647456620219225" order="20" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_634647456620219225" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_634647456620219225" order="40" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_634647456620219225" xlink:to="us-gaap_LiabilitiesCurrent_634647456620219225" order="60" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634647456620219225" xlink:to="us-gaap_AccountsPayableCurrent_634647456620219225" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_634647456620219225" xlink:to="us-gaap_AccruedLiabilitiesCurrent_634647456620219225" order="40" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_634255826889996504" xlink:to="us-gaap_StockholdersEquity_634647456620219225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634647456620219225" xlink:to="us-gaap_CommonStockValue_634647456620219225" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634647456620219225" xlink:to="us-gaap_AdditionalPaidInCapital_634647456620219225" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634647456620219225" xlink:to="us-gaap_TreasuryStockValue_634647456620219225" order="60" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634647456620219225" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_634647456620219225" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_634647456620219225" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_634647456620219225" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_634647456620219225" xlink:to="loc_WarrantsAndRightsOutstanding" order="20" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://curis.com/2010-09-30/role/StatementsOfCashFlows" xlink:type="extended" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634255871714196504" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634255871714196504" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_634647456620219225" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_NetIncomeLoss_634647456620219225" order="20" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" order="40" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_DepreciationAndAmortization_634647456620219225" order="20" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_ShareBasedCompensation_634647456620219225" order="40" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_634647456620219225" order="60" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_634647456620219225" order="80" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_634647456620219225" order="100" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_634647456620219225" order="120" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_GainLossOnDispositionOfAssets_634647456620219225" order="140" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620219225" order="160" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634255871714196504" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620219225" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620219225" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_634647456620219225" order="20" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620219225" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634647456620219225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620219225" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_634647456620219225" order="60" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620219225" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634647456620219225" order="80" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620219225" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_634647456620219225" order="100" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_634647456620219225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634255871714196504" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_634647456620219225" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_634647456620687225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_634647456620219225" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_634647456620687225" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_IssuanceOfCommonStockToLicensees" xlink:label="cris_IssuanceOfCommonStockToLicensees" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620219225" xlink:to="cris_IssuanceOfCommonStockToLicensees" order="50" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:type="extended" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue_634647456620375225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue_634647456620375225" order="40" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_634647456620375225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_634647456620375225" order="60" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MoneyMarketFundsFairValue" xlink:label="cris_MoneyMarketFundsFairValue_634647456620375225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="cris_MoneyMarketFundsFairValue_634647456620375225" order="80" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" xlink:label="loc_AvailableForSaleSecuritiesFairValueDisclosure" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="loc_AvailableForSaleSecuritiesFairValueDisclosure" order="20" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/DocumentDocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/NatureOfBusiness" xlink:title="0201 - Disclosure - Nature of Business" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/BasisOfPresentation" xlink:title="0202 - Disclosure - Basis of Presentation" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/RevenueRecognition" xlink:title="0203 - Disclosure - Revenue Recognition" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurements" xlink:title="0205 - Disclosure - Fair Value Measurements" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiability" xlink:title="0207 - Disclosure - Common Stock and Warrant Liability" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccruedLiabilities" xlink:title="0208 - Disclosure - Accrued Liabilities" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensation" xlink:title="0210 - Disclosure - Accounting for Stock-Based Compensation" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShare" xlink:title="0211 - Disclosure - Loss Per Common Share" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsTables" xlink:title="0505 - Disclosure - Fair Value Measurements (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccruedLiabilitiesTables" xlink:title="0508 - Disclosure - Accrued Liabilities (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationTables" xlink:title="0510 - Disclosure - Accounting for Stock-Based Compensation (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareTables" xlink:title="0511 - Disclosure - Loss Per Common Share (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails1" xlink:title="06051 - Disclosure - Fair Value Measurements (Details 1)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccruedLiabilitiesDetails" xlink:title="0608 - Disclosure - Accrued Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_634647456620687225" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_634647456620687225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_634647456620687225" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_634647456620687225" order="60" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_634647456620687225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_634647456620687225" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_634647456620687225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_634647456620687225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_634647456620687225" xlink:to="us-gaap_AccruedSalariesCurrent_634647456620687225" order="20" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" xlink:title="0610 - Disclosure - Accounting for Stock-Based Compensation (Details)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" xlink:title="06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" xlink:title="06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" xlink:title="06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" xlink:title="0611 - Disclosure - Loss Per Common Share (Details)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreements" xlink:title="0204 - Disclosure - Collaboration Agreements" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/RelatedPartyTransaction" xlink:title="0209 - Disclosure - Related Party Transaction" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/RelatedPartyTransactionDetails" xlink:title="0609 - Disclosure - Related Party Transaction (Details)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/Investments" xlink:title="0206 - Disclosure - Investments" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsTables" xlink:title="0506 - Disclosure - Investments (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsDetails" xlink:title="0606 - Disclosure - Investments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="40" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://curis.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="us-gaap_NonoperatingIncomeExpense_634647456620531225" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634647456620531225" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_634647456620531225" xlink:to="us-gaap_InvestmentIncomeInterest_634647456620531225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="us-gaap_OperatingIncomeLoss_634647456620531225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_634647456620531225" xlink:to="us-gaap_CostsAndExpenses_634647456620531225" order="20" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_634647456620531225" xlink:to="us-gaap_GeneralAndAdministrativeExpense_634647456620531225" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_634647456620531225" xlink:to="us-gaap_ResearchAndDevelopmentExpense_634647456620531225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_DirectOperatingCostRoyaltyExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_634647456620531225" xlink:to="loc_DirectOperatingCostRoyaltyExpense" order="60" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_634647456620531225" xlink:to="us-gaap_Revenues_634647456620531225" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_634647456620531225" xlink:to="us-gaap_LicensesRevenue_634647456620531225" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_RoyaltyRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_634647456620531225" xlink:to="loc_RoyaltyRevenue" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ResearchAndDevelopmentRevenue" xlink:label="cris_ResearchAndDevelopmentRevenue_634647456620531225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_634647456620531225" xlink:to="cris_ResearchAndDevelopmentRevenue_634647456620531225" order="60" use="optional" weight="1" priority="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cris-20120630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.199; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CollaborationAgreementsDetails" roleURI="http://curis.com/role/CollaborationAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurementsDetails" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#InvestmentsDetails" roleURI="http://curis.com/role/InvestmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CommonStockAndWarrantLiabilityDetails" roleURI="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails1" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails2" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetailsTextual" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" />
  <link:roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#IncomeLossPerCommonShareDetails" roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_GenentechIncMember" xlink:label="cris_GenentechIncMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_LeukemiaAndLymphomaSocietyMember" xlink:label="cris_LeukemiaAndLymphomaSocietyMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FHoffmannLaRocheLimitedMember" xlink:label="cris_FHoffmannLaRocheLimitedMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FoodAndDrugAdministrationMember" xlink:label="cris_FoodAndDrugAdministrationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_GenentechIncMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_LeukemiaAndLymphomaSocietyMember" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_FHoffmannLaRocheLimitedMember" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_FoodAndDrugAdministrationMember" order="4" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_UniversityLicensorsMember" xlink:label="cris_UniversityLicensorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cris_UniversityLicensorsMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementScenarioAxis" order="3" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_OutOfPeriodAdjustmentMember" xlink:label="cris_OutOfPeriodAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="cris_OutOfPeriodAdjustmentMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="4" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementsTextualAbstract" xlink:label="cris_CollaborationAgreementsTextualAbstract" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" xlink:label="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MilestonesRecognizedFromPartner" xlink:label="cris_MilestonesRecognizedFromPartner" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AdditionalMilestoneRecognizedFromPartner" xlink:label="cris_AdditionalMilestoneRecognizedFromPartner" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:label="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:label="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SublicenseFeesPaid" xlink:label="cris_SublicenseFeesPaid" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SharesIssuedToSublicensees" xlink:label="cris_SharesIssuedToSublicensees" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="us-gaap_DirectOperatingCostRoyaltyExpense" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" xlink:label="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CashPaymentToUniversityLicensor" xlink:label="cris_CashPaymentToUniversityLicensor" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" xlink:label="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ResearchAndDevelopmentExpenseForMarketingRegistration" xlink:label="cris_ResearchAndDevelopmentExpenseForMarketingRegistration" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PercentageOfContributionToFund" xlink:label="cris_PercentageOfContributionToFund" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ProceedsFromContributionOfFund" xlink:label="cris_ProceedsFromContributionOfFund" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ContingentObligations" xlink:label="cris_ContingentObligations" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PaymentAssociatedFda" xlink:label="cris_PaymentAssociatedFda" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_MilestonesRecognizedFromPartner" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_AdditionalMilestoneRecognizedFromPartner" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_SublicenseFeesPaid" order="7" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="8" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="9" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_SharesIssuedToSublicensees" order="10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="11" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DirectOperatingCostRoyaltyExpense" order="12" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" order="13" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_CashPaymentToUniversityLicensor" order="14" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" order="15" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_ResearchAndDevelopmentExpenseForMarketingRegistration" order="16" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="17" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_PercentageOfContributionToFund" order="18" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_ProceedsFromContributionOfFund" order="19" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_ContingentObligations" order="20" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_PaymentAssociatedFda" order="21" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" order="1" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="2" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="3" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="us-gaap_InvestmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_InvestmentsMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="4" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MoneyMarketFundsFairValue" xlink:label="cris_MoneyMarketFundsFairValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cris_MoneyMarketFundsFairValue" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="7" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" order="8" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="2" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="3" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsDetails" xlink:title="0606 - Disclosure - Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsDetails" xlink:title="0606 - Disclosure - Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_UsGovernmentObligationsMember" xlink:label="cris_UsGovernmentObligationsMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CorporateBondsNotesAndStockMember" xlink:label="cris_CorporateBondsNotesAndStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cris_UsGovernmentObligationsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cris_CorporateBondsNotesAndStockMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsDetails" xlink:title="0606 - Disclosure - Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:ScheduleOfAvailableForSaleSecuritiesLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsDetails" xlink:title="0606 - Disclosure - Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" order="4" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsDetails" xlink:title="0606 - Disclosure - Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTable" xlink:label="cris_CommonStockAndWarrantLiabilityTable" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassAxis" xlink:label="cris_SaleOfStockByOfferingClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cris_CommonStockAndWarrantLiabilityTable" xlink:to="cris_SaleOfStockByOfferingClassAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassAxis" xlink:label="cris_SaleOfStockByOfferingClassAxis" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassDomain" xlink:label="cris_SaleOfStockByOfferingClassDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cris_SaleOfStockByOfferingClassAxis" xlink:to="cris_SaleOfStockByOfferingClassDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cris_SaleOfStockByOfferingClassDomain" xlink:to="us-gaap_WarrantMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTable" xlink:label="cris_CommonStockAndWarrantLiabilityTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cris_CommonStockAndWarrantLiabilityTable" xlink:to="us-gaap_RangeAxis" order="2" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTable" xlink:label="cris_CommonStockAndWarrantLiabilityTable" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityLineItems" xlink:label="cris_CommonStockAndWarrantLiabilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cris_CommonStockAndWarrantLiabilityLineItems" xlink:to="cris_CommonStockAndWarrantLiabilityTable" order="3" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  cris:CommonStockAndWarrantLiabilityLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityLineItems" xlink:label="cris_CommonStockAndWarrantLiabilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityTextualAbstract" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" xlink:label="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_EstimatedRiskFreeInterestRate" xlink:label="cris_EstimatedRiskFreeInterestRate" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ExpectedLivesOfWarrantsYears" xlink:label="cris_ExpectedLivesOfWarrantsYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cris_CommonStockAndWarrantLiabilityLineItems" xlink:to="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cris_CommonStockAndWarrantLiabilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cris_CommonStockAndWarrantLiabilityLineItems" xlink:to="cris_EstimatedRiskFreeInterestRate" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cris_CommonStockAndWarrantLiabilityLineItems" xlink:to="cris_ExpectedLivesOfWarrantsYears" order="5" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassAxis" xlink:label="cris_SaleOfStockByOfferingClassAxis" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassDomain" xlink:label="cris_SaleOfStockByOfferingClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cris_SaleOfStockByOfferingClassAxis" xlink:to="cris_SaleOfStockByOfferingClassDomain" order="1" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" xlink:title="0610 - Disclosure - Accounting for Stock-Based Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" xlink:title="0610 - Disclosure - Accounting for Stock-Based Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_DirectorMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" xlink:title="0610 - Disclosure - Accounting for Stock-Based Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" xlink:title="0610 - Disclosure - Accounting for Stock-Based Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" xlink:title="0610 - Disclosure - Accounting for Stock-Based Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" xlink:title="06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" xlink:title="06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" xlink:title="06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" xlink:title="06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationAbstract" xlink:label="cris_AccountingForStockBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="2" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" xlink:title="06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" xlink:title="06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" xlink:title="06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" xlink:label="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" xlink:label="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" xlink:label="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" xlink:label="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" xlink:label="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" order="5" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" xlink:title="06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" xlink:title="06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:label="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" xlink:title="06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" xlink:title="06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" xlink:title="06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_NonEmployeeDirectorsMember" xlink:label="cris_NonEmployeeDirectorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cris_NonEmployeeDirectorsMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" xlink:title="06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" xlink:title="06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationTextualAbstract" xlink:label="cris_AccountingForStockBasedCompensationTextualAbstract" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ShareBasedCompensationPlans" xlink:label="cris_ShareBasedCompensationPlans" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cris_ShareBasedCompensationPlans" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="8" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" order="11" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="12" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense" order="13" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" xlink:title="06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" xlink:title="0611 - Disclosure - Loss Per Common Share (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" xlink:title="0611 - Disclosure - Loss Per Common Share (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" xlink:title="0611 - Disclosure - Loss Per Common Share (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" xlink:title="0611 - Disclosure - Loss Per Common Share (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" xlink:label="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" xlink:title="0611 - Disclosure - Loss Per Common Share (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cris-20120630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 4.3.96.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Modified on: 8/8/2012 9:36:52 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <!--<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />-->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_DocumentAndEntityInformationAbstract" xlink:label="cris_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="cris_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and entity information.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expense and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl" xml:lang="en-US">Restricted Investments, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl" xml:lang="en-US">Long-term investment - restricted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value 125,000,000 shares authorized; 80,581,596 shares issued and 79,533,889 shares outstanding at June 30, 2012; and 78,165,360 shares issued and 77,117,653 shares outstanding at December 31, 2011</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock (at cost, 1,047,707 shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, at cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US">Licenses Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US">License fees</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ResearchAndDevelopmentRevenue" xlink:label="cris_ResearchAndDevelopmentRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ResearchAndDevelopmentRevenue" xlink:to="cris_ResearchAndDevelopmentRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ResearchAndDevelopmentRevenue_lbl" xml:lang="en-US">Research and Development Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ResearchAndDevelopmentRevenue_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ResearchAndDevelopmentRevenue_lbl" xml:lang="en-US">Historically, this has included FTE reimbursement.  It also includes reimbursement of other costs that have been incurred on behalf of a partner.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">COSTS AND EXPENSES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME/(EXPENSE):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Non-cash interest (income)/expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Net gain on sale of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Total adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by/(used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Sale of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Decrease in restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Proceeds from Sale of Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Proceeds from sale of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in)/ provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:to="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Registered Direct Offering of Common Stock and Warrants Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from registered direct offering of units, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from registered direct offering of common stock and warrants net of issuance costs.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_NatureOfBusinessAbstract" xlink:label="cris_NatureOfBusinessAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_NatureOfBusinessAbstract" xlink:to="cris_NatureOfBusinessAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_NatureOfBusinessAbstract_lbl" xml:lang="en-US">Nature of Business [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_NatureOfBusinessAbstract_lbl" xml:lang="en-US">Nature of business.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Basis of Presentation and Collaborative Arrangement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US">Revenue Recognition [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CommonStockAndWarrantLiabilityAbstract" xlink:to="cris_CommonStockAndWarrantLiabilityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CommonStockAndWarrantLiabilityAbstract_lbl" xml:lang="en-US">Common Stock and Warrant Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CommonStockAndWarrantLiabilityAbstract_lbl" xml:lang="en-US">Common stock and warrant liability.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTextBlock" xlink:label="cris_CommonStockAndWarrantLiabilityTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CommonStockAndWarrantLiabilityTextBlock" xlink:to="cris_CommonStockAndWarrantLiabilityTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CommonStockAndWarrantLiabilityTextBlock_lbl" xml:lang="en-US">Common Stock and Warrant Liability [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CommonStockAndWarrantLiabilityTextBlock_lbl" xml:lang="en-US">Common Stock and Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CommonStockAndWarrantLiabilityTextBlock_lbl" xml:lang="en-US">Common stock and warrant liability.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Accounting For Stock-Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Accounting for Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Common Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Financial Assets Measured at Fair Value on Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Fair Value of Warrant Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Valuation assumptions used to calculate fair value of employee options awarded</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:label="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:to="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xml:lang="en-US">Schedule of Employee and Non Employee Share Based Compensation Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xml:lang="en-US">Employee and non employee share based compensation expense allocation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xml:lang="en-US">Schedule of employee and non employee share based compensation allocation of recognized period costs.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Options outstanding and exercisable under exercise price range</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Antidilutive Securities - Stock Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">Effect of Dilutive Securities on Diluted Income Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_lbl" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Quoted Prices In Active Markets (Level 1) [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Other Observable Inputs (Level 2) [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Unobservable Inputs (Level 3) [Member]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MoneyMarketFundsFairValue" xlink:label="cris_MoneyMarketFundsFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_MoneyMarketFundsFairValue" xlink:to="cris_MoneyMarketFundsFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_MoneyMarketFundsFairValue_lbl" xml:lang="en-US">Money Market Funds, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_MoneyMarketFundsFairValue_lbl" xml:lang="en-US">Money market funds, fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_MoneyMarketFundsFairValue_lbl" xml:lang="en-US">Money market funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue_lbl" xml:lang="en-US">Financial Instruments, Owned, State and Municipal Government Obligations, at Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue_lbl" xml:lang="en-US">Municipal bonds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_lbl" xml:lang="en-US">Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_lbl" xml:lang="en-US">US government obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets at fair value</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTable" xlink:label="cris_CommonStockAndWarrantLiabilityTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CommonStockAndWarrantLiabilityTable" xlink:to="cris_CommonStockAndWarrantLiabilityTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CommonStockAndWarrantLiabilityTable_lbl" xml:lang="en-US">Common Stock and Warrant Liability [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CommonStockAndWarrantLiabilityTable_lbl" xml:lang="en-US">Common stock and warrant liability.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityLineItems" xlink:label="cris_CommonStockAndWarrantLiabilityLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CommonStockAndWarrantLiabilityLineItems" xlink:to="cris_CommonStockAndWarrantLiabilityLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CommonStockAndWarrantLiabilityLineItems_lbl" xml:lang="en-US">Common Stock and Warrant Liability [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CommonStockAndWarrantLiabilityLineItems_lbl" xml:lang="en-US">Common stock and warrant liability.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Company's share-based compensation plans and warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingUnits" xlink:label="cris_RegisteredDirectOfferingUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_RegisteredDirectOfferingUnits" xlink:to="cris_RegisteredDirectOfferingUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_RegisteredDirectOfferingUnits_lbl" xml:lang="en-US">Registered Direct Offering Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_RegisteredDirectOfferingUnits_lbl" xml:lang="en-US">Issuance of registered direct offering, units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_RegisteredDirectOfferingUnits_lbl" xml:lang="en-US">Registered direct offering units.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_DirectOfferingPurchasePrice" xlink:label="cris_DirectOfferingPurchasePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_DirectOfferingPurchasePrice" xlink:to="cris_DirectOfferingPurchasePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_DirectOfferingPurchasePrice_lbl" xml:lang="en-US">Direct Offering Purchase Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_DirectOfferingPurchasePrice_lbl" xml:lang="en-US">Direct offering purchase price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_DirectOfferingPurchasePrice_lbl" xml:lang="en-US">Direct offering purchase price.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Aggregate number of shares of stock available to purchase using warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_TermOfWarrantsYears" xlink:label="cris_TermOfWarrantsYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_TermOfWarrantsYears" xlink:to="cris_TermOfWarrantsYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_TermOfWarrantsYears_lbl" xml:lang="en-US">Term of Warrants, Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_TermOfWarrantsYears_lbl" xml:lang="en-US">Term of warrants, years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_TermOfWarrantsYears_lbl" xml:lang="en-US">Term of warrants, years.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RangeOfExpectedVolatilities" xlink:label="cris_RangeOfExpectedVolatilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_RangeOfExpectedVolatilities" xlink:to="cris_RangeOfExpectedVolatilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_RangeOfExpectedVolatilities_lbl" xml:lang="en-US">Range of Expected Volatilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_RangeOfExpectedVolatilities_lbl" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_RangeOfExpectedVolatilities_lbl" xml:lang="en-US">Range of expected volatilities</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_EstimatedRiskFreeInterestRate" xlink:label="cris_EstimatedRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_EstimatedRiskFreeInterestRate" xlink:to="cris_EstimatedRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_EstimatedRiskFreeInterestRate_lbl" xml:lang="en-US">Estimated Risk-free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_EstimatedRiskFreeInterestRate_lbl" xml:lang="en-US">Estimated risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_EstimatedRiskFreeInterestRate_lbl" xml:lang="en-US">Estimated risk-free interest rate.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments, by Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_NonEmployeeDirectorsMember" xlink:label="cris_NonEmployeeDirectorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_NonEmployeeDirectorsMember" xlink:to="cris_NonEmployeeDirectorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non Employee Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-Employee Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-employee directors.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ShareBasedCompensationPlans" xlink:label="cris_ShareBasedCompensationPlans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ShareBasedCompensationPlans" xlink:to="cris_ShareBasedCompensationPlans_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ShareBasedCompensationPlans_lbl" xml:lang="en-US">Share-Based Compensation Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ShareBasedCompensationPlans_lbl" xml:lang="en-US">Share-based compensation, number of plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ShareBasedCompensationPlans_lbl" xml:lang="en-US">Share-based compensation, number of plans.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of employee options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value of exercisable options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair values of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost net of estimated forfeitures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic values of employee stock options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense_lbl" xml:lang="en-US">Non-employee compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Minimum risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Maximum risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Minimum volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Maximum volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividends</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_lbl" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs Report Line [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionsMember" xlink:to="us-gaap_StockOptionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionsMember_lbl" xml:lang="en-US">Stock options outstanding [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total antidilutive securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_LiabilitiesCurrentAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="lab_AssetsCurrentAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:to="cris_CommonStockAndWarrantLiabilityTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CommonStockAndWarrantLiabilityTextualAbstract_lbl" xml:lang="en-US">Common Stock and Warrant Liability (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CommonStockAndWarrantLiabilityTextualAbstract_lbl" xml:lang="en-US">Common Stock and Warrant Liability (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CommonStockAndWarrantLiabilityTextualAbstract_lbl" xml:lang="en-US">Common stock and warrant liability.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Financial Assets Measured at Fair Value on Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US">Fair Value of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract_lbl" xml:lang="en-US">Common Stock and Warrant Liability (Additional Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract_lbl" xml:lang="en-US">Common Stock and Warrant Liability (Additional Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract_lbl" xml:lang="en-US">Common stock and warrant liability.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CurrentAccruedLiabilitiesAbstract" xlink:label="cris_CurrentAccruedLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CurrentAccruedLiabilitiesAbstract" xlink:to="cris_CurrentAccruedLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CurrentAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Current Accrued Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CurrentAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Current accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CurrentAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" xlink:label="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" xlink:to="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract_lbl" xml:lang="en-US">Income Loss Per Common Share Antidilutive Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract_lbl" xml:lang="en-US">Income (Loss) Per Common Share Antidilutive Securities - Stock Options And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract_lbl" xml:lang="en-US">Income (loss) per common share antidilutive securities.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationTextualAbstract" xlink:label="cris_AccountingForStockBasedCompensationTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="cris_AccountingForStockBasedCompensationTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_AccountingForStockBasedCompensationTextualAbstract_lbl" xml:lang="en-US">Accounting for Stock-Based Compensation (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_AccountingForStockBasedCompensationTextualAbstract_lbl" xml:lang="en-US">Accounting for Stock-Based Compensation (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_AccountingForStockBasedCompensationTextualAbstract_lbl" xml:lang="en-US">Accounting for stock-based compensation.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:label="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:to="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract_lbl" xml:lang="en-US">Accounting for Stock Based Compensation Options Outstanding and Exercisable [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract_lbl" xml:lang="en-US">Accounting for Stock-Based Compensation (Options Outstanding And Exercisable)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract_lbl" xml:lang="en-US">Accounting for stock based compensation options outstanding and exercisable.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationAbstract" xlink:label="cris_AccountingForStockBasedCompensationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_AccountingForStockBasedCompensationAbstract" xlink:to="cris_AccountingForStockBasedCompensationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_AccountingForStockBasedCompensationAbstract_lbl" xml:lang="en-US">Accounting for Stock Based Compensation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_AccountingForStockBasedCompensationAbstract_lbl" xml:lang="en-US">Accounting for Stock-Based Compensation (Stock Based Compensation Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_AccountingForStockBasedCompensationAbstract_lbl" xml:lang="en-US">Accounting for stock-based compensation.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Accounting For Stock-Based Compensation (Black-Scholes Option Pricing Model)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xml:lang="en-US">Compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized compensation cost, weighted average period for recognition, years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share based compensation arrangement vesting period, years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="lab_WarrantMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_WarrantMember" xml:lang="en-US">Warrants outstanding [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xml:lang="en-US">Fair values of vested stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" xlink:to="lab_AvailableForSaleSecuritiesFairValueDisclosure" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesFairValueDisclosure" xml:lang="en-US">Available-for-sale Securities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesFairValueDisclosure" xml:lang="en-US">Corporate commercial paper, stock, bonds and notes</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassAxis" xlink:label="cris_SaleOfStockByOfferingClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_SaleOfStockByOfferingClassAxis" xlink:to="cris_SaleOfStockByOfferingClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_SaleOfStockByOfferingClassAxis_lbl" xml:lang="en-US">Sale of Stock by Offering Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_SaleOfStockByOfferingClassAxis_lbl" xml:lang="en-US">Sale Of Stock By Offering Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_SaleOfStockByOfferingClassAxis_lbl" xml:lang="en-US">Sale of stock by offering class.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassDomain" xlink:label="cris_SaleOfStockByOfferingClassDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_SaleOfStockByOfferingClassDomain" xlink:to="cris_SaleOfStockByOfferingClassDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_SaleOfStockByOfferingClassDomain_lbl" xml:lang="en-US">Sale of Stock by Offering Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_SaleOfStockByOfferingClassDomain_lbl" xml:lang="en-US">Sale Of Stock By Offering Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_SaleOfStockByOfferingClassDomain_lbl" xml:lang="en-US">Sale of stock by offering class.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_WarrantsAndRightsOutstanding" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_WarrantsAndRightsOutstanding" xml:lang="en-US">Fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="lab_RoyaltyRevenue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RoyaltyRevenue" xml:lang="en-US">Royalty Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RoyaltyRevenue" xml:lang="en-US">Royalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_RelatedPartyTransactionsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transaction [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_RelatedPartyTransactionsDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_GenentechIncMember" xlink:label="cris_GenentechIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_GenentechIncMember" xlink:to="cris_GenentechIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_GenentechIncMember_lbl" xml:lang="en-US">Genentech Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_GenentechIncMember_lbl" xml:lang="en-US">Genentech Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_GenentechIncMember_lbl" xml:lang="en-US">Genentech, inc.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_LeukemiaAndLymphomaSocietyMember" xlink:label="cris_LeukemiaAndLymphomaSocietyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_LeukemiaAndLymphomaSocietyMember" xlink:to="cris_LeukemiaAndLymphomaSocietyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_LeukemiaAndLymphomaSocietyMember_lbl" xml:lang="en-US">Leukemia and Lymphoma Society [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_LeukemiaAndLymphomaSocietyMember_lbl" xml:lang="en-US">Leukemia and Lymphoma Society [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_LeukemiaAndLymphomaSocietyMember_lbl" xml:lang="en-US">Leukemia and lymphoma society.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementsTextualAbstract" xlink:label="cris_CollaborationAgreementsTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_CollaborationAgreementsTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CollaborationAgreementsTextualAbstract_lbl" xml:lang="en-US">Collaboration Agreements (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CollaborationAgreementsTextualAbstract_lbl" xml:lang="en-US">Collaboration Agreements (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CollaborationAgreementsTextualAbstract_lbl" xml:lang="en-US">Collaboration agreements.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" xlink:label="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" xlink:to="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue_lbl" xml:lang="en-US">Revenue Recognized Milestone Payments License Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue_lbl" xml:lang="en-US">Revenue recognized milestone payments as license revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue_lbl" xml:lang="en-US">Revenue recognized milestone payments license revenue.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="lab_RoyaltyExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RoyaltyExpense" xml:lang="en-US">Costs of royalty revenues recorded</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CashPaymentToUniversityLicensor" xlink:label="cris_CashPaymentToUniversityLicensor" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CashPaymentToUniversityLicensor" xlink:to="cris_CashPaymentToUniversityLicensor_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CashPaymentToUniversityLicensor_lbl" xml:lang="en-US">Cash Payment to University Licensor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CashPaymentToUniversityLicensor_lbl" xml:lang="en-US">Cash payment to university licensor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CashPaymentToUniversityLicensor_lbl" xml:lang="en-US">Cash payment to university licensor.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_UniversityLicensorsMember" xlink:label="cris_UniversityLicensorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_UniversityLicensorsMember" xlink:to="cris_UniversityLicensorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_UniversityLicensorsMember_lbl" xml:lang="en-US">University Licensors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_UniversityLicensorsMember_lbl" xml:lang="en-US">University Licensors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_UniversityLicensorsMember_lbl" xml:lang="en-US">University licensors.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" xlink:to="lab_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" xml:lang="en-US">Derivative Financial Instruments, Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities at fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_CashAndCashEquivalentsMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CashAndCashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="us-gaap_InvestmentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsMember" xlink:to="lab_InvestmentsMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InvestmentsMember" xml:lang="en-US">Investments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_InvestmentsMember" xml:lang="en-US">Investments [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="lab_TypeOfArrangementAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_ArrangementsAndNonarrangementTransactionsMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="lab_FairValueByAssetClassAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Fair Value by Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RelatedPartyTransactionTextualAbstract" xlink:label="cris_RelatedPartyTransactionTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_RelatedPartyTransactionTextualAbstract" xlink:to="cris_RelatedPartyTransactionTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_RelatedPartyTransactionTextualAbstract_lbl" xml:lang="en-US">Related Party Transaction (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_RelatedPartyTransactionTextualAbstract_lbl" xml:lang="en-US">Related Party Transaction (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_RelatedPartyTransactionTextualAbstract_lbl" xml:lang="en-US">Related Party Transaction.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_IssuanceOfCommonStockToLicensees" xlink:label="cris_IssuanceOfCommonStockToLicensees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_IssuanceOfCommonStockToLicensees" xlink:to="cris_IssuanceOfCommonStockToLicensees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_IssuanceOfCommonStockToLicensees_lbl" xml:lang="en-US">Issuance of Common Stock to Licensees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_IssuanceOfCommonStockToLicensees_lbl" xml:lang="en-US">Issuance of common stock to licensees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_IssuanceOfCommonStockToLicensees_lbl" xml:lang="en-US">Issuance of common stock to licensees.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="lab_EquityFairValueDisclosure" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EquityFairValueDisclosure" xml:lang="en-US">Equity, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EquityFairValueDisclosure" xml:lang="en-US">Fair value of one-time issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:label="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:to="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_lbl" xml:lang="en-US">Collaboration Agreement Contingent Consideration Potential Cash Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_lbl" xml:lang="en-US">Eligibility to receive contingent cash payments under the collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_lbl" xml:lang="en-US">Collaboration agreement contingent consideration potential cash payment.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="us-gaap_DirectOperatingCostRoyaltyExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCostRoyaltyExpense" xlink:to="lab_DirectOperatingCostRoyaltyExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DirectOperatingCostRoyaltyExpense" xml:lang="en-US">Direct Operating Cost, Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_DirectOperatingCostRoyaltyExpense" xml:lang="en-US">Costs of royalty revenues, company obligated to pay to university licensors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DirectOperatingCostRoyaltyExpense" xml:lang="en-US">Cost of royalty revenues</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_StockIssuedDuringPeriodDueToExerciseOfWarrants" xlink:label="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants" xlink:to="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period Due to Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants_lbl" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants_lbl" xml:lang="en-US">Stock issued during period due to exercise of warrants.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementsAbstract" xlink:label="cris_CollaborationAgreementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CollaborationAgreementsAbstract" xlink:to="cris_CollaborationAgreementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CollaborationAgreementsAbstract_lbl" xml:lang="en-US">Collaboration Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CollaborationAgreementsAbstract_lbl" xml:lang="en-US">Collaboration agreements.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SublicenseFeesPaid" xlink:label="cris_SublicenseFeesPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_SublicenseFeesPaid" xlink:to="cris_SublicenseFeesPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_SublicenseFeesPaid_lbl" xml:lang="en-US">Sublicense Fees Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_SublicenseFeesPaid_lbl" xml:lang="en-US">Research and development expenses related to the FDA's approval and payments received for Erivedge</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_SublicenseFeesPaid_lbl" xml:lang="en-US">Sublicense fees paid.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" xlink:label="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" xlink:to="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned_lbl" xml:lang="en-US">Percentage of Sublicense Fees Paid on Royalties Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned_lbl" xml:lang="en-US">Percentage of royalties earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned_lbl" xml:lang="en-US">Percentage of sublicense fees paid on royalties earned.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PercentageOfContributionToFund" xlink:label="cris_PercentageOfContributionToFund" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_PercentageOfContributionToFund" xlink:to="cris_PercentageOfContributionToFund_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_PercentageOfContributionToFund_lbl" xml:lang="en-US">Percentage of Contribution to Fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_PercentageOfContributionToFund_lbl" xml:lang="en-US">Percentage of contribution of fund from LLS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_PercentageOfContributionToFund_lbl" xml:lang="en-US">Percentage of contribution to fund.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ContingentObligations" xlink:label="cris_ContingentObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ContingentObligations" xlink:to="cris_ContingentObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ContingentObligations_lbl" xml:lang="en-US">Contingent Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_ContingentObligations_lbl" xml:lang="en-US">Company under obligation to make payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ContingentObligations_lbl" xml:lang="en-US">Contingent obligations.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ChangeInFairValueUponWarrantExercise" xlink:label="cris_ChangeInFairValueUponWarrantExercise" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ChangeInFairValueUponWarrantExercise" xlink:to="cris_ChangeInFairValueUponWarrantExercise_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ChangeInFairValueUponWarrantExercise_lbl" xml:lang="en-US">Change in Fair Value Upon Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_ChangeInFairValueUponWarrantExercise_lbl" xml:lang="en-US">Change in fair value of warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ChangeInFairValueUponWarrantExercise_lbl" xml:lang="en-US">Change in warrants liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ChangeInFairValueUponWarrantExercise_lbl" xml:lang="en-US">Change in fair value upon warrant exercise.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ExpectedLivesOfWarrantsYears" xlink:label="cris_ExpectedLivesOfWarrantsYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ExpectedLivesOfWarrantsYears" xlink:to="cris_ExpectedLivesOfWarrantsYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ExpectedLivesOfWarrantsYears_lbl" xml:lang="en-US">Expected Lives of Warrants Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_ExpectedLivesOfWarrantsYears_lbl" xml:lang="en-US">Expected lives of warrants, years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ExpectedLivesOfWarrantsYears_lbl" xml:lang="en-US">Expected lives of warrants years.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SharesIssuedToSublicensees" xlink:label="cris_SharesIssuedToSublicensees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_SharesIssuedToSublicensees" xlink:to="cris_SharesIssuedToSublicensees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_SharesIssuedToSublicensees_lbl" xml:lang="en-US">Shares Issued to Sublicensees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_SharesIssuedToSublicensees_lbl" xml:lang="en-US">Number of common stock shares issued to university licensors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_SharesIssuedToSublicensees_lbl" xml:lang="en-US">Shares issued to sublicensees.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ProceedsFromContributionOfFund" xlink:label="cris_ProceedsFromContributionOfFund" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ProceedsFromContributionOfFund" xlink:to="cris_ProceedsFromContributionOfFund_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ProceedsFromContributionOfFund_lbl" xml:lang="en-US">Proceeds from Contribution of Fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_ProceedsFromContributionOfFund_lbl" xml:lang="en-US">Contribution of fund from LLS amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ProceedsFromContributionOfFund_lbl" xml:lang="en-US">Proceeds from contribution of fund.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MaximumFinancialSupportToRelatedParty" xlink:label="cris_MaximumFinancialSupportToRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_MaximumFinancialSupportToRelatedParty" xlink:to="cris_MaximumFinancialSupportToRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_MaximumFinancialSupportToRelatedParty_lbl" xml:lang="en-US">Maximum Financial Support to Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_MaximumFinancialSupportToRelatedParty_lbl" xml:lang="en-US">Maximum Financial Support to GBMT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_MaximumFinancialSupportToRelatedParty_lbl" xml:lang="en-US">Maximum financial support to related party.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SeveranceAgreementToRelatedParty" xlink:label="cris_SeveranceAgreementToRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_SeveranceAgreementToRelatedParty" xlink:to="cris_SeveranceAgreementToRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_SeveranceAgreementToRelatedParty_lbl" xml:lang="en-US">Severance Agreement to Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_SeveranceAgreementToRelatedParty_lbl" xml:lang="en-US">Severance Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_SeveranceAgreementToRelatedParty_lbl" xml:lang="en-US">Severance agreement to related party.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MilestonesRecognizedFromPartner" xlink:label="cris_MilestonesRecognizedFromPartner" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_MilestonesRecognizedFromPartner" xlink:to="cris_MilestonesRecognizedFromPartner_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_MilestonesRecognizedFromPartner_lbl" xml:lang="en-US">Milestones Recognized From Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_MilestonesRecognizedFromPartner_lbl" xml:lang="en-US">Earned milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_MilestonesRecognizedFromPartner_lbl" xml:lang="en-US">Milestones recognized from partner.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AdditionalMilestoneRecognizedFromPartner" xlink:label="cris_AdditionalMilestoneRecognizedFromPartner" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_AdditionalMilestoneRecognizedFromPartner" xlink:to="cris_AdditionalMilestoneRecognizedFromPartner_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_AdditionalMilestoneRecognizedFromPartner_lbl" xml:lang="en-US">Additional Milestone Recognized From Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_AdditionalMilestoneRecognizedFromPartner_lbl" xml:lang="en-US">Earned an additional milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_AdditionalMilestoneRecognizedFromPartner_lbl" xml:lang="en-US">Additional milestone recognized from partner.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:label="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:to="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_lbl" xml:lang="en-US">Collaboration Agreement Contingent Consideration Received From Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_lbl" xml:lang="en-US">Amount received for specified clinical development and regulatory objectives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_lbl" xml:lang="en-US">Collaboration agreement contingent consideration received from partner.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_EarningsPerShareBasicAndDiluted" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share (basic and diluted)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares (basic and diluted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" xlink:label="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" xlink:to="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber_lbl" xml:lang="en-US">Common Stock Issued One Time Issuance to University Licenses Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber_lbl" xml:lang="en-US">Number of university licensors in connection with the FDA-approval of Erivedge</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber_lbl" xml:lang="en-US">Common stock issued one time issuance to university licenses number.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit" xlink:label="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit" xlink:to="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit_lbl" xml:lang="en-US">Registered Direct Offering Number of Common Stock Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit_lbl" xml:lang="en-US">Registered direct offering, no. of common stock per units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit_lbl" xml:lang="en-US">Registered direct offering number of common stock per unit.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" xlink:label="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" xlink:to="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant_lbl" xml:lang="en-US">Registered Direct Offering Unit Number of Common Stock to Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant_lbl" xml:lang="en-US">Value of warrant in terms of percentage of stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant_lbl" xml:lang="en-US">Registered direct offering unit number of common stock to warrant.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingNumberOfWarrantPerUnit" xlink:label="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit" xlink:to="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit_lbl" xml:lang="en-US">Registered Direct Offering Number of Warrant Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit_lbl" xml:lang="en-US">Registered direct offering, no. of warrants per units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit_lbl" xml:lang="en-US">Registered direct offering number of warrant per unit.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" xlink:label="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" xlink:to="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember_lbl" xml:lang="en-US">Zero Point Seven Nine Us Dollars to One Point Three Us Dollars [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember_lbl" xml:lang="en-US">$0.79 - $1.39 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember_lbl" xml:lang="en-US">Zero point seven nine us dollars to one point three us dollars.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" xlink:label="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" xlink:to="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember_lbl" xml:lang="en-US">One Point Four Three Us Dollars to Two Point One Five Us Dollars [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember_lbl" xml:lang="en-US">1.43 - 2.15 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember_lbl" xml:lang="en-US">One point four three us dollars to two point one five us dollars.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" xlink:label="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" xlink:to="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember_lbl" xml:lang="en-US">Two Point Two Seven Us Dollars to Three Point Seven Six Us Dollars [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember_lbl" xml:lang="en-US">2.27 - 3.76 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember_lbl" xml:lang="en-US">Two point two seven us dollars to three point seven six us dollars.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" xlink:label="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" xlink:to="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember_lbl" xml:lang="en-US">Three Point Nine Eight Us Dollars to Four Point Five Two Us Dollars [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember_lbl" xml:lang="en-US">3.98 - 4.52 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember_lbl" xml:lang="en-US">Three point nine eight us dollars to four point five two us dollars.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" xlink:label="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" xlink:to="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember_lbl" xml:lang="en-US">Four Point Five Six Us Dollars to Five Point Six Zero Us Dollars [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember_lbl" xml:lang="en-US">4.56 - 5.60 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember_lbl" xml:lang="en-US">Four point five six us dollars o five point six zero us dollars.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments [Abstract]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_OutOfPeriodAdjustmentMember" xlink:label="cris_OutOfPeriodAdjustmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_OutOfPeriodAdjustmentMember" xlink:to="cris_OutOfPeriodAdjustmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_OutOfPeriodAdjustmentMember_lbl" xml:lang="en-US">Out of Period Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_OutOfPeriodAdjustmentMember_lbl" xml:lang="en-US">Out of period adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_OutOfPeriodAdjustmentMember_lbl" xml:lang="en-US">Out of Period Adjustment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xml:lang="en-US">The amortized cost, unrealized gains and fair value of marketable securities available-for-sale with maturity dates ranging between one and twelve months and with a weighted average maturity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xml:lang="en-US">The amortized cost, unrealized gains and fair value of marketable securities available-for-sale</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CorporateBondsNotesAndStockMember" xlink:label="cris_CorporateBondsNotesAndStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_CorporateBondsNotesAndStockMember" xlink:to="cris_CorporateBondsNotesAndStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_CorporateBondsNotesAndStockMember_lbl" xml:lang="en-US">Corporate Bonds Notes and Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_CorporateBondsNotesAndStockMember_lbl" xml:lang="en-US">Corporate bonds notes and stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_CorporateBondsNotesAndStockMember_lbl" xml:lang="en-US">Corporate Bonds Notes and Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_AvailableForSaleSecuritiesAmortizedCost" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesAmortizedCost" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesAmortizedCost" xml:lang="en-US">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" xlink:to="lab_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" xml:lang="en-US">Unrealized Gain</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="lab_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xml:lang="en-US">Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="lab_StatementScenarioAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_ScenarioUnspecifiedDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_ScheduleOfAvailableForSaleSecuritiesTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfAvailableForSaleSecuritiesTable" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="lab_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="lab_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_UsGovernmentObligationsMember" xlink:label="cris_UsGovernmentObligationsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_UsGovernmentObligationsMember" xlink:to="cris_UsGovernmentObligationsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_UsGovernmentObligationsMember_lbl" xml:lang="en-US">Us Government Obligations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_UsGovernmentObligationsMember_lbl" xml:lang="en-US">U. S. Government Obligations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_UsGovernmentObligationsMember_lbl" xml:lang="en-US">Us government obligations.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd#invest_InvestmentTextBlock" xlink:label="invest_InvestmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentTextBlock" xlink:to="lab_InvestmentTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InvestmentTextBlock" xml:lang="en-US">Investment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_InvestmentTextBlock" xml:lang="en-US">Investments</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ResearchAndDevelopmentExpenseForMarketingRegistration" xlink:label="cris_ResearchAndDevelopmentExpenseForMarketingRegistration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_ResearchAndDevelopmentExpenseForMarketingRegistration" xlink:to="cris_ResearchAndDevelopmentExpenseForMarketingRegistration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_ResearchAndDevelopmentExpenseForMarketingRegistration_lbl" xml:lang="en-US">Research and Development Expense for Marketing Registration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_ResearchAndDevelopmentExpenseForMarketingRegistration_lbl" xml:lang="en-US">Obligations of Company incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_ResearchAndDevelopmentExpenseForMarketingRegistration_lbl" xml:lang="en-US">Research and development expense for marketing registration.</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PaymentAssociatedFda" xlink:label="cris_PaymentAssociatedFda" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_PaymentAssociatedFda" xlink:to="cris_PaymentAssociatedFda_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_PaymentAssociatedFda_lbl" xml:lang="en-US">Payment Associated Fda</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_PaymentAssociatedFda_lbl" xml:lang="en-US">Payment associated fda.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cris_PaymentAssociatedFda_lbl" xml:lang="en-US">Payment Associated Fda</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_RoyaltyRevenue" xml:lang="en-US">Recognized royalty revenue</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FoodAndDrugAdministrationMember" xlink:label="cris_FoodAndDrugAdministrationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_FoodAndDrugAdministrationMember" xlink:to="cris_FoodAndDrugAdministrationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_FoodAndDrugAdministrationMember_lbl" xml:lang="en-US">Food and Drug Administration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_FoodAndDrugAdministrationMember_lbl" xml:lang="en-US">Food and Drug Administration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_FoodAndDrugAdministrationMember_lbl" xml:lang="en-US">FDA's [Member]</label>
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FHoffmannLaRocheLimitedMember" xlink:label="cris_FHoffmannLaRocheLimitedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cris_FHoffmannLaRocheLimitedMember" xlink:to="cris_FHoffmannLaRocheLimitedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cris_FHoffmannLaRocheLimitedMember_lbl" xml:lang="en-US">F Hoffmann La Roche Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cris_FHoffmannLaRocheLimitedMember_lbl" xml:lang="en-US">F Hoffmann La Roche Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cris_FHoffmannLaRocheLimitedMember_lbl" xml:lang="en-US">Roche [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cris-20120630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Crossfire by Rivet Software version 4.3.96.0 http://www.rivetsoftware.com-->
<!--Based on XBRL 2.1-->
<!--Modified on: 8/8/2012 9:36:52 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://curis.com/2010-09-30/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#BalanceSheets" roleURI="http://curis.com/2010-09-30/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#BalanceSheetsParenthetical" roleURI="http://curis.com/2010-09-30/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#StatementsOfCashFlows" roleURI="http://curis.com/2010-09-30/role/StatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#NatureOfBusiness" roleURI="http://curis.com/2010-09-30/role/NatureOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#BasisOfPresentation" roleURI="http://curis.com/2010-09-30/role/BasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#RevenueRecognition" roleURI="http://curis.com/2010-09-30/role/RevenueRecognition" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurements" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CommonStockAndWarrantLiability" roleURI="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiability" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccruedLiabilities" roleURI="http://curis.com/2010-09-30/role/AccruedLiabilities" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensation" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#IncomeLossPerCommonShare" roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShare" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurementsTables" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccruedLiabilitiesTables" roleURI="http://curis.com/2010-09-30/role/AccruedLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationTables" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#IncomeLossPerCommonShareTables" roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurementsDetails" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#FairValueMeasurementsDetails1" roleURI="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails1" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CommonStockAndWarrantLiabilityDetails" roleURI="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccruedLiabilitiesDetails" roleURI="http://curis.com/2010-09-30/role/AccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetailsTextual" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails1" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#AccountingForStockBasedCompensationDetails2" roleURI="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#IncomeLossPerCommonShareDetails" roleURI="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CollaborationAgreements" roleURI="http://curis.com/role/CollaborationAgreements" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#RelatedPartyTransaction" roleURI="http://curis.com/role/RelatedPartyTransaction" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#CollaborationAgreementsDetails" roleURI="http://curis.com/role/CollaborationAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#RelatedPartyTransactionDetails" roleURI="http://curis.com/role/RelatedPartyTransactionDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#Investments" roleURI="http://curis.com/role/Investments" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#InvestmentsTables" roleURI="http://curis.com/role/InvestmentsTables" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#InvestmentsDetails" roleURI="http://curis.com/role/InvestmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="cris-20120630.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://curis.com/role/StatementsOfOperationsAndComprehensiveLoss" />
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_DocumentAndEntityInformationAbstract" xlink:label="cris_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_634647456620531225" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_634647456620531225" order="100" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_634647456620531225" order="120" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_634647456620531225" order="140" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_634647456620531225" order="160" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_634647456620531225" order="180" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_634647456620531225" order="200" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_634647456620531225" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_634647456620531225" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_634647456620531225" order="80" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/BalanceSheets" xlink:type="extended" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_634255826879066504" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634255826879066504" xlink:to="us-gaap_AssetsAbstract_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634647456620531225" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634647456620531225" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent_634647456620531225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634647456620531225" xlink:to="us-gaap_Goodwill_634647456620531225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634647456620531225" xlink:to="us-gaap_OtherAssetsNoncurrent_634647456620531225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634647456620531225" xlink:to="us-gaap_Assets_634647456620531225" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634255826879066504" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_634647456620531225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_Liabilities_634647456620531225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_CommitmentsAndContingencies_634647456620531225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_StockholdersEquityAbstract_634647456620531225" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_CommonStockValue_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_AdditionalPaidInCapital_634647456620531225" order="40" use="optional" priority="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_634647456620531225" order="60" use="optional" priority="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_634647456620531225" order="80" use="optional" priority="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_StockholdersEquity_634647456620531225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_634647456620531225" xlink:to="loc_AssetsCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent_634647456620531225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_634647456620531225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent_634647456620531225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" xlink:to="loc_LiabilitiesCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent_634647456620531225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_634647456620531225" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_634647456620531225" xlink:to="loc_WarrantsAndRightsOutstanding" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_634647456620531225" xlink:to="us-gaap_TreasuryStockValue_634647456620531225" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/BalanceSheetsParenthetical" xlink:type="extended" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_634255828129016504" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634255828129016504" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634255828129016504" xlink:to="us-gaap_CommonStockSharesAuthorized_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634255828129016504" xlink:to="us-gaap_CommonStockSharesIssued_634647456620531225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634255828129016504" xlink:to="us-gaap_CommonStockSharesOutstanding_634647456620531225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_634255828129016504" xlink:to="us-gaap_TreasuryStockShares_634647456620531225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/StatementsOfCashFlows" xlink:type="extended" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_634255871700816504" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634255871700816504" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_NetIncomeLoss_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_634647456620531225" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_GainLossOnDispositionOfAssets_634647456620531225" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_634647456620531225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_634647456620531225" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_634647456620531225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_634647456620531225" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_634647456620531225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_634647456620531225" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_634647456620531225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_634647456620531225" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634255871700816504" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_634647456620531225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_634647456620687225" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634255871700816504" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634647456620687225" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634255871700816504" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_634647456620687225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634255871700816504" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_634647456620687225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6346474566206872251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_634255871700816504" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6346474566206872251" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_634647456620687225" order="2.5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_634647456620687225" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_DepreciationAndAmortization_634647456620531225" order="1.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_ShareBasedCompensation_634647456620531225" order="2.25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_634647456620531225" order="1.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_634647456620531225" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_634647456620687225" order="2.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_IssuanceOfCommonStockToLicensees" xlink:label="cris_IssuanceOfCommonStockToLicensees" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_634647456620531225" xlink:to="cris_IssuanceOfCommonStockToLicensees" order="2.4375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/NatureOfBusiness" xlink:type="extended" xlink:title="0201 - Disclosure - Nature of Business">
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_NatureOfBusinessAbstract" xlink:label="cris_NatureOfBusinessAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_NatureOfBusinessAbstract" xlink:to="us-gaap_NatureOfOperations_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/BasisOfPresentation" xlink:type="extended" xlink:title="0202 - Disclosure - Basis of Presentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/RevenueRecognition" xlink:type="extended" xlink:title="0203 - Disclosure - Revenue Recognition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract_634437491080726818" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_634437491080726818" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurements" xlink:type="extended" xlink:title="0205 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiability" xlink:type="extended" xlink:title="0207 - Disclosure - Common Stock and Warrant Liability">
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTextBlock" xlink:label="cris_CommonStockAndWarrantLiabilityTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAbstract" xlink:to="cris_CommonStockAndWarrantLiabilityTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccruedLiabilities" xlink:type="extended" xlink:title="0208 - Disclosure - Accrued Liabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensation" xlink:type="extended" xlink:title="0210 - Disclosure - Accounting for Stock-Based Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShare" xlink:type="extended" xlink:title="0211 - Disclosure - Loss Per Common Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsTables" xlink:type="extended" xlink:title="0505 - Disclosure - Fair Value Measurements (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccruedLiabilitiesTables" xlink:type="extended" xlink:title="0508 - Disclosure - Accrued Liabilities (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationTables" xlink:type="extended" xlink:title="0510 - Disclosure - Accounting for Stock-Based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:label="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareTables" xlink:type="extended" xlink:title="0511 - Disclosure - Loss Per Common Share (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails" xlink:type="extended" xlink:title="0605 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_634647456620687225" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_634647456620687225" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_634647456620687225" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_634647456620687225" xlink:to="us-gaap_FairValueInputsLevel1Member_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_634647456620687225" xlink:to="us-gaap_FairValueInputsLevel2Member_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_634647456620687225" xlink:to="us-gaap_FairValueInputsLevel3Member_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_634647456620687225" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634647456620687225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_FairValueByMeasurementFrequencyAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_634647456620687225" xlink:to="loc_FairValueByMeasurementFrequencyAxis" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_FairValueMeasurementFrequencyDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueByMeasurementFrequencyAxis" xlink:to="loc_FairValueMeasurementFrequencyDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_FairValueMeasurementsRecurringMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueMeasurementFrequencyDomain" xlink:to="loc_FairValueMeasurementsRecurringMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_AssetsFairValueDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634647456620687225" xlink:to="loc_AssetsFairValueDisclosureAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MoneyMarketFundsFairValue" xlink:label="cris_MoneyMarketFundsFairValue_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsFairValueDisclosureAbstract" xlink:to="cris_MoneyMarketFundsFairValue_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueDisclosure" xlink:label="loc_AvailableForSaleSecuritiesFairValueDisclosure" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsFairValueDisclosureAbstract" xlink:to="loc_AvailableForSaleSecuritiesFairValueDisclosure" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_FairValueByAssetClassAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_634647456620687225" xlink:to="loc_FairValueByAssetClassAxis" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueByAssetClassAxis" xlink:to="loc_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_CashAndCashEquivalentsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_CashAndCashEquivalentsMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="loc_InvestmentsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_InvestmentsMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure_634647456620687225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" xlink:label="loc_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsFairValueDisclosureAbstract" xlink:to="loc_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsFairValueDisclosureAbstract" xlink:to="loc_WarrantsAndRightsOutstanding" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/FairValueMeasurementsDetails1" xlink:type="extended" xlink:title="06051 - Disclosure - Fair Value Measurements (Details 1)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ChangeInFairValueUponWarrantExercise" xlink:label="cris_ChangeInFairValueUponWarrantExercise" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="cris_ChangeInFairValueUponWarrantExercise" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_WarrantsAndRightsOutstanding" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails" xlink:type="extended" xlink:title="0607 - Disclosure - Common Stock and Warrant Liability (Details)">
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTable" xlink:label="cris_CommonStockAndWarrantLiabilityTable_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAbstract" xlink:to="cris_CommonStockAndWarrantLiabilityTable_634647456620687225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityTable_634647456620687225" xlink:to="us-gaap_RangeAxis_634647456620687225" order="40" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_634647456620687225" xlink:to="us-gaap_RangeMember_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_634647456620687225" xlink:to="us-gaap_MinimumMember_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_634647456620687225" xlink:to="us-gaap_MaximumMember_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityLineItems" xlink:label="cris_CommonStockAndWarrantLiabilityLineItems_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityTable_634647456620687225" xlink:to="cris_CommonStockAndWarrantLiabilityLineItems_634647456620687225" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityLineItems_634647456620687225" xlink:to="cris_CommonStockAndWarrantLiabilityTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:label="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAbstract" xlink:to="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingUnits" xlink:label="cris_RegisteredDirectOfferingUnits_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_RegisteredDirectOfferingUnits_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_DirectOfferingPurchasePrice" xlink:label="cris_DirectOfferingPurchasePrice_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_DirectOfferingPurchasePrice_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts_634647456620687225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_634647456620687225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_TermOfWarrantsYears" xlink:label="cris_TermOfWarrantsYears_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_TermOfWarrantsYears_634647456620687225" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassAxis" xlink:label="cris_SaleOfStockByOfferingClassAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityTable_634647456620687225" xlink:to="cris_SaleOfStockByOfferingClassAxis" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SaleOfStockByOfferingClassDomain" xlink:label="cris_SaleOfStockByOfferingClassDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_SaleOfStockByOfferingClassAxis" xlink:to="cris_SaleOfStockByOfferingClassDomain" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_WarrantMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_SaleOfStockByOfferingClassDomain" xlink:to="loc_WarrantMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="loc_WarrantsAndRightsOutstanding" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RangeOfExpectedVolatilities" xlink:label="cris_RangeOfExpectedVolatilities_2" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_RangeOfExpectedVolatilities_2" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_634647456620687225" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_EstimatedRiskFreeInterestRate" xlink:label="cris_EstimatedRiskFreeInterestRate_2" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:to="cris_EstimatedRiskFreeInterestRate_2" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_634647456620687225" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_StockIssuedDuringPeriodDueToExerciseOfWarrants" xlink:label="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_StockIssuedDuringPeriodDueToExerciseOfWarrants" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ExpectedLivesOfWarrantsYears" xlink:label="cris_ExpectedLivesOfWarrantsYears" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:to="cris_ExpectedLivesOfWarrantsYears" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" order="170" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ChangeInFairValueUponWarrantExercise" xlink:label="cris_ChangeInFairValueUponWarrantExercise" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_ChangeInFairValueUponWarrantExercise" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit" xlink:label="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" xlink:label="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityTextualAbstract" xlink:to="cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RegisteredDirectOfferingNumberOfWarrantPerUnit" xlink:label="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract" xlink:to="cris_RegisteredDirectOfferingNumberOfWarrantPerUnit" order="51.25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccruedLiabilitiesDetails" xlink:type="extended" xlink:title="0608 - Disclosure - Accrued Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CurrentAccruedLiabilitiesAbstract" xlink:label="cris_CurrentAccruedLiabilitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="cris_CurrentAccruedLiabilitiesAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CurrentAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_634647456620687225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CurrentAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CurrentAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CurrentAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedSalariesCurrent_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual" xlink:type="extended" xlink:title="06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_634647456620687225" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_634647456620687225" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_NonEmployeeDirectorsMember" xlink:label="cris_NonEmployeeDirectorsMember_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_634647456620687225" xlink:to="cris_NonEmployeeDirectorsMember_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_634647456620687225" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationTextualAbstract" xlink:label="cris_AccountingForStockBasedCompensationTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_634647456620687225" xlink:to="cris_AccountingForStockBasedCompensationTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ShareBasedCompensationPlans" xlink:label="cris_ShareBasedCompensationPlans_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="cris_ShareBasedCompensationPlans_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_634647456620687225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_634647456620687225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_634647456620687225" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_634647456620687225" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_634647456620687225" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationTextualAbstract" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense_634647456620687225" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails" xlink:type="extended" xlink:title="0610 - Disclosure - Accounting for Stock-Based Compensation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_634647456620687225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_634647456620687225" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_634647456620687225" xlink:to="us-gaap_DirectorMember_634647456620687225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_634647456620687225" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_634647456620687225" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_634647456620687225" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_634647456620687225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_634647456620687225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_634647456620687225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_634647456620687225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_634647456620687225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_634647456620687225" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1" xlink:type="extended" xlink:title="06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_634647456620843225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_634647456620843225" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_634647456620843225" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_634647456620843225" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_634647456620843225" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_634647456620843225" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_634647456620843225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_634647456620843225" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_634647456620843225" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationAbstract" xlink:label="cris_AccountingForStockBasedCompensationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_634647456620843225" xlink:to="cris_AccountingForStockBasedCompensationAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensation_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2" xlink:type="extended" xlink:title="06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_634647456620843225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_634647456620843225" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634647456620843225" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634647456620843225" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_634647456620843225" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_634647456620843225" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:label="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_634647456620843225" xlink:to="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_634647456620843225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_634647456620843225" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_634647456620843225" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract" xlink:to="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" xlink:label="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634647456620843225" xlink:to="cris_ZeroPointSevenNineUsDollarsToOnePointThreeUsDollarsMember" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" xlink:label="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634647456620843225" xlink:to="cris_OnePointFourThreeUsDollarsToTwoPointOneFiveUsDollarsMember" order="55" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" xlink:label="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634647456620843225" xlink:to="cris_TwoPointTwoSevenUsDollarsToThreePointSevenSixUsDollarsMember" order="57.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" xlink:label="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634647456620843225" xlink:to="cris_ThreePointNineEightUsDollarsToFourPointFiveTwoUsDollarsMember" order="58.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" xlink:label="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634647456620843225" xlink:to="cris_FourPointFiveSixUsDollarsToFivePointSixZeroUsDollarsMember" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails" xlink:type="extended" xlink:title="0611 - Disclosure - Loss Per Common Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_634647456620843225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_634647456620843225" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_634647456620843225" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_634647456620843225" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_634647456620843225" xlink:to="us-gaap_StockOptionsMember_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_634647456620843225" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_634647456620843225" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" xlink:label="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_634647456620843225" xlink:to="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_634647456620843225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_634647456620843225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_WarrantMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_634647456620843225" xlink:to="loc_WarrantMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreements" xlink:title="0204 - Disclosure - Collaboration Agreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_CollaborativeArrangementDisclosureTextBlock" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementsAbstract" xlink:label="cris_CollaborationAgreementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsAbstract" xlink:to="loc_CollaborativeArrangementDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/RelatedPartyTransaction" xlink:title="0209 - Disclosure - Related Party Transaction">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_RelatedPartyTransactionsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RelatedPartyTransactionsAbstract" xlink:to="loc_RelatedPartyTransactionsDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/CollaborationAgreementsDetails" xlink:title="0604 - Disclosure - Collaboration Agreements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_GenentechIncMember" xlink:label="cris_GenentechIncMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_GenentechIncMember" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_LeukemiaAndLymphomaSocietyMember" xlink:label="cris_LeukemiaAndLymphomaSocietyMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_LeukemiaAndLymphomaSocietyMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementsTextualAbstract" xlink:label="cris_CollaborationAgreementsTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cris_CollaborationAgreementsTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_RoyaltyRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="loc_RoyaltyRevenue" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_RoyaltyExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="loc_RoyaltyExpense" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CashPaymentToUniversityLicensor" xlink:label="cris_CashPaymentToUniversityLicensor" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_CashPaymentToUniversityLicensor" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_TypeOfArrangementAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_TypeOfArrangementAxis" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TypeOfArrangementAxis" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_UniversityLicensorsMember" xlink:label="cris_UniversityLicensorsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cris_UniversityLicensorsMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_EquityFairValueDisclosure" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="loc_EquityFairValueDisclosure" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:label="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementsAbstract" xlink:label="cris_CollaborationAgreementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsAbstract" xlink:to="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SublicenseFeesPaid" xlink:label="cris_SublicenseFeesPaid" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_SublicenseFeesPaid" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" xlink:label="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PercentageOfContributionToFund" xlink:label="cris_PercentageOfContributionToFund" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_PercentageOfContributionToFund" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ContingentObligations" xlink:label="cris_ContingentObligations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_ContingentObligations" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SharesIssuedToSublicensees" xlink:label="cris_SharesIssuedToSublicensees" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_SharesIssuedToSublicensees" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ProceedsFromContributionOfFund" xlink:label="cris_ProceedsFromContributionOfFund" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_ProceedsFromContributionOfFund" order="315" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MilestonesRecognizedFromPartner" xlink:label="cris_MilestonesRecognizedFromPartner" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_MilestonesRecognizedFromPartner" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_AdditionalMilestoneRecognizedFromPartner" xlink:label="cris_AdditionalMilestoneRecognizedFromPartner" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_AdditionalMilestoneRecognizedFromPartner" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:label="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" xlink:label="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_DirectOperatingCostRoyaltyExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="loc_DirectOperatingCostRoyaltyExpense" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" xlink:label="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_RevenueRecognizedMilestonePaymentsLicenseRevenue" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementScenarioAxis" order="50" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_OutOfPeriodAdjustmentMember" xlink:label="cris_OutOfPeriodAdjustmentMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="cris_OutOfPeriodAdjustmentMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ResearchAndDevelopmentExpenseForMarketingRegistration" xlink:label="cris_ResearchAndDevelopmentExpenseForMarketingRegistration" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_ResearchAndDevelopmentExpenseForMarketingRegistration" order="275" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense_634647456620531225" order="277.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_PaymentAssociatedFda" xlink:label="cris_PaymentAssociatedFda" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_CollaborationAgreementsTextualAbstract" xlink:to="cris_PaymentAssociatedFda" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FoodAndDrugAdministrationMember" xlink:label="cris_FoodAndDrugAdministrationMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_FoodAndDrugAdministrationMember" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_FHoffmannLaRocheLimitedMember" xlink:label="cris_FHoffmannLaRocheLimitedMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="cris_FHoffmannLaRocheLimitedMember" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/RelatedPartyTransactionDetails" xlink:title="0609 - Disclosure - Related Party Transaction (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_RelatedPartyTransactionTextualAbstract" xlink:label="cris_RelatedPartyTransactionTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RelatedPartyTransactionsAbstract" xlink:to="cris_RelatedPartyTransactionTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_RelatedPartyTransactionTextualAbstract" xlink:to="loc_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_MaximumFinancialSupportToRelatedParty" xlink:label="cris_MaximumFinancialSupportToRelatedParty" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_RelatedPartyTransactionTextualAbstract" xlink:to="cris_MaximumFinancialSupportToRelatedParty" order="30" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_SeveranceAgreementToRelatedParty" xlink:label="cris_SeveranceAgreementToRelatedParty" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cris_RelatedPartyTransactionTextualAbstract" xlink:to="cris_SeveranceAgreementToRelatedParty" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/Investments" xlink:title="0206 - Disclosure - Investments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd#invest_InvestmentTextBlock" xlink:label="invest_InvestmentTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="invest_InvestmentTextBlock" order="10" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsTables" xlink:title="0506 - Disclosure - Investments (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/InvestmentsDetails" xlink:title="0606 - Disclosure - Investments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="40" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_CorporateBondsNotesAndStockMember" xlink:label="cris_CorporateBondsNotesAndStockMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cris_CorporateBondsNotesAndStockMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_UsGovernmentObligationsMember" xlink:label="cris_UsGovernmentObligationsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cris_UsGovernmentObligationsMember" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss" order="12.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="7.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://curis.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_634255829165046504" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="us-gaap_RevenuesAbstract_634647456620531225" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="us-gaap_CostsAndExpensesAbstract_634647456620531225" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_634647456620531225" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="95" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_ComprehensiveIncomeNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="loc_ComprehensiveIncomeNetOfTax" order="97.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="us-gaap_NetIncomeLoss_2" order="85" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634647456620531225" xlink:to="us-gaap_NonoperatingIncomeExpense_634647456620531225" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634647456620531225" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_634647456620531225" order="45" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_634647456620531225" xlink:to="us-gaap_InvestmentIncomeInterest_634647456620531225" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_634255829165046504" xlink:to="us-gaap_OperatingIncomeLoss_634647456620531225" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_634647456620531225" xlink:to="us-gaap_CostsAndExpenses_634647456620531225" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_634647456620531225" xlink:to="us-gaap_GeneralAndAdministrativeExpense_634647456620531225" order="65" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_634647456620531225" xlink:to="us-gaap_ResearchAndDevelopmentExpense_634647456620531225" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_DirectOperatingCostRoyaltyExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_634647456620531225" xlink:to="loc_DirectOperatingCostRoyaltyExpense" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_634647456620531225" xlink:to="us-gaap_Revenues_634647456620531225" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_634647456620531225" xlink:to="us-gaap_LicensesRevenue_634647456620531225" order="65" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_RoyaltyRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_634647456620531225" xlink:to="loc_RoyaltyRevenue" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cris-20120630.xsd#cris_ResearchAndDevelopmentRevenue" xlink:label="cris_ResearchAndDevelopmentRevenue_634647456620531225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_634647456620531225" xlink:to="cris_ResearchAndDevelopmentRevenue_634647456620531225" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Common Share (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract', window );"><strong>Income (Loss) Per Common Share Antidilutive Securities - Stock Options And Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
        <td class="nump">12,120,042<span></span></td>
        <td class="nump">13,439,045<span></span></td>
        <td class="nump">12,120,042<span></span></td>
        <td class="nump">13,439,045<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options outstanding [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract', window );"><strong>Income (Loss) Per Common Share Antidilutive Securities - Stock Options And Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
        <td class="nump">10,721,724<span></span></td>
        <td class="nump">11,828,227<span></span></td>
        <td class="nump">10,721,724<span></span></td>
        <td class="nump">11,828,227<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants outstanding [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract', window );"><strong>Income (Loss) Per Common Share Antidilutive Securities - Stock Options And Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
        <td class="nump">1,398,318<span></span></td>
        <td class="nump">1,610,818<span></span></td>
        <td class="nump">1,398,318<span></span></td>
        <td class="nump">1,610,818<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_IncomeLossPerCommonShareAntidilutiveSecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETNAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Investments (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>The amortized cost, unrealized gains and fair value of marketable securities available-for-sale</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">$ 32,608,962<span></span></td>
        <td class="nump">$ 22,596,419<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss', window );">Unrealized Gain</a></td>
        <td class="nump">7,185<span></span></td>
        <td class="nump">1,426<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Value</a></td>
        <td class="nump">32,616,147<span></span></td>
        <td class="nump">22,597,845<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U. S. Government Obligations [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>The amortized cost, unrealized gains and fair value of marketable securities available-for-sale</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,808,641<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss', window );">Unrealized Gain</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">63<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,808,704<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Corporate Bonds Notes and Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>The amortized cost, unrealized gains and fair value of marketable securities available-for-sale</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">32,608,962<span></span></td>
        <td class="nump">18,787,778<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss', window );">Unrealized Gain</a></td>
        <td class="nump">7,185<span></span></td>
        <td class="nump">1,363<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Value</a></td>
        <td class="nump">$ 32,616,147<span></span></td>
        <td class="nump">$ 18,789,141<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 7<br><br> -Footnote 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 19<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesAmortizedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 17<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-1<br><br> -Paragraph 21<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of gross unrealized gains (losses) for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27357-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - us-gaap:CollaborativeArrangementDisclosureTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>4.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Collaboration Agreements</u> </b></font></td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">(a)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">Genentech June 2003 Collaboration </font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">
   In January 2012, the FDA approved Genentech&#8217;s New Drug Application for the Erivedge capsule for the treatment of adults with basal cell carcinoma that has spread to other parts of the body or that
   has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is being developed and commercialized by F. Hoffmann-La Roche Ltd, or Roche, and Genentech, a member of the Roche Group,
   under a collaboration agreement between the Company and Genentech. As a result of the FDA's approval of Erivedge in this indication, the Company earned a $10,000,000 milestone payment from Genentech and is also entitled to receive royalties on
   future sales of the product. In May 2012, Roche announced that it has submitted an application for marketing registration for Erivedge to Australia&#8217;s Therapeutic Goods Administration, or TGA, and as a result, the Company earned an additional
   $4,000,000 milestone payment. The Company is eligible to receive up to an aggregate of $115,000,000 in contingent cash payments under the collaboration for the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming
   the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. As of June&#160;30, 2012, the Company has received $46,000,000 in the aggregate since the inception of the agreement. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company recognized $4,000,000 and $14,000,000 in milestone payments as license revenue in its Condensed Consolidated
   Statement of Operations for the three and six months ended June&#160;30, 2012, respectively, as the Company does not have any further substantive performance obligations under the collaboration. The Company did not recognize license revenue under
   this collaboration during the three and six months ended June&#160;20, 2011. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">In connection with the receipt of
   milestone payments from Genentech, the Company recorded research and development expenses of $650,000 and $2,114,000 during the three and six months ended June&#160;30, 2012, respectively, which represents the Company&#8217;s obligations to
   university licensors. Research and development expenses of $650,000 recorded during the three months ended June&#160;30, 2012 include $550,000 for obligations the Company incurred in connection with Roche&#8217;s application to the TGA for marketing
   registration for Erivedge in Australia and the related $4,000,000 milestone that the Company received. The remaining $100,000 in research and development expense recorded during the three months ended June&#160;30, 2012 represents an immaterial
   out-of-period expense associated with Roche's 2009 investigational new drug filing in Australia. The Company also recorded research and development expenses of $500,000 during the six months ended June&#160;30, 2012, related to the Company&#8217;s
   receipt of the $10,000,000 milestone payment associated with the FDA&#8217;s U.S. approval of Erivedge in January 2012. The remaining expense of $964,000 recognized during the six months ended June&#160;30, 2012 represents the fair value of a
   one-time issuance of an aggregate of 200,000 shares of the Company&#8217;s common stock in March 2012 to two university licensors in connection with the FDA-approval of Erivedge. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company also recognized $252,750 and $523,372 in royalty revenue from Genentech&#8217;s net sales of Erivedge during
   the three and six months ended June&#160;30, 2012, respectively. The Company recorded cost of royalty revenues within the costs and expenses section of its Condensed Consolidated Statements of Operations of $12,637 and $126,168 during these same
   periods. Cost of royalty revenues include $12,637 and $26,168 for the three and six months ended June&#160;30, 2012, respectively, which represents 5% of the royalties earned by the Company with respect to Erivedge that the Company is obligated to
   pay to two university licensors. Cost of royalty revenues for the six months ended June&#160;30, 2012 also includes a one-time cash payment of $100,000 paid to a university licensor upon the first commercial sale of Erivedge. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">(b)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">The Leukemia&#160;&#038; Lymphoma Society Agreement </font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">
   In November 2011, the Company entered into an agreement with The Leukemia&#160;&#038; Lymphoma Society, or LLS, under which LLS will support the Company&#8217;s ongoing development of CUDC-907 for patients
   with B-cell lymphoma and multiple myeloma. Under the agreement, LLS will fund approximately 50% of the direct costs of the development of CUDC-907, up to $4,000,000. Under certain conditions associated with the successful partnering and/or
   commercialization of CUDC-907 in these indications, the Company may be obligated to make payments to LLS up to a maximum of $10,000,000. As of June&#160;30, 2012, the Company has not received any payments or recorded any revenue under this agreement
   to date and expects that the first milestone could be achieved in the second half of 2012 as CUDC-907 nears the filing of an investigational new drug application, or IND. Additional milestones would be earned as the Company progresses CUDC-907 into
   a phase Ia clinical trial. </font></p>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CollaborationAgreementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-1<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.871U
M<F5?;V9?0G5S:6YE<W,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y"87-I<U]O9E]0<F5S96YT871I;VX\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2979E;G5E7U)E8V]G;FET:6]N/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]L;&%B;W)A
M=&EO;E]!9W)E96UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N=',\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E<W1M96YT<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UO;E]3=&]C:U]A
M;F1?5V%R<F%N=%],:6%B:3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D%C8W)U961?3&EA8FEL:71I97,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T
M:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C
M;W5N=&EN9U]F;W)?4W1O8VM"87-E9%]#;VUP/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3&]S<U]097)?0V]M;6]N7U-H87)E/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU
M95]-96%S=7)E;65N='-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^26YV97-T;65N='-?5&%B;&5S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C<G5E9%],:6%B:6QI=&EE
M<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y!8V-O=6YT:6YG7V9O<E]3=&]C:T)A<V5D7T-O;7`Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&]S<U]097)?0V]M;6]N7U-H
M87)E7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D-O;&QA8F]R871I;VY?06=R965M96YT<U]$971A:3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R
M96UE;G1S7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S7T1E=&%I;#$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E<W1M96YT<U]$
M971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M0V]M;6]N7U-T;V-K7V%N9%]787)R86YT7TQI86)I,3PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8W)U961?3&EA8FEL:71I97-?
M1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VY?1&5T83PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8V]U;G1I;F=?9F]R7U-T;V-K
M0F%S961?0V]M<#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y!8V-O=6YT:6YG7V9O<E]3=&]C:T)A<V5D7T-O;7`S/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C;W5N=&EN9U]F;W)?
M4W1O8VM"87-E9%]#;VUP-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D%C8V]U;G1I;F=?9F]R7U-T;V-K0F%S961?0V]M<#4\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,;W-S7U!E<E]#
M;VUM;VY?4VAA<F5?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^
M#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC
M<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@
M/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E
M/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W
M<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*
M/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@
M;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V%A-3(R
M-#DQ7V)B,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]A834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E
M86%C-S,W,&(O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44%!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y
M($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M075G+B`P,BP@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^0U5225,@24Y#/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!)
M;F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#$Q
M,#@R,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^2G5N(#,P+`T*"0DR,#$R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N
M9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L
M<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D
M($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R
M<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E;&5R871E9"!&:6QE
M<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.2PV,C(L-3DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%#04<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!"
M86QA;F-E(%-H965T<R`H56YA=61I=&5D*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#=7)R96YT($%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPP.#DL-C4U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2PQ
M,3DL-S,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,R+#8Q-BPQ-#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPU.3<L.#0U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,3@L,S`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#(L,#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V4@86YD(&]T:&5R(&-U<G)E
M;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3<L
M,3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S0S+#<Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-2PT,C$L,C0W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L-3`S+#0T,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,C@L.34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#4U+#<S,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT97)M(&EN=F5S=&UE
M;G0@+2!R97-T<FEC=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.30L,C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C,U+#DQ-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L.3@R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.3@R+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DX,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-2PP,CDL-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#@L,3@P+#`V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT($QI86)I;&ET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#0R.2PS,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#,V-"PT,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#8R+#8R-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#(R
M+#$P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L-#DQ+#DT,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S@V+#4T-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S`T+#DR,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M,S8Q+#$V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@;&]N9RUT97)M(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S<L-S`S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#,Y-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#DW-"PU-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX+#,P-"PQ,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)#`N,#$@
M<&%R('9A;'5E(#$R-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R`X,"PU
M.#$L-3DV('-H87)E<R!I<W-U960@86YD(#<Y+#4S,RPX.#D@<VAA<F5S(&]U
M='-T86YD:6YG(&%T($IU;F4@,S`L(#(P,3([(&%N9"`W."PQ-C4L,S8P('-H
M87)E<R!I<W-U960@86YD(#<W+#$Q-RPV-3,@<VAA<F5S(&]U='-T86YD:6YG
M(&%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX,#4L.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S@Q+#8U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A
M<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W.2PX-#@L
M.3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S<R+#`S.2PR-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K("AA="!C;W-T+"`Q+#`T
M-RPW,#<@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.#DQ+#(W-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@X.3$L,C<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S,R+#<T."PS-3<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S,R+#`X-RPV
M-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-U;75L871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDL-S(S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L.38U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0W+#`U-"PX.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PX-S4L.34W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA
M8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4U+#`R.2PT-3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X+#$X,"PP-C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V%A-3(R
M-#DQ7V)B,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]A834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E
M86%C-S,W,&(O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-DA!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A
M=&5D($)A;&%N8V4@4VAE971S("A087)E;G1H971I8V%L*2`H56YA=61I=&5D
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE;G0@;V8@1FEN86YC:6%L
M(%!O<VET:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX,"PU.#$L-3DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S@L,38U+#,V,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S
M:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<Y+#4S,RPX.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-RPQ,3<L-C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@870@
M8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-#<L-S`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP-#<L-S`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]A834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E86%C-S,W,&(-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86$U,C(T.3%?8F(S,%\T,68Q
M7V$W9F1?-C8P96%A8S<S-S!B+U=O<FMS:&5E=',O4VAE970P-"YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P15%,04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N9&5N<V5D
M($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@86YD($-O
M;7!R96AE;G-I=F4@3&]S<R`H56YA=61I=&5D*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY2159%3E5%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DX+#@R-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3(L.#8W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q.#0L-#4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R,C8L-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U,BPW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,C,L,S<R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&9E97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,U,2PU-S0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3(L.#8W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L-S`W
M+#@R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4R-BPT,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0T]35%,@04Y$($584$5.4T53.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W-T(&]F
M(')O>6%L='D@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R+#8S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R-BPQ-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,#`L-#4V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-#0L
M,#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.2PW-#(L-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPR,#(L-30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A
M=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-C0L-3@V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PX-C<L-S@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PP-C4L-C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PR-S4L,3,Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]S=',@86YD
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<W
M-RPV-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU+#`Q,2PX,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-"PY,S0L,C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-#<W+#8X,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O
M;2!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#0R-BPQ,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-"PV,3@L.38U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(R-BPT,3`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PY-3$L,C<U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/5$A%4B!)3D-/344O*$584$5.4T4I.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#DY-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#,T,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#`Y-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X
M+#DQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N="!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0Y-2PS-#$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S(P
M+#0T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T.#<L-#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L.#(Q+#@U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-C`L,S0W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y-2PP
M.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-#,T+#,P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q+#<V,BPY-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(L.#@V+#0U,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#DQ-"PP-C0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C8P+#<Q
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,2PW,30L,C$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R92`H8F%S
M:6,@86YD(&1I;'5T960I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#`N,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@P+C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XP,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,34I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R
M86=E(&-O;6UO;B!S:&%R97,@*&)A<VEC(&%N9"!D:6QU=&5D*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL,#4R+#4Q-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+#,W."PS-CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M."PS,#0L-#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S8L,3`S+#8Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]M<')E:&5N<VEV92!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(L.#DY+#(S,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#0L.3,Q+#$X.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#8U-"PY-3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,2PW,C4L.#<S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?86$U,C(T.3%?8F(S,%\T
M,68Q7V$W9F1?-C8P96%A8S<S-S!B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V%A-3(R-#DQ7V)B,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8B]7
M;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5#1$%'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M
M96YT<R!O9B!#87-H($9L;W=S("A5;F%U9&ET960I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!
M4T@@1DQ/5U,@1E)/32!/4$52051)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-C8P+#<Q-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q+#<Q
M-"PR,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@
M;&]S<R!T;R!N970@8V%S:"!P<F]V:61E9"!B>2\H=7-E9"!I;BD@;W!E<F%T
M:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,"PT,S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PP.#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#`S,"PT,3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`S.2PU-3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E
M(&]F(&-O;6UO;B!S=&]C:R!T;R!L:6-E;G-E97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDV-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E
M(&]F('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT.#<L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PX,C$L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!I;G1E<F5S="`H
M:6YC;VUE*2]E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Y.2PQ-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(P+#,V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&=A:6X@;VX@<V%L92!O9B!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V+#0T-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C<V+#(S.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W+#$U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T
M:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8X
M+#0X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(R+#$X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<S+#(Y
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,3<L-S8P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&%D:G5S=&UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#,V,BPP,S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@X-RPV.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S
M:"!P<F]V:61E9"!B>2\H=7-E9"!I;BD@;W!E<F%T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S`Q+#,Q-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L.#(V
M+#4S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($E.5D535$E.1R!!0U1)
M5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0=7)C:&%S92!O9B!M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,P+#$V,RPX,C,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4L-C$Q+#$W
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-A;&4@;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,"PR-3`L-#4P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L,#DW+#@Q-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R
M8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,S+#8U,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#8L,S<X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!S86QE(&]F(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S8L-#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$96-R96%S92!I;B!R97-T<FEC=&5D(&-A<V@\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#8S,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q.2PT-3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@8V%S:"`H=7-E9"!I;BDO('!R;W9I9&5D(&)Y(&EN=F5S=&EN9R!A8W1I
M=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#DP-2PS
M.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPT.38L,38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!&24Y!3D-)
M3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@=6YD97(@=&AE($-O;7!A;GDG<R!S:&%R92UB87-E9"!C;VUP96YS
M871I;VX@<&QA;G,@86YD('=A<G)A;G0@97AE<F-I<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#$W-"PP,#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(Y-2PV,C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ-S0L,#`R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.34L-C(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3D54($1%0U)%05-%($E.($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,#,P+#`W-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`S-"PW
M-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#05-(($%.1"!#05-(($5154E604Q%3E13+"!"14=)3DY)3D<@3T8@
M4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PQ,3DL
M-S,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPX,C8L-30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#05-(($%.1"!#05-(($5154E604Q%3E13+"!%3D0@
M3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R
M+#`X.2PV-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#8L-SDQ+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?86$U,C(T.3%?8F(S,%\T,68Q7V$W9F1?-C8P96%A
M8S<S-S!B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V%A-3(R-#DQ
M7V)B,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8B]7;W)K<VAE971S+U-H965T
M,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.
M871U<F4@;V8@0G5S:6YE<W,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY.871U<F4@;V8@0G5S:6YE<W,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.871U<F4@;V8@0G5S:6YE<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!8
M2%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G
M+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*
M("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`Q("T@=7,M9V%A<#I.
M871U<F5/9D]P97)A=&EO;G,M+3X-"B`@(#PA+2T@>&)R;"QN<R`M+3X-"B`@
M(#PA+2T@>&)R;"QN>"`M+3X-"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/"]B/CPO9F]N=#X-
M"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^/&(^/"]B/CPO9F]N=#X-"B`@(#QT86)L92!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G
M(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#0E('9A
M;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXQ+CPO8CX\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CQB/CQU/DYA='5R92!O9B!"=7-I;F5S<SPO=3X@/"]B/CPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS
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M;GD-"B`@('1H870@:7,@8V]M;6ET=&5D('1O(&QE=F5R86=I;F<@:71S(&EN
M;F]V871I=F4@<VEG;F%L:6YG('!A=&AW87D@9')U9R!T96-H;F]L;V=I97,@
M:6X@<V5E:VEN9R!T;R!D979E;&]P(&YE>'0@9V5N97)A=&EO;B!N971W;W)K
M+71A<F=E=&5D(&-A;F-E<B!T:&5R87!I97,N($-U<FES(&ES(&)U:6QD:6YG
M('5P;VX@:71S('!A<W0@97AP97)I96YC97,@:6X@=&%R9V5T:6YG('-I9VYA
M;&EN9R!P871H=V%Y<RP@:6YC;'5D:6YG('1H90T*("`@2&5D9V5H;V<@<VEG
M;F%L:6YG('!A=&AW87DL(&EN(&ET<R!E9F9O<G1S('1O(&1E=F5L;W`@;F5T
M=V]R:RUT87)G971E9"!C86YC97(@=&AE<F%P:65S+B!#=7)I<R!C;VYD=6-T
M<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@<')O9W)A;7,@8F]T:"!I;G1E
M<FYA;&QY(&%N9"!T:')O=6=H('-T<F%T96=I8R!C;VQL86)O<F%T:6]N<RX@
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
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M=F%I;&%B;&4@:6X@1F5B<G5A<GD@,C`Q,B`H<V5E($YO=&4@-"DN(#PO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z-"4[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/@T*("`@5&AE($-O;7!A;GD@:7,@<W5B:F5C="!T;R!R:7-K<R!C
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M="!A<'!R;V%C:&5S.PT*("`@<F5L:6%N8V4@;VX@8V]R<&]R871E(&-O;&QA
M8F]R871O<G,@86YD(&QI8V5N<V5E<R!T;R!S=6-C97-S9G5L;'D@<F5S96%R
M8V@L(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@<')O9'5C=',@8F%S960@
M;VX@:71S('1E8VAN;VQO9VEE<SL@:71S(&%B:6QI='D@=&\@8V]M<&QY('=I
M=&@@1D1!(')E9W5L871I;VYS(&%N9"!A<'!R;W9A;"!R97%U:7)E;65N=',[
M(&ET<R!A8FEL:71Y('1O(&5X96-U=&4@;VX@:71S(&)U<VEN97-S#0H@("!S
M=')A=&5G:65S.R!A;F0@:71S(&%B:6QI='D@=&\@;V)T86EN(&%D97%U871E
M(&9I;F%N8VEN9R!T;R!F=6YD(&ET<R!O<&5R871I;VYS+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O
M;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY4:&4@0V]M<&%N>28C.#(Q-SMS(&9U='5R90T*("`@;W!E<F%T:6YG(')E
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M("`@0V]M<&%N>28C.#(Q-SMS(&]P97)A=&EO;G,@=VEL;"!V87)Y('-I9VYI
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M86P@<F5S;W5R8V5S(&%T($IU;F4F(S$V,#LS,"P@,C`Q,B!S:&]U;&0@96YA
M8FQE('1H92!#;VUP86YY('1O(&UA:6YT86EN(&ET<R!C=7)R96YT(&%N9`T*
M("`@<&QA;FYE9"!O<&5R871I;VYS(&EN=&\@=&AE(&9I<G-T(&AA;&8@;V8@
M,C`Q-"X@5&AE($-O;7!A;GDF(S@R,3<[<R!A8FEL:71Y('1O(&-O;G1I;G5E
M(&9U;F1I;F<@:71S('!L86YN960@;W!E<F%T:6]N<R!I;G1O(&%N9"!B97EO
M;F0@=&AE(&9I<G-T(&AA;&8@;V8@,C`Q-"!I<R!D97!E;F1E;G0@=7!O;BP@
M86UO;F<@;W1H97(@=&AI;F=S+"!T:&4@<W5C8V5S<R!O9B!I=',@8V]L;&%B
M;W)A=&EO;G,@=VET:"!'96YE;G1E8V@-"B`@($EN8RXL(&]R($=E;F5N=&5C
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M;VQL86)O<F%T:6]N<R!I<R!H:6=H;'D-"B`@('5N8V5R=&%I;BX@07,@82!R
M97-U;'0L('1H92!#;VUP86YY(&-A;FYO="!A<W-U<F4@=&AA="!I="!W:6QL
M(&%T=&%I;B!A;GD@9G5R=&AE<B!R979E;G5E('5N9&5R(&%N>2!C;VQL86)O
M<F%T:6]N<R!O<B!L:6-E;G-I;F<@87)R86YG96UE;G1S+B!)9B!T:&4@0V]M
M<&%N>2!I<R!U;F%B;&4@=&\@;V)T86EN(&%D97%U871E(&9I;F%N8VEN9RP@
M=&AE($-O;7!A;GD@;6%Y(&)E(')E<75I<F5D('1O(')E9'5C92!O<B!D96QA
M>0T*("`@<W!E;F1I;F<@;VX@:71S(')E<V5A<F-H(&%N9"]O<B!D979E;&]P
M;65N="!P<F]G<F%M<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N
M="US:7IE.C$X<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^
M)B,Q-C`[/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]A834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E86%C-S,W,&(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86$U,C(T.3%?8F(S,%\T
M,68Q7V$W9F1?-C8P96%A8S<S-S!B+U=O<FMS:&5E=',O4VAE970P-RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D)A<VES(&]F
M(%!R97-E;G1A=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@0V]L
M;&%B;W)A=&EV92!!<G)A;F=E;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E
M;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/
M0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N
M<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T14
M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN
M($)L;V-K(%1A9V=E9"!.;W1E(#(@+2!U<RUG86%P.D]R9V%N:7IA=&EO;D-O
M;G-O;&ED871I;VY!;F10<F5S96YT871I;VY/9D9I;F%N8VEA;%-T871E;65N
M='-$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\=&%B;&4@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!B
M;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED
M=&@],T0Q,#`E/B`-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0T)2!V86QI
M9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^,BX\+V(^/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CX\8CX\=3Y"87-I<R!O9B!0<F5S96YT871I;VX\+W4^(#PO8CX\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4]
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M86YD($%R=&EC;&4@,3`@;V8@4F5G=6QA=&EO;B!3+5@N(%1H97-E('-T871E
M;65N=',L(&AO=V5V97(L(&%R92!C;VYD96YS960@86YD(&1O(&YO="!I;F-L
M=61E(&%L;"!D:7-C;&]S=7)E<R!R97%U:7)E9"!B>2!G96YE<F%L;'D@86-C
M97!T960@86-C;W5N=&EN9R!P<FEN8VEP;&5S+"!O<B!'04%0+"!I;B!T:&4@
M52Y3+B!F;W(@8V]M<&QE=&4-"B`@(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N
M9"!S:&]U;&0@8F4@<F5A9"!I;B!C;VYJ=6YC=&EO;B!W:71H('1H92!#;VUP
M86YY)B,X,C$W.W,@06YN=6%L(%)E<&]R="!O;B!&;W)M(#$P+4L@9F]R('1H
M92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L(&%S(&9I;&5D
M('=I=&@@=&AE(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@
M;VX@1F5B<G5A<GDF(S$V,#LR.2P@,C`Q,BX@/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M
M87)G:6XM;&5F=#HT)3L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^26X@=&AE
M(&]P:6YI;VX@;V8@=&AE($-O;7!A;GDL('1H92!U;F%U9&ET960@9FEN86YC
M:6%L('-T871E;65N=',@8V]N=&%I;B!A;&P@861J=7-T;65N=',@*&%L;"!O
M9B!W:&EC:"!W97)E(&-O;G-I9&5R960-"B`@(&YO<FUA;"!A;F0@<F5C=7)R
M:6YG*2!N96-E<W-A<GD@9F]R(&$@9F%I<B!S=&%T96UE;G0@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!F:6YA;F-I86P@<&]S:71I;VX@870@2G5N928C,38P
M.S,P+"`R,#$R(&%N9"!T:&4@<F5S=6QT<R!O9B!O<&5R871I;VYS(&%N9"!C
M87-H(&9L;W=S(&9O<B!T:&4@<VEX+6UO;G1H('!E<FEO9',@96YD960@2G5N
M928C,38P.S,P+"`R,#$R(&%N9"`R,#$Q+B!4:&4@<')E<&%R871I;VX@;V8@
M=&AE#0H@("!#;VUP86YY)B,X,C$W.W,@0V]N9&5N<V5D($-O;G-O;&ED871E
M9"!&:6YA;F-I86P@4W1A=&5M96YT<R!I;B!C;VYF;W)M:71Y('=I=&@@1T%!
M4"!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA:V4@97-T:6UA=&5S(&%N9"!A
M<W-U;7!T:6]N<R!T:&%T(&%F9F5C="!T:&4@<F5P;W)T960@86UO=6YT<R!A
M;F0@9&ES8VQO<W5R92!O9B!C97)T86EN(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@870@=&AE(&)A;&%N8V4@<VAE970@9&%T92X-"B`@(%-U8V@@97-T:6UA
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M(&5S=&EM871E<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US
M:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q
M-C`[/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'@[;6%R9VEN
M+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY4:&5S90T*("`@:6YT97)I;2!R97-U;'1S(&%R92!N;W0@;F5C
M97-S87)I;'D@:6YD:6-A=&EV92!O9B!R97-U;'1S('1O(&)E(&5X<&5C=&5D
M(&9O<B!A(&9U;&P@>65A<B!O<B!S=6)S97%U96YT(&EN=&5R:6T@<&5R:6]D
M<RX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3AP>#MM
M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V%A-3(R
M-#DQ7V)B,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]A834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E
M86%C-S,W,&(O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5V96YU92!296-O9VYI=&EO;CQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E=F5N=64@4F5C;V=N:71I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(%)E8V]G;FET
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E0
M12!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I
M;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH
M=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO
M8VL@5&%G9V5D($YO=&4@,R`M('5S+6=A87`Z4VEG;FEF:6-A;G1!8V-O=6YT
M:6YG4&]L:6-I97-497AT0FQO8VLM+3X-"B`@(#QT86)L92!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&)O
M<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#0E('9A;&EG
M;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXS+CPO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/CQB/CQU/E)E=F5N=64@4F5C;V=N:71I;VX\+W4^(#PO8CX\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T
M.C0E.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>28C.#(Q
M-SMS(&)U<VEN97-S('-T<F%T96=Y(&EN8VQU9&5S(&5N=&5R:6YG(&EN=&\@
M8V]L;&%B;W)A=&EV92!L:6-E;G-E(&%N9"!D979E;&]P;65N=`T*("`@86=R
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M;VX@<&]L:6-Y+"!S964@3F]T92`R*&,I(&EN8VQU9&5D(&EN(&ET<R!A;FYU
M86P@<F5P;W)T(&]N($9O<FT@,3`M2RP@87,@<')E=FEO=7-L>2!F:6QE9"!W
M:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S:6]N(&]N
M($9E8G)U87)Y)B,Q-C`[,CDL(#(P,3(N#0H@("`\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3AP>#MM87)G:6XM=&]P.C!P>#MM87)G
M:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V%A-3(R-#DQ7V)B,S!?-#%F,5]A-V9D
M7S8V,&5A86,W,S<P8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A
M834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E86%C-S,W,&(O5V]R:W-H965T
M<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]L;&%B;W)A=&EO;B!!9W)E96UE;G1S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]L;&%B;W)A=&EO
M;B!!9W)E96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!!9W)E96UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H
M=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA
M;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL
M,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@
M5&%G9V5D($YO=&4@-"`M('5S+6=A87`Z0V]L;&%B;W)A=&EV94%R<F%N9V5M
M96YT1&ES8VQO<W5R951E>'1";&]C:RTM/@T*("`@/'1A8FQE('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@
M8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I
M9'1H/3-$,3`P)3X@#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-"4@=F%L
M:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C0N/"]B/CPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^/&(^/'4^0V]L;&%B;W)A=&EO;B!!9W)E96UE;G1S/"]U/B`\+V(^
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T
M>6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T
M=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!B;W)D97(]
M,T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q
M,#`E/B`-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0T)3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=VED=&@],T0T)2!V
M86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*&$I/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY'96YE;G1E8V@@2G5N92`R,#`S($-O;&QA8F]R871I;VX@/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT
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M96-H+"!A(&UE;6)E<B!O9B!T:&4@4F]C:&4@1W)O=7`L#0H@("!U;F1E<B!A
M(&-O;&QA8F]R871I;VX@86=R965M96YT(&)E='=E96X@=&AE($-O;7!A;GD@
M86YD($=E;F5N=&5C:"X@07,@82!R97-U;'0@;V8@=&AE($9$02=S(&%P<')O
M=F%L(&]F($5R:79E9&=E(&EN('1H:7,@:6YD:6-A=&EO;BP@=&AE($-O;7!A
M;GD@96%R;F5D(&$@)#$P+#`P,"PP,#`@;6EL97-T;VYE('!A>6UE;G0@9G)O
M;2!'96YE;G1E8V@@86YD(&ES(&%L<V\@96YT:71L960@=&\@<F5C96EV92!R
M;WEA;'1I97,@;VX-"B`@(&9U='5R92!S86QE<R!O9B!T:&4@<')O9'5C="X@
M26X@36%Y(#(P,3(L(%)O8VAE(&%N;F]U;F-E9"!T:&%T(&ET(&AA<R!S=6)M
M:71T960@86X@87!P;&EC871I;VX@9F]R(&UA<FME=&EN9R!R96=I<W1R871I
M;VX@9F]R($5R:79E9&=E('1O($%U<W1R86QI828C.#(Q-SMS(%1H97)A<&5U
M=&EC($=O;V1S($%D;6EN:7-T<F%T:6]N+"!O<B!41T$L(&%N9"!A<R!A(')E
M<W5L="P@=&AE($-O;7!A;GD@96%R;F5D(&%N(&%D9&ET:6]N86P-"B`@("0T
M+#`P,"PP,#`@;6EL97-T;VYE('!A>6UE;G0N(%1H92!#;VUP86YY(&ES(&5L
M:6=I8FQE('1O(')E8V5I=F4@=7`@=&\@86X@86=G<F5G871E(&]F("0Q,34L
M,#`P+#`P,"!I;B!C;VYT:6YG96YT(&-A<V@@<&%Y;65N=',@=6YD97(@=&AE
M(&-O;&QA8F]R871I;VX@9F]R('1H92!D979E;&]P;65N="!O9B!%<FEV961G
M92!O<B!A;F]T:&5R('-M86QL(&UO;&5C=6QE($AE9&=E:&]G('!A=&AW87D@
M:6YH:6)I=&]R+"!A<W-U;6EN9PT*("`@=&AE('-U8V-E<W-F=6P@86-H:65V
M96UE;G0@8GD@1V5N96YT96-H(&%N9"!2;V-H92!O9B!S<&5C:69I960@8VQI
M;FEC86P@9&5V96QO<&UE;G0@86YD(')E9W5L871O<GD@;V)J96-T:79E<RX@
M07,@;V8@2G5N928C,38P.S,P+"`R,#$R+"!T:&4@0V]M<&%N>2!H87,@<F5C
M96EV960@)#0V+#`P,"PP,#`@:6X@=&AE(&%G9W)E9V%T92!S:6YC92!T:&4@
M:6YC97!T:6]N(&]F('1H92!A9W)E96UE;G0N(#PO9F]N=#X\+W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@
M;6%R9VEN+6QE9G0Z-"4[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!#
M;VUP86YY(')E8V]G;FEZ960@)#0L,#`P+#`P,"!A;F0@)#$T+#`P,"PP,#`@
M:6X@;6EL97-T;VYE('!A>6UE;G1S(&%S(&QI8V5N<V4@<F5V96YU92!I;B!I
M=',@0V]N9&5N<V5D($-O;G-O;&ED871E9`T*("`@4W1A=&5M96YT(&]F($]P
M97)A=&EO;G,@9F]R('1H92!T:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*
M=6YE)B,Q-C`[,S`L(#(P,3(L(')E<W!E8W1I=F5L>2P@87,@=&AE($-O;7!A
M;GD@9&]E<R!N;W0@:&%V92!A;GD@9G5R=&AE<B!S=6)S=&%N=&EV92!P97)F
M;W)M86YC92!O8FQI9V%T:6]N<R!U;F1E<B!T:&4@8V]L;&%B;W)A=&EO;BX@
M5&AE($-O;7!A;GD@9&ED(&YO="!R96-O9VYI>F4@;&EC96YS92!R979E;G5E
M('5N9&5R#0H@("!T:&ES(&-O;&QA8F]R871I;VX@9'5R:6YG('1H92!T:')E
M92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,C`L(#(P,3$N(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z-"4[('1E>'0M:6YD96YT.C0E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@<F5C96EP="!O9@T*
M("`@;6EL97-T;VYE('!A>6UE;G1S(&9R;VT@1V5N96YT96-H+"!T:&4@0V]M
M<&%N>2!R96-O<F1E9"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS
M97,@;V8@)#8U,"PP,#`@86YD("0R+#$Q-"PP,#`@9'5R:6YG('1H92!T:')E
M92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3(L(')E
M<W!E8W1I=F5L>2P@=VAI8V@@<F5P<F5S96YT<R!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&]B;&EG871I;VYS('1O#0H@("!U;FEV97)S:71Y(&QI8V5N<V]R<RX@
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S(&]F("0V-3`L,#`P
M(')E8V]R9&5D(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($IU;F4F
M(S$V,#LS,"P@,C`Q,B!I;F-L=61E("0U-3`L,#`P(&9O<B!O8FQI9V%T:6]N
M<R!T:&4@0V]M<&%N>2!I;F-U<G)E9"!I;B!C;VYN96-T:6]N('=I=&@@4F]C
M:&4F(S@R,3<[<R!A<'!L:6-A=&EO;B!T;R!T:&4@5$=!(&9O<B!M87)K971I
M;F<-"B`@(')E9VES=')A=&EO;B!F;W(@17)I=F5D9V4@:6X@075S=')A;&EA
M(&%N9"!T:&4@<F5L871E9"`D-"PP,#`L,#`P(&UI;&5S=&]N92!T:&%T('1H
M92!#;VUP86YY(')E8V5I=F5D+B!4:&4@<F5M86EN:6YG("0Q,#`L,#`P(&EN
M(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E(')E8V]R9&5D(&1U
M<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q
M,B!R97!R97-E;G1S(&%N(&EM;6%T97)I86P-"B`@(&]U="UO9BUP97)I;V0@
M97AP96YS92!A<W-O8VEA=&5D('=I=&@@4F]C:&4G<R`R,#`Y(&EN=F5S=&EG
M871I;VYA;"!N97<@9')U9R!F:6QI;F<@:6X@075S=')A;&EA+B!4:&4@0V]M
M<&%N>2!A;'-O(')E8V]R9&5D(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E
M>'!E;G-E<R!O9B`D-3`P+#`P,"!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD
M960@2G5N928C,38P.S,P+"`R,#$R+"!R96QA=&5D('1O('1H92!#;VUP86YY
M)B,X,C$W.W,-"B`@(')E8V5I<'0@;V8@=&AE("0Q,"PP,#`L,#`P(&UI;&5S
M=&]N92!P87EM96YT(&%S<V]C:6%T960@=VET:"!T:&4@1D1!)B,X,C$W.W,@
M52Y3+B!A<'!R;W9A;"!O9B!%<FEV961G92!I;B!*86YU87)Y(#(P,3(N(%1H
M92!R96UA:6YI;F<@97AP96YS92!O9B`D.38T+#`P,"!R96-O9VYI>F5D(&1U
M<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3(@
M<F5P<F5S96YT<R!T:&4@9F%I<B!V86QU92!O9B!A#0H@("!O;F4M=&EM92!I
M<W-U86YC92!O9B!A;B!A9V=R96=A=&4@;V8@,C`P+#`P,"!S:&%R97,@;V8@
M=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@:6X@36%R8V@@,C`Q
M,B!T;R!T=V\@=6YI=F5R<VET>2!L:6-E;G-O<G,@:6X@8V]N;F5C=&EO;B!W
M:71H('1H92!&1$$M87!P<F]V86P@;V8@17)I=F5D9V4N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@;6%R9VEN+6QE9G0Z-"4[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E1H92!#;VUP86YY(&%L<V\@<F5C;V=N:7IE9"`D,C4R+#<U,"!A;F0@)#4R
M,RPS-S(@:6X@<F]Y86QT>2!R979E;G5E(&9R;VT@1V5N96YT96-H)B,X,C$W
M.W,@;F5T('-A;&5S(&]F($5R:79E9&=E(&1U<FEN9PT*("`@=&AE('1H<F5E
M(&%N9"!S:7@@;6]N=&AS(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,BP@<F5S
M<&5C=&EV96QY+B!4:&4@0V]M<&%N>2!R96-O<F1E9"!C;W-T(&]F(')O>6%L
M='D@<F5V96YU97,@=VET:&EN('1H92!C;W-T<R!A;F0@97AP96YS97,@<V5C
M=&EO;B!O9B!I=',@0V]N9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S
M(&]F($]P97)A=&EO;G,@;V8@)#$R+#8S-R!A;F0@)#$R-BPQ-C@@9'5R:6YG
M('1H97-E('-A;64-"B`@('!E<FEO9',N($-O<W0@;V8@<F]Y86QT>2!R979E
M;G5E<R!I;F-L=61E("0Q,BPV,S<@86YD("0R-BPQ-C@@9F]R('1H92!T:')E
M92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3(L(')E
M<W!E8W1I=F5L>2P@=VAI8V@@<F5P<F5S96YT<R`U)2!O9B!T:&4@<F]Y86QT
M:65S(&5A<FYE9"!B>2!T:&4@0V]M<&%N>2!W:71H(')E<W!E8W0@=&\@17)I
M=F5D9V4@=&AA="!T:&4@0V]M<&%N>2!I<R!O8FQI9V%T960@=&\-"B`@('!A
M>2!T;R!T=V\@=6YI=F5R<VET>2!L:6-E;G-O<G,N($-O<W0@;V8@<F]Y86QT
M>2!R979E;G5E<R!F;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N928C,38P
M.S,P+"`R,#$R(&%L<V\@:6YC;'5D97,@82!O;F4M=&EM92!C87-H('!A>6UE
M;G0@;V8@)#$P,"PP,#`@<&%I9"!T;R!A('5N:79E<G-I='D@;&EC96YS;W(@
M=7!O;B!T:&4@9FER<W0@8V]M;65R8VEA;"!S86QE(&]F($5R:79E9&=E+B`\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I
M;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT
M86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M
M86QI9VXZ(&QE9G0G(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W
M:61T:#TS1#0E/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!W:61T:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXH8BD\+V9O;G0^/"]T9#X@#0H@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!,975K96UI828C,38P.R8C,#,X
M.R!,>6UP:&]M82!3;V-I971Y($%G<F5E;65N="`\+V9O;G0^/"]T9#X-"B`@
M(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@($EN($YO=F5M8F5R(#(P,3$L('1H
M92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!A9W)E96UE;G0@=VET:"!4:&4@
M3&5U:V5M:6$F(S$V,#LF(S`S.#L@3'EM<&AO;6$@4V]C:65T>2P@;W(@3$Q3
M+"!U;F1E<B!W:&EC:"!,3%,@=VEL;"!S=7!P;W)T('1H92!#;VUP86YY)B,X
M,C$W.W,@;VYG;VEN9R!D979E;&]P;65N="!O9B!#541#+3DP-R!F;W(@<&%T
M:65N=',-"B`@('=I=&@@0BUC96QL(&QY;7!H;VUA(&%N9"!M=6QT:7!L92!M
M>65L;VUA+B!5;F1E<B!T:&4@86=R965M96YT+"!,3%,@=VEL;"!F=6YD(&%P
M<')O>&EM871E;'D@-3`E(&]F('1H92!D:7)E8W0@8V]S=',@;V8@=&AE(&1E
M=F5L;W!M96YT(&]F($-51$,M.3`W+"!U<"!T;R`D-"PP,#`L,#`P+B!5;F1E
M<B!C97)T86EN(&-O;F1I=&EO;G,@87-S;V-I871E9"!W:71H('1H92!S=6-C
M97-S9G5L('!A<G1N97)I;F<@86YD+V]R#0H@("!C;VUM97)C:6%L:7IA=&EO
M;B!O9B!#541#+3DP-R!I;B!T:&5S92!I;F1I8V%T:6]N<RP@=&AE($-O;7!A
M;GD@;6%Y(&)E(&]B;&EG871E9"!T;R!M86ME('!A>6UE;G1S('1O($Q,4R!U
M<"!T;R!A(&UA>&EM=6T@;V8@)#$P+#`P,"PP,#`N($%S(&]F($IU;F4F(S$V
M,#LS,"P@,C`Q,BP@=&AE($-O;7!A;GD@:&%S(&YO="!R96-E:79E9"!A;GD@
M<&%Y;65N=',@;W(@<F5C;W)D960@86YY(')E=F5N=64@=6YD97(@=&AI<R!A
M9W)E96UE;G0-"B`@('1O(&1A=&4@86YD(&5X<&5C=',@=&AA="!T:&4@9FER
M<W0@;6EL97-T;VYE(&-O=6QD(&)E(&%C:&EE=F5D(&EN('1H92!S96-O;F0@
M:&%L9B!O9B`R,#$R(&%S($-51$,M.3`W(&YE87)S('1H92!F:6QI;F<@;V8@
M86X@:6YV97-T:6=A=&EO;F%L(&YE=R!D<G5G(&%P<&QI8V%T:6]N+"!O<B!)
M3D0N($%D9&ET:6]N86P@;6EL97-T;VYE<R!W;W5L9"!B92!E87)N960@87,@
M=&AE($-O;7!A;GD@<')O9W)E<W-E<R!#541#+3DP-R!I;G1O#0H@("!A('!H
M87-E($EA(&-L:6YI8V%L('1R:6%L+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,3AP>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T
M=&]M.C!P>#XF(S$V,#L\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1F%I<B!686QU92!-96%S=7)E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M
M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)
M0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H
M='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET
M:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO
M=&4@-2`M('5S+6=A87`Z1F%I<E9A;'5E365A<W5R96UE;G1);G!U='-$:7-C
M;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\=&%B;&4@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!B;W)D97(]
M,T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q
M,#`E/B`-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0T)2!V86QI9VX],T1T
M;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^-2X\+V(^/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\
M8CX\=3Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO=3X@/"]B/CPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS1"=M
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M;65N=',N($=!05`@86QS;R!D969I;F5S(&9A:7(@=F%L=64@87,@=&AE(&5X
M8VAA;F=E('!R:6-E('1H870@=V]U;&0@8F4@<F5C96EV960@9F]R(&%N(&%S
M<V5T(&]R('!A:60@=&\@=')A;G-F97(@82!L:6%B:6QI='D@*&%N(&5X:70@
M<')I8V4I(&EN('1H92!P<FEN8VEP86P@;W(@;6]S="!A9'9A;G1A9V5O=7,@
M;6%R:V5T(&9O<B!T:&4@87-S970-"B`@(&]R(&QI86)I;&ET>2!I;B!A;B!O
M<F1E<FQY('1R86YS86-T:6]N(&)E='=E96X@;6%R:V5T('!A<G1I8VEP86YT
M<R!O;B!T:&4@;65A<W5R96UE;G0@9&%T92X@36%R:V5T('!A<G1I8VEP86YT
M<R!A<F4@8G5Y97)S(&%N9"!S96QL97)S(&EN('1H92!P<FEN8VEP86P@;6%R
M:V5T('1H870@87)E("AI*28C,38P.VEN9&5P96YD96YT+"`H:6DI)B,Q-C`[
M:VYO=VQE9&=E86)L92P@*&EI:2DF(S$V,#MA8FQE('1O('1R86YS86-T+"!A
M;F0-"B`@("AI=BDF(S$V,#MW:6QL:6YG('1O('1R86YS86-T+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY4:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D
M+"!O<B!&05-"+"!#;V1I9FEC871I;VX@5&]P:6,@.#(P+`T*("`@/&D^1F%I
M<B!686QU92!-96%S=7)E;65N=',@86YD($1I<V-L;W-U<F5S+"`\+VD^<F5Q
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M<')E<V5N="!A;6]U;G0@;VX@82!D:7-C;W5N=&5D(&)A<VES+B!4:&4-"B`@
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M97)A<F-H>2!W:&EC:"!R97%U:7)E<R!A;@T*("`@96YT:71Y('1O(&UA>&EM
M:7IE('1H92!U<V4@;V8@;V)S97)V86)L92!I;G!U=',L('=H97)E(&%V86EL
M86)L92P@86YD(&UI;FEM:7IE('1H92!U<V4@;V8@=6YO8G-E<G9A8FQE(&EN
M<'5T<R!W:&5N(&UE87-U<FEN9R!F86ER('9A;'5E+B!4:&4@<W1A;F1A<F0@
M9&5S8W)I8F5S('1H<F5E(&QE=F5L<R!O9B!I;G!U=',@=&AA="!M87D@8F4@
M=7-E9"!T;R!M96%S=7)E(&9A:7(@=F%L=64Z(#PO9F]N=#X\+W`^#0H@("`\
M<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I
M;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.30E(&)O<F1E<CTS1#`@
M<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N
M.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@
M2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=VED=&@],T0Y,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!"
M;V1Y("TM/@T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX\8CY,979E;"8C,38P.S$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^475O=&5D('!R:6-E
M<R!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L
M:6%B:6QI=&EE<RX\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!C;VQS<&%N/3-$,CXF(S$V
M,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/CQB/DQE=F5L(#(\+V(^/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3V)S97)V
M86)L92!I;G!U=',@;W1H97(@=&AA;B!,979E;"`Q('!R:6-E<RP@<W5C:"!A
M<R!Q=6]T960@<')I8V5S(&9O<B!S:6UI;&%R(&%S<V5T<R!O<B!L:6%B:6QI
M=&EE<SL@<75O=&5D('!R:6-E<R!I;B!M87)K971S('1H870@87)E(&YO="!A
M8W1I=F4[(&]R(&]T:&5R(&EN<'5T<R!T:&%T(&%R90T*("`@;V)S97)V86)L
M92!O<B!C86X@8F4@8V]R<F]B;W)A=&5D(&)Y(&]B<V5R=F%B;&4@;6%R:V5T
M(&1A=&$@9F]R('-U8G-T86YT:6%L;'D@=&AE(&9U;&P@=&5R;2!O9B!T:&4@
M87-S971S(&]R(&QI86)I;&ET:65S+CPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P
M86X],T0R/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^3&5V96P@,SPO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O
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M('=A<PT*("`@=F%L=65D('5S:6YG(&$@<')O8F%B:6QI='DM=V5I9VAT960@
M0FQA8VLM4V-H;VQE<R!M;V1E;"P@9&ES8W5S<V5D(&9U<G1H97(@:6X@3F]T
M92`V+"!A;F0@:7,@=&AE<F5F;W)E(&-L87-S:69I960@87,@3&5V96PF(S$V
M,#LS+CPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"B`@(#QP('-T>6QE/3-$9F]N="US
M:7IE.C%P>#MM87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V
M,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z-"4[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/DEN#0H@("!A8V-O<F1A;F-E('=I=&@@=&AE(&9A:7(@=F%L=64@
M:&EE<F%R8VAY+"!T:&4@9F]L;&]W:6YG('1A8FQE('-H;W=S('1H92!F86ER
M('9A;'5E(&%S(&]F($IU;F4@,S`L(#(P,3(@86YD($1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,3$@;V8@=&AO<V4@9FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL
M:71I97,@=&AA="!A<F4@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E
M8W5R<FEN9R!B87-I<RP@86-C;W)D:6YG('1O('1H90T*("`@=F%L=6%T:6]N
M('1E8VAN:7%U97,@=&AE($-O;7!A;GD@=7-E9"!T;R!D971E<FUI;F4@=&AE
M:7(@9F%I<B!M87)K970@=F%L=64N($YO(&9I;F%N8VEA;"!A<W-E=',@;W(@
M;&EA8FEL:71I97,@87)E(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!N
M;VYR96-U<G)I;F<@8F%S:7,@870@2G5N928C,38P.S,P+"`R,#$R(&%N9"!$
M96-E;6)E<B8C,38P.S,Q+"`R,#$Q+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T
M=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE
M/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F
M="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-#DE/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY1=6]T960F(S$V,#M0<FEC
M97,F(S$V,#MI;CQB<B`O/D%C=&EV92!-87)K971S/&)R("\^*$QE=F5L(#$I
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D]T:&5R/&)R("\^3V)S
M97)V86)L93QB<B`O/DEN<'5T<R8C,38P.RA,979E;"8C,38P.S(I/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E5N;V)S97)V86)L93QB<B`O/DEN
M<'5T<R8C,38P.RA,979E;"8C,38P.S,I/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/D9A:7(@5F%L=64\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*
M("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(]
M,T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^/&(^07,@;V8@2G5N928C,38P.S,P+"`R,#$R.CPO8CX\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#87-H
M(&5Q=6EV86QE;G1S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^36]N97D@;6%R:V5T(&9U
M;F1S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<L
M.#,R+#`V-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-RPX,S(L,#8V/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M375N:6-I<&%L(&)O;F1S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^,BPQ-#4L,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXR+#$T-2PP,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY);G9E<W1M96YT<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/D-O<G!O<F%T92!C;VUM97)C:6%L('!A<&5R+"!S
M=&]C:RP@8F]N9',@86YD(&YO=&5S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,38L-#(S+#0T.3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,38L,3DR+#8Y.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,S(L-C$V+#$T-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&]T86P@87-S971S(&%T(&9A:7(@
M=F%L=64\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,C0L,C4U+#4Q-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$X+#,S-RPV.3@\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([
M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^-#(L-3DS+#(Q,SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL
M93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D(&-O;'-P86X],T0T/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O
M;'-P86X],T0T/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0T/B8C
M,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0T/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/E=A<G)A;G1S/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M-"PS,#0L.3(R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+#,P-"PY,C(\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y
M;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L(&QI86)I
M;&ET:65S(&%T(&9A:7(@=F%L=64\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+#,P-"PY,C(\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT
M+#,P-"PY,C(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M/&(^07,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q,3H\+V(^/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(]
M,T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^0V%S:"!E<75I=F%L96YT<SPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DUO;F5Y(&UA<FME="!F=6YD<SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+#,V-BPW
M-#<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C4L,S8V+#<T-SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O
M;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/DUU;FEC:7!A;"!B;VYD<SPO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L,S<U+#`P,#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPS-S4L,#`P/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M26YV97-T;65N=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY54R!G;W9E<FYM96YT(&]B
M;&EG871I;VYS/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPX
M,#@L-S`T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXS+#@P."PW,#0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C4N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@8V]M;65R8VEA
M;"!P87!E<BP@<W1O8VLL(&)O;F1S(&%N9"!N;W1E<SPO9F]N=#X\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<L,S8U+#@T,3PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,3$L-#(S+#,P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P
M.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3@L-S@Y+#$T,3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL
M93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V
M86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P
M96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&]T86P@87-S971S
M(&%T(&9A:7(@=F%L=64\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,34L,3`W+#4X.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$U+#(S,BPP,#0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,S`L,S,Y+#4Y,CPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY787)R86YT<SPO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q
M,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C0L,S8Q+#$V.#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PS-C$L
M,38X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY4;W1A;"!L:6%B:6QI=&EE<R!A="!F86ER('9A;'5E/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PS
M-C$L,38X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^-"PS-C$L,38X/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N
M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B
M;&4^(`T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB
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M;F5D(&)Y($QE=F5L)B,Q-C`[,R!I;G!U=',@9F]R('1H92!S:7@@;6]N=&AS
M(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,2!A;F0@,C`Q,CH@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP
M<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@8F]R
M9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E
M>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I
M;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#@U
M)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-
M"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A
M8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY"86QA;F-E
M(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`\+V9O;G0^/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PV,#0L-S0R/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0VAA;F=E
M(&EN(&9A:7(@=F%L=64@/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,2PX,C$L.#4P/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N
M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY"86QA;F-E(&%T($IU;F4F(S$V,#LS,"P@,C`Q,3PO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS+#0R-BPU
M.3(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!C;VQS<&%N/3-$-#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY"86QA;F-E(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PS-C$L,38X/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HU+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5V%R<F%N=',@97AE<F-I<V5D(#PO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@U
M-#,L-C0V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/D-H86YG92!I;B!F86ER('9A;'5E(#PO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0X-RPT,#`\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D)A;&%N8V4@870@
M2G5N928C,38P.S,P+"`R,#$R/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C0L,S`T+#DR,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"B`@(#QP('-T>6QE/3-$
M9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP
M<'@^)B,Q-C`[/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=F5S
M=&UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YV97-T;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!0
M54),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.
M(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A
M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E
M9"!.;W1E(#8@+2!I;G9E<W0Z26YV97-T;65N=%1E>'1";&]C:RTM/@T*("`@
M/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X
M="UA;&EG;CH@;&5F="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X@#0H@("`\='(^(`T*("`@/'1D
M('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/CQB/C8N/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/'4^26YV97-T;65N=',\+W4^(#PO
M8CX\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@
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M<R!O9@T*("`@2G5N928C,38P.S,P+"`R,#$R+"!W:71H(&UA='5R:71Y(&1A
M=&5S(')A;F=I;F<@8F5T=V5E;B!O;F4@86YD('1W96QV92!M;VYT:',@86YD
M('=I=&@@82!W96EG:'1E9"!A=F5R86=E(&UA='5R:71Y(&]F(#0N-R!M;VYT
M:',@87)E(&%S(&9O;&QO=W,Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1&9O;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ
M,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&)O<F1E<CTS1#`@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!A
M;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-
M"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0V,R4^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^06UO<G1I
M>F5D/&)R("\^0V]S=#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E5N<F5A;&EZ960\8G(@+SY'
M86EN/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^1F%I<B!686QU93PO8CX\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE
M860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@
M8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@8F]N9',L(&YO=&5S(&%N9"!S
M=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS
M,BPV,#@L.38R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^-RPQ.#4\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS,BPV,38L,30W/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E1O=&%L(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS,BPV,#@L.38R/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^-RPQ.#4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXS,BPV,38L,30W/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$
M9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%
M;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE
M9G0Z."4[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!A;6]R=&EZ960@
M8V]S="P@=6YR96%L:7IE9"!G86EN<R!A;F0@9F%I<B!V86QU92!O9B!M87)K
M971A8FQE('-E8W5R:71I97,-"B`@(&%V86EL86)L92UF;W(M<V%L92!A<R!O
M9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!W:71H(&UA='5R:71Y(&1A=&5S
M(')A;F=I;F<@8F5T=V5E;B!O;F4@86YD('1W96QV92!M;VYT:',@86YD('=I
M=&@@82!W96EG:'1E9"!A=F5R86=E(&UA='5R:71Y(&]F(#,N-R!M;VYT:',@
M87)E(&%S(&9O;&QO=W,Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O
M;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X
M/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.#0E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R
M9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG
M;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@
M(#QT<CX@#0H@("`\=&0@=VED=&@],T0V,R4^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^06UO<G1I>F5D
M/&)R("\^0V]S=#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E5N<F5A;&EZ960\8G(@+SY'86EN
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^1F%I<B!686QU93PO8CX\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@
M+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY5+E,N($=O=F5R;FUE;G0@;V)L:6=A=&EO;G,\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPX,#@L-C0Q
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^-C,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXS+#@P."PW,#0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W)P;W)A
M=&4@8F]N9',L(&YO=&5S(&%N9"!S=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$X+#<X-RPW-S@\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C$L,S8S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ."PW.#DL,30Q/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B
M9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/E1O=&%L(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR,BPU.38L
M-#$Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,2PT,C8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR,BPU.3<L.#0U/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@
M/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3AP>#MM87)G:6XM=&]P.C!P>#MM87)G
M:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]M;6]N(%-T;V-K(&%N9"!787)R86YT($QI86)I;&ET>3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O
M;6UO;B!3=&]C:R!A;F0@5V%R<F%N="!,:6%B:6QI='D@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@4W1O8VL@86YD(%=A<G)A;G0@3&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O
M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O
M=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN
M9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@-R`M
M(&-R:7,Z0V]M;6]N4W1O8VM!;F1787)R86YT3&EA8FEL:71Y5&5X=$)L;V-K
M+2T^#0H@("`\=&%B;&4@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!T97AT+6%L:6=N.B!L969T)R!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=VED=&@],T0T)2!V86QI9VX],T1T;W`@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^/&(^-RX\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\=3Y#;VUM;VX@4W1O
M8VL@86YD(%=A<G)A;G0@3&EA8FEL:71Y/"]U/B`\+V(^/"]F;VYT/CPO=&0^
M#0H@("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT)3L@
M=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3VX@2F%N=6%R>28C,38P.S(W+"`R
M,#$P+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82!R96=I<W1E<F5D(&1I<F5C
M="!O9F9E<FEN9R!O9B`V+#0T.2PR.#@@=6YI=',@=VET:`T*("`@96%C:"!U
M;FET(&-O;G-I<W1I;F<@;V8@*&DI)B,Q-C`[;VYE('-H87)E(&]F('1H92!#
M;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%N9"`H:6DI)B,Q-C`[;VYE
M('=A<G)A;G0@=&\@<'5R8VAA<V4@,"XR-28C,38P.V]F(&]N92!S:&%R92!O
M9B!C;VUM;VX@<W1O8VL@870@82!P=7)C:&%S92!P<FEC92!O9B`D,BXU,B!P
M97(@=6YI="X@5&AE($-O;7!A;GD@<F5C96EV960@;F5T('!R;V-E961S(&9R
M;VT@=&AE('-A;&4@;V8@=&AE#0H@("!U;FET<RP@869T97(@9&5D=6-T:6YG
M(&]F9F5R:6YG(&5X<&5N<V5S+"!O9B!A<'!R;WAI;6%T96QY("0Q-"PY-#(L
M,#`P+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
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M;VX@<W1O8VLN($%S(&]F($IU;F4F(S$V,#LS,"P@,C`Q,BP@=V%R<F%N=',@
M=&\@<'5R8VAA<V4@,C$T+#`P-"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!C;VUM;VX@<W1O8VL@:&%V92!B965N(&5X97)C:7-E9"X@5&AE('=A
M<G)A;G1S(&AA=F4@86X@:6YI=&EA;"!E>&5R8VES92!P<FEC90T*("`@;V8@
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M-C`[,C<L(#(P,3(N($1U92!T;R!T:&4@=&5R;7,L('1H92!W87)R86YT<R!A
M<F4-"B`@(&-L87-S:69I960@87,@82!L:6%B:6QI='D@86YD+"!T:&5R969O
M<F4L('1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT<R!W87,@<F5C;W)D
M960@87,@82!L:6%B:6QI='D@:6X@=&AE($-O;G-O;&ED871E9"!"86QA;F-E
M(%-H965T<R!A<R!O9B!*=6YE)B,Q-C`[,S`L(#(P,3(@86YD($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,3$N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z
M-"4[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&AA<R!E
M<W1I;6%T960@=&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S('5S:6YG
M(&$@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"!U;F1E<B!V
M87)I;W5S#0H@("!P<F]B86)I;&ET>2UW96EG:'1E9"!O=71C;VUE<R!W:&EC
M:"!T86ME(&EN=&\@8V]N<VED97)A=&EO;B!T:&4@<')O=&5C=&EV92P@8G5T
M(&QI;6ET960L(&-A<V@M<V5T=&QE;65N="!F96%T=7)E(&]F('1H92!W87)R
M86YT<RP@=VET:"!U<&1A=&5D(&%S<W5M<'1I;VYS(&%T(&5A8V@@<F5P;W)T
M:6YG(&1A=&4N(%1H92!#;VUP86YY(&5S=&EM871E9"!T:&%T('1H92!F86ER
M('9A;'5E(&]F('1H92!W87)R86YT<R!A=`T*("`@2G5N928C,38P.S,P+"`R
M,#$R('=A<R`D-"PS,#0L.3(R+"!U<VEN9R!T:&4@9F]L;&]W:6YG(&%S<W5M
M<'1I;VYS.B!E>'!E8W1E9"!V;VQA=&EL:71Y(&]F(#<U+C0E+"!R:7-K(&9R
M964@:6YT97)E<W0@<F%T92!O9B`P+C0E+"!E>'!E8W1E9"!L:69E(&]F(#(N
M-B!Y96%R<RP@86YD(&YO(&1I=FED96YD<RX@5&AE($-O;7!A;GD@97-T:6UA
M=&5D('1H870@=&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T#0H@
M("!*=6YE)B,Q-C`[,S`L(#(P,3$@=V%S("0S+#0R-BPU.3(@=7-I;F<@=&AI
M<R!S86UE(&UO9&5L('=I=&@@=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<R!A
M<W-I9VYE9"!T;R!T:&4@=F%R>6EN9R!O=71C;VUE<SH@97AP96-T960@=F]L
M871I;&ET>2!O9B`X,"4L(')I<VL@9G)E92!I;G1E<F5S="!R871E<R!R86YG
M:6YG(&9R;VT@,"XX)2!T;R`Q+C$E+"!E>'!E8W1E9"!L:79E<R!O9B!T:')E
M92!T;R!F;W5R('EE87)S+"!A;F0@;F\-"B`@(&1I=FED96YD<RX@5&AE('=A
M<G)A;G1S(&%R92!R979A;'5E9"!A="!E86-H(')E<&]R=&EN9R!P97)I;V0@
M86YD('1H92!R97-U;'1I;F<@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=&AE
M('=A<G)A;G0@;&EA8FEL:71Y(&ES(')E8V]G;FEZ960@:6X@=&AE($-O;G-O
M;&ED871E9"!3=&%T96UE;G0@;V8@3W!E<F%T:6]N<RX@/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!M87)G:6XM;&5F=#HT)3L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M5&AE($-O;7!A;GD@<F5C;W)D960@;W1H97(@97AP96YS92!O9B!A<'!R;WAI
M;6%T96QY("0T.34L,S0Q(&%N9"`D-#@W+#0P,"!F;W(@=&AE('1H<F5E(&%N
M9"!S:7@@;6]N=&AS(&5N9&5D($IU;F4F(S$V,#LS,"P-"B`@(#(P,3(L(')E
M<W!E8W1I=F5L>2P@9'5E('1O(&-H86YG97,@:6X@9F%I<B!V86QU92!O9B!T
M:&4@=V%R<F%N="!L:6%B:6QI='DN($1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E
M;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3(L(&%S(&$@<F5S=6QT(&]F('1H92!E
M>&5R8VES92!O9B!W87)R86YT<R!T;R!P=7)C:&%S92`R,3(L-3`P('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RP@=&AE('=A
M<G)A;G0@;&EA8FEL:71Y#0H@("!D96-R96%S960@)#4T,RPV-#8@=VET:"!A
M;B!O9F9S971T:6YG(&EN8W)E87-E('1O(&%D9&ET:6]N86P@<&%I9"UI;BUC
M87!I=&%L+B!4:&4@0V]M<&%N>2!R96-O<F1E9"!O=&AE<B!E>'!E;G-E(&]F
M(&%P<')O>&EM871E;'D@)#,R,"PT-#`@86YD("0Q+#@R,2PX-3`@9F]R('1H
M92!T:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P
M,3$L(')E<W!E8W1I=F5L>2P@87,@82!R97-U;'0@;V8@82!C:&%N9V4@:6X-
M"B`@('1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT(&QI86)I;&ET>2!T
M:&%T('=A<R!P<FEM87)I;'D@9'5E('1O(&%N(&EN8W)E87-E(&EN('1H92!#
M;VUP86YY)B,X,C$W.W,@<W1O8VL@<')I8V4@9'5R:6YG('1H92!P<FEO<B!Y
M96%R('!E<FEO9',N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@[;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C
M,38P.SPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?86$U,C(T.3%?8F(S,%\T,68Q7V$W9F1?-C8P96%A8S<S-S!B#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V%A-3(R-#DQ7V)B,S!?-#%F
M,5]A-V9D7S8V,&5A86,W,S<P8B]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!8V-R=65D($QI
M86)I;&ET:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U
M960@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q
M+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH
M=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M
M+2!"96=I;B!";&]C:R!486=G960@3F]T92`X("T@=7,M9V%A<#I/=&AE<DQI
M86)I;&ET:65S1&ES8VQO<W5R951E>'1";&]C:RTM/@T*("`@/'1A8FQE('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@
M;&5F="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$
M-"4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C@N/"]B
M/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^/&(^/'4^06-C<G5E9"!,:6%B:6QI=&EE<SPO=3X@/"]B
M/CPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R
M9VEN+6QE9G0Z."4[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D%C8W)U960@
M;&EA8FEL:71I97,@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG.B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P
M.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!B
M;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@
M=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E
M9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$
M-S0E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/DIU;F4F(S$V,#LS,"P\
M+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/D1E8V5M8F5R)B,Q-C`[,S$L/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!4
M86)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^06-C<G5E
M9"!C;VUP96YS871I;VX\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^-S@W+#0X,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,#8U+#4W,#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E!R
M;V9E<W-I;VYA;"!F965S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,34Y+#8R-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3DP+#4P,#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]T:&5R/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$U+#4Q.#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^,38V+#`S-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/E1O=&%L/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C$L,#8R+#8R-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C$L-#(R+#$P-SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL
M93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^
M#0H@("`\+W1A8FQE/B`-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C$X<'@[
M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A
M8W1I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S
M,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5L
M871E9"!087)T>2!4<F%N<V%C=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$
M(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO
M<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^
M#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#D@+2!U<RUG86%P
M.E)E;&%T961087)T>51R86YS86-T:6]N<T1I<V-L;W-U<F5497AT0FQO8VLM
M+3X-"B`@(#QT86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P
M<V4[('1E>'0M86QI9VXZ(&QE9G0G(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4^(`T*("`@/'1R/B`-
M"B`@(#QT9"!W:61T:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CX\8CXY+CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQU/E)E;&%T960@4&%R
M='D@5')A;G-A8W1I;VX\+W4^(#PO8CX\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[
M;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C8E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI
M/DQI8V5N<V4@06=R965M96YT(#PO:3X\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I
M;BUL969T.C0E.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@($5F9F5C
M=&EV92!O;B!&96)R=6%R>28C,38P.S(T+"`R,#$R+"!T:&4@0V]M<&%N>2!E
M;G1E<F5D(&EN=&\@82!$<G5G($1E=F5L;W!M96YT(%!A<G1N97)S:&EP(&%N
M9"!,:6-E;G-E($%G<F5E;65N="!F;W(@0U4M.3`V(&%N9"!#52TY,#@@*'1H
M92`F(S@R,C`[;&EC96YS92!A9W)E96UE;G0F(S@R,C$[*2!W:71H($=U86YG
M>FAO=2!"94)E='1E<@T*("`@365D:6-I;F4@5&5C:&YO;&]G>2!#;VUP86YY
M($QT9"XL(&$@8V]M<&%N>2!O<F=A;FEZ960@=6YD97(@=&AE(&QA=W,@;V8@
M=&AE(%!E;W!L928C.#(Q-SMS(%)E<'5B;&EC(&]F($-H:6YA("@F(S@R,C`[
M1T)-5"8C.#(R,3LI+B!$<BXF(S$V,#M#:&%N9V=E;F<@46EA;BP@=&AE($-O
M;7!A;GDF(S@R,3<[<R!F;W)M97(@4V5N:6]R(%9I8V4@4')E<VED96YT+"!$
M:7-C;W9E<GD@86YD(%!R96-L:6YI8V%L($1E=F5L;W!M96YT+"!I<R!T:&4-
M"B`@(&9O=6YD97(L(&]W;F5R+"!A;F0@;&5G86P@<F5P<F5S96YT871I=F4@
M;V8@1T)-5"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT)3L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^4'5R<W5A;G0@=&\@=&AE(&QI8V5N<V4@
M86=R965M96YT+"!T:&4@0V]M<&%N>2!H87,@9W)A;G1E9`T*("`@=&\@1T)-
M5"!A;B!E>&-L=7-I=F4@<F]Y86QT>2UF<F5E(&QI8V5N<V4L('=I=&@@=&AE
M(')I9VAT('1O(&=R86YT('-U8FQI8V5N<V5S('-U8FIE8W0@=&\@8V5R=&%I
M;B!C;VYD:71I;VYS+"!T;R!D979E;&]P+"!M86YU9F%C='5R92P@;6%R:V5T
M(&%N9"!S96QL(&%N>2!P<F]D=6-T(&-O;G1A:6YI;F<@0U4M.3`V(&]R($-5
M+3DP."!I;B!#:&EN82P@36%C874L(%1A:7=A;B!A;F0@2&]N9R!+;VYG+"!O
M<B!T:&4@1T)-5`T*("`@=&5R<FET;W)Y+B!4:&4@0V]M<&%N>2!D;V5S(&YO
M="!I;G1E;F0@=&\@:6YT97)N86QL>2!D979E;&]P('1H97-E(&-O;7!O=6YD
M<RX@26X@861D:71I;VXL('1H92!#;VUP86YY(&AA<R!G<F%N=&5D('1O($="
M350@82!N;VXM97AC;'5S:79E+"!R;WEA;'1Y+69R964@;6%N=69A8W1U<FEN
M9R!L:6-E;G-E+"!W:71H('1H92!R:6=H="!T;R!G<F%N="!S=6)L:6-E;G-E
M<R!S=6)J96-T('1O(&-E<G1A:6X@8V]N9&ET:6]N<RP@=&\-"B`@(&UA;G5F
M86-T=7)E($-5+3DP-B!O<B!#52TY,#@@;W(@86YY('!R;V1U8W0@8V]N=&%I
M;FEN9R!#52TY,#8@;W(@0U4M.3`X(&]U='-I9&4@;V8@=&AE($="350@5&5R
M<FET;W)Y('-O;&5L>2!T;R!I;7!O<G0@=&AE(&-O;7!O=6YD<R!O<B!P<F]D
M=6-T<R!I;G1O('1H92!'0DU4('1E<G)I=&]R>2X@4'5R<W5A;G0@=&\@=&AE
M('1E<FUS(&]F('1H92!L:6-E;G-E(&%G<F5E;65N="P@=&AE($-O;7!A;GD@
M:&%S(')E=&%I;F5D#0H@("!R:6=H=',L(&EN8VQU9&EN9R!T:&4@<FEG:'0@
M=&\@9W)A;G0@<W5B;&EC96YS97,L('1O(&1E=F5L;W`L(&UA;G5F86-T=7)E
M+"!M87)K970@86YD('-E;&P@86YY('!R;V1U8W0@8V]N=&%I;FEN9R!#52TY
M,#8@;W(@0U4M.3`X('=O<FQD=VED92!E>&-L=61I;F<@=&AE($="350@5&5R
M<FET;W)Y+B!4:&4@0V]M<&%N>2!A;'-O(&AA<R!C97)T86EN('-P96-I9FEE
M9"!R:6=H=',@=&\@86YY($="350@=&5C:&YO;&]G>2!D979E;&]P960-"B`@
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M92!T;R!#52TY,#8@;W(@0U4M.3`X(&9O<@T*("`@=&AE($="350@5&5R<FET
M;W)Y(&9R;VT@1T)-5"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT
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M("`@;6%Y(&UA;G5F86-T=7)E+"!M87)K970@86YD('-E;&P@86YY('!R;V1U
M8W0@8V]N=&%I;FEN9R!#52TY,#8@;W(@0U4M.3`X(&EN('1H92!'0DU4('1E
M<G)I=&]R>2X@1G5R=&AE<FUO<F4L('1H92!#;VUP86YY('=I;&P@<')O=FED
M92!'0DU4('=I=&@@=7`@=&\@)#0P,"PP,#`@:6X@9FEN86YC:6%L('-U<'!O
M<G0@9F]R('-P96-I9FEE9"!#52TY,#@@<')E+6-L:6YI8V%L(&%C=&EV:71I
M97,@<F5L871E9"!T;R!E;F%B;&EN9R!T:&4-"B`@(&9I;&EN9R!B>2!T:&4@
M0V]M<&%N>2!O9B!A;B!)3D0@=VET:"!T:&4@1D1!+"!P<F]V:61E9"!T:&%T
M($=-0E0@8V]M<&QE=&5S('-U8V@@0U4M.3`X($E.1"UE;F%B;&EN9R!A8W1I
M=FET:65S(&EN(&%C8V]R9&%N8V4@=VET:"!S<&5C:69I960@8W)I=&5R:6$@
M86YD(&1E;&EV97)S(&$@52Y3+B!)3D0@<&%C:V%G92!F;W(@0U4M.3`X('1O
M('1H92!#;VUP86YY('=I=&AI;B!P<F5S8W)I8F5D('1I;65F<F%M97,@87,@
M<W!E8VEF:65D#0H@("!I;B!T:&4@;&EC96YS92!A9W)E96UE;G0N($%L;"!C
M;W-T<R!I;F-U<G)E9"!U;F1E<B!T:&ES(&%G<F5E;65N="!W:6QL(&)E(&5X
M<&5N<V5D(&%S(&EN8W5R<F5D+B!!<R!O9B!*=6YE)B,Q-C`[,S`L(#(P,3(L
M('1H92!#;VUP86YY(&AA9"!N;W0@:6YC=7)R960@86YY(&5X<&5N<V5S('5N
M9&5R('1H:7,@86=R965M96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
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M<&UE;G0L(')E9VES=')A=&EO;@T*("`@86YD(&-O;6UE<F-I86QI>F%T:6]N
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M;&4@9F]R(&%L;"!T:&4@8V]S=',-"B`@(')E;&%T:6YG('1H97)E=&\N(%1H
M92!#;VUP86YY(&%N9"!'0DU4(&UU<W0@86=R964@=&\@86YY(&-H86YG97,@
M=&\@=&AE(&1E=F5L;W!M96YT('!L86X@86YD('-U8V@@<F5V:7-E9"!D979E
M;&]P;65N="!P;&%N(&ES('-U8FIE8W0@=&\@<F5V:65W(&%N9"!A<'!R;W9A
M;"!B>2!T:&4@:F]I;G0@<W1E97)I;F<@8V]M;6ET=&5E+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O
M;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY5;FQE<W,@=&5R;6EN871E9"!E87)L:65R(&EN(&%C8V]R9&%N8V4@=VET
M:"!T:&4@=&5R;7,@;V8@=&AE(&QI8V5N<V4@86=R965M96YT+"!T:&4@;&EC
M96YS92!A9W)E96UE;G0@=VEL;"!E>'!I<F4@;VX@=&AE#0H@("!L871E<B!O
M9B`H:2DF(S$V,#MT:&4@97AP:7)A=&EO;B!O9B!T:&4@;&%S="UT;RUE>'!I
M<F4@=F%L:60@8VQA:6T@;V8@=&AE($-O;7!A;GD@<&%T96YT<R!A;F0@=&AE
M($-O;7!A;GD@;F]N+6%S<V5R="!P871E;G1S(')E;&%T:6YG('1O('1H92!P
M<F]D=6-T<RP@86YD("AI:2DF(S$V,#MS=6-H('1I;64@87,@;F]N92!O9B!'
M0DU4+"!I=',@869F:6QI871E<R!A;F0@<W5B;&EC96YS965S(&ES(&-O;6UE
M<F-I86QI>FEN9R!A;GD-"B`@(&-O;7!O=6YD(&]R('!R;V1U8W0@:6X@=&AE
M($="350@5&5R<FET;W)Y+B!0=7)S=6%N="!T;R!T:&4@;&EC96YS92!A9W)E
M96UE;G0L(&5I=&AE<B!P87)T>2!C86X@=&5R;6EN871E('1H92!L:6-E;G-E
M(&%G<F5E;65N="!U<&]N(&YO=&EC92!U;F1E<B!P<F5S8W)I8F5D(&-I<F-U
M;7-T86YC97,L(&%N9"!T:&4@;&EC96YS92!A9W)E96UE;G0@<W!E8VEF:65S
M('1H92!C;VYS97%U96YC97,@=&\@96%C:"!P87)T>2!F;W(@<W5C:`T*("`@
M96%R;'D@=&5R;6EN871I;VXN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@[;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP
M<'@^)B,Q-C`[/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'@[
M;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT+6EN9&5N
M=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY4:&4-"B`@(&QI8V5N<V4@86=R965M96YT(&%L<V\@
M<V5T<R!F;W)T:"!C=7-T;VUA<GD@=&5R;7,@<F5G87)D:6YG(&5A8V@@<&%R
M='DF(S@R,3<[<R!I;G1E;&QE8W1U86P@<')O<&5R='D@;W=N97)S:&EP(')I
M9VAT<RP@<F5P<F5S96YT871I;VYS(&%N9"!W87)R86YT:65S+"!I;F1E;6YI
M9FEC871I;VX@;V)L:6=A=&EO;G,L(&-O;F9I9&5N=&EA;&ET>2!R:6=H=',@
M86YD(&]B;&EG871I;VYS+"!A;F0@<&%T96YT('!R;W-E8W5T:6]N+`T*("`@
M;6%I;G1E;F%N8V4L(&5N9F]R8V5M96YT(&%N9"!D969E;G-E(')I9VAT<R!A
M;F0@;V)L:6=A=&EO;G,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/CQI/E-E=F5R86YC92!!9W)E96UE;G0@/"]I/CPO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z-"4[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D]N($9E8G)U87)Y)B,Q-C`[,38L(#(P,3(L('1H92!#;VUP86YY
M(&%N9"!$<BXF(S$V,#M1:6%N(&5N=&5R960@:6YT;R!A('-E=F5R86YC92!A
M9W)E96UE;G0@=&AA="!B96-A;64@8FEN9&EN9R!A;F0-"B`@(&5F9F5C=&EV
M92!O;B!&96)R=6%R>28C,38P.S(T+"`R,#$R+B!4:&4@<V5V97)A;F-E(&%G
M<F5E;65N="!P<F]V:61E<R!T:&%T($1R+B8C,38P.U%I86XL(&EN(&5X8VAA
M;F=E(&9O<B!H:7,@97AE8W5T:6]N(&%N9"!N;VYR979O8V%T:6]N(&]F(&$@
M9V5N97)A;"!R96QE87-E(&]F(&-L86EM<R!I;B!F879O<B!O9B!T:&4@0V]M
M<&%N>2!A<R!S970@9F]R=&@@:6X@=&AE('-E=F5R86YC92!A9W)E96UE;G0L
M('=I;&P@8F4-"B`@('!R;W9I9&5D(&-E<G1A:6X@<V5V97)A;F-E(&)E;F5F
M:71S+"!I;F-L=61I;F<@82!L=6UP+7-U;2!P87EM96YT(&5Q=6EV86QE;G0@
M=&\@;VYE+6AA;&8@=&EM97,@:&ES(&)A<V4@86YN=6%L('-A;&%R>2!R871E
M(&EN(&5F9F5C="!A<R!O9B!H:7,@=&5R;6EN871I;VX@9&%T92!T;R!B92!P
M86ED(&EN($%U9W5S="`R,#$R+B!!<R!A(')E<W5L="P@=&AE($-O;7!A;GD@
M:&%D(&%C8W)U960@)#$S-RPU,#`@<F5L871E9"!T;PT*("`@1'(N)B,Q-C`[
M46EA;B8C.#(Q-SMS('-E=F5R86YC92!I;B!T:&4@86-C<G5E9"!L:6%B:6QI
M=&EE<R!S96-T:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@0V]N9&5N<V5D
M($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R!A<R!O9B!*=6YE)B,Q-C`[
M,S`L(#(P,3(N(%1H92!S979E<F%N8V4@86=R965M96YT(&%L<V\@<')O=FED
M97,@9F]R('1H92!E;F=A9V5M96YT(&]F($1R+B8C,38P.U%I86X@87,@82!C
M;VYS=6QT86YT#0H@("!P=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@82!C;VYS
M=6QT:6YG(&%G<F5E;65N="X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M9F]N="US:7IE.C$X<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP
M<'@^)B,Q-C`[/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C8V]U
M;G1I;F<@9F]R(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I
M;F<@1F]R(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1I;F<@9F]R(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E
M(#$P("T@=7,M9V%A<#I$:7-C;&]S=7)E3V9#;VUP96YS871I;VY296QA=&5D
M0V]S='-3:&%R94)A<V5D4&%Y;65N='-497AT0FQO8VLM+3X-"B`@(#QT86)L
M92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI
M9VXZ(&QE9G0G(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T
M:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXQ
M,"X\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CX\8CX\=3Y!8V-O=6YT:6YG(&9O<B!3=&]C:RU"
M87-E9"!#;VUP96YS871I;VX\+W4^(#PO8CX\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
M<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT+6EN
M9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY!<R!O9B!*=6YE)B,Q-C`[,S`L(#(P,3(L('1H
M92!#;VUP86YY(&AA9"!T=V\@<VAA<F5H;VQD97(M87!P<F]V960L('-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;B!P;&%N<SH@=&AE#0H@("`R,#$P(%-T;V-K
M($EN8V5N=&EV92!0;&%N(&%N9"!T:&4@,C`Q,"!%;7!L;WEE92!3=&]C:R!0
M=7)C:&%S92!0;&%N+B!4:&5S92!P;&%N<R!W97)E(&%D;W!T960@8GD@=&AE
M(&)O87)D(&]F(&1I<F5C=&]R<R!I;B!!<')I;"`R,#$P(&%N9"!A<'!R;W9E
M9"!B>2!S:&%R96AO;&1E<G,@:6X@2G5N92`R,#$P+B!);B!T:&4@9FER<W0@
M<75A<G1E<B!O9B`R,#$P+"!T:&4@0V]M<&%N>28C.#(Q-SMS(#(P,#`@4W1O
M8VL@26YC96YT:79E#0H@("!0;&%N(&5X<&ER960@:6X@86-C;W)D86YC92!W
M:71H(&ET<R!T97)M<R!A;F0@:71S(#(P,#`@1&ER96-T;W(@4W1O8VL@3W!T
M:6]N(%!L86X@:&%D(&YO(&%V86EL86)L92!S:&%R97,@<F5M86EN:6YG('5N
M9&5R('1H92!P;&%N+B!.;R!A9&1I=&EO;F%L(&%W87)D<R!W:6QL(&)E(&UA
M9&4@=6YD97(@=&AE<V4@<&QA;G,L(&%L=&AO=6=H(&%L;"!O=71S=&%N9&EN
M9R!A=V%R9',@=6YD97(@=&AE<V4@<&QA;G,@=VEL;"!R96UA:6X@:6X-"B`@
M(&5F9F5C="!U;G1I;"!T:&5Y(&%R92!E>&5R8VES960@;W(@=&AE>2!E>'!I
M<F4@:6X@86-C;W)D86YC92!W:71H('1H96ER('1E<FUS+B!&;W(@82!C;VUP
M;&5T92!D:7-C=7-S:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@<VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N('!L86YS+"!S964@3F]T92`U(&EN8VQU9&5D
M(&EN('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E<&]R="!O;B!&;W)M
M(#$P+4L@9F]R('1H92!Y96%R(&5N9&5D#0H@("!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$Q+"!A<R!P<F5V:6]U<VQY(&9I;&5D('=I=&@@=&AE(%-E8W5R:71I
M97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@;VX@1F5B<G5A<GDF(S$V,#LR
M.2P@,C`Q,BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT)3L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("!$=7)I;F<@=&AE('-I>"!M;VYT
M:',@96YD960@2G5N928C,38P.S,P+"`R,#$R+"!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&)O87)D(&]F(&1I<F5C=&]R<R!G<F%N=&5D(&]P=&EO;G,@=&\@<'5R
M8VAA<V4@,2PQ.#(L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&-O;6UO;B!S=&]C:R!T;R!O9F9I8V5R<R!A;F0@96UP;&]Y965S(&]F('1H
M90T*("`@0V]M<&%N>2!U;F1E<B!T:&4@,C`Q,"!3=&]C:R!);F-E;G1I=F4@
M4&QA;BX@5&AE<V4@;W!T:6]N<R!V97-T(&]V97(@82!F;W5R+7EE87(@<&5R
M:6]D(&%N9"!B96%R(&5X97)C:7-E('!R:6-E<R!T:&%T(&%R92!E<75A;"!T
M;R!T:&4@8VQO<VEN9R!M87)K970@<')I8V4@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!C;VUM;VX@<W1O8VL@;VX@=&AE($Y!4T1!42!';&]B86P@36%R:V5T
M(&]N('1H92!G<F%N="!D871E+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL
M969T.C0E.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY$=7)I;F<@=&AE('-I
M>"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$R+"!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&)O87)D(&]F(&1I<F5C=&]R<R!A;'-O(&=R86YT960@;W!T
M:6]N<R!T;R!I=',-"B`@(&YO;BUE;7!L;WEE92!D:7)E8W1O<G,@=&\@<'5R
M8VAA<V4@-#<P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('5N9&5R('1H
M92`R,#$P(%-T;V-K($EN8V5N=&EV92!0;&%N+B!4:&5S92!O<'1I;VYS('=I
M;&P@=F5S="!M;VYT:&QY(&]V97(@82!O;F4M>65A<B!P97)I;V0@86YD(&)E
M87(@97AE<F-I<V4@<')I8V5S('1H870@87)E(&5Q=6%L('1O('1H92!C;&]S
M:6YG(&UA<FME="!P<FEC92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS#0H@("!C
M;VUM;VX@<W1O8VL@;VX@=&AE($Y!4T1!42!';&]B86P@36%R:V5T(&]N('1H
M92!G<F%N="!D871E+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CX\8CX\=3Y%;7!L;WEE92!A;F0@1&ER96-T;W(@1W)A;G1S
M/"]U/B`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT)3L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^26X@9&5T97)M:6YI;F<@=&AE(&9A:7(@
M=F%L=64@;V8@<W1O8VL@;W!T:6]N<RP@=&AE($-O;7!A;GD@=7-E<R!T:&4@
M0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"X@5&AE($-O;7!A
M;GD-"B`@(&-A;&-U;&%T960@=&AE($)L86-K+5-C:&]L97,@=F%L=64@;V8@
M96UP;&]Y964@86YD(&1I<F5C=&]R(&]P=&EO;G,@87=A<F1E9"!D=7)I;F<@
M=&AE('-I>"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$R(&%N9"`R
M,#$Q(&)A<V5D(&]N('1H92!A<W-U;7!T:6]N<R!N;W1E9"!I;B!T:&4@9F]L
M;&]W:6YG('1A8FQE.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT
M+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF
M(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#<V)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX]
M,T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\
M='(^(`T*("`@/'1D('=I9'1H/3-$.#(E/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/E-I>"!-;VYT:',@16YD960\8G(@+SY*=6YE)B,Q
M-C`[,S`L/"]B/CPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@
M0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F
M9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/D5X<&5C=&5D(&QI9F4@*'EE87)S*2`F(S@R,3$[(&5M<&QO>65E<SPO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXV/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D5X<&5C=&5D(&QI9F4@*'EE87)S*2`F(S@R,3$[(&1I<F5C=&]R
M<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E)I<VLM9G)E92!I;G1E
M<F5S="!R871E/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$N,"TQ+C(E/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(N-"TR+C4E/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E9O;&%T:6QI='D\+V9O;G0^/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-S0M
M-S8E/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C<S+3<T)3PO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY$:79I9&5N9',\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY.;VYE/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^3F]N93PO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE
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M<W1O8VL@<')I8V4N(%1H92!R:7-K+69R964-"B`@(')A=&4@:7,@8F%S960@
M;VX@=&AE(%4N4RX@5')E87-U<GD@>6EE;&0@8W5R=F4@:6X@969F96-T(&%T
M('1H92!T:6UE(&]F(&=R86YT+B!4:&4@0V]M<&%N>2!D;V5S(&YO="!A;G1I
M8VEP871E(&1E8VQA<FEN9R!D:79I9&5N9',@:6X@=&AE(&9O<F5S965A8FQE
M(&9U='5R92X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT)3L@=&5X
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M90T*("`@0FQA8VLM4V-H;VQE<R!M971H;V1O;&]G>2!A;F0L('5L=&EM871E
M;'DL('1H92!E>'!E;G-E('1H870@=VEL;"!B92!R96-O9VYI>F5D(&]V97(@
M=&AE(&QI9F4@;V8@=&AE(&]P=&EO;BX@1T%!4"!A;'-O(')E<75I<F5S('1H
M870@=&AE($-O;7!A;GD@<F5C;V=N:7IE(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M(&9O<B!O;FQY('1H92!P;W)T:6]N(&]F(&]P=&EO;G,@=&AA="!A<F4@97AP
M96-T960-"B`@('1O('9E<W0N(%1H97)E9F]R92P@;6%N86=E;65N="!C86QC
M=6QA=&5D(&%N(&5S=&EM871E9"!A;FYU86P@<')E+79E<W1I;F<@9F]R9F5I
M='5R92!R871E('1H870@:7,@9&5R:79E9"!F<F]M(&AI<W1O<FEC86P@96UP
M;&]Y964@=&5R;6EN871I;VX@8F5H879I;W(@<VEN8V4@=&AE(&EN8V5P=&EO
M;B!O9B!T:&4@0V]M<&%N>2P@87,@861J=7-T960N($EF('1H92!A8W1U86P@
M;G5M8F5R(&]F(&9O<F9E:71U<F5S(&1I9F9E<G,@9G)O;0T*("`@=&AO<V4@
M97-T:6UA=&5D(&)Y(&UA;F%G96UE;G0L(&%D9&ET:6]N86P@861J=7-T;65N
M=',@=&\@8V]M<&5N<V%T:6]N(&5X<&5N<V4@;6%Y(&)E(')E<75I<F5D(&EN
M(&9U='5R92!P97)I;V1S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T
M.C0E.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@86=G<F5G871E(&EN
M=')I;G-I8R!V86QU92!O9B!E;7!L;WEE92!O<'1I;VYS(&]U='-T86YD:6YG
M(&%T($IU;F4F(S$V,#LS,"P@,C`Q,B!W87,@)#,P+#`R,2PP,#`L(&]F('=H
M:6-H("0R-"PT-C0L,#`P#0H@("!R96QA=&5D('1O(&5X97)C:7-A8FQE(&]P
M=&EO;G,N(%1H92!W96EG:'1E9"!A=F5R86=E(&=R86YT+61A=&4@9F%I<B!V
M86QU97,@;V8@<W1O8VL@;W!T:6]N<R!G<F%N=&5D(&1U<FEN9R!T:&4@<VEX
M(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3(@86YD(#(P,3$@=V5R
M92`D,BXY.2!A;F0@)#$N-#,L(')E<W!E8W1I=F5L>2X@07,@;V8@2G5N928C
M,38P.S,P+"`R,#$R+"!T:&5R92!W87,@87!P<F]X:6UA=&5L>0T*("`@)#4L
M-S8U+#`P,"P@;F5T(&]F('1H92!I;7!A8W0@;V8@97-T:6UA=&5D(&9O<F9E
M:71U<F5S+"!O9B!U;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&-O<W0@<F5L
M871E9"!T;R!U;G9E<W1E9"!E;7!L;WEE92!S=&]C:R!O<'1I;VX@87=A<F1S
M(&]U='-T86YD:6YG('5N9&5R('1H92!#;VUP86YY)B,X,C$W.W,@,C`P,"!A
M;F0@,C`Q,"!3=&]C:R!);F-E;G1I=F4@4&QA;G,@=&AA="!I<R!E>'!E8W1E
M9"!T;R!B92!R96-O9VYI>F5D(&%S#0H@("!E>'!E;G-E(&]V97(@82!W96EG
M:'1E9"!A=F5R86=E('!E<FEO9"!O9B`R+C4@>65A<G,N(%1H92!I;G1R:6YS
M:6,@=F%L=65S(&]F(&5M<&QO>65E('-T;V-K(&]P=&EO;G,@97AE<F-I<V5D
M(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P
M,3(@86YD(#(P,3$@=V5R92`D-2PW-SDL,#`P(&%N9"`D.#(V+#`P,"P@<F5S
M<&5C=&EV96QY+B!4:&4@=&]T86P@9F%I<B!V86QU97,@;V8@=F5S=&5D('-T
M;V-K#0H@("!O<'1I;VYS(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE
M)B,Q-C`[,S`L(#(P,3(@86YD(#(P,3$@=V5R92`D,2PR,C@L,#`P(&%N9"`D
M,2PP-3`L,#`P+"!R97-P96-T:79E;'DN(#PO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R
M9VEN+6QE9G0Z-"4[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H90T*("`@
M0V]M<&%N>2!R96-O<F1E9"`D.#,S+#0Y-R!A;F0@)#$L-C0Y+#<R-2!I;B!C
M;VUP96YS871I;VX@97AP96YS92!F;W(@=&AE('1H<F5E(&%N9"!S:7@@;6]N
M=&AS(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,BP@<F5S<&5C=&EV96QY+"!A
M;F0@)#,T."PW-#(@86YD("0Q+#`Q,2PW,S@@:6X@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4@9F]R('1H92!T:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE
M)B,Q-C`[,S`L(#(P,3$L#0H@("!R97-P96-T:79E;'DL(')E;&%T960@=&\@
M96UP;&]Y964@86YD(&1I<F5C=&]R('-T;V-K(&]P=&EO;B!G<F%N=',N(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'@[;6%R
M9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQU
M/DYO;BU%;7!L;WEE92!'<F%N=',\+W4^(#PO8CX\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[
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M<F5C;V=N:7IE9`T*("`@97AP96YS92!R96QA=&5D('1O(&YO;BUE;7!L;WEE
M92!S=&]C:R!O<'1I;VYS(&]F("0Q-S0L,C0U(&%N9"`D,S@P+#8Y,RP@9F]R
M('1H92!T:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L
M(#(P,3(L(')E<W!E8W1I=F5L>2P@86YD(&5X<&5N<V4@;V8@)#$S+#$P-"!A
M;F0@)#(W+#@R,"!F;W(@=&AE('1H<F5E(&%N9"!S:7@@;6]N=&AS(&5N9&5D
M($IU;F4F(S$V,#LS,"P@,C`Q,2P@<F5S<&5C=&EV96QY+@T*("`@/"]F;VYT
M/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP>#MM87)G:6XM
M8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/'4^5&]T
M86P@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N($5X<&5N<V4@/"]U/B`\+V(^
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT)3L@=&5X="UI;F1E;G0Z
M-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^1F]R('1H92!T:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E
M9"!*=6YE)B,Q-C`[,S`L(#(P,3(@86YD(#(P,3$L('1H92!#;VUP86YY(')E
M8V]R9&5D(&5M<&QO>65E(&%N9"!N;VXM96UP;&]Y964@<W1O8VLM8F%S960-
M"B`@(&-O;7!E;G-A=&EO;B!E>'!E;G-E('1O('1H92!F;VQL;W=I;F<@;&EN
M92!I=&5M<R!I;B!I=',@0V]S=',@86YD($5X<&5N<V5S('-E8W1I;VX@;V8@
M=&AE($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,L(&EN
M8VQU9&EN9R!E>'!E;G-E(')E;&%T960@=&\@:71S(#(P,3`@16UP;&]Y964@
M4W1O8VL@4'5R8VAA<V4@4&QA;CH@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O
M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G
M(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM
M/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#4X)3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT
M97(^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1F]R)B,Q-C`[=&AE
M)B,Q-C`[5&AR964F(S$V,#M-;VYT:',F(S$V,#M%;F1E9#PO8CX\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T
M=&]M.C%P>"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/DIU;F4F(S$V,#LS
M,"P\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#8@86QI9VX],T1C96YT97(^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z
M,'!X.VUA<F=I;BUB;W1T;VTZ,'!X(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^
M/&(^1F]R('1H92!3:7@@36]N=&AS($5N9&5D/"]B/CPO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,7!X
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^2G5N928C,38P.S,P+#PO8CX\
M+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X
M('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@
M(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M
M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O
M;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E
M<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS-C4L
M.#4U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,3<X+#@P.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<V-2PP,3`\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS
M-#,L.#8Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ
M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP
M96YS97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXV-#$L.#@W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ.#,L,#,X/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXQ+#(V-2PT,#@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8Y-2PV.3<\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y
M;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L('-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]F;VYT/CPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C$L,#`W+#<T,CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,V,2PX
M-#8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXR+#`S,"PT,3@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#`S.2PU-3@\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y
M("TM/@T*("`@/"]T86)L93X@#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C0E.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@=&%B;&4@8F5L;W<@<W5M;6%R:7IE
M<R!O<'1I;VYS(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!A="!*=6YE
M)B,Q-C`[,S`L(#(P,3(Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O
M;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X
M/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI
M9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@
M("`\='(^(`T*("`@/'1D('=I9'1H/3-$-38E/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,3`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY/<'1I;VYS($]U='-T86YD
M:6YG/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^3W!T:6]N<R!%>&5R8VES86)L93PO8CX\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W=I
M9'1H.C<R<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#$^/&(^17AE<F-I<V4@4')I8V4@4F%N9V4\+V(^
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#$^/&(^3G5M8F5R(&]F/&)R("\^4VAA<F5S/"]B/CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^5V5I
M9VAT960\8G(@+SY!=F5R86=E/&)R("\^4F5M86EN:6YG/&)R("\^0V]N=')A
M8W1U86P\8G(@+SY,:69E)B,Q-C`[*&EN)B,Q-C`[>65A<G,I/"]B/CPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#$^/&(^5V5I9VAT960\8G(@+SY!=F5R86=E/&)R("\^17AE<F-I<V4F(S$V
M,#M0<FEC93QB<B`O/G!E<B8C,38P.U-H87)E/"]B/CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^3G5M
M8F5R(&]F/&)R("\^4VAA<F5S/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^5V5I9VAT960\8G(@
M+SY!=F5R86=E/&)R("\^17AE<F-I<V4F(S$V,#M0<FEC93QB<B`O/G!E<B8C
M,38P.U-H87)E/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G
M:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0@
M,"XW.2`M("0@,2XS.3PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C(L-S,U+#@P.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"XY-SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C$N,3@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C(L-38W+#4Q.3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$N,3D\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#LF(S$V,#L@,2XT,R`M("8C,38P.R8C,38P.R`R+C$U
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,BPV,C@L-38X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+C8S/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+C<S
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXR+#`V,RPS,3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$N-C(\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#LF(S$V,#L@,BXR-R`M("8C
M,38P.R8C,38P.R`S+C<V/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,BPT,S(L-S,S/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+C`S/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXR+C<U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#4U-2PT-#8\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C(N-3(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#LF(S$V,#L@,RXY."`M("8C,38P
M.R8C,38P.R`T+C4R/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,BPR,#0L-C$T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW+C@U/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXT+C,Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW-3@L-#0U/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXT+C$S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V
M86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P
M96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[
M(#0N-38@+2`F(S$V,#LF(S$V,#L@-2XV,#PO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<R,"PP,#`\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$N.#@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C0N-S0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<Q,BPP,#`\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C0N-S0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z
M,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C$P+#<R,2PW,C0\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C4N-3,\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXR+C4W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW+#8U-BPW,C`\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR
M+C(P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B
M;&4^(`T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z
M,3AP>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^3&]S<R!097(@0V]M;6]N(%-H87)E/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]S<R!0
M97(@0V]M;6]N(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!097(@0V]M;6]N(%-H87)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H
M=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA
M;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL
M,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@
M5&%G9V5D($YO=&4@,3$@+2!U<RUG86%P.D5A<FYI;F=S4&5R4VAA<F5497AT
M0FQO8VLM+3X-"B`@(#QT86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&)O<F1E<CTS1#`@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4^(`T*("`@
M/'1R/B`-"B`@(#QT9"!W:61T:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CX\8CXQ,2X\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\=3Y,;W-S
M(%!E<B!#;VUM;VX@4VAA<F4@/"]U/B`\+V(^/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HT)3L@=&5X="UI
M;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@87!P;&EE<R!!4T,@5&]P
M:6,@,C8P)B,X,C$R.SQI/D5A<FYI;F=S)B,Q-C`[<&5R(%-H87)E/"]I/BP@
M=VAI8V@@97-T86)L:7-H97,@<W1A;F1A<F1S(&9O<@T*("`@8V]M<'5T:6YG
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M;6]N=&AS(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,B!A;F0@,C`Q,2P@87,@
M=&AE(&5F9F5C="!O9B!T:&4@<&]T96YT:6%L(&-O;6UO;B!S=&]C:R!E<75I
M=F%L96YT<R!I<R!A;G1I9&EL=71I=F4@9'5E('1O('1H92!#;VUP86YY)B,X
M,C$W.W,@;F5T(&QO<W,@<&]S:71I;VX@9F]R('1H97-E('!E<FEO9',N($%N
M=&ED:6QU=&EV92!S96-U<FET:65S(&-O;G-I<W0@;V8@<W1O8VL-"B`@(&]P
M=&EO;G,@86YD('=A<G)A;G1S(&]U='-T86YD:6YG(&%S(&]F('1H92!R97-P
M96-T:79E(')E<&]R=&EN9R!P97)I;V0@87,@9F]L;&]W<SH@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP
M<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R
M9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E
M>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I
M;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#<T
M)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT
M;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#$^/&(^1F]R('1H93QB<B`O/E1H<F5E(&%N9#QB<B`O/E-I>"!-;VYT:',\
M8G(@+SY%;F1E9#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G
M:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C%P>"!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/DIU;F4F(S$V,#LS,"P\8G(@+SXR,#$R/"]B/CPO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T
M=&]M.C!P>"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D9O<B!T:&4\8G(@
M+SY4:')E92!A;F0\8G(@+SY3:7@@36]N=&AS/&)R("\^16YD960\+V(^/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R9VEN
M+6)O='1O;3HQ<'@@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY*=6YE)B,Q
M-C`[,S`L/&)R("\^,C`Q,3PO8CX\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@
M+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY3=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3`L-S(Q
M+#<R-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,3$L.#(X+#(R-SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E=A<G)A;G1S
M(&]U='-T86YD:6YG/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,2PS.3@L,S$X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#8Q,"PX,3@\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS
M1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY4;W1A;"!A;G1I9&EL=71I=F4@<V5C=7)I=&EE<SPO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$R+#$R,"PP
M-#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C$S+#0S.2PP-#4\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F
M;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@
M/"]T86)L93X@#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU
M92!-96%S=7)E;65N=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M
M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9I;F%N8VEA;"!!<W-E=',@365A<W5R960@870@1F%I
M<B!686QU92!O;B!296-U<G)I;F<@0F%S:7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O
M+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N
M=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B
M("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92!486)L93H@
M8W)I<RTR,#$R,#8S,%]N;W1E-5]T86)L93$@+2!U<RUG86%P.D9A:7)686QU
M94%S<V5T<TUE87-U<F5D3VY296-U<G)I;F="87-I<U1E>'1";&]C:RTM/@T*
M("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*
M("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT
M9"!W:61T:#TS1#0Y)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^475O=&5D)B,Q-C`[4')I8V5S)B,Q-C`[:6X\8G(@+SY!8W1I
M=F4@36%R:V5T<SQB<B`O/BA,979E;"`Q*3PO8CX\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,3X\8CY/=&AE<CQB<B`O/D]B<V5R=F%B;&4\8G(@+SY);G!U=',F
M(S$V,#LH3&5V96PF(S$V,#LR*3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,3X\8CY5;F]B<V5R=F%B;&4\8G(@+SY);G!U=',F(S$V,#LH3&5V96PF(S$V
M,#LS*3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY&86ER(%9A;'5E
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@
M/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@
M0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/D%S(&]F($IU
M;F4F(S$V,#LS,"P@,C`Q,CH\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V%S:"!E<75I=F%L96YT<SPO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R
M/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/DUO;F5Y(&UA<FME="!F=6YD<SPO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW+#@S,BPP-C8\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R
M,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C<L.#,R+#`V-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DUU;FEC:7!A;"!B;VYD<SPO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q
M,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L,30U+#`P,#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPQ-#4L
M,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^26YV97-T;65N=',\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C,N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W)P
M;W)A=&4@8V]M;65R8VEA;"!P87!E<BP@<W1O8VLL(&)O;F1S(&%N9"!N;W1E
M<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$V+#0R,RPT-#D\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$V+#$Y,BPV.3@\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,R+#8Q-BPQ
M-#<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C
M965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/E1O=&%L(&%S<V5T<R!A="!F86ER('9A;'5E/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(T+#(U-2PU,34\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ
M."PS,S<L-CDX/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C0R+#4Y,RPR,3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!C;VQS<&%N/3-$
M-#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!C;VQS<&%N/3-$-#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!C;VQS<&%N/3-$-#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!C
M;VQS<&%N/3-$-#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C,N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY787)R
M86YT<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF
M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0L,S`T+#DR,CPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^-"PS,#0L.3(R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY4;W1A;"!L:6%B:6QI=&EE<R!A="!F86ER('9A;'5E
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q
M,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-"PS,#0L.3(R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PS,#0L.3(R/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/D%S(&]F($1E8V5M8F5R)B,Q
M-C`[,S$L(#(P,3$Z/"]B/CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-A<V@@97%U:79A
M;&5N=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY-;VYE>2!M87)K970@9G5N9',\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^-2PS-C8L-S0W/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C
M,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXU+#,V-BPW-#<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C,N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY-=6YI8VEP
M86P@8F]N9',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXR+#,W-2PP,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C(L,S<U+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN=F5S=&UE;G1S/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(]
M,T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^55,@9V]V97)N;65N="!O8FQI9V%T:6]N<SPO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V
M,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C,L.#`X+#<P-#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPX,#@L-S`T/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HU+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^0V]R<&]R871E(&-O;6UE<F-I86P@<&%P97(L('-T;V-K+"!B;VYD
M<R!A;F0@;F]T97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXW+#,V-2PX-#$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$Q+#0R,RPS,#`\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$X+#<X.2PQ-#$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O
M;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/E1O=&%L(&%S<V5T<R!A="!F86ER('9A;'5E/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$U+#$P-RPU.#@\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXQ-2PR,S(L,#`T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C,P+#,S.2PU.3(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5V%R<F%N=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+#,V
M,2PQ-C@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C0L,S8Q+#$V.#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&]T86P@;&EA8FEL:71I
M97,@870@9F%I<B!V86QU93PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C0L,S8Q+#$V.#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0L,S8Q
M+#$V.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O
M9B!787)R86YT($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(
M5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O
M5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@
M("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(%1A8FQE.B!C<FES+3(P
M,3(P-C,P7VYO=&4U7W1A8FQE,B`M('5S+6=A87`Z1F%I<E9A;'5E3&EA8FEL
M:71I97--96%S=7)E9$]N4F5C=7)R:6YG0F%S:7-5;F]B<V5R=F%B;&5);G!U
M=%)E8V]N8VEL:6%T:6]N5&5X=$)L;V-K+2T^#0H@("`\=&%B;&4@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!B;W)D97(]
M,T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA
M;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A
M8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$.#4E/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@
M0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D)A;&%N8V4@870@
M1&5C96UB97(F(S$V,#LS,2P@,C`Q,#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXQ+#8P-"PW-#(\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#:&%N9V4@:6X@
M9F%I<B!V86QU92`\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXQ+#@R,2PX-3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R
M/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/D)A;&%N8V4@870@2G5N928C,38P.S,P+"`R,#$Q/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,L-#(V+#4Y,CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D(&-O;'-P86X],T0T/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/D)A;&%N8V4@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,3PO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+#,V,2PQ-C@\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C4N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY787)R86YT<R!E>&5R8VES960@/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*#4T,RPV
M-#8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^0VAA;F=E(&EN(&9A:7(@=F%L=64@/"]F;VYT/CPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-#@W+#0P,#PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0F%L86YC92!A="!*=6YE
M)B,Q-C`[,S`L(#(P,3(\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^-"PS,#0L.3(R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE
M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B
M;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DEN=F5S=&UE;G1S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV97-T;65N=',@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4:&4@86UO<G1I>F5D(&-O<W0L('5N<F5A;&EZ960@9V%I;G,@86YD
M(&9A:7(@=F%L=64@;V8@;6%R:V5T86)L92!S96-U<FET:65S(&%V86EL86)L
M92UF;W(M<V%L92!W:71H(&UA='5R:71Y(&1A=&5S(')A;F=I;F<@8F5T=V5E
M;B!O;F4@86YD('1W96QV92!M;VYT:',@86YD('=I=&@@82!W96EG:'1E9"!A
M=F5R86=E(&UA='5R:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA
M+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@5&%B;&4Z(&-R:7,M,C`Q,C`V
M,S!?;F]T939?=&%B;&4Q("T@=7,M9V%A<#I38VAE9'5L94]F56YR96%L:7IE
M9$QO<W-/;DEN=F5S=&UE;G1S5&%B;&5497AT0FQO8VLM+3X-"B`@(#QT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E
M(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@
M0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@]
M,T0V,R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^06UO<G1I>F5D/&)R("\^0V]S=#PO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q
M/CQB/E5N<F5A;&EZ960\8G(@+SY'86EN/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1F%I<B!6
M86QU93PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-
M"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A
M8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W)P;W)A
M=&4@8F]N9',L(&YO=&5S(&%N9"!S=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXS,BPV,#@L.38R/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-RPQ.#4\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXS,BPV,38L,30W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE
M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L(&UA<FME=&%B;&4@
M<V5C=7)I=&EE<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXS,BPV,#@L.38R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-RPQ.#4\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS,BPV,38L
M,30W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO
M=&%B;&4^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z."4[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E1H92!A;6]R=&EZ960@8V]S="P@=6YR96%L:7IE9"!G86EN<R!A
M;F0@9F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R:71I97,-"B`@(&%V
M86EL86)L92UF;W(M<V%L92!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q
M+"!W:71H(&UA='5R:71Y(&1A=&5S(')A;F=I;F<@8F5T=V5E;B!O;F4@86YD
M('1W96QV92!M;VYT:',@86YD('=I=&@@82!W96EG:'1E9"!A=F5R86=E(&UA
M='5R:71Y(&]F(#,N-R!M;VYT:',@87)E(&%S(&9O;&QO=W,Z(#PO9F]N=#X\
M+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z
M,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&)O
M<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T
M97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G
M:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0V
M,R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#$^/&(^06UO<G1I>F5D/&)R("\^0V]S=#PO8CX\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/E5N<F5A;&EZ960\8G(@+SY'86EN/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1F%I<B!686QU
M93PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@
M(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE
M($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY5+E,N($=O=F5R
M;FUE;G0@;V)L:6=A=&EO;G,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,RPX,#@L-C0Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-C,\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS+#@P
M."PW,#0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@8F]N9',L(&YO=&5S(&%N9"!S=&]C
M:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$X+#<X-RPW-S@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,S8S/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ
M."PW.#DL,30Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L(&UA
M<FME=&%B;&4@<V5C=7)I=&EE<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXR,BPU.38L-#$Y/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PT,C8\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXR,BPU.3<L.#0U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M
M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C
M8W)U960@3&EA8FEL:71I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-R=65D($QI86)I;&ET
M:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C<G5E9"!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO
M+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO
M+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L
M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(%1A
M8FQE.B!C<FES+3(P,3(P-C,P7VYO=&4X7W1A8FQE,2`M('5S+6=A87`Z4V-H
M961U;&5/9D%C8W)U961,:6%B:6QI=&EE<U1A8FQE5&5X=$)L;V-K+2T^#0H@
M("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#<V)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC
M;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D
M('=I9'1H/3-$-S0E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/DIU;F4F
M(S$V,#LS,"P\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L/"]B/CPO9F]N=#X\8G(@+SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M
M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E
M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^06-C<G5E9"!C;VUP96YS871I;VX\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^-S@W+#0X,SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,#8U+#4W,#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E!R;V9E<W-I;VYA;"!F965S/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,34Y+#8R-3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,3DP+#4P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]T:&5R/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$U+#4Q
M.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,38V+#`S-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/E1O=&%L/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C$L,#8R+#8R-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L-#(R+#$P-SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?86$U,C(T.3%?8F(S,%\T,68Q7V$W9F1?
M-C8P96%A8S<S-S!B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V%A
M-3(R-#DQ7V)B,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8B]7;W)K<VAE971S
M+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5+2#X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY!8V-O=6YT:6YG(&9O<B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8V-O=6YT:6YG($9O<B!3=&]C:RU"87-E9"!#;VUP96YS
M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y686QU871I;VX@87-S=6UP=&EO;G,@=7-E9"!T;R!C
M86QC=6QA=&4@9F%I<B!V86QU92!O9B!E;7!L;WEE92!O<'1I;VYS(&%W87)D
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%
M(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO
M;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT
M;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C
M:R!486=G960@3F]T92!486)L93H@8W)I<RTR,#$R,#8S,%]N;W1E,3!?=&%B
M;&4Q("T@=7,M9V%A<#I38VAE9'5L94]F4VAA<F5"87-E9%!A>6UE;G1!=V%R
M9%-T;V-K3W!T:6]N<U9A;'5A=&EO;D%S<W5M<'1I;VYS5&%B;&5497AT0FQO
M8VLM+3X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$-S8E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O
M;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E
M;G1E<CX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@
M#0H@("`\=&0@=VED=&@],T0X,B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#$^/&(^4VEX($UO;G1H<R!%;F1E9#QB<B`O/DIU;F4F(S$V,#LS
M,"P\+V(^/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I
M;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17AP
M96-T960@;&EF92`H>65A<G,I("8C.#(Q,3L@96UP;&]Y965S/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C8\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^17AP96-T960@;&EF92`H>65A<G,I("8C.#(Q,3L@9&ER96-T;W)S/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C8\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4FES:RUF<F5E(&EN=&5R97-T
M(')A=&4\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,2XP+3$N,B4\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BXT+3(N-24\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT
M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^5F]L871I;&ET>3PO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW-"TW-B4\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M-S,M-S0E/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R
M/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/D1I=FED96YD<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/DYO;F4\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY.;VYE/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B
M;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!A;F0@;F]N
M(&5M<&QO>65E('-H87)E(&)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&%L
M;&]C871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$
M3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A
M;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$
M5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I
M;B!";&]C:R!486=G960@3F]T92!486)L93H@8W)I<RTR,#$R,#8S,%]N;W1E
M,3!?=&%B;&4R("T@8W)I<SI38VAE9'5L94]F16UP;&]Y965!;F1.;VY%;7!L
M;WEE95-H87)E0F%S961#;VUP96YS871I;VY!;&QO8V%T:6]N3V9296-O9VYI
M>F5D4&5R:6]D0V]S='-486)L951E>'1";&]C:RTM/@T*("`@/'1A8FQE(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R
M9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E
M>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I
M;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#4X
M)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#8@86QI9VX],T1C96YT97(^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z
M,'!X.VUA<F=I;BUB;W1T;VTZ,'!X(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^
M/&(^1F]R)B,Q-C`[=&AE)B,Q-C`[5&AR964F(S$V,#M-;VYT:',F(S$V,#M%
M;F1E9#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P
M.C!P>#MM87)G:6XM8F]T=&]M.C%P>"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q
M/CQB/DIU;F4F(S$V,#LS,"P\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@("`\<"!S='EL
M93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^1F]R('1H92!3:7@@36]N=&AS($5N9&5D/"]B
M/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,'!X.VUA
M<F=I;BUB;W1T;VTZ,7!X(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^2G5N
M928C,38P.S,P+#PO8CX\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q
M,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%
M;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M
M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!E>'!E;G-E<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXS-C4L.#4U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3<X+#@P.#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<V
M-2PP,3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXS-#,L.#8Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1V5N97)A;"!A;F0@861M
M:6YI<W1R871I=F4@97AP96YS97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXV-#$L.#@W/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ.#,L
M,#,X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXQ+#(V-2PT,#@\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8Y-2PV
M.3<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C
M965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,#`W+#<T
M,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C,V,2PX-#8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#`S,"PT,3@\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ
M+#`S.2PU-3@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM
M($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X@#0H\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@
M;W5T<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE('5N9&5R(&5X97)C:7-E('!R
M:6-E(')A;F=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM
M1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R
M86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O
M1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G
M:6X@0FQO8VL@5&%G9V5D($YO=&4@5&%B;&4Z(&-R:7,M,C`Q,C`V,S!?;F]T
M93$P7W1A8FQE,R`M('5S+6=A87`Z4V-H961U;&5/9E-H87)E0F%S961#;VUP
M96YS871I;VY3:&%R97-!=71H;W)I>F5D56YD97)3=&]C:T]P=&EO;E!L86YS
M0GE%>&5R8VES95!R:6-E4F%N9V5497AT0FQO8VLM+3X-"B`@(#QT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B
M;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@
M=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E
M9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$
M-38E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,3X\8CY/<'1I;VYS($]U='-T86YD:6YG/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^3W!T:6]N
M<R!%>&5R8VES86)L93PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^#0H@("`\<"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W=I9'1H.C<R<'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^17AE
M<F-I<V4@4')I8V4@4F%N9V4\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X
M('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^3G5M8F5R(&]F/&)R("\^4VAA
M<F5S/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^5V5I9VAT960\8G(@+SY!=F5R86=E/&)R("\^
M4F5M86EN:6YG/&)R("\^0V]N=')A8W1U86P\8G(@+SY,:69E)B,Q-C`[*&EN
M)B,Q-C`[>65A<G,I/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X
M('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^5V5I9VAT960\8G(@+SY!=F5R
M86=E/&)R("\^17AE<F-I<V4F(S$V,#M0<FEC93QB<B`O/G!E<B8C,38P.U-H
M87)E/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^3G5M8F5R(&]F/&)R("\^4VAA<F5S/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^5V5I9VAT960\8G(@+SY!=F5R86=E/&)R("\^17AE<F-I<V4F
M(S$V,#M0<FEC93QB<B`O/G!E<B8C,38P.U-H87)E/"]B/CPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@
M2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT
M<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B0@,"XW.2`M("0@,2XS.3PO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L-S,U+#@P.3PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^-"XY-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$N,3@\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L
M-38W+#4Q.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C$N,3D\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#LF(S$V,#L@,2XT
M,R`M("8C,38P.R8C,38P.R`R+C$U/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPV,C@L-38X/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU
M+C8S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXQ+C<S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#`V,RPS,3`\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C$N-C(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#LF(S$V,#L@,BXR-R`M("8C,38P.R8C,38P.R`S+C<V/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPT,S(L-S,S
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXU+C`S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+C<U/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXQ+#4U-2PT-#8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(N-3(\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#LF(S$V,#L@,RXY."`M("8C,38P.R8C,38P.R`T+C4R/"]F;VYT/CPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPR,#0L-C$T/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXW+C@U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+C,Y/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXW-3@L-#0U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+C$S/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(]
M,T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[(#0N-38@+2`F(S$V,#LF(S$V,#L@-2XV
M,#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C<R,"PP,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C$N.#@\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0N-S0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C<Q,BPP,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0N-S0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$P+#<R,2PW
M,C0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C4N-3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+C4W/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXW+#8U-BPW,C`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXR+C(P/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N
M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B
M;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DQO<W,@4&5R($-O;6UO;B!3:&%R92`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO<W,@
M4&5R($-O;6UO;B!3:&%R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&ED:6QU=&EV92!396-U<FET
M:65S("T@4W1O8VL@3W!T:6]N<R!A;F0@5V%R<F%N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M
M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z
M+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA
M;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92!4
M86)L93H@8W)I<RTR,#$R,#8S,%]N;W1E,3%?=&%B;&4Q("T@=7,M9V%A<#I3
M8VAE9'5L94]F06YT:61I;'5T:79E4V5C=7)I=&EE<T5X8VQU9&5D1G)O;4-O
M;7!U=&%T:6]N3V9%87)N:6YG<U!E<E-H87)E5&5X=$)L;V-K+2T^#0H@("`\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#<V)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL
M87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\
M(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I
M9'1H/3-$-S0E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`@(#QP('-T>6QE/3-$
M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,3X\8CY&;W(@=&AE/&)R("\^5&AR964@86YD/&)R("\^4VEX
M($UO;G1H<SQB<B`O/D5N9&5D/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,7!X(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^2G5N928C,38P.S,P+#QB<B`O/C(P,3(\+V(^
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,'!X.VUA
M<F=I;BUB;W1T;VTZ,'!X(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1F]R
M('1H93QB<B`O/E1H<F5E(&%N9#QB<B`O/E-I>"!-;VYT:',\8G(@+SY%;F1E
M9#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C!P
M>#MM87)G:6XM8F]T=&]M.C%P>"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/DIU;F4F(S$V,#LS,"P\8G(@+SXR,#$Q/"]B/CPO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B
M;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@
M(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I
M;F<\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXQ,"PW,C$L-S(T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,2PX,C@L,C(W/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M5V%R<F%N=',@;W5T<W1A;F1I;F<\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#,Y."PS,3@\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L
M-C$P+#@Q.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B
M9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/E1O=&%L(&%N=&ED:6QU=&EV92!S96-U<FET:65S
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,3(L,3(P+#`T,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3,L-#,Y+#`T-3PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S
M='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@
M+2T^#0H@("`\+W1A8FQE/B`-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?86$U,C(T.3%?8F(S,%\T,68Q7V$W9F1?-C8P96%A
M8S<S-S!B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V%A-3(R-#DQ
M7V)B,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8B]7;W)K<VAE971S+U-H965T
M,C(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5.2$1)/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;&QA8F]R871I;VX@06=R965M96YT<R`H1&5T86EL<RD@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q,CQB<CY5;FEV97)S:71Y/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q,CQB<CY/=70@;V8@4&5R:6]D($%D:G5S=&UE;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB
M<CY5;FEV97)S:71Y($QI8V5N<V]R<R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/E5N:79E<G-I
M='D@3&EC96YS;W)S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^1V5N96YT96-H($EN8R!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$R/&)R/D=E;F5N=&5C:"!);F,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CY'96YE;G1E
M8V@@26YC(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3(\8G(^1V5N96YT96-H($EN8R!;365M8F5R73QB
M<CY5;FEV97)S:71Y($QI8V5N<V]R<R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/D=E;F5N=&5C
M:"!);F,@6TUE;6)E<ET\8G(^56YI=F5R<VET>2!,:6-E;G-O<G,@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q,CQB<CY'96YE;G1E8V@@26YC(%M-96UB97)=/&)R/E5N:79E<G-I='D@
M3&EC96YS;W)S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^3&5U:V5M:6$@86YD($QY;7!H;VUA
M(%-O8VEE='D@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CY2;V-H92!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/D9$
M02=S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-O;&QA8F]R871I;VX@06=R965M96YT<R`H5&5X='5A
M;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2979E;G5E(')E8V]G;FEZ960@;6EL97-T;VYE('!A>6UE
M;G1S(&%S(&QI8V5N<V4@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5A<FYE9"!M:6QE
M<W1O;F4@<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5A<FYE9"!A;B!A9&1I=&EO;F%L(&UI
M;&5S=&]N92!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5L:6=I8FEL:71Y('1O(')E8V5I=F4@8V]N=&EN9V5N
M="!C87-H('!A>6UE;G1S('5N9&5R('1H92!C;VQL86)O<F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,34L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-2PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;6]U;G0@<F5C96EV960@9F]R('-P96-I9FEE9"!C;&EN:6-A;"!D
M979E;&]P;65N="!A;F0@<F5G=6QA=&]R>2!O8FIE8W1I=F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S(')E;&%T960@=&\@
M=&AE($9$02=S(&%P<')O=F%L(&%N9"!P87EM96YT<R!R96-E:79E9"!F;W(@
M17)I=F5D9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;V=N:7IE9"!R;WEA;'1Y
M(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,BPW
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,C,L,S<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4R+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4R,RPS-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@;VYE+71I
M;64@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY-C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.38T+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV-"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!C;VUM;VX@<W1O8VL@<VAA<F5S(&ES<W5E9"!T;R!U;FEV97)S:71Y(&QI
M8V5N<V]R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;W-T<R!O9B!R;WEA;'1Y(')E=F5N=65S(')E
M8V]R9&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV,S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,C8L,38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T<R!O9B!R;WEA;'1Y(')E=F5N=65S+"!C;VUP86YY(&]B
M;&EG871E9"!T;R!P87D@=&\@=6YI=F5R<VET>2!L:6-E;G-O<G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#8S-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-BPQ-C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV,S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-BPQ-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!E<F-E;G1A9V4@;V8@<F]Y86QT:65S(&5A<FYE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%Y;65N="!T
M;R!U;FEV97)S:71Y(&QI8V5N<V]R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@=6YI=F5R<VET>2!L:6-E;G-O
M<G,@:6X@8V]N;F5C=&EO;B!W:71H('1H92!&1$$M87!P<F]V86P@;V8@17)I
M=F5D9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PU,#`L-#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-#0L,#4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PW-#(L-#`U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR
M,#(L-30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,3$T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!C;VYT<FEB
M=71I;VX@;V8@9G5N9"!F<F]M($Q,4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYT<FEB=71I;VX@;V8@9G5N9"!F<F]M($Q,
M4R!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<&%N>2!U;F1E<B!O8FQI9V%T:6]N('1O(&UA:V4@<&%Y;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?86$U
M,C(T.3%?8F(S,%\T,68Q7V$W9F1?-C8P96%A8S<S-S!B#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V%A-3(R-#DQ7V)B,S!?-#%F,5]A-V9D7S8V
M,&5A86,W,S<P8B]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S
M5$))/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R
M96UE;G1S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN
M86YC:6%L($%S<V5T<R!-96%S=7)E9"!A="!&86ER(%9A;'5E(&]N(%)E8W5R
M<FEN9R!"87-I<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T+#,P-"PY,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0L,S8Q+#$V.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPT,C8L-3DR/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#8P-"PW
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&QI86)I;&ET:65S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S`T+#DR,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S8Q+#$V.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!686QU92!-96%S=7)E;65N=',@4F5C=7)R:6YG(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6%L
M($%S<V5T<R!-96%S=7)E9"!A="!&86ER(%9A;'5E(&]N(%)E8W5R<FEN9R!"
M87-I<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-=6YI8VEP86P@8F]N9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,30U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<R!A="!F86ER('9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPU.3,L,C$S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,S,Y
M+#4Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,S`T+#DR,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L,S8Q+#$V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N=',@
M4F5C=7)R:6YG(%M-96UB97)=('P@0V%S:"!%<75I=F%L96YT<R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I
M;F%N8VEA;"!!<W-E=',@365A<W5R960@870@1F%I<B!686QU92!O;B!296-U
M<G)I;F<@0F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36]N97D@;6%R:V5T(&9U;F1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#@S,BPP-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,V-BPW-#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUU;FEC:7!A;"!B
M;VYD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS-S4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!296-U<G)I;F<@6TUE;6)E<ET@
M?"!);G9E<W1M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9I;F%N8VEA;"!!<W-E=',@365A<W5R960@
M870@1F%I<B!686QU92!O;B!296-U<G)I;F<@0F%S:7,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^55,@9V]V97)N;65N="!O
M8FQI9V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX
M,#@L-S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W)P;W)A=&4@8V]M;65R8VEA;"!P87!E<BP@<W1O8VLL(&)O
M;F1S(&%N9"!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S(L-C$V+#$T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X+#<X.2PQ-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E%U;W1E9"!0<FEC97,@26X@06-T:79E
M($UA<FME=',@*$QE=F5L(#$I(%M-96UB97)=('P@1F%I<B!686QU92!-96%S
M=7)E;65N=',@4F5C=7)R:6YG(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6%L($%S<V5T<R!-96%S
M=7)E9"!A="!&86ER(%9A;'5E(&]N(%)E8W5R<FEN9R!"87-I<SPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S
M971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(T+#(U-2PU,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-2PQ,#<L-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y1=6]T960@4')I8V5S($EN($%C
M=&EV92!-87)K971S("A,979E;"`Q*2!;365M8F5R72!\($9A:7(@5F%L=64@
M365A<W5R96UE;G1S(%)E8W5R<FEN9R!;365M8F5R72!\($-A<V@@17%U:79A
M;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&:6YA;F-I86P@07-S971S($UE87-U<F5D(&%T($9A:7(@
M5F%L=64@;VX@4F5C=7)R:6YG($)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;F5Y(&UA<FME="!F=6YD<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX,S(L,#8V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS-C8L-S0W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-=6YI8VEP86P@8F]N9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,S<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^475O=&5D(%!R:6-E<R!);B!!8W1I=F4@36%R:V5T
M<R`H3&5V96P@,2D@6TUE;6)E<ET@?"!&86ER(%9A;'5E($UE87-U<F5M96YT
M<R!296-U<G)I;F<@6TUE;6)E<ET@?"!);G9E<W1M96YT<R!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;F%N
M8VEA;"!!<W-E=',@365A<W5R960@870@1F%I<B!686QU92!O;B!296-U<G)I
M;F<@0F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]R<&]R871E(&-O;6UE<F-I86P@<&%P97(L('-T;V-K+"!B;VYD
M<R!A;F0@;F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M+#0R,RPT-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#,V-2PX-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R($]B<V5R=F%B;&4@26YP=71S("A,
M979E;"`R*2!;365M8F5R72!\($9A:7(@5F%L=64@365A<W5R96UE;G1S(%)E
M8W5R<FEN9R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D9I;F%N8VEA;"!!<W-E=',@365A<W5R960@870@1F%I
M<B!686QU92!O;B!296-U<G)I;F<@0F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<R!A="!F86ER
M('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PS,S<L
M-CDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34L,C,R+#`P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W1H97(@3V)S97)V86)L92!);G!U=',@*$QE=F5L
M(#(I(%M-96UB97)=('P@1F%I<B!686QU92!-96%S=7)E;65N=',@4F5C=7)R
M:6YG(%M-96UB97)=('P@0V%S:"!%<75I=F%L96YT<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;F%N8VEA
M;"!!<W-E=',@365A<W5R960@870@1F%I<B!686QU92!O;B!296-U<G)I;F<@
M0F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^375N:6-I<&%L(&)O;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#$T-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]T:&5R($]B<V5R=F%B;&4@26YP=71S("A,979E
M;"`R*2!;365M8F5R72!\($9A:7(@5F%L=64@365A<W5R96UE;G1S(%)E8W5R
M<FEN9R!;365M8F5R72!\($EN=F5S=&UE;G1S(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6%L($%S
M<V5T<R!-96%S=7)E9"!A="!&86ER(%9A;'5E(&]N(%)E8W5R<FEN9R!"87-I
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M4R!G;W9E<FYM96YT(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#@P."PW,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<G!O<F%T92!C;VUM97)C:6%L('!A
M<&5R+"!S=&]C:RP@8F]N9',@86YD(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-BPQ.3(L-CDX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-#(S+#,P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YO8G-E<G9A
M8FQE($EN<'5T<R`H3&5V96P@,RD@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&:6YA;F-I86P@07-S971S($UE
M87-U<F5D(&%T($9A:7(@5F%L=64@;VX@4F5C=7)R:6YG($)A<VES/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI
M86)I;&ET:65S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L,S`T+#DR,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L,S8Q+#$V.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YO8G-E<G9A8FQE($EN
M<'5T<R`H3&5V96P@,RD@6TUE;6)E<ET@?"!&86ER(%9A;'5E($UE87-U<F5M
M96YT<R!296-U<G)I;F<@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY&:6YA;F-I86P@07-S971S($UE87-U<F5D
M(&%T($9A:7(@5F%L=64@;VX@4F5C=7)R:6YG($)A<VES/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L,S`T+#DR,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PS-C$L
M,38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A
M834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E86%C-S,W,&(-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86$U,C(T.3%?8F(S,%\T,68Q7V$W9F1?
M-C8P96%A8S<S-S!B+U=O<FMS:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14].04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S
M=7)E;65N=',@*$1E=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1F%I<B!686QU92!O9B!787)R86YT($QI86)I;&ET>3PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E($)E9VEN
M;FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#,V,2PQ
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L-C`T+#<T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N
M="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y
M-2PS-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,C`L-#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#@W+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L.#(Q+#@U,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@
M=F%L=64@;V8@=V%R<F%N=',@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@U-#,L-C0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!%;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PS,#0L.3(R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#0R-BPU
M.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0L,S`T+#DR,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,RPT,C8L-3DR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]A834R,C0Y,5]B8C,P7S0Q9C%?83=F9%\V
M-C!E86%C-S,W,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86$U
M,C(T.3%?8F(S,%\T,68Q7V$W9F1?-C8P96%A8S<S-S!B+U=O<FMS:&5E=',O
M4VAE970R-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P151.044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^26YV97-T;65N=',@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E1H92!A;6]R=&EZ960@8V]S="P@=6YR96%L:7IE9"!G86EN<R!A;F0@
M9F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R:71I97,@879A:6QA8FQE
M+69O<BUS86QE/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%M;W)T:7IE9"!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,R+#8P."PY-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(R+#4Y-BPT,3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@
M1V%I;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPQ.#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0R
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,R+#8Q-BPQ-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,BPU.3<L.#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5+B!3+B!';W9E<FYM96YT($]B;&EG
M871I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^5&AE(&%M;W)T:7IE9"!C;W-T+"!U;G)E86QI>F5D(&=A
M:6YS(&%N9"!F86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!A
M=F%I;&%B;&4M9F]R+7-A;&4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UO<G1I>F5D($-O<W0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L.#`X+#8T,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!'86EN/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#`X+#<P-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]R
M<&]R871E($)O;F1S($YO=&5S(&%N9"!3=&]C:R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E1H92!A;6]R=&EZ
M960@8V]S="P@=6YR96%L:7IE9"!G86EN<R!A;F0@9F%I<B!V86QU92!O9B!M
M87)K971A8FQE('-E8W5R:71I97,@879A:6QA8FQE+69O<BUS86QE/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE
M9"!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,BPV,#@L
M.38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3@L-S@W+#<W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!'86EN/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#$X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S8S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,BPV,38L,30W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q."PW
M.#DL,30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14\R0DD^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6]N(%-T;V-K
M(&%N9"!787)R86YT($QI86)I;&ET>2`H1&5T86EL<RD@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA
M;BX@,C<L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V]M;6]N(%-T;V-K(&%N9"!787)R86YT($QI86)I;&ET
M>2`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@;G5M8F5R(&]F('-H87)E
M<R!O9B!S=&]C:R!A=F%I;&%B;&4@=&\@<'5R8VAA<V4@=7-I;F<@=V%R<F%N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C$R+#,R,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-C$R+#,R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17-T:6UA=&5D(')I<VLM9G)E92!I;G1E<F5S="!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C0P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@
M;&EV97,@;V8@=V%R<F%N=',L('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XR('EE87)S(#<@;6]N=&AS(#8@9&%Y<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;VUM;VX@4W1O8VL@86YD(%=A<G)A;G0@3&EA8FEL:71Y("A!9&1I=&EO;F%L
M(%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<F5G:7-T97)E9"!D:7)E
M8W0@;V9F97)I;F<L('5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#0T.2PR.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E9VES=&5R960@9&ER96-T(&]F9F5R:6YG+"!N
M;RX@;V8@8V]M;6]N('-T;V-K('!E<B!U;FET<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5G:7-T97)E9"!D:7)E8W0@;V9F97)I;F<L
M(&YO+B!O9B!W87)R86YT<R!P97(@=6YI=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1I<F5C="!O9F9E<FEN9R!P=7)C:&%S92!P<FEC
M92!P97(@=6YI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(')E9VES=&5R960@9&ER96-T(&]F9F5R:6YG
M(&]F('5N:71S+"!N970@;V8@:7-S=6%N8V4@8V]S=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,30L.30R+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I
M8V4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,N-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y497)M(&]F('=A<G)A;G1S+"!Y96%R<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AE<F-I
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,30L,#`T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$T
M+#`P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PS,#0L.3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT,C8L-3DR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,#0L.3(R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT
M,C8L-3DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PS-C$L,38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV,#0L-S0R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU
M92!O9B!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#DU+#,T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,R,"PT-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#<L-#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,C$L.#4P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E
M8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW-2XT,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]M
M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$W
M-"PP,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#(Y-2PV,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!W87)R86YT<R!L:6%B:6QI='D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-30S+#8T-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M;VX@4W1O8VL@86YD(%=A<G)A;G0@3&EA8FEL:71Y("A497AT=6%L*2!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5S=&EM871E9"!R:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XX,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&QI=F5S
M(&]F('=A<G)A;G1S+"!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UO;B!3=&]C:R!A;F0@
M5V%R<F%N="!,:6%B:6QI='D@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D
M(')I<VLM9G)E92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+C$P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EV97,@;V8@=V%R<F%N=',L
M('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UO;B!3=&]C:R!A;F0@5V%R<F%N="!,:6%B
M:6QI='D@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64@;V8@=V%R<F%N="!I;B!T
M97)M<R!O9B!P97)C96YT86=E(&]F('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@;G5M8F5R(&]F('-H87)E
M<R!O9B!S=&]C:R!A=F%I;&%B;&4@=&\@<'5R8VAA<V4@=7-I;F<@=V%R<F%N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,BPU,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3(L
M-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14%&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI
M=&EE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C<G5E9"!L
M:6%B:6QI=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`W.#<L-#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`V-2PU-S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V9E<W-I
M;VYA;"!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3DL
M-C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3DP+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q-2PU,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-C8L,#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2PP-C(L-C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0R,BPQ,#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5D@^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B`H1&5T
M86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VX@*%1E
M>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%X:6UU;2!&:6YA;F-I86P@4W5P<&]R="!T;R!'
M0DU4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E=F5R86YC92!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/E1H92!S979E<F%N8V4@86=R965M96YT('!R;W9I9&5S('1H870@
M1'(N)B,Q-C`[46EA;BP@:6X@97AC:&%N9V4@9F]R(&AI<R!E>&5C=71I;VX@
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M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-R=65D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$S-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%24-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!8V-O
M=6YT:6YG(&9O<B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E=&%I;',I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!8V-O=6YT:6YG($9O<B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@
M*$)L86-K+5-C:&]L97,@3W!T:6]N(%!R:6-I;F<@36]D96PI/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E
M<FT@*'EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-B!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C8@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;FEM=6T@<FES:RUF<F5E(&EN=&5R97-T(')A=&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXT,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA
M>&EM=6T@<FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$N,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BXU,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@=F]L871I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-87AI;75M('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<V+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<T+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I
M<F5C=&]R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^06-C;W5N=&EN9R!&;W(@4W1O8VLM0F%S960@0V]M<&5N
M<V%T:6]N("A";&%C:RU38VAO;&5S($]P=&EO;B!0<FEC:6YG($UO9&5L*3PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E
M8W1E9"!T97)M("AY96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C8@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XV('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15I/044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M06-C;W5N=&EN9R!F;W(@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A
M:6QS(#$I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@
M9F]R(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H4W1O8VL@0F%S960@0V]M
M<&5N<V%T:6]N($5X<&5N<V4I/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M,#`W+#<T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S8Q+#@T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,BPP,S`L-#$X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`S.2PU-3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A
M<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!F
M;W(@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A3=&]C:R!"87-E9"!#;VUP
M96YS871I;VX@17AP96YS92D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V-2PX
M-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-S@L.#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S8U+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,T,RPX-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD($%D;6EN:7-T
M<F%T:79E($5X<&5N<V4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(&9O<B!3=&]C:RU"87-E
M9"!#;VUP96YS871I;VX@*%-T;V-K($)A<V5D($-O;7!E;G-A=&EO;B!%>'!E
M;G-E*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V-#$L.#@W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#,L,#,X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#(V-2PT,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8Y-2PV.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-5I!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY!8V-O=6YT:6YG(&9O<B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E
M=&%I;',@,BD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@9F]R(%-T;V-K+4)A<V5D
M($-O;7!E;G-A=&EO;B`H3W!T:6]N<R!/=71S=&%N9&EN9R!!;F0@17AE<F-I
M<V%B;&4I/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L($YU;6)E<B!O9B!3:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#<R,2PW,C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O
M;G1R86-T=6%L($QI9F4@*&EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^-2!Y96%R<R`V(&UO;G1H<R`Q,2!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS
M($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E
M('!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!.=6UB97(@;V8@4VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#8U-BPW,C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@17AE<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I
M8V4@<&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(N,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^)#`N-SD@+2`D,2XS.2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@9F]R(%-T;V-K
M+4)A<V5D($-O;7!E;G-A=&EO;B`H3W!T:6]N<R!/=71S=&%N9&EN9R!!;F0@
M17AE<F-I<V%B;&4I/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L($YU;6)E<B!O9B!3:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S,U+#@P.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N<R!/=71S=&%N9&EN9RP@5V5I9VAT960@079E<F%G92!296UA:6YI
M;F<@0V]N=')A8W1U86P@3&EF92`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XT('EE87)S(#$Q(&UO;G1H<R`Q.2!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<'1I;VYS($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E
M(%!R:6-E('!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+C$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!.=6UB97(@;V8@4VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4V-RPU,3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@17AE<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I
M<V4@4')I8V4@<&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$N,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C$N-#,@+2`R+C$U(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!F;W(@
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A/<'1I;VYS($]U='-T86YD:6YG
M($%N9"!%>&5R8VES86)L92D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@3G5M8F5R(&]F
M(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV,C@L
M-38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E(%)E
M;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E("AI;B!Y96%R<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,@-R!M;VYT:',@,3<@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@5V5I9VAT960@079E<F%G92!%>&5R
M8VES92!0<FEC92!P97(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XW,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92P@3G5M8F5R(&]F
M(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP-C,L
M,S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E($5X
M97)C:7-E(%!R:6-E('!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#XR+C(W("T@,RXW-B!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@
M9F]R(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H3W!T:6]N<R!/=71S=&%N
M9&EN9R!!;F0@17AE<F-I<V%B;&4I/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L($YU;6)E
M<B!O9B!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M-#,R+#<S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@5V5I9VAT960@079E<F%G
M92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF92`H:6X@>65A<G,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#$Q(&1A>7,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@
M4')I8V4@<&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(N-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4L($YU;6)E<B!O9B!3:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-34U+#0T-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N<R!%>&5R8VES86)L92P@5V5I9VAT960@079E<F%G92!%>&5R8VES
M92!0<FEC92!P97(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BXU,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^,RXY."`M(#0N-3(@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(&9O<B!3
M=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$]P=&EO;G,@3W5T<W1A;F1I;F<@
M06YD($5X97)C:7-A8FQE*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG+"!.=6UB97(@;V8@
M4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(P-"PV
M,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@4F5M
M86EN:6YG($-O;G1R86-T=6%L($QI9F4@*&EN('EE87)S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^-R!Y96%R<R`Q,"!M;VYT:',@-B!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E('!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`T+C,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!.=6UB97(@;V8@
M4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3@L-#0U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E('!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`T+C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XT+C4V("T@-2XV,"!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@9F]R
M(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H3W!T:6]N<R!/=71S=&%N9&EN
M9R!!;F0@17AE<F-I<V%B;&4I/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L($YU;6)E<B!O
M9B!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@4F5M
M86EN:6YG($-O;G1R86-T=6%L($QI9F4@*&EN('EE87)S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,2!Y96%R(#$P(&UO;G1H<R`Q-R!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E('!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`T+C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!.=6UB97(@;V8@
M4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,3(L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E('!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`T+C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U-04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C;W5N
M=&EN9R!F;W(@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS(%1E
M>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CY0;&%N/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C
M;W5N=&EN9R!F;W(@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A497AT=6%L
M*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;BP@;G5M8F5R(&]F
M('!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I
M;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,3@R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4@8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT
M('9E<W1I;F<@<&5R:6]D+"!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@:6YT<FEN<VEC('9A;'5E(&]F
M(&5M<&QO>65E(&]P=&EO;G,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,S`L,#(Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`L,#(Q+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT
M<FEN<VEC('9A;'5E(&]F(&5X97)C:7-A8FQE(&]P=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(T+#0V-"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PT-C0L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"!A=F5R86=E(&=R86YT+61A=&4@9F%I<B!V86QU97,@;V8@<W1O
M8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+CDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+C0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&-O<W0@;F5T
M(&]F(&5S=&EM871E9"!F;W)F96ET=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PW-C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW-C4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@
M8V]M<&5N<V%T:6]N(&-O<W0L('=E:6=H=&5D(&%V97)A9V4@<&5R:6]D(&9O
M<B!R96-O9VYI=&EO;BP@>65A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C(@>65A<G,@-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=')I;G-I8R!V86QU97,@;V8@
M96UP;&]Y964@<W1O8VL@;W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L-S<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R-BPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L
M=65S(&]F('9E<W1E9"!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#(R."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`U,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!E;G-A=&EO
M;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,S,L
M-#DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S0X+#<T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-C0Y+#<R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#$Q+#<S.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+65M<&QO>65E(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$W-"PR-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$S+#$P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S@P+#8Y,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<L.#(P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM
M16UP;&]Y964@1&ER96-T;W)S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!F;W(@4W1O8VLM
M0F%S960@0V]M<&5N<V%T:6]N("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@
M9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4@8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT('9E<W1I
M;F<@<&5R:6]D+"!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^-"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?86$U,C(T.3%?8F(S,%\T,68Q7V$W9F1?-C8P96%A8S<S-S!B#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V%A-3(R-#DQ7V)B,S!?-#%F
M,5]A-V9D7S8V,&5A86,W,S<P8B]7;W)K<VAE971S+U-H965T,S,N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5:3T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQO<W,@4&5R
M($-O;6UO;B!3:&%R92`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN
M8V]M92`H3&]S<RD@4&5R($-O;6UO;B!3:&%R92!!;G1I9&EL=71I=F4@4V5C
M=7)I=&EE<R`M(%-T;V-K($]P=&EO;G,@06YD(%=A<G)A;G1S/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%N=&ED
M:6QU=&EV92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPQ,C`L,#0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,L-#,Y+#`T-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#$R,"PP-#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPT,SDL,#0U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE("A,;W-S
M*2!097(@0V]M;6]N(%-H87)E($%N=&ED:6QU=&EV92!396-U<FET:65S("T@
M4W1O8VL@3W!T:6]N<R!!;F0@5V%R<F%N=',\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@86YT:61I;'5T:79E('-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#<R
M,2PW,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,2PX,C@L,C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`L-S(Q+#<R-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#@R."PR,C<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M(&]U='-T86YD:6YG(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE("A,;W-S*2!097(@0V]M;6]N(%-H
M87)E($%N=&ED:6QU=&EV92!396-U<FET:65S("T@4W1O8VL@3W!T:6]N<R!!
M;F0@5V%R<F%N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@86YT:61I;'5T:79E('-E8W5R:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,SDX+#,Q.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C$P+#@Q.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,SDX+#,Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-C$P+#@Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?86$U,C(T.3%?8F(S,%\T,68Q7V$W9F1?-C8P96%A8S<S
M-S!B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V%A-3(R-#DQ7V)B
M,S!?-#%F,5]A-V9D7S8V,&5A86,W,S<P8B]7;W)K<VAE971S+V9I;&5L:7-T
M+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T
M+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN
M+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,CDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,S+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]A834R
D,C0Y,5]B8C,P7S0Q9C%?83=F9%\V-C!E86%C-S,W,&(M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EICAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting for Stock-Based Compensation (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Accounting For Stock-Based Compensation (Black-Scholes Option Pricing Model)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">6 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum risk-free interest rate</a></td>
        <td class="nump">1.00%<span></span></td>
        <td class="nump">2.40%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum risk-free interest rate</a></td>
        <td class="nump">1.20%<span></span></td>
        <td class="nump">2.50%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Minimum volatility</a></td>
        <td class="nump">74.00%<span></span></td>
        <td class="nump">73.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Maximum volatility</a></td>
        <td class="nump">76.00%<span></span></td>
        <td class="nump">74.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividends</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Director [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Accounting For Stock-Based Compensation (Black-Scholes Option Pricing Model)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">6 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transaction (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RelatedPartyTransactionTextualAbstract', window );"><strong>Related Party Transaction (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_MaximumFinancialSupportToRelatedParty', window );">Maximum Financial Support to GBMT</a></td>
        <td class="nump">$ 400,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_SeveranceAgreementToRelatedParty', window );">Severance Agreement</a></td>
        <td class="text">The severance agreement provides that Dr.&#160;Qian, in exchange for his execution and nonrevocation of a general release of claims in favor of the Company as set forth in the severance agreement, will be provided certain severance benefits, including a lump-sum payment equivalent to one-half times his base annual salary rate in effect as of his termination date to be paid out in August 2012.<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
        <td class="nump">$ 137,500<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_MaximumFinancialSupportToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum financial support to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_MaximumFinancialSupportToRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RelatedPartyTransactionTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_RelatedPartyTransactionTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_SeveranceAgreementToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Severance agreement to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_SeveranceAgreementToRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting for Stock-Based Compensation (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationAbstract', window );"><strong>Accounting for Stock-Based Compensation (Stock Based Compensation Expense)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 1,007,742<span></span></td>
        <td class="nump">$ 361,846<span></span></td>
        <td class="nump">$ 2,030,418<span></span></td>
        <td class="nump">$ 1,039,558<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationAbstract', window );"><strong>Accounting for Stock-Based Compensation (Stock Based Compensation Expense)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
        <td class="nump">365,855<span></span></td>
        <td class="nump">178,808<span></span></td>
        <td class="nump">765,010<span></span></td>
        <td class="nump">343,861<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationAbstract', window );"><strong>Accounting for Stock-Based Compensation (Stock Based Compensation Expense)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 641,887<span></span></td>
        <td class="nump">$ 183,038<span></span></td>
        <td class="nump">$ 1,265,408<span></span></td>
        <td class="nump">$ 695,697<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AccountingForStockBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_AccountingForStockBasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5ZAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting for Stock-Based Compensation (Details 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract', window );"><strong>Accounting for Stock-Based Compensation (Options Outstanding And Exercisable)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares</a></td>
        <td class="nump">10,721,724<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
        <td class="text">5 years 6 months 11 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 2.57<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares</a></td>
        <td class="nump">7,656,720<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 2.20<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$0.79 - $1.39 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract', window );"><strong>Accounting for Stock-Based Compensation (Options Outstanding And Exercisable)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares</a></td>
        <td class="nump">2,735,809<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
        <td class="text">4 years 11 months 19 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 1.18<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares</a></td>
        <td class="nump">2,567,519<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 1.19<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">1.43 - 2.15 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract', window );"><strong>Accounting for Stock-Based Compensation (Options Outstanding And Exercisable)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares</a></td>
        <td class="nump">2,628,568<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
        <td class="text">5 years 7 months 17 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 1.73<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares</a></td>
        <td class="nump">2,063,310<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 1.62<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2.27 - 3.76 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract', window );"><strong>Accounting for Stock-Based Compensation (Options Outstanding And Exercisable)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares</a></td>
        <td class="nump">2,432,733<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
        <td class="text">5 years 11 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 2.75<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares</a></td>
        <td class="nump">1,555,446<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 2.52<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">3.98 - 4.52 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract', window );"><strong>Accounting for Stock-Based Compensation (Options Outstanding And Exercisable)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares</a></td>
        <td class="nump">2,204,614<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
        <td class="text">7 years 10 months 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 4.39<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares</a></td>
        <td class="nump">758,445<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 4.13<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">4.56 - 5.60 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract', window );"><strong>Accounting for Stock-Based Compensation (Options Outstanding And Exercisable)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares</a></td>
        <td class="nump">720,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
        <td class="text">1 year 10 months 17 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 4.74<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares</a></td>
        <td class="nump">712,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price per Share</a></td>
        <td class="nump">$ 4.74<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_AccountingForStockBasedCompensationOptionsOutstandingAndExercisableAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a, b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenue Recognition<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:SignificantAccountingPoliciesTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>3.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Revenue Recognition</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company&#8217;s business strategy includes entering into collaborative license and development
   agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&#8217;s product candidates. The terms of these agreements may provide for the Company&#8217;s licensees and collaborators to agree to
   make non-refundable license fee payments, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales if any products are successfully
   commercialized. For a complete discussion of the Company&#8217;s revenue recognition policy, see Note 2(c) included in its annual report on Form 10-K, as previously filed with the Securities and Exchange Commission on February&#160;29, 2012.
   </font></p>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting for Stock-Based Compensation (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Plan</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationTextualAbstract', window );"><strong>Accounting for Stock-Based Compensation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShareBasedCompensationPlans', window );">Share-based compensation, number of plans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,182,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation arrangement vesting period, years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of employee options outstanding</a></td>
        <td class="nump">$ 30,021,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 30,021,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of exercisable options</a></td>
        <td class="nump">24,464,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,464,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair values of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.99<span></span></td>
        <td class="nump">$ 1.43<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost net of estimated forfeitures</a></td>
        <td class="nump">5,765,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,765,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period for recognition, years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic values of employee stock options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,779,000<span></span></td>
        <td class="nump">826,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue', window );">Fair values of vested stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,228,000<span></span></td>
        <td class="nump">1,050,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Compensation expense</a></td>
        <td class="nump">833,497<span></span></td>
        <td class="nump">348,742<span></span></td>
        <td class="nump">1,649,725<span></span></td>
        <td class="nump">1,011,738<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense', window );">Non-employee compensation expense</a></td>
        <td class="nump">$ 174,245<span></span></td>
        <td class="nump">$ 13,104<span></span></td>
        <td class="nump">$ 380,693<span></span></td>
        <td class="nump">$ 27,820<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Non-Employee Directors [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AccountingForStockBasedCompensationTextualAbstract', window );"><strong>Accounting for Stock-Based Compensation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">470,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation arrangement vesting period, years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AccountingForStockBasedCompensationTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_AccountingForStockBasedCompensationTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ShareBasedCompensationPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share-based compensation, number of plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ShareBasedCompensationPlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph c(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph d(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense reported during the period resulting from the transaction in which equity securities were issued to pay for goods or nonemployee services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 65<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 12,089,655<span></span></td>
        <td class="nump">$ 15,119,730<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump">32,616,147<span></span></td>
        <td class="nump">22,597,845<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">318,306<span></span></td>
        <td class="nump">42,067<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
        <td class="nump">397,139<span></span></td>
        <td class="nump">743,799<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">45,421,247<span></span></td>
        <td class="nump">38,503,441<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">428,950<span></span></td>
        <td class="nump">455,730<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Long-term investment - restricted</a></td>
        <td class="nump">194,282<span></span></td>
        <td class="nump">235,914<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">8,982,000<span></span></td>
        <td class="nump">8,982,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">2,980<span></span></td>
        <td class="nump">2,980<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">55,029,459<span></span></td>
        <td class="nump">48,180,065<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,429,316<span></span></td>
        <td class="nump">2,364,437<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">1,062,626<span></span></td>
        <td class="nump">1,422,107<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">3,491,942<span></span></td>
        <td class="nump">3,786,544<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
        <td class="nump">4,304,922<span></span></td>
        <td class="nump">4,361,168<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump">177,703<span></span></td>
        <td class="nump">156,396<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">7,974,567<span></span></td>
        <td class="nump">8,304,108<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value 125,000,000 shares authorized; 80,581,596 shares issued and 79,533,889 shares outstanding at June 30, 2012; and 78,165,360 shares issued and 77,117,653 shares outstanding at December 31, 2011</a></td>
        <td class="nump">805,816<span></span></td>
        <td class="nump">781,654<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">779,848,984<span></span></td>
        <td class="nump">772,039,254<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock (at cost, 1,047,707 shares)</a></td>
        <td class="num">(891,274)<span></span></td>
        <td class="num">(891,274)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(732,748,357)<span></span></td>
        <td class="num">(732,087,642)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump">39,723<span></span></td>
        <td class="nump">33,965<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">47,054,892<span></span></td>
        <td class="nump">39,875,957<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 55,029,459<span></span></td>
        <td class="nump">$ 48,180,065<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 14, 17, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedInvestmentsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-6<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 98-5<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 00-27<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Nature of Business<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NatureOfBusinessAbstract', window );"><strong>Nature of Business [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations-->
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2"><b></b></font>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>1.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Nature of Business</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">Curis, Inc. (the &#8220;Company&#8221; or &#8220;Curis&#8221;) is a drug discovery and development company
   that is committed to leveraging its innovative signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. Curis is building upon its past experiences in targeting signaling pathways, including the
   Hedgehog signaling pathway, in its efforts to develop network-targeted cancer therapies. Curis conducts research and development programs both internally and through strategic collaborations. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company operates in a single reportable segment, which is the research and development of innovative cancer
   therapeutics. The Company expects that any successful products would be used in the health care industry and would be regulated in the United States, or the U.S., by the U.S. Food and Drug Administration, or FDA, and in overseas markets by similar
   regulatory agencies. In January 2012, the Erivedge&#8482; capsule was approved by the FDA and became commercially available in February 2012 (see Note 4). </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">
   The Company is subject to risks common to companies in the biotechnology industry including, but not limited to: development by its competitors of new or better technological innovations; dependence on
   key personnel; its ability to protect proprietary technology; its ability to successfully advance discovery, preclinical and clinical stage drug candidates in its internally funded programs; unproven technologies and drug development approaches;
   reliance on corporate collaborators and licensees to successfully research, develop and commercialize products based on its technologies; its ability to comply with FDA regulations and approval requirements; its ability to execute on its business
   strategies; and its ability to obtain adequate financing to fund its operations. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company&#8217;s future
   operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its research and development pipeline. The results of the
   Company&#8217;s operations will vary significantly from year to year and quarter to quarter and depend on, among other factors, the timing of its entry into new collaborations, if any, the timing of the receipt of payments from new or existing
   collaborators and the cost and outcome of any preclinical development or clinical trials then being conducted. The Company anticipates that existing capital resources at June&#160;30, 2012 should enable the Company to maintain its current and
   planned operations into the first half of 2014. The Company&#8217;s ability to continue funding its planned operations into and beyond the first half of 2014 is dependent upon, among other things, the success of its collaborations with Genentech
   Inc., or Genentech, and Debiopharm S.A., or Debiopharm, and receipt of additional cash payments under these collaborations, its ability to control expenses and its ability to raise additional funds through equity or debt financings, new
   collaborations or other sources of financing. The Company may not be able to successfully enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly
   uncertain. As a result, the Company cannot assure that it will attain any further revenue under any collaborations or licensing arrangements. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay
   spending on its research and/or development programs. </font></p>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NatureOfBusinessAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_NatureOfBusinessAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENHDI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration Agreements (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>University</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Out of Period Adjustment [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>University Licensors [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>University Licensors [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Genentech Inc [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Genentech Inc [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Genentech Inc [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Genentech Inc [Member]

</div>
          <div>University Licensors [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Genentech Inc [Member]

</div>
          <div>University Licensors [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Genentech Inc [Member]

</div>
          <div>University Licensors [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Leukemia and Lymphoma Society [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Roche [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>FDA's [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementsTextualAbstract', window );"><strong>Collaboration Agreements (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RevenueRecognizedMilestonePaymentsLicenseRevenue', window );">Revenue recognized milestone payments as license revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 14,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_MilestonesRecognizedFromPartner', window );">Earned milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AdditionalMilestoneRecognizedFromPartner', window );">Earned an additional milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment', window );">Eligibility to receive contingent cash payments under the collaboration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">115,000,000<span></span></td>
        <td class="nump">115,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner', window );">Amount received for specified clinical development and regulatory objectives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,000,000<span></span></td>
        <td class="nump">46,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_SublicenseFeesPaid', window );">Research and development expenses related to the FDA's approval and payments received for Erivedge</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">650,000<span></span></td>
        <td class="nump">1,150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">550,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Recognized royalty revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">252,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">523,372<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">252,750<span></span></td>
        <td class="nump">523,372<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Fair value of one-time issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">964,000<span></span></td>
        <td class="nump">964,000<span></span></td>
        <td class="nump">964,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_SharesIssuedToSublicensees', window );">Number of common stock shares issued to university licensors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Costs of royalty revenues recorded</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,637<span></span></td>
        <td class="nump">126,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCostRoyaltyExpense', window );">Costs of royalty revenues, company obligated to pay to university licensors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,637<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">126,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,637<span></span></td>
        <td class="nump">26,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned', window );">Percentage of royalties earned</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CashPaymentToUniversityLicensor', window );">Cash payment to university licensor</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber', window );">Number of university licensors in connection with the FDA-approval of Erivedge</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500,456<span></span></td>
        <td class="nump">3,144,050<span></span></td>
        <td class="nump">9,742,405<span></span></td>
        <td class="nump">6,202,549<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">650,000<span></span></td>
        <td class="nump">2,114,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PercentageOfContributionToFund', window );">Percentage of contribution of fund from LLS</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ProceedsFromContributionOfFund', window );">Contribution of fund from LLS amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ContingentObligations', window );">Company under obligation to make payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AdditionalMilestoneRecognizedFromPartner">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional milestone recognized from partner.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_AdditionalMilestoneRecognizedFromPartner</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CashPaymentToUniversityLicensor">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash payment to university licensor.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CashPaymentToUniversityLicensor</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement contingent consideration potential cash payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CollaborationAgreementContingentConsiderationPotentialCashPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement contingent consideration received from partner.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CollaborationAgreementContingentConsiderationReceivedFromPartner</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CollaborationAgreementsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock issued one time issuance to university licenses number.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ContingentObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ContingentObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_MilestonesRecognizedFromPartner">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestones recognized from partner.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_MilestonesRecognizedFromPartner</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PercentageOfContributionToFund">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of contribution to fund.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_PercentageOfContributionToFund</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of sublicense fees paid on royalties earned.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ProceedsFromContributionOfFund">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from contribution of fund.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ProceedsFromContributionOfFund</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RevenueRecognizedMilestonePaymentsLicenseRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue recognized milestone payments license revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_RevenueRecognizedMilestonePaymentsLicenseRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_SharesIssuedToSublicensees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued to sublicensees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_SharesIssuedToSublicensees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_SublicenseFeesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sublicense fees paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_SublicenseFeesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCostRoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty expense incurred and are directly related to goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DirectOperatingCostRoyaltyExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of equity valued at fair value by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EONAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value of Warrant Liability</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance Beginning</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,361,168<span></span></td>
        <td class="nump">$ 1,604,742<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">495,341<span></span></td>
        <td class="nump">320,440<span></span></td>
        <td class="nump">487,400<span></span></td>
        <td class="nump">1,821,850<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ChangeInFairValueUponWarrantExercise', window );">Change in fair value of warrants exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(543,646)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance Ending</a></td>
        <td class="nump">$ 4,304,922<span></span></td>
        <td class="nump">$ 3,426,592<span></span></td>
        <td class="nump">$ 4,304,922<span></span></td>
        <td class="nump">$ 3,426,592<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ChangeInFairValueUponWarrantExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value upon warrant exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ChangeInFairValueUponWarrantExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 98-5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 00-27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation and Collaborative Arrangement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>2.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Basis of Presentation</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The accompanying condensed consolidated financial statements of the Company have been prepared in
   accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by generally accepted accounting principles, or GAAP, in the U.S. for complete
   financial statements and should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2011, as filed with the Securities and Exchange Commission on February&#160;29, 2012. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">In the opinion of the Company, the unaudited financial statements contain all adjustments (all of which were considered
   normal and recurring) necessary for a fair statement of the Company&#8217;s financial position at June&#160;30, 2012 and the results of operations and cash flows for the six-month periods ended June&#160;30, 2012 and 2011. The preparation of the
   Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date.
   Such estimates include revenue recognition, the collectibility of receivables, the carrying value of property and equipment and intangible assets, management assumptions used in its calculations of stock-based compensation expense, and the value of
   certain investments and liabilities, including the value of its warrant liability. Actual results may differ from such estimates. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">These
   interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</font></p>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7880789&amp;loc=SL6228881-111685<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6HAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">125,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">80,581,596<span></span></td>
        <td class="nump">78,165,360<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">79,533,889<span></span></td>
        <td class="nump">77,117,653<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost</a></td>
        <td class="nump">1,047,707<span></span></td>
        <td class="nump">1,047,707<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets Measured at Fair Value on Recurring Basis</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note5_table1 - us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock-->
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="49%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted&#160;Prices&#160;in<br />Active Markets<br />(Level 1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Other<br />Observable<br />Inputs&#160;(Level&#160;2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unobservable<br />Inputs&#160;(Level&#160;3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>As of June&#160;30, 2012:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Money market funds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,832,066</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,832,066</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Municipal bonds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,145,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,145,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Investments</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate commercial paper, stock, bonds and notes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16,423,449</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16,192,698</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,616,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">24,255,515</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,337,698</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">42,593,213</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>As of December&#160;31, 2011:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Money market funds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,366,747</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,366,747</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Municipal bonds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,375,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,375,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Investments</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">US government obligations</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,704</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,704</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate commercial paper, stock, bonds and notes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,365,841</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,423,300</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,789,141</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,107,588</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,232,004</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">30,339,592</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value of Warrant Liability</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note5_table2 - us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-->
   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="85%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at December&#160;31, 2010</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,604,742</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Change in fair value </font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,821,850</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at June&#160;30, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,426,592</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at December&#160;31, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants exercised </font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(543,646</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Change in fair value </font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">487,400</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at June&#160;30, 2012</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 6<br><br> -Footnote 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19190-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19279-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 02, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">CURIS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001108205<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,622,590<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">The amortized cost, unrealized gains and fair value of marketable securities available-for-sale with maturity dates ranging between one and twelve months and with a weighted average maturity</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note6_table1 - us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock-->
   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="63%">&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom">&#160;<font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amortized<br />Cost</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unrealized<br />Gain</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate bonds, notes and stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,608,962</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,185</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,616,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total marketable securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,608,962</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,185</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,616,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><font style="font-family:times new roman" size="2">The amortized cost, unrealized gains and fair value of marketable securities
   available-for-sale as of December&#160;31, 2011, with maturity dates ranging between one and twelve months and with a weighted average maturity of 3.7 months are as follows: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="63%">&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom">&#160;<font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amortized<br />Cost</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unrealized<br />Gain</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,641</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">63</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,704</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate bonds, notes and stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,787,778</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,363</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,789,141</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total marketable securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22,596,419</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,426</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22,597,845</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27290-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ResearchAndDevelopmentRevenue', window );">Research and development</a></td>
        <td class="nump">$ 98,824<span></span></td>
        <td class="nump">$ 92,867<span></span></td>
        <td class="nump">$ 184,454<span></span></td>
        <td class="nump">$ 226,405<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalties</a></td>
        <td class="nump">252,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">523,372<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fees</a></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">14,000,000<span></span></td>
        <td class="nump">300,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">4,351,574<span></span></td>
        <td class="nump">392,867<span></span></td>
        <td class="nump">14,707,826<span></span></td>
        <td class="nump">526,405<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>COSTS AND EXPENSES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCostRoyaltyExpense', window );">Cost of royalty revenues</a></td>
        <td class="nump">12,637<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">126,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">4,500,456<span></span></td>
        <td class="nump">3,144,050<span></span></td>
        <td class="nump">9,742,405<span></span></td>
        <td class="nump">6,202,549<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">2,264,586<span></span></td>
        <td class="nump">1,867,782<span></span></td>
        <td class="nump">5,065,663<span></span></td>
        <td class="nump">4,275,131<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">6,777,679<span></span></td>
        <td class="nump">5,011,832<span></span></td>
        <td class="nump">14,934,236<span></span></td>
        <td class="nump">10,477,680<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(2,426,105)<span></span></td>
        <td class="num">(4,618,965)<span></span></td>
        <td class="num">(226,410)<span></span></td>
        <td class="num">(9,951,275)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME/(EXPENSE):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">34,994<span></span></td>
        <td class="nump">25,341<span></span></td>
        <td class="nump">53,095<span></span></td>
        <td class="nump">58,910<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="num">(495,341)<span></span></td>
        <td class="num">(320,440)<span></span></td>
        <td class="num">(487,400)<span></span></td>
        <td class="num">(1,821,850)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
        <td class="num">(460,347)<span></span></td>
        <td class="num">(295,099)<span></span></td>
        <td class="num">(434,305)<span></span></td>
        <td class="num">(1,762,940)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(2,886,452)<span></span></td>
        <td class="num">(4,914,064)<span></span></td>
        <td class="num">(660,715)<span></span></td>
        <td class="num">(11,714,215)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share (basic and diluted)</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.01)<span></span></td>
        <td class="num">$ (0.15)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares (basic and diluted)</a></td>
        <td class="nump">79,052,517<span></span></td>
        <td class="nump">76,378,369<span></span></td>
        <td class="nump">78,304,441<span></span></td>
        <td class="nump">76,103,611<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
        <td class="num">$ (2,899,231)<span></span></td>
        <td class="num">$ (4,931,189)<span></span></td>
        <td class="num">$ (654,957)<span></span></td>
        <td class="num">$ (11,725,873)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ResearchAndDevelopmentRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Historically, this has included FTE reimbursement.  It also includes reimbursement of other costs that have been incurred on behalf of a partner.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ResearchAndDevelopmentRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e557-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCostRoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty expense incurred and are directly related to goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DirectOperatingCostRoyaltyExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Common Stock and Warrant Liability<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockAndWarrantLiabilityAbstract', window );"><strong>Common Stock and Warrant Liability [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockAndWarrantLiabilityTextBlock', window );">Common Stock and Warrant Liability</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 7 - cris:CommonStockAndWarrantLiabilityTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>7.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Common Stock and Warrant Liability</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">On January&#160;27, 2010, the Company completed a registered direct offering of 6,449,288 units with
   each unit consisting of (i)&#160;one share of the Company&#8217;s common stock and (ii)&#160;one warrant to purchase 0.25&#160;of one share of common stock at a purchase price of $2.52 per unit. The Company received net proceeds from the sale of the
   units, after deducting offering expenses, of approximately $14,942,000. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">In connection with this offering, the
   Company issued warrants to purchase an aggregate of 1,612,322 shares of common stock. As of June&#160;30, 2012, warrants to purchase 214,004 shares of the Company&#8217;s common stock have been exercised. The warrants have an initial exercise price
   of $3.55 per share and a five-year term. The warrants contain antidilution adjustment provisions that will result in a decrease in the price and an increase in the number of shares of common stock issuable upon exercise of such warrants in the event
   of certain issuances of common stock by the Company at prices below $3.55 per share. The warrants also included a cash-settlement option in the event of a change of control that expired on January&#160;27, 2012. Due to the terms, the warrants are
   classified as a liability and, therefore, the fair value of the warrants was recorded as a liability in the Consolidated Balance Sheets as of June&#160;30, 2012 and December&#160;31, 2011. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has estimated the fair value of the warrants using a Black-Scholes option pricing model under various
   probability-weighted outcomes which take into consideration the protective, but limited, cash-settlement feature of the warrants, with updated assumptions at each reporting date. The Company estimated that the fair value of the warrants at
   June&#160;30, 2012 was $4,304,922, using the following assumptions: expected volatility of 75.4%, risk free interest rate of 0.4%, expected life of 2.6 years, and no dividends. The Company estimated that the fair value of the warrants at
   June&#160;30, 2011 was $3,426,592 using this same model with the following assumptions assigned to the varying outcomes: expected volatility of 80%, risk free interest rates ranging from 0.8% to 1.1%, expected lives of three to four years, and no
   dividends. The warrants are revalued at each reporting period and the resulting change in fair value of the warrant liability is recognized in the Consolidated Statement of Operations. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company recorded other expense of approximately $495,341 and $487,400 for the three and six months ended June&#160;30,
   2012, respectively, due to changes in fair value of the warrant liability. During the six months ended June&#160;30, 2012, as a result of the exercise of warrants to purchase 212,500 shares of the Company&#8217;s common stock, the warrant liability
   decreased $543,646 with an offsetting increase to additional paid-in-capital. The Company recorded other expense of approximately $320,440 and $1,821,850 for the three and six months ended June&#160;30, 2011, respectively, as a result of a change in
   the fair value of the warrant liability that was primarily due to an increase in the Company&#8217;s stock price during the prior year periods. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CommonStockAndWarrantLiabilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CommonStockAndWarrantLiabilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CommonStockAndWarrantLiabilityTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock and warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CommonStockAndWarrantLiabilityTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentTextBlock', window );">Investments</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - invest:InvestmentTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>6.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Investments</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><font style="font-family:times new roman" size="2">The amortized cost, unrealized gains and fair value of marketable securities available-for-sale as of
   June&#160;30, 2012, with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="63%">&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom">&#160;<font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amortized<br />Cost</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unrealized<br />Gain</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate bonds, notes and stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,608,962</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,185</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,616,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total marketable securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,608,962</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,185</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,616,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><font style="font-family:times new roman" size="2">The amortized cost, unrealized gains and fair value of marketable securities
   available-for-sale as of December&#160;31, 2011, with maturity dates ranging between one and twelve months and with a weighted average maturity of 3.7 months are as follows: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="63%">&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom">&#160;<font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amortized<br />Cost</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unrealized<br />Gain</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,641</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">63</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,704</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate bonds, notes and stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,787,778</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,363</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,789,141</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total marketable securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22,596,419</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,426</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22,597,845</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for investments, including all tables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 6<br><br> -Section 10<br><br> -Paragraph (c)<br><br> -Subparagraph (1)<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E3TBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
        <td class="nump">$ 4,304,922<span></span></td>
        <td class="nump">$ 4,361,168<span></span></td>
        <td class="nump">$ 3,426,592<span></span></td>
        <td class="nump">$ 1,604,742<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
        <td class="nump">4,304,922<span></span></td>
        <td class="nump">4,361,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Measurements Recurring [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue', window );">Municipal bonds</a></td>
        <td class="nump">2,145,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
        <td class="nump">42,593,213<span></span></td>
        <td class="nump">30,339,592<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
        <td class="nump">4,304,922<span></span></td>
        <td class="nump">4,361,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Measurements Recurring [Member] | Cash Equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_MoneyMarketFundsFairValue', window );">Money market funds</a></td>
        <td class="nump">7,832,066<span></span></td>
        <td class="nump">5,366,747<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue', window );">Municipal bonds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,375,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Measurements Recurring [Member] | Investments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue', window );">US government obligations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,808,704<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueDisclosure', window );">Corporate commercial paper, stock, bonds and notes</a></td>
        <td class="nump">32,616,147<span></span></td>
        <td class="nump">18,789,141<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices In Active Markets (Level 1) [Member] | Fair Value Measurements Recurring [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
        <td class="nump">24,255,515<span></span></td>
        <td class="nump">15,107,588<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices In Active Markets (Level 1) [Member] | Fair Value Measurements Recurring [Member] | Cash Equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_MoneyMarketFundsFairValue', window );">Money market funds</a></td>
        <td class="nump">7,832,066<span></span></td>
        <td class="nump">5,366,747<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue', window );">Municipal bonds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,375,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices In Active Markets (Level 1) [Member] | Fair Value Measurements Recurring [Member] | Investments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueDisclosure', window );">Corporate commercial paper, stock, bonds and notes</a></td>
        <td class="nump">16,423,449<span></span></td>
        <td class="nump">7,365,841<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Other Observable Inputs (Level 2) [Member] | Fair Value Measurements Recurring [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
        <td class="nump">18,337,698<span></span></td>
        <td class="nump">15,232,004<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Other Observable Inputs (Level 2) [Member] | Fair Value Measurements Recurring [Member] | Cash Equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue', window );">Municipal bonds</a></td>
        <td class="nump">2,145,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Other Observable Inputs (Level 2) [Member] | Fair Value Measurements Recurring [Member] | Investments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue', window );">US government obligations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,808,704<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueDisclosure', window );">Corporate commercial paper, stock, bonds and notes</a></td>
        <td class="nump">16,192,698<span></span></td>
        <td class="nump">11,423,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Unobservable Inputs (Level 3) [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
        <td class="nump">4,304,922<span></span></td>
        <td class="nump">4,361,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Unobservable Inputs (Level 3) [Member] | Fair Value Measurements Recurring [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets Measured at Fair Value on Recurring Basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
        <td class="nump">$ 4,304,922<span></span></td>
        <td class="nump">$ 4,361,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_MoneyMarketFundsFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Money market funds, fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_MoneyMarketFundsFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7534914&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 12<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Available-for-Sale Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative instrument obligations meeting the definition of a liability which the Company is a party to as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 15<br><br> -Paragraph 83<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6913464&amp;loc=d3e34841-113949<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 10<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value as of the balance sheet date of firm holdings in fixed income obligations issued by state and local governments and authorities. Includes both pledged (to counterparties as collateral for financing transactions) and unpledged holdings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 940<br><br> -SubTopic 320<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6475986&amp;loc=d3e42546-110969<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialInstrumentsOwnedStateAndMunicipalGovernmentObligationsAtFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value as of the balance sheet date of firm holdings in debt obligations issued by the US government including short-term Treasury bills, medium-term Treasury notes, and long-term Treasury bonds, as well as debt issued by agencies. Includes both pledged (to counterparties as collateral for financing transactions) and unpledged holdings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 940<br><br> -SubTopic 320<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6475986&amp;loc=d3e42546-110969<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 98-5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 00-27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note8_table1 - us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock-->
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="74%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>June&#160;30,</b></font><br /><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font><br /><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued compensation</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">787,483</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,065,570</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Professional fees</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">159,625</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">190,500</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">115,518</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">166,037</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,062,626</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,422,107</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting for Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Accounting For Stock-Based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Accounting for Stock-Based Compensation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 10 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>10.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Accounting for Stock-Based Compensation</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">As of June&#160;30, 2012, the Company had two shareholder-approved, share-based compensation plans: the
   2010 Stock Incentive Plan and the 2010 Employee Stock Purchase Plan. These plans were adopted by the board of directors in April 2010 and approved by shareholders in June 2010. In the first quarter of 2010, the Company&#8217;s 2000 Stock Incentive
   Plan expired in accordance with its terms and its 2000 Director Stock Option Plan had no available shares remaining under the plan. No additional awards will be made under these plans, although all outstanding awards under these plans will remain in
   effect until they are exercised or they expire in accordance with their terms. For a complete discussion of the Company&#8217;s share-based compensation plans, see Note 5 included in the Company&#8217;s Annual Report on Form 10-K for the year ended
   December&#160;31, 2011, as previously filed with the Securities and Exchange Commission on February&#160;29, 2012. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">
   During the six months ended June&#160;30, 2012, the Company&#8217;s board of directors granted options to purchase 1,182,000 shares of the Company&#8217;s common stock to officers and employees of the
   Company under the 2010 Stock Incentive Plan. These options vest over a four-year period and bear exercise prices that are equal to the closing market price of the Company&#8217;s common stock on the NASDAQ Global Market on the grant date. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">During the six months ended June&#160;30, 2012, the Company&#8217;s board of directors also granted options to its
   non-employee directors to purchase 470,000 shares of common stock under the 2010 Stock Incentive Plan. These options will vest monthly over a one-year period and bear exercise prices that are equal to the closing market price of the Company&#8217;s
   common stock on the NASDAQ Global Market on the grant date. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:4%"><font style="font-family:times new roman" size="2"><b><u>Employee and Director Grants</u> </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">In determining the fair value of stock options, the Company uses the Black-Scholes option pricing model. The Company
   calculated the Black-Scholes value of employee and director options awarded during the six months ended June&#160;30, 2012 and 2011 based on the assumptions noted in the following table: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="82%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="3" align="center"><font style="font-family:times new roman" size="1"><b>Six Months Ended<br />June&#160;30,</b></font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life (years) &#8211; employees</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life (years) &#8211; directors</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">1.0-1.2%</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">2.4-2.5%</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Volatility</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">74-76%</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">73-74%</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dividends</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">None</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">None</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The expected volatility is based on the annualized daily historical volatility of the Company&#8217;s
   stock price through the grant date for a time period consistent with the expected term of a grant. Management believes that the historical volatility of the Company&#8217;s stock price best represents the volatility of the stock price. The risk-free
   rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company does not anticipate declaring dividends in the foreseeable future. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">
   The stock price volatility and expected terms utilized in the calculation involve management&#8217;s best estimates at that time, both of which impact the fair value of the option calculated under the
   Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected
   to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from
   those estimated by management, additional adjustments to compensation expense may be required in future periods. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The aggregate intrinsic value of employee options outstanding at June&#160;30, 2012 was $30,021,000, of which $24,464,000
   related to exercisable options. The weighted average grant-date fair values of stock options granted during the six months ended June&#160;30, 2012 and 2011 were $2.99 and $1.43, respectively. As of June&#160;30, 2012, there was approximately
   $5,765,000, net of the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding under the Company&#8217;s 2000 and 2010 Stock Incentive Plans that is expected to be recognized as
   expense over a weighted average period of 2.5 years. The intrinsic values of employee stock options exercised during the six months ended June&#160;30, 2012 and 2011 were $5,779,000 and $826,000, respectively. The total fair values of vested stock
   options for the six months ended June&#160;30, 2012 and 2011 were $1,228,000 and $1,050,000, respectively. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The
   Company recorded $833,497 and $1,649,725 in compensation expense for the three and six months ended June&#160;30, 2012, respectively, and $348,742 and $1,011,738 in compensation expense for the three and six months ended June&#160;30, 2011,
   respectively, related to employee and director stock option grants. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:4%"><font style="font-family:times new roman" size="2"><b><u>Non-Employee Grants</u> </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has periodically granted stock options and unrestricted stock awards to consultants for services, pursuant to
   the Company&#8217;s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled. The Company recognized
   expense related to non-employee stock options of $174,245 and $380,693, for the three and six months ended June&#160;30, 2012, respectively, and expense of $13,104 and $27,820 for the three and six months ended June&#160;30, 2011, respectively.
   </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:4%"><font style="font-family:times new roman" size="2"><b><u>Total Stock-Based Compensation Expense </u> </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">For the three and six months ended June&#160;30, 2012 and 2011, the Company recorded employee and non-employee stock-based
   compensation expense to the following line items in its Costs and Expenses section of the Consolidated Statements of Operations, including expense related to its 2010 Employee Stock Purchase Plan: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="58%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For&#160;the&#160;Three&#160;Months&#160;Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For the Six Months Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">365,855</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">178,808</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">765,010</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">343,861</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">General and administrative expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">641,887</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">183,038</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,265,408</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">695,697</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total stock-based compensation expense</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,007,742</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">361,846</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,030,418</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,039,558</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The table below summarizes options outstanding and exercisable at June&#160;30, 2012: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="56%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options Outstanding</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options Exercisable</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap">
   <p style="border-bottom:1px solid #000000;width:72pt"><font style="font-family:times new roman" size="1"><b>Exercise Price Range</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Number of<br />Shares</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Remaining<br />Contractual<br />Life&#160;(in&#160;years)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise&#160;Price<br />per&#160;Share</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Number of<br />Shares</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise&#160;Price<br />per&#160;Share</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">$ 0.79 - $ 1.39</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,735,809</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.97</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.18</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,567,519</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.19</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 1.43 - &#160;&#160; 2.15</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,628,568</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.63</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.73</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,063,310</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.62</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 2.27 - &#160;&#160; 3.76</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,432,733</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.03</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.75</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,555,446</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.52</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 3.98 - &#160;&#160; 4.52</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,204,614</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7.85</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.39</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">758,445</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.13</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 4.56 - &#160;&#160; 5.60</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">720,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.88</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.74</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">712,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.74</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,721,724</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.53</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.57</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,656,720</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.20</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 8 - us-gaap:OtherLiabilitiesDisclosureTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>8.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Accrued Liabilities</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><font style="font-family:times new roman" size="2">Accrued liabilities consist of the following: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="74%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>June&#160;30,</b></font><br /><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font><br /><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued compensation</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">787,483</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,065,570</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Professional fees</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">159,625</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">190,500</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">115,518</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">166,037</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,062,626</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,422,107</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transaction<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transaction</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 9 - us-gaap:RelatedPartyTransactionsDisclosureTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>9.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Related Party Transaction</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:6%"><font style="font-family:times new roman" size="2"><i>License Agreement </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">
   Effective on February&#160;24, 2012, the Company entered into a Drug Development Partnership and License Agreement for CU-906 and CU-908 (the &#8220;license agreement&#8221;) with Guangzhou BeBetter
   Medicine Technology Company Ltd., a company organized under the laws of the People&#8217;s Republic of China (&#8220;GBMT&#8221;). Dr.&#160;Changgeng Qian, the Company&#8217;s former Senior Vice President, Discovery and Preclinical Development, is the
   founder, owner, and legal representative of GBMT. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">Pursuant to the license agreement, the Company has granted
   to GBMT an exclusive royalty-free license, with the right to grant sublicenses subject to certain conditions, to develop, manufacture, market and sell any product containing CU-906 or CU-908 in China, Macau, Taiwan and Hong Kong, or the GBMT
   territory. The Company does not intend to internally develop these compounds. In addition, the Company has granted to GBMT a non-exclusive, royalty-free manufacturing license, with the right to grant sublicenses subject to certain conditions, to
   manufacture CU-906 or CU-908 or any product containing CU-906 or CU-908 outside of the GBMT Territory solely to import the compounds or products into the GBMT territory. Pursuant to the terms of the license agreement, the Company has retained
   rights, including the right to grant sublicenses, to develop, manufacture, market and sell any product containing CU-906 or CU-908 worldwide excluding the GBMT Territory. The Company also has certain specified rights to any GBMT technology developed
   under the license agreement as well as certain specified rights to GBMT&#8217;s interest in joint technology developed under the license agreement. Furthermore, the Company has a right of first negotiation to obtain a license to CU-906 or CU-908 for
   the GBMT Territory from GBMT. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has agreed to transfer to GBMT know how, information and materials
   necessary for GBMT to continue the development of products in accordance with the development plan outlined in the license agreement and has agreed not to assert certain Company patents against GMBT, its affiliates or sublicensee so that such party
   may manufacture, market and sell any product containing CU-906 or CU-908 in the GBMT territory. Furthermore, the Company will provide GBMT with up to $400,000 in financial support for specified CU-908 pre-clinical activities related to enabling the
   filing by the Company of an IND with the FDA, provided that GMBT completes such CU-908 IND-enabling activities in accordance with specified criteria and delivers a U.S. IND package for CU-908 to the Company within prescribed timeframes as specified
   in the license agreement. All costs incurred under this agreement will be expensed as incurred. As of June&#160;30, 2012, the Company had not incurred any expenses under this agreement. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">GBMT will assume all future development responsibility and incur all future costs related to the development, registration
   and commercialization of products in the GMBT Territory under the license agreement. Pursuant to the terms of the license agreement, GBMT has agreed to undertake reasonable commercial efforts, and to use qualified third party service providers
   approved by the Company, to implement the development plan in the timeframes described in the license agreement in order to develop, register and commercialize the products in the GBMT Territory and will be solely responsible for all the costs
   relating thereto. The Company and GBMT must agree to any changes to the development plan and such revised development plan is subject to review and approval by the joint steering committee. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">Unless terminated earlier in accordance with the terms of the license agreement, the license agreement will expire on the
   later of (i)&#160;the expiration of the last-to-expire valid claim of the Company patents and the Company non-assert patents relating to the products, and (ii)&#160;such time as none of GBMT, its affiliates and sublicensees is commercializing any
   compound or product in the GBMT Territory. Pursuant to the license agreement, either party can terminate the license agreement upon notice under prescribed circumstances, and the license agreement specifies the consequences to each party for such
   early termination. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The
   license agreement also sets forth customary terms regarding each party&#8217;s intellectual property ownership rights, representations and warranties, indemnification obligations, confidentiality rights and obligations, and patent prosecution,
   maintenance, enforcement and defense rights and obligations. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:4%"><font style="font-family:times new roman" size="2"><i>Severance Agreement </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">On February&#160;16, 2012, the Company and Dr.&#160;Qian entered into a severance agreement that became binding and
   effective on February&#160;24, 2012. The severance agreement provides that Dr.&#160;Qian, in exchange for his execution and nonrevocation of a general release of claims in favor of the Company as set forth in the severance agreement, will be
   provided certain severance benefits, including a lump-sum payment equivalent to one-half times his base annual salary rate in effect as of his termination date to be paid in August 2012. As a result, the Company had accrued $137,500 related to
   Dr.&#160;Qian&#8217;s severance in the accrued liabilities section of the Company&#8217;s Condensed Consolidated Balance Sheets as of June&#160;30, 2012. The severance agreement also provides for the engagement of Dr.&#160;Qian as a consultant
   pursuant to the terms of a consulting agreement. </font></p>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 11 - us-gaap:EarningsPerShareTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>11.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Loss Per Common Share </u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company applies ASC Topic 260&#8212;<i>Earnings&#160;per Share</i>, which establishes standards for
   computing and presenting earnings per share. Basic and diluted loss per common share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common
   share for the three and six months ended June&#160;30, 2012 and 2011, as the effect of the potential common stock equivalents is antidilutive due to the Company&#8217;s net loss position for these periods. Antidilutive securities consist of stock
   options and warrants outstanding as of the respective reporting period as follows: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="74%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For the<br />Three and<br />Six Months<br />Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,<br />2012</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For the<br />Three and<br />Six Months<br />Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,<br />2011</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,721,724</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,828,227</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,398,318</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,610,818</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total antidilutive securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,120,042</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,439,045</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16381557&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities - Stock Options and Warrants</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note11_table1 - us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-->
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="74%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For the<br />Three and<br />Six Months<br />Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,<br />2012</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For the<br />Three and<br />Six Months<br />Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,<br />2011</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,721,724</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,828,227</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,398,318</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,610,818</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total antidilutive securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,120,042</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,439,045</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>43
<FILENAME>0001193125-12-345451-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-12-345451-xbrl.zip
M4$L#!!0````(`#`X"4$'V?IROW,``$/,!@`1`!P`8W)I<RTR,#$R,#8S,"YX
M;6Q55`D``XN8(U"+F"-0=7@+``$$)0X```0Y`0``[%WI4QO)DO^^$?L_U-/N
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MI/!M/5#CEB?/-Y-&;78[/WQNR:Z%[P"`&'*>Y!T&W/2I<7:#9FBV.\V-3KYJ
M&$]^!5/P;EAT*#=^TW(W\Z9&3F,'M.RT?G]_<A&,Q)@W[TX@XVMA;'4"(X+U
MH;INN7M3J`B%G-X#;I2;`Q88VT%1;!F:_EP,&(EFRTX2\:YAY#B)<"UT;02(
M?->X`ST3-EC+#83:LJ]B*VXMNQ`$?:<K<"_(KLOP76./1TCBKCD=]#;:OZ8Q
MCM8[XE+W_LFC5/2.XR2UIG<BKD6TT7LOQGVAR_??"VY2+5#53.]<`&0T6("L
MH:,*IH2[TDZR;_!=AGAE($'YB%I1$8=GT?[Q/QH_M4$H3B%W6D6W8B@CACAY
M?@$N.6%OB=LDDH&T;BTLE-#.6:L,=%M(!Y&Q-\D__@*C<QV,)D3R[JTTC9_N
MM7=<<4QQP^^TIL[ZK<LJL?=(BW^E8&(G,]94ED0NB(<M;J=5Y>).JR*PG41H
MJ<*2^$@S[$\.OV^:&^V=EK_F1RCUV6EED/L"_CH'(H`A.S7^:OP]%'^=)D!P
MH_-7\7<A;]_#UY$YC$,1EDS@_PFM>F=*QK9W`6R.>Q]D+'H?3>]`11'7IG>I
M>J=PQ36Y!'M<N;L<^+L8<2THJ-I7XP3N<G04=-7LIG:DM/Q3A!^!-?K"JN#J
M-,'[9Z"R9F]R>"MT((TXTS(0YSP>"@<,=$I;R#YB#3$/>??19+RY5,`WND=<
MRZ\_#50`%-H>0,SYDW>V;0!+<35O*.*PU,S9-'_MD3!U>>,AA9\<K*J(<C@J
MPPX&JW%5X`H8YZ!SHX@_)501[PK,`>->$K1*P"%+=8CIRAUT':E49VV.Y+4@
M%-;8*K"5`P@Y2`PLP0N91S>1=<"Y%P2NPL\1@NXY.S1<N6G#QH2N&EDYLKS#
M0_95G1Z8K<RB01MDVPN"U5US=,?5H<'"RYDWA)L4D]6PRF%5,4EE?P?6"JXX
M7RAOD6VK!ZOIE8LZ;%^-L/V)*@QU*+Z:H?B3PZ4.KU<KO'YJP-0A\\J$S$\-
ME3H,7IDP^/&@,C-I.I!:!%;I)9'Z@1@(K:LRW]4:)8AC_B;MZ#@.Y;4,4QX5
M$#GC$]I'V)M<2AN)TT'1J+K[X-FQ,FG-#,%W:L'/3?"=APF^\T1ED@\J[AV.
MDTA-((3P9"^+U7\J&)#A!\YXQN1\61E#0$'/=$2<"R-PB[BW&X>]`]P$5@D2
MTSN\12:+)<$&'K,)4Y2NE^*%T-?@X*>'"KM1I`+Z=#HX%X$:QA@PG!$S]Y5!
ML)R+1&E[`NE%U5AXA@&_2NS*N/4\B-F<*V+<P;N(`+,;CF4LC=7`2X@K:\Q,
MQTS&,N!8E6&KAIJ9?J>V,LMG9>:YG5/;F.6T,?.,93JUE5DV*]-YF%?ZQFSH
M,XBI[<P2VIGG0<W,XDEM99;/RLROYE+;F&6U,<^`F2]DV=`0S,QQ'/AG%3[&
MDIZ2LY/>"?`]-LM3O-O'O9*^<G(L5>T,"/F#BH,9MR_AD^'TS)$I5>MR[@!S
M'O^9A<M)`B`OK:(T<R&"7`(KD[Y/WU/<Y\;Y.OIP^*]47O,()?>U3]#,>A2G
MNR00+CW*LFN,L/L1-Z9JN)!%P"K\4V+4"CQ5\Q<7]Y>?1.HN^J9J]6&S]TC;
M3+N]Z,">MVW^-BEN?,,C6Y]QP$OL:U^J_YI93JQEN71EOK_T,/FB"_,9G]%=
M%,_XP,>P:\D]AN2^\0'FZ3KW&T?C8Q=<4&00+SA6)^C(W][D=#`0&.!."=,S
MDI9*DWP]Z<D%\%5X>W1+T5XD^MI/H4]?R((?GDX?TWMBQJ54?%&5<PZ9X2IF
MT[.J#B4@+*-)FZD2G5HE'J02G5HE5EDE5ACR-;:>$5M?RL7J"*2.0)9`)1XS
MR?V22M012!V!U"JQRI"OL?6,V"K.%"B=X(:BZ.VI.#0]>A4R'3*@XMV2P.@]
M_T-IW*`!X@Y$W\+Z<=??3BX0'=)*4=X7S6DFDHEBZ$#T+F<8^='T?E;70L=T
M^O&T'\DA'?=:%BOP=>+[:`IB2[0NE?[EHJOU[WGU[TF,Z&.E<8LNYCIG6RC[
M_^A5VY>`OU5(D!88?ZN"KQ<ER$>O1RZ1H&M'-O]`ZM&+?R\!?R_<D<VUTK9$
M^%IU07[FX/ARG)?S8MB%T4(9I7BVOTB;#V^#*`6RCK0:XS-]J<T>Y#OD.@;Q
MF#.AW5-_D^D#/.-YN\5Z.XZKG[@7#BY+(>Q9,%!Z$>,+>.*@-@+S-0+S?'E-
M;0(6Q@3,]WTTM1&8HQ&8^[ME:C.P&&9@SJ^+J8W`?(W`/%_]4IN`A3$!SP"#
MJ<6=17J<Z1&+5^WN;CK$X&F1Z(-([FVSW7V"FLYI:GM`M7MY46\W_"-UQZ^6
M1*<O0%NIP'81B)@##>4?QTCMZ<`15M"U,@GZ9V1ZU/M%#09C'L>]$]X[5R"?
MWHD<2PNMED.LC_O>CB//CA-.S,AXL3)0F+Z)7+]GZX6_9VL^KP2J(?9B(?9$
M[RNJ7SSU]"^>6J@`9NZ1]R)Q8_YYUAQJ3F6'T_WA5XZ,:"])P6DAW]?2QCI!
M]X='_J&UQ</F<Q=#'O]%#U]Z*>FBPKX^BO6D#\9]R_M7%R1Q^/HW0*R0+M2@
M6\RCV+6!K@WT,NO*?!^07R%=J$$WQR/&6%-TH8'"72C\^1F=#BL_*J+B)<'4
M(^]=`$/PYV6`'55N+-0QLPZAX1'SJ;DGED_^(^40>(`TQ^EX26!=^CWY_"EU
M1\#*''.8+2E^N^22<@2LC*2FU@<7R68\3;VM"SE+>B7&DI.//)F,DY$:\]Z%
M"J2PDR7!Y^,Z2,\1Z.SYD;%CH3SDX^X-^'AI[I!?E'BAWB1\]E^G>8*8J#Y1
M\.)/%"S2XTZU37G^@P?/(&\(%RDZ0Q&#J&&DYC+[TJ]EQ=^:3=!FRRX$B;O9
M=)=3O(;L.0/WFO-B[$I=#@UX9Z?E+[FAL=N=`3Y>')P)C7/DPX3R&MA14(!M
M/Z1C`3A4%6/E!Y=&;78[/VS!6-49'773^].P!R)68QG/&I@(P7:SAKW??Z=5
M6OY4BL]@F'LL0SV16PE\?!C/#L\N%I!?C@J##T"8QV19X5"F8ZVX_P#NT?,9
M9H8$IJU]E@SN#3&3K^410*/8841VU&L5\VJ%]_;$4,9L+U+!%;ODPZ$(&;ZD
M+V_C;?<';F'XT\%I(ER-S[!,<\_%X#-VZ_O(;L,\!Z?[E_][=LA&=ARQLX][
M)\?[K-%LM7[;V&^U#BX/V.^_7+X_89WU-B-S+W$*'K5:AQ\:K&S2;C;6E1ZV
M+L];MSA6!SMG'YNVU',]M&$#J/A^:+>);]E"9A+<84TVF]@I`Z$$UX`-,V_=
MWKTU`(8Q8R<16&G\W!SPL8PF6Q9<I6&QN&$:,L2XP8S\$YIT&]@;._;]AU;Q
M"0=XQM$M[T?"#P]..A2Z20X[,6++?]AF"(@FC^0PWF*1&-@&<VW?-=H-%H@H
M2G@8RGB8?S<)#_SW&QG:T;M&I]W^CA;'BMGUG>^A;[SY78-=TX3O&E8E#99]
MILD].=_&FL[Z#.;0%QO>6UIY"97%/<YZ\$.*'QQ,F1JPO=3(6!A#*Z)[[,MK
MSI?<<NPM?4=A5RXE?KECKD%_FD#-UIOD=CO[VE?6JO%6&ZZP[!)2O[7Y708)
M&6/$`=^_C0?[*=C?-081WSI[94>"?<_'R?9_O.UVV]OX@!R/)_F5SC93NM(`
M.Y=NOV;2,,Y"G0XA6C4!OFAVPG@<LA#WD55"1C-PPQ(G[(A;[`37QM):,!U6
M`<RA'P>2ATQ:PV0<JVL*86'E0[!$>"/A=G3#)VXNC%EC%:FA%-B<&2&NL!&,
ME4T,Y$,\.*3?8R>+'0M[H_15$^*MH<!Y`RPS:%@0M$A@G'5&U.'B^JF,4,58
MFD!/7%+"C640$T/8):`;3>I&PF;W5@D,EC$^>$B+&@DB_1<1#L5(36F.K6D:
M,1@H#7\K=#QPW>!+PC2`SN`.!>[VWY-#HM50\S'0I^P(IK1"PSHB)S`[TBH=
MCAAM0(&!#U@IF0#SO<[N*T&RB`"_!$QG0&:*O(\3%X=6\1`LL!8),-D98Y?,
MK+&;D02&`1=1(V8R$,Q$"9M.$!FJ41@BM3(`1I57@)A!H1#N\8))`\"/&:01
MRL-)[$:E4<CZ`KPG"!BA!2.,!(]`3`&$-W`I3$$P3E)Y:RV&:<1MT06#<OA&
M3\T!!)5V5]<OUM=8?Y)_8;CK2$/AOB.K;CQ2MZ.#W35J``.C3@,_#`KM2L!J
M820C00[<T9ZM0N'J0-\"@N1QS"">23E<Q"!FC>8^U,`VT(',@&R^[6X#>8E)
M01(W,`%/@"/0PJ\55D&+Z(N`CP69#*$#Z2![S6$%*$-8XI'HZWPN]@JL@0M(
M-E\O#6II/67@`!9-VO\#P(/6`!3\RAE-,$CPW9G4S/HAK_I2Y49Q4N`EMT(`
M@-2R6%D6N<?C8)2M"KB!Z6B"<&2P:B!/@WC'Y0(@^@)LM2[9W8!'N2Z`==B&
MH1*!K`C`F\9$S968,-`_H^)81-LT.._+"&)^I`!$;9$X^)N`4;4HOH*">\T+
MM4'AA]>H>X7+68-A1``FE=:%F,F_0((]%,YK@,*&,O3VP'F:W`8.4BP/Y39R
MFZ4QH3&N.ALR">3N2JPCX/)@),QVIA*1Y(X3P,_L[=TE>XJ\Q8$B*K8)8>Y1
MZ$W06NX'B*A<`P`YA?GH<S0;F:<JK_8>%U&X,/J-!,."VI7I+N4B.('30.`:
M'I&1V1F8>Z.(6Q&D5O@9^UGD1*1[]X&3DP&I=E5]R]$6AS`^\F0`>64<9*X;
M14`=5)XT+(W^EE37QT>='[8-T(0!)JTVHPIH!>FF$=I]&44L0L<.0G$*A$Q%
M?1[S(1CS-*38-.$3D@0;P,Q.2U.M"7G0(P%%BBV`(IOLLY##L0GC(#`<^JYB
M9`-'$Z\BLZ,)F0#,8^'\G2<)AO3QSC1V%))UQ%^CVF,\)`>@K30OT3B!.1$2
M]!=G!KAHLD`J_^@6E#$-W!68QB%3Z(K9@`=(L7,[(#=D.CIO#+%B9Q=A(!1E
M-<B!0&R`7OIN1Q<5!$(F]KX\,A,I;L&'0GNB?3KC`V6<R%1J015)MFCKR\:K
M$F_HPHY9#1*F^"0&:XSKR@(^$58C#N"B#&1"TJ2HPR\,?:VTI-Q&I1JC6+C[
M:QIG#KGSIKV]T5YS3M2,*,H0,?E86QH?&#<&'28]O@-%(CV).!C\L"QJXC:.
M,9`:.##BT0!)AXDV*VNO0*5BMH"F.!5D(7R6,&L>%S%,5,;S^U.B:_7>RE*(
M7P6/'>%[01P$,J/LP5-%B[.C>1&=J,>\BD*H_+(+I`X$>.ADQ/687:SONB;%
M-=>FA#!,\5T5!J1F1@7BT$M16&?$?>S>-?8`=151"`I>QDRSQYI+&*@T&W+8
MY,F`H%^EP+6&HF\+:PV3`>KO()U8`DT=%SW$@)B\6Q6H8\CF,""!2-:![(X/
M1/9I)U-4!(\![#K-PN5.K%!=DFN:F<E(7H&]&F'HFVFT7PCQ_=KE8Q4VPW)&
M=V<`\(SD<!2Y=#;%%`!589WM8B;LS.!:97BP:T@F-UA=S!)@Z\P?M\X=QAA_
M:.*;!OU',MT*'+%W.>SB!EPP+VT!0=1=I4LB'9ZU,SUO=;$H%$HMR/]3=@Y_
M4HQE$`01=W0;5!\RCO>]1(M:WD\[O\*7D]M%][K5>5OX<G3M[6FNW;GNW(B5
M1]YIS:Y(ELJ[@(_9!=RO*?*>ZB'$Y7_2!/LPAXK0L<*7W3@\0R[%_@5$1TX`
M/,I?<F(.()Z-%,+D$D(3-]EJE8B[I1+Q8[/JSC)><+FUNZCEUCUN)+F$LGQ7
MO>**/H\'61'4!V[HD3&A\["'+P./<LQ9,YC?=54C?@VYOH`8$&+&A&NJ_1#!
M.(,.*>NDL`1[X>D=G;IM?[3D1PK"CTZ[^3_D$'<U!(J@(ITVSG*>IX+LHOD[
M>6HC2BM98R-U@W5:<*J48W@:*`Q7Y,E=M0&H!=<6Y@IJ"F_2GV0E6<KBP=<G
M2#@N/8TI1$TTC"&3*"M?_;R[>[:65[>P=#6@4`"R6&%=EC&5:[BF+((E9\:I
MD@5K_@,<-M&8\VA:Z+D;QRD,>$Z%0G1QGG'_H/FQ&R4F@DH&!Q`^X"&)4A3=
MH2@:_N>0(\A(A,5\Q9OE:)6'M\$(/3BN8RP-GO:@";.*5C%F]T<7F2]-1GSL
MI*822&"0J`J07=`!T4D:RIG81]=',0M&2ODKO@Q[A1=@/%>TO1$.CD:"U18N
M!XE!7EDA2/LG>%[#0C&XQ(P3I<@A2Y2ZF._."JM9?+Z\1#G?]YG4R<>@I92X
ME*-0'0=#^D&D;DR.)R-OFV,\IL3<T0Z3@>LS<R#"7$3M;(%3WB\DX/NYWNZ7
M;4_N85GA8C.5@16.,0EPR0XHI%=GK`C'W`6?+BN\$DQ`JCFFW)/J21#SCI/,
M_E`%?#"@BN;(E^%1_2E&STIKN=5`0K+8&H<1UI?,7/8B7?9*I4]W8A047@C+
MD)YU(O\"H_=B/=XX^0`;@*&PQD(U;Y>=1Q%N[V?9$<SO$@/T*UDZ&$"\32;\
M&A_<HE*`1ME:5YE'OF050:J=6]!LB5&((V"MS+`R:WS9GU),'@5Y30XF,/B2
MB:8K\5%M-C9.T%E:MY;CS:_)I649ZV3QBZMW^7=GCZJ@"9=QX]Y<D;>?0((3
MV-15#PC6F"F$$M]]X<H@IL+NOQ;L5V/]3O<K@_W/&,"I><.3^WWC%)'*S'*<
MLPX=*/I+;Y`DE=M"&;B-)4*>:PEJ!0[,;2*AF71V"])CYX`4YJA]0\\SVGR:
MS(*LSS7=>NSH_BF2M8NB\+B;QR!G"@\^"K.J*=A&*05[&`/JQ,HG,AN+FEB=
M9T[MO'!J+R&MFA;A^.THOQ7E-T&%<15%JA_'5!\M'9;V>W%WMSE<;C74(HN)
M*`JJ;K;2'@Q6<7E`)P"P9IMOS_KXKK)=>&<KKQRX324IV^DK[=.XN`^H&?L4
M$9=>+!.=,V[E04R<+V':R,4.I%M4>=<":^DX(GP@+E!\%ZNXJ056B<D*>*X-
MH)DOGJ[-WC/R]?NBJ2OK#NF84*70[2(>.H##@Y&$07R0/G6KQ(7Z^4D$13OG
M(%>3E=;5A$<4-*HX9Z?A$<:%?@\FVTU%YURN0V=5[M+.:X@G*-`1^T24PM8T
M2]YFBW%*Y`GY!+`0TJ'\S$+W5?#:(S8/"KE+2/7]A)123(C_KZ5*#>Z>/7*V
M61B">042#_-13Q$>S'K88O7+M)NE&.$KN%`'"MXQ;RYJH+!?WDQBN[G'>/IH
MH;`-;[[--"P^NJHR(WETIA'T)5`\.5Y?\==S1&>^14Y5+O`W[0U6Q><*A:O9
MZ8`IQR+IF*,_^ICSI!(Y?(`QW5G-!!_+<\SQ<9T_5IF?I?0WK!;<^JB)A]F1
M(XQ?N<$@%<".%2U`.RS7U>=&$$V8A`KFN&=,.]()U\5&1%^%$W>PE+O8&'O0
M698^!R?"!Y;VS?40#X)G[;"CU-F!5CK/FH6FN$\<2(S,LSWR?K9H'\*4!M(\
ME$3W>D$P'M6FHS!9))CM1E2#-=QT.%IG_D<"FB><T<\$L!,;TB8#?7-A8OG0
M!AN[IS`SPEV?G[5*D[5LZY\VZ*O;\T4,CD<F;W"CIKQ]4YFC<F3`3P-@^"]3
MG,.#JP6U.!8>4,\J1;YNF1\UYAK/PW#VGYWV6KM-_Q@`4QBKXCP\=\6Z0O6H
M4@DS1D8Q>H`Q\KO^6/L4_\_>ES:WC22)_A4\K?N][@B0P@W0?43(\C&>M2V-
M)??L?')`9%'$-@AP<$C6_/J7656X2)#B*0)@[4:/11*HRJNR,K,RLRJ6,SMP
M84EFS'CF4'/CF>;]?G8SX68D0\YBFL0H3WV@0I;>\?Q_-T!T*U+-,HU9IMQ]
MGIE,?\JI`2!>8(XK,-FMK)7;(A=;^A!B)+TFP?GV`T]P=I=E;634#$K9,13_
M5\9RXO;G4W@)J$J/9V!D%$UGU+5"60%AN<=D#"#C*U4U\X%9Y+W>,<HS@.8D
MK\[3+(L/>BP!S\V9X@G*-/3!.P#8\L*$K,;""R;>':8`RRQ,G66UE3*B,'^]
M[)?!(JO*%&,^!K!GL,;''AEMZ+C1Y0'OUY^`5)F%$L7).P(&665"XG,%I6,/
MCPK8X2@>/Y9<MGSIMN:(K2QLW*G\#R5`CC]2]Y5JE.FQ(+0Q+H+,D<]\5.YX
MUA\7L>.5\L%9J:8QWWVPK0D[B?5^2/1L:_6A%HT;S!CW_2?JV)9Y/`J1$&'"
MSL#+*5,8`L<N%;BX``X\L&+9UW>P^CA42U9-=<&.O!&=(:?E`EGH,'PM>'/Y
M@-(HC;*SE+61UQCR:FMD[B-530&9.T8O<A=9K&A1R*K[3G7](L$C),[2R%&>
MQ(BJTC)+TJW)*A/PK>B_3/C8V7)$9NRHHB**U8SFDI#Q0%F:%S=S^0DCT&9?
M-T(MI\@"4FL@DY]UOC+Y<+@H*Y"6MZF`IO!F*1(5UE(M7DW++>W5/*L7-M/J
MMIW5!2W9NF&>?.LNG9:S4J;:[36S(N=2-K/4YXA@1C*2"4R?7-$])TL[TK@D
M&["7>U,\]L0<;9;KGR:]<-QC)W'YA+"9AF"6YN8MI2Z8>^#Y#/A)+><0;)*X
M_FAV_MCS6<RZH-I<QC?:;ALN(9/3J83Z!BN%L8JSOV95<`'(TYGQL=56Z3QI
MN"U<$3V:`+3,-"[[5?-2D=$?$1]81K[`^'ZY.0WF%0/-),G/SUTF`@'IH28%
M,S!.V7XT7K#Z-$X0UL5@5?"8UW[1=`#$EU[3Q(!!/CR&M6JG;DUSTO;J*-F:
M;:A6_C/[1S,UV3;Y_F!JNJS;&M4(U)=YRG?SZI94(7=`DL+%R>6,24IN"^^X
MRU17<;Z`:94(Y@!4H66^.S=H\1D6TL]7=<QYS!,XEB3ZW%12"TMF&W5!--G2
M;6XT:I:L6DYI<6`ZH#ME&0U9B@$,O@38?`LJ#\K'W)N)N+!+FS_EY3JYW\H]
M.5Y4FI&;+@4^&JZ@PK&<WVN\?).G.H_A[SZM6G8KZ%)*^%I+TU#ASD\PW4*M
ME+U"QCVN2V:N1W6S6P<:.U$K"F.*6`D5]RUUP=(4GEK-(&*[+Q+;O3MF;!<U
M6]:[LT09^I>B.[]*63=/B;?S+,XBNACU_1(^L&@B2PNN!)HP*8%:WUE4**,#
M55$;$Y+&MSY]NI&YS\MT)'S!2H[B=$8/D9?Z,\%]6`JI9MKE\MO;R]Y`L:G^
MFL&>@>J68D>A?-.CT60_@P5U^C0%_3N#=3Q]@I&F8+1^RYWP'$FY@(R6_U*C
MY`?-(?2?)%/)]?G(BU!3LXTO^ZX>1IF'V`I7(ILZRXK$['6/Y^/6&)[E'@UN
ME`0L:825-BVD`^39&SF)V!X=DU*D-JZMLBIO*RR](O>6X0LD#(\5PH^TPS/7
M\P5:FX7(>&R#A<EHTD,V'0;8,_N#&2/E*C0:Z\A9QLR?D&;:YB9(WN.BV%H*
M(W^89>+SB&'>L`)L%JS3+%5G:ACVR2D9P-[-+6SF!#$3>JFK5').Z3+X^.4M
MT*BH;LQ!*O7<R`*]5:<XJY$F<9FO?/=W,=\'^/O1G:O//7*)VP9']8?(EZB[
M08/=*M/]C`FSE#&Q$1U$SD26HV`V-6<"^2E1ADKENV%.*,$RJ\M`_Z4(=4Q+
MQ"B:D+C@5H.;B$VK,`R&+2*H\T5+1S*'C1604(QA]W"I`U2M&+MW(YHJN&2^
M/AN/>D<C,L:,S_*C7)N3+-]M%GE#[MJ5VB?QG9!FU?,J$XF:-\R!H@IA3`]Y
M\S((Z6<72R^\A`WY2[:3\<(UC*9$X-=AGP=L4H/-9\(TZYV4.W]T*A8EBDIC
MTU)PB2YD,'Z2HFEO?IC,QT&KA#9YH'LW[QA24(<5P6"(:.%A/'V_2Y\([TH1
M@VH@4;R(!9^(%>W`.S][OQ2[#PH8[Y\@PR_EG_X*PD<?O4>4:OIC^=>L&#U#
M3<Z[1OSL/92>0WN0-X7)'FU59*HHIRI2%C'T$HQ`JF/I30C_L$9;%S=O9%AE
M(YKA2%E]&\Z\H>1HBIQCYJW00JR[1+%T9$8G^DI>J$6+[5@`%-<'C]YC"K/W
M[S3K$^)F=71QDGL?5+"8*&1-CN3L]!23/K(OL[K_+#:5_\!B7'-#("PQ6T`,
M_I"W/O`)KAD8G)[A(924!KR-'],CF6266EJC01CZM(,#:\L\9.N0IF%';E&!
M-5\"Q:";QX5"5T\GVE7C`;R(+`V"%Z_)K/P)<V&*VCYL"@/&)>\F$A8=Z'BX
M*NM.094F[64%GQ!)K)*FH'%GHT1/FO.2J5JJ2M@8E(-%\YZ2DBLW<ICY+C_]
MCDGT@"IQZ*)AP,K=<AWX,W^2=V^,DU_Z5/(6Z%'4V!:"@Y6]:(;CX4RAH\'L
M!CYX\80&L4J:>I+=33BW-P`T;'N@3;69@P0^$![*EJ0YO$-$>!\XM+`P)H@%
MH7E_.);F@0D@\^^FP<+;^'+`-6EU\V&2$O,E#%M./(R\.[IT,(:)'2Q]UB:&
M#43YP=T\6MZ'"+!E6QKU]5;^@K;'_,EYVW#>=N3FWP#MOY*)N86!RNVS(8UW
MG"TQK&\I4'_#_+-YPWC!-*W!L,9(S.Q"1IJS^4C>L^]G!%!7O+#4N,O\J^5H
MS:/^!O/KGD7]`-8NO?BSP$[=T!:?(_.^HJ1[P_,?:9C0]GX>[][JTD.$O*DE
M6F;%WL%WBY)QAIO%NK;]2G]J0KS[2?+[F;.F_!7/8[8)+-4@9]TZHK@2E@-)
MD:1U3'BN%O:)K%,8;)D,996+5F$(_+LB<2A?O&MJO73].O>"%^2RF5MGM(T4
ME=M?BT9;Y0W'S5H-%@"C&>0&;(N.HI!&AY@A57J(VU3@-K@,TBRCBC;JH/$W
MK#G&>K,\6TXLD5V6B-ZQ)?*MQIC*Y9:?.3"Q`TE)F%P&8>X8H%![2=:).GNM
MJ/S*<DVJB1;+Y;!\LO[_:KH98+]A2@<ZUDA*63<U#/O>\4=ZCU2L"$9'W>%?
MO9OA),1\@&DX(KZ<E?QA^("G(7H!"P5:<I94C5\36$^P]O!R7Y8%"ZIA;J_5
MUUXV2PR+.J.AB"L5##_8>6U#.BY\7-X*J<[C8)[L&&S6\)%&&UCL=8*^V]P[
M;G[.(E5ZL"SO_</D,XQ)J7G,DCXFN<!S!V&$G4W*DA[0''7>QX:YAS+',HN2
M<%]QB7=?!/(R7V1$4)E[-+<.BS/H='PU<H?G2[@(>G69/0MT$`9S<#_3-V<Y
M/;<[6CF&JZ0USU7*O9[!NF[/CF[3"S\DP#UQ<+>RZ0YD2QUVV+*)"_KU,7)G
MOY^Q?^<5QYSJX1H/=GR)Y@-*_Z70_]MVSU6K=BWSL`ODKJD?4SXTH(]&TCD^
M?<'<;W9$$9=_^9D[5+\TRT(^4:Y>H0U;9D_A"Y>_9<?;!0U^GC-Q-<'-)G"S
M[*5MPCY=L*\)["N.`(_&CH.'NJ6[>R!_"+;S?PV'A(S'\RDJBT&+I6XH=3+5
MOJ*0:=71[+$O]Q31696$]WH5IV9S%#WJ.MK4"GSAEP36`NM68[U3V/E(*NX2
MDQGP0![@R5/>A`H38BVP/D6L5ZFPO=MM^J&4VN<P('D:&;WOJ.%J;5M$7VWE
M_/"/$1Y^[3:_+3NZ)BN6M18<\X[6/BG12#>SU;S-:\:T,A4VHX?@N."XX'AS
M.=XF_7U`[^IPAD@:>*S:XB[LKA6R8RQ6*##!^IU9K\FJ0;LK"B9WE\EB?9\L
MZ]NTOE\TB'*PR/#'XEZQAMLM(E#8P)<$UIW!NHV>UV7I_OB\_]G,G>'MMK3#
MHLQ<,IJ3'(0):;J2:_T.KEJRH>FR80Q:L(4++F_/976@R=;`$5SN+I>%(W:R
MK-=A<>,B-^P6<'FE)U97*;?<&SN*.;9H//$T5'IY<GT.:G6>K6R8%YA6T%'0
ML4G3"CH>F([="(K=ADFIRK=<#MM1]_'8)]2:(6NF*9NJV0)S0S!W0V?1D77=
M%LYB)YDK?,13X[BAR>9`ES55;P%S.^T:ZF#+C<(4:_!>U(;<T[R"DH*2@I(G
M1\F-SAGWT4+.Z-:[;3RG_2?KVR9.7X4UWC%K7+!>L/[8K#=D73'D@:8))@LF
M-X')G?:ZNWEP(^@HZ"CHV#TZ=NE`MM*Q6)S*"I>B<]:FX+C@N'`K!&]/C[>=
M=AF[>I0C*"DH*2C954H>\*#QI7HY+[^&1O1SWM-+`FN!=:NQ[D:$3'1X%H(N
ML!98MSA)3/1S?J&XD"GKEB7;K:CM%KP5$7S!<<%QP?%VZN\7]:Y$A^<CKM2]
MM@'5[;:T`15,%ON68+U@O6!]YU1[&P_`1#]G$1846`NLN^)Y?;N1[L,'$@6H
MTJ3P#H!R$R\,FJ[=6K]1"QOM9%FORX[BR+9B""9WE\EB?9\LZ]NTO@_H@YGB
M5HI3D7A;UBU3=@RU!1(OF+QMGU&57CVBMR*V)+@L[!;!^HT;"=O.0%9;H<97
MAE_:7M#6S5X)@HZ"CH*.W:/CBT;"Q:4474FS4TU956S9=,2]!9UDKJ9KLM**
M()A@KO`1!<=7AK056=<'LCD0O4Z.;$)VM1N"H*2@I*!D5REYP&-&<:E"R\/.
MPIH4K!>L/S76&[)NJ;)JB>"/8'(CF-QIK[&;!P^"CH*.@H[=HV.7#A3%I0K"
MI>BVM2DX+C@NW`K!V]/C;:==QJX>10A*"DH*2G:5DO,J.?_\?WH]Z5TPDFY=
MG/M-.'J2>KVY-_"GZDSS'B-U?K79CU_Y9X;V:P6^D<I.I?%3U:$T?MK1EYP0
M:1SZ?OCH!?<2!10>\_T8OHT>W6@D)?A$[ESBY0SXS64XG;G!4VXBV[_&TB,[
MU\P]TR<Y?YGBG0_P./&&$\F+I1%)2#3U`C*2[IZD3^2!^`7Q=<D+9FE"(:$#
MQ=X/:0J(36*)`/8CZ>]I0$K/*^R&"%J="7]HKZ7G7.%9S69:8@(R1:GCR?.B
MQ2@Y)$#)F3L$VOY^IIS1SS-W-,H^/WJC9/+[F>7\="8Q6:9?5Z5[".QP9S%Y
MG?W!)8`ND-<2BD5N)PU!)DATMB"@;P@@P$7T;\0=S8MHS6$YA\TQ?]I.4^3(
MK?G^"SRTYAJN(]`\$>O6>9MB2&]<WPV&!"-'2^]:J2G'%)&D?:0PRY9BR+;1
M]I3''67[8/DUEQ,WN">P>Y3WK8[*<F-.9%49K`#9,=M0P]UI]UJ<W+1BUZVW
M73NJI8Z]X^JRH5FBR.#XRNE4H@,KS:0)08D&UVI-(A?/2Z#GP)\$Q(WE[Q[0
M9#NJ.R*4HS@8>5$SX&!]QK("`(G\P"9C,1D)]^3`0OZS:>BR95A'E_%?A,\M
MA'I?FMNQ9:,57=,Z;=0*C[N]'G>-1]@)'=4`HU(QY($F/&[A<;?J/+["Z/)!
ML.IL>!+\VWD:]^Y==_;Z/9A$?Z)%])FX<1H1O!+A(SW;?NO%0S_$[VY!\[WQ
MP^%??R!,OV58T*\`E_M[<!*^A`D!9(HGV(GD\F<\>JG,Z^)NF7P6:0AXPH>O
M9/S[V=_=H*>H/52'WT%+]G2%_GWV!Z?GVZO+VW]=OY,FR=27KK^]^?3Q4CKK
MG9__4[\\/W][^U;ZG[_=?OXD@;Z6;L&QB3V\Z,'US\_??3F3SB9),GM]?O[X
M^-A_U/MA=']^^_7\!XZEXLO\SUY2>K,_2D9GRX]@%Q&VI)ZT'-GY<UHJ&5L<
MLI>.Z.=/\N=/^OGAMZHH/\UKBZ5'[<9/9Y5M,U/'=/+==""\>(=_6'TJH7>Y
M!GQ.,Y=!6-C3=X<'_TCQC_GKC^B7TO/`+E4#Q2)?:GG@JK:>3[EQ#I!RXT[#
M*('O1K`.XT26TB`B0%S\XM[U`M9AO)IUP^[79J)+AFG$*S\>7,_'+WOC,.K%
M+OSJQO`X1;K>XI%!WI()C)?@($_2R$U@(%A]]Y@"=$>21T("*0P(!0(^^0\D
MR[O!;^C;KO1(HY(`L/M`(A=\OWQ``-;HV_DK$06))1G%K<G)<8SFYN18^HXY
M.>OF]+SP0P+<0V<\K15*6FJ/'M3!V=NPQ2&)-K\&YU8Q5QY+'.G-];M:W=PN
M,B5/OXFD<_SR$O3]AGOP,=S-[G'C6[[%EMGQ`79;P8XCL`-](NG/O%[U&.1?
MTX4\A730XN8;>L&-S&ZWH>8>O?CF.:.M*>ND95$R79,MQ9$'5AO"9(*YF\UO
MRZIC"KYVCJ^X:%5+5@V[!<SM=&R[FP=O@HZ"CDVBXU8QA$:TR*D-F0I35IBR
M@KG"E!5\%:9L<TR'KJ9I"$H*2C:-DFO&?5>G#G4YJX#BMBRS8$6!SDMD%N@B
MLT!D%G3QJ+YEX(K,`I%9(+@A,@N:QPZ16="D2.RW_DU?^A"")1=@=J\4W@%8
M+J9YBTCL@8(ZLJ,XLF74U,LW+J8C>+O9_)8NF-HYIK(%:[?B1NLV'@:>:'+;
MCN;<_N1;!>%V;-FVV]!A1'!YZP:`NMB=.LU@7,8#66V%8=GIP\)NYAD).@HZ
M-HF.*U5(:^(O(A/NI?=)39/-@24;ZJ`%^Z1@[J96KJ$=OXF<X.M!%JTM.T8;
MTAP[;=QV->M(4%)0LFF47/.<<I<F6LYN"5:_G2]OZ[3/3EG#R(M?7X;3:1C<
M8$SX(ACQ+KV?LMNLNMH[RY9ZTB;HBVY:/L\TL)O:38MQ4J*LI.<<G)E2SDT*
M88.:;.W[7KNK0(*5F;K14Z%7-)M=:R67;["#Q3R=^82FFTH1+)$X(1%\&'D1
M&292.!Z3"+-7P[$$/ITQD#7'D=+`2V*:KDKQ)NYP0K]#S1##"/R%G[U2MV=,
M>XTGF+.ZX@J](6-<G#/N9V]^C.R6O2249FDTG+@QD92^9I:>&DN5R:J#)H!G
M_N(L\H;TF5=:W]2D&8DH'GWIMD0A(`3Q'H`F`4G@C7!(R"B6QD!U=BT?I@8S
MG"@U*'%DR1T#(:41&:5#3@].2?)C1H*8P"/PDCN#`7]X4S<A_I/T2C7D@:')
ML-'UI>?"$PV1M(\!<CT`80'URU*8DXD7Y_C*.6$R>GIQG`(U'[,N\&5.NH$$
MJAGD$(\K@3ZJ;*F:K&L:8V<\S\^^=$&_6]KJK6X2#<BL*$9IR+7D<>(^$.D.
M4[CSOO5,4/))Z!.`@@<BX+E^_AR3,TH$E#6];YI4UIB(HIR[TAA$K/=$W$C"
M.R'G!L8=UX7="SYX(\]/*:W=T?^FS"1`J7SP8DPJ`E1`Q!\]WP>YC5,_P9[D
M+LCA,"*(.WQ"9)G@TYD1W.J/08KY[0AJ/=$I!^FVE\["@AKTA11400XV'X\\
M`(P9]D,2453H&,&P9O2[IXJ"<A,&;0RT]\/'>?+-4<KUXQ`1\M,156E#-Y[T
M8I(D/F'Y5S-*NS)D=!U*0];!G0(3)%'H,TK":O50'X;+%:K6E]ZF!"4,AT3N
MQ4S%%D!%C/E#WXUC;^PA9/!M<5,H<H*^$Y%Q&!%YR:VC^8"/\#JH);0@%H;B
MJ%V",&!PV$75GK6!OID0@O"L6#-4*);7.+1&+Y4U.*QZ":QGJF:7W>B:TS:-
M44N[8"FZ8.S=#">ACT+*Y`8E$7^>AB/B@ZH'"PZ&B;PP954CL!#O."-Z>1U'
MF"8@X#`(N_@U<?_"I0;R0K=+&(+F`_)U"28IJ-('D(&[%.^2G7HPA+P@QV."
M12$+T/,2E'3&^`[BEDXIY#&N([I11V2&V=.`!#Y3W>K*1(+GGZ&4RQ;U$CE"
M&7V5]\&6.5V3RH6[)?A>TXUQB',_A#Y0Q.<5+[;9-WZ2);#0_X)-EU#2P3J)
M$RGBFX1"'\A?][TQ_5KK6Q(J5-R,`XQ9@5'S`.0.1O&AL%89UOE]6SG2L"'&
M[I1PN>&[Y!)*X-]@&2,X3*6`@#U1$X++T5)2.<IR0A6%2-1R4?K.3SB^VE>K
MM'O(=D0<`1X8AVE4)2-%?XZ4954'$D8I-ZH1.5#;7CAB]4\3PK<H_&%8=X%&
ME?1E'<?4WWU`B[OJ--Y-`O],N7:_FO$U%K=2?>6:/L0=(C,@:\Q'8V#*NL%N
M@'[%;\?(KX]F'*597\]>)$VIP2PH8-&,:23_299&;*-CW(K79!?NCU&V^->[
MQ1HFIML:MV'XR&5+8XEEI\DFX+R992?7@\WDG!M.0%!^A0XOTPO0PD6%C(CE
M%A0`@WX\"T5(,]<;@4#TAN[,2UQ_P:U8CZNZIH#GI3"NYO>,;L577J98Y>D<
MH=UB+5(*K%2'I37)#$\8#/9(6!D@X9FTU)B8=2QAUA^S3$>%P,`7(=-`7'ML
MLH@KQP`[MK/?)$BTS]A<UD;_"N4DF\HC=<WS.Q::<Z2>M`'V(C*71<*<ID;F
M+H;#""V#$B.;%HK;=V5ZAK)?H)S%R3)EFIN!K2GBMJWF%G';QHY%W.N^_\(/
MM0#<52?S:QU=^@=.R^A>N>>"C;="B6:UN;O/FE\=MOX6(]B]#\+71N9>BN7J
MT5B^YDG]*5049_8$'MR!QTCC&L]9#4U9CRW+BL.R+<,153W=XZPJ*Y8IFW;;
M+X]MJI*ZCL(QB6,6!AN3SB;;-Z<ZS1S(EM:&[%W!XFU9/%`PN-T"%J],T&Z-
MH44CCD)O'5BH5=B&55$9WV466Y:LZ*+%LJA2[40Q1#?IV$8G@];V=G2#;H*#
MK(%'(8H]N\A;0]-D51%;LJBKZ\BFW%5*KGGN<=0*Q0TR=`Z1%O65^)CQ>>U&
MR1/-4W)I*<H)I$<-2NE1&U!!I$GY_$AST-0T*<Y-B;)3*O&3`M:@9"EKQ^0H
M?-'#/SYY0YK^>G$?$9:W30'UZO%K9,HVA>?=>,PR:[%BZ#VYB^9*AHPLO;E<
MXD03"6@B.V;+2F^C]%YZ2QZ('\XH*5`,`A+%$V]&$WT7B87)P)??>@/%H@_0
M/QWI9YPDR['5E%]]_IZ;O9?_IO[Z"\MK_I"ZP?U_)F$*6N<-20`NBM9G,L+"
M%R+=DN$D"/WP_BF'_E,RZLN8-LP_@[)S66(^JX]!('SW,4_'OB;AS">5U-^O
M9`9[J#?$1RXG7N!*/Y?`_O#F\VT9TCY0J%_0]!+3E>])<"_]PW,#>6E^,=!H
M"N#<D``3BO_$-./KB&`!3I#($BI*;---:['PAZ'O!=[0]<N<D+'R(*MG'(<4
M/UD*'P/\!]_SR;V+E7<S&!B>=YDDC"5$H36U!]=IA+5Y259_LB`V5>G%ZJI[
M3(,F(XH)O(7H8MHW^3'TTQAI$(5/KI\\]6AA"A]0+@IAJ%>#;]*!I)A*`RV3
MQ;__%TN1L>R`UP["-LYR[+'0+I1&C$$R$"5(QZ`H4RRA8SV_6&(\;$<2@CJ+
M0JS'S>HI,<6<KYIL_3B8H4Y%4)8^NT,WE6'+]1ZQ+A4&^EL(;_QWB%6M//L>
M,658DRCRDC!ZJF;YCT*D<YC08IR`EO30LAS8[S%!GD&.(P%]<0&A3,5]Z6.0
MUQ$L)79!:)@@Z.6TEJO$+HB"Z.Z7]!3S$M47J0E_K4OX,$UP,69J@J)VFU$5
M8U]8#8'TFV(U$7TFIQ@.P^>(F1K-AR@Q9EZP::UF-M\:4AX1!)Z+.:4;4($5
MFV;5"LNI>0!1?0PC?_2(-*/,SX&HDJXJD+1`%I').(JE(*PFE6'$*C:>,N+E
MZIZ#SK$OJ?9YNF%!R2-%8_4D9;5.%71>KP8O_&_H(9]JIE\U=5]ZGT;HADSS
M*MHR_US.'N#XV(M@HH#<AXG'RR]#*;QC5=;YP/#=`M%A&V$+?E%&:65=JU3]
M?)4LI20K/$2C<XR$YEKFKR!\E";A(TH\;J6,:BBS6*@4>2!8%+N`#$D<NT@.
M(!J3(EKJFG@!U@/!C*.2;0.\*"U<R1UB510M5LXU5/GQF8^55VGBXSK,JHEJ
M1!#`*N&#"AC%.HY!'G.AS!"?`?RT=I'>$I=('SZ_N04L\9OQ&)Q96CT)N!2+
M&?RED!4\T8+W&9KI7!<^[6T7JM-@2\6;5OS3-@`C_A8O!$:\7QF*@DTE:+T>
M;&W!$+L3Q.F,*E)D4[$^^?Q@P/1R"PA]CP=6N1!QSP1&)0%X$5SE,(/(HQ_G
MZO>QI"R0/GYY6S#T_=L+.0.6%]TBS?->)#$C*P<%7NWE<Y5`J9&6`HTA4`R%
MDE)^1+"N-4(%0.]C06#`._T++]<;%S3GNT)!T@3L`*1$#*/=(:2PE,:1B^L)
M9"N?C"*_3!3[T@5P!B\D1(B':1255)@7EV26LO".9)6`M+`_>^.Y/A=533?B
M%@>?C;H8O.M([=2M45=<L.G>$J=3(#/\.4ZIZ5'6$EC@B"4V17<%1HWR\XPE
M)7F>4S4R;X?#*H<I)7`<+!S%*E1P_O_#5."<!J/+%J6YV!=6[EB;&B64!E5=
M3<>G;06PR#(,6"5/#JA$QB#E"2_@QN=AQ'^G@`%=*B`+T8CI,-!1T0,Z1GQQ
M1OPN3"Q(Q0XXU:4M<VN,MR2H5=6<(*65,\J7TU+M#3_0V%+%8LJ:$RUP@62=
M$ZHLJ&[-['Y-ML"X*9D+B<^T`,H&,RI!,)B)A\+!-1S8?N&<)05#TEFF*6P:
M%/K,=LKJHQ>EBE&%;@<IK8Q_P#XR-72K6-_X&*P(VJ^%\@*8RGG!#"4@#.LN
MA(3QP&TGK5G3WP(?[`4J]K`UX5HD;N1[P.@EYL`Z5ONB3%'FLVXN$FNV00F!
MJS]::%;%BLWAV7R%LR!&G`"5>GP4C/^-L*>+-YVK-"\L"M[G(/L>_31NA&2/
M%#(65N18KNE_144&B8E;0X!-KGAH8<%:80*6FRLQRE-YS="M-&`V2^9$E7RH
M^D6TJ*MJJ$\\6L[.U,D0)#EG[!+&T!Y"L%^AVF&*LK3C#KUHF$[CA'8*DG-Z
M+HZ2;<8Q7\+PZ[]30OL+H:GB9E8:LW:`CA1UE+2G'$)@]3Y*RVO7T//'0G7+
ML?8PYN`>`5L8BS8U>HXQ]@_"W60B#4'MP?O1$U^1V+4KHCYH0>X%_\[W0:6E
M+K559P090J-G-+29>=3E\%G(KVWF_08\0CWN$9D&P.TA7Y[%G7HRLGY,0WHH
MYS`\]S=QC,IS^`5;@P@*=H6GP19NQ=-H#0H="#1Z.\/"K1B1,25,_<#;J=WZ
M;@3SC-Y3J/V&X+W2J%);'&R_JHNNJU:=/4P;6I4#QA@FGH^YQSE1"H&GCLD=
M&6+CGCN`FRE-9NZ3]>+\S&*H&YQ;6+QAVP)\*.48U6&M.%!IH<5.?G`YY:UX
M`C`,PF&^2;G2/8'%1"/0/FVW@>W,<(/BK5H>PFA^JT)'AB1\27.U7P.OG%E/
M%/O<=\OC._D;=P#!V*L&QES)3Z>S'ECLL.2>*/J@G3W80`G;2V`KZTU<?RPQ
MGB.J=ZP=8("Z(G9]5#.TWQ.2A=*>=S'#9TL*G#:UPB'!SL/V*_C\17J/%AKC
MQT71[631;7)Y;=TK5;=I(YG"/:!X+["IVL`D)P*GHUM3^A_S3HDK>M-<AKA&
MT"S<MHG;<K&C2CR7O:R'#`GNP1?.XC&+BX7&SG!3!:JYO)??;)G?DC])6;^%
MCWF(Y(0-SL</D:103',UOBP5;G*P\.[J^`:;%KW!7D/7;)'$74U<4)52YL*.
MI!'9#%GV@*HT-9WA`KRX-*#Z`#4.[9[4H^R4+N>KF!N4W+!OFV6S$%[R&+(^
M9I/01RG.@C`R^[9W1^E7K@*GD8/X=>[;8K-GW@3[8X#="M!<N<[B#S@??>+=
M=.:'3X3P1Z^S9FKX)-U(L($MCBP]$FQ7.PIG21$+N@O!Z$>\6,?H,**FQL4L
M\GPV?!&T8"^5<**/(CWHD_34D[;#H6<S_P:+BOOF"UVK*]NEAI'M.30I_A35
MK(%K33`!?6:V:]$`8<*'>LL1X6->L<Z?=#`66I7<!]?SF:)AC>8B,N6!_"+4
M-Z/D^U)I".>"&S.*\T#4U!V1XHV,S.";^,DD3.\G-"2%QZ*PZ3)#BKV_\$K6
M\'=*.^L&)0M5PG5'XUI/M#=CWKJ8'V`_93&1^F"+Q]H1@UOS'B-D>80>N!V#
M_Q<_8\FLEE209)`ZNB.81<_>%1WB+I@Y^)6VDZ2&=QA-83?I_7=NR=`^<;3[
M'3/8EC:RI7WO9AA8"]/8?\+#"VQ*G069;O)KPJAPO,LL<>S_YG&\:PW_06:!
MM<218F3:HC_C,B;5*(0L82'D#4[++1M5675HQ_--VW&CVS`>>T-ZK@,L(ER-
M92-0Q#*%6BS+I4HQ4W49D'C?AH090=B<.TRC7JD%(9WPCHI:I<4W]^;H0L,`
M>V8;HX%#VP:ST\"\[?Q:B/+6P%\N;MY>_$/ZX(=W,/!G-A+_C24;L'Z^+9&[
M`XL<]7-JY,[CH7V:,9-M?,5K9<DT;&5.+BMLV4*DJ):F<D71!:W#Y0O]WY<3
MKRSJ^Z(B]E(AKJKEF=LV-`B4;>P?:.?8-<W-1JX>L)1&A(4]\J[:E1ZMG*^S
M+%6K9%RF,8^2/]_AO'+@Q<3&]8>IG_=1KPZ1ST[*9,]65[X,J!6#AUX;JP`Z
M'NVSS6P*+IOEYMEXN7UN1!3]M:E3(-HKSKGFV[17=+0FM5<\V"1;%<2VO+>=
M7B<V6^BHN<YQ-["X/[/%_0X7-_V!]Z7;I'WAZ7'FF)T&&]OB\=A46:,+XIIE
M>Z?0KO!=Y5J.G^E-$K_D12FJ^FOAN#VW.3=&Y'8BR'H5]1W":RM]W7BIS7U&
M(;6=Q&N5U+9'^W[UXK]ZBY<!-5AFY]M-[)'70%`@JO93DT3Y@.AJ?:.G]<VE
MZ+91+_^9WW=UFB)L&SW;.A4!MO6>;6PEONU1T&^S>]0:+,][9.F7,*C9?#J/
MVIK^X,9M7,KQ=>TXU8-U5Q'R]+TB/DO/;6E+@)&+%X--O!A,9UI;5KW!<-6)
M1?E^L&02T0/RZLD$*^-@&?+\)(7?M,,J`/C9;@XR!M!YWB2.T9<^NT&6!W='
M?(\\9$<N^-JF0%<`OJ.F5Y;8S.+OBZ.4WF"A]RBSWU@]"DV`G",NK6B[Q<*?
M-'J2GCSB`]9I]%!)E4SR*AR<BF-;6Z>.2=9##S.C\>X[WZ4A^ORVQR*PCH@0
M*K6LGJHU!X\4GMLJL<NLH&?)90F)I11_*MTTF1V"L)N$X=T'6F;/1:=Z-(E\
MSRX8C1DC\'\`0ED"E"?T+D-Z+ZP'G!@NNWZ4G\Z4CE_R\T>*4/4@9DJ223AB
MA=/T:F',QF3W"<KY$J`%SOEMT7>D?*4F/9=DE1;C.1CZTH>+BVMVP!IA&F]4
M7B3EVPWI6-6\CVQ>7*AAX+,4(GHY*$LDR4]J\W-.S@E6<AW2TU,JN=E-R07=
MR\3!Q)_\5E>>18PEK?@Z3T,;$X_6`4:L-`7F\[`X+:)7O=-*[M*"SP^TRJG&
M=V3B/F`OD=@+AJR\!?^8U>3WLEL6Z87=6,SY<<SS@VDI1''?=@$6@.+A#>KL
MHGE><!X"Y0JT[IY*R,N5-*/\9O"8U5[7<``KE2G/*0>I://"R,UO63Q^#7MQ
M:3SXN:"R8F]8<QJ925<EI2I9>8$Q?%(T%?,`Y&*EOM(,V;#P$GFEJ!/D1='L
MP)XJ1CX=OR$WNPW:Q:3L>[YM]=BVE2_W>.'L-D]BV.6TE";NO=+Z@P&_1;1O
MZ-5K0-<H,(X()4GE=E**_BM3MBV3T2@@^:UV7)\A`W*9+0DXI6<:E)1.14ZQ
M"K-,V#3`M4N*/)\*F;+,N#)GBP2-I5F#G$#UV1MQKA6*[2"<TY,N,TWRRUM9
M.L<"K[DQ0B^E-MEMRDPJYJ0UKHAK50Z*S+W=)0$89@_DC`*O',UBW*M*!`*8
M8(_=>0'EG*#P4?PS&+,LO"W!4F5-<PJP8-F92AU@[5%,E22T_,;?5XZNR\;`
MSM"TC(%L:Y@#N7RWI/;;AE?]+ES?3.?3#4>V#2VGL:K*MN[L?7)5YKJQ#$!9
M4];FB%06-55]#2^IJ^8;@1/8RW..VI]F5/80L.4`TV-H$8'IEFU,536%W$2M
M'H-B&Q8_<_W,.L'P,B*F+WC+`=@/2A5%W.!9Z5=1%>V6#&:>_L;W?6:J%^)'
M/<2XY/[<3,+4K]9G%[7*O',))H7753/QE*I\4\JPIWN._Y2IY^)YZ9%.1JWF
M._0@`DS]05OPMLYJ'E6VE=*JJ>0M5BD/X+Y2;4/6#),O=$>1K0%L]'O5'Z6+
MRE^INJPJ!IM-LV5'V]NUY/TB`-**A4][T2^M;)'><:*U61F\WU:*\FU>7G`1
MZ798V0D6!9S5#V1)JXL;%$^"+7+]L#<4K%S"JEYQ"=,B,I[(S_O@+-1AEBHM
M;Q+XARU;^/D*M%Y6-5[4M-:L359!\DQ%36MR$`=:<W,036?''$2].7<F"W`%
MN*>8VYAGG5HK%<7:;5$.D[L*FUZE+5#QX1:WP>(C2W`M/N>9KMOO\8MHJH="
M<Z,TW*8<3)Z\9+)*Q9KL:B%SNPC'*2KA(U]KW]AD\Q,@_!KY[(+P0N([1/CC
M2;PH#"E2DTE,W&@XX4WUBOZG6:OBMAB>+;O]3[=,V3'%3?'=XZQJ.[*CB+NT
MN\=9FEZA*H*SG>.L;NBR8ZDMX&P;RT4^\':HM`?9")MEL'[^#Z3K5L9^\N+W
M(."6H<J.TX:KA@6+M[4['%U6=&%W=)G%L@8FB"&,RRXSV1J8LC5H@ZI>98O4
M9$^TZU;X)8&O58D=S9E6T%'0L4G3"CH>F(XK57%K@M$L?;.4;EB;:MA17_'8
M,1`LK[*Q)*$%EH?@[::G#>#^&^MU#Q*<;1-G-?#Y%=E0A4O8/=Z"1M8'LFFV
M@;>=]@5U,-Y&88KG_2]J-.YI7D%)04E!R9.CY+Q*SC^WO]T1*Z&Z(W[X*,7I
M%*:#!^+ZSA*T6+)H![&TTT1K2L+HC6>-K0FSFM27?G\/"7`%N&T"=Y4]W@A?
M[``IS:IRW)SF*[[]7!7;#\7A+L>F&10[.",6*K:.PX=WQ;9_-#[LL@[G7?J5
M%N4RFOY*==-K6YMM'8V8(^^[[#:L:]JT[RO>R+>*ODV)SC>F]N%+UFF.?L.O
M8*&7Z\:GJ2^.S(]_\D9A979<L)YAY:^^9M>+EK^\A-DBUD&P_/4G;UQR,7[V
M@N(#N\5`,+JYC,X47($UU73E1V;ERTSITA4,%9KTY/G1R06V9ASM%*H%7TE*
MWQY(/>F5I/;U07-MO9VP;$PJJ";;NBD[2@VA&W<`*)B\)2!&OQ7)OFWC[]$/
M[_LB)Z/+RU:33<N6357HYDZNW3:P=:O8XI$MR!)6^5\2-L('H[+V-ZVOUG1)
M$';F?G69I3F@S\2&U6$FFWU+%_SM+G_5OBWXVV'^:K)BZ;(N^H]TF<EJWVI#
M_<TJR[,]T<PE]J9F+[-%];Y=4T,C;-']JCE#Q[BGV,LZS&2SKPC^=IB_6M\6
MK0T[S%]5-DU3-D1%:9>9K/7-MMNBK;(\]?[`669Y&K6\$);G?BU/33%D2S5:
M(/2"R5L"8O<=89ETF+]&;5J2X&]7^&N;#MB=8@EWF,5&7VU#<*##,5"P-JUE
MEJC9MVI.((0ENE<EI]$+UUNP"`2+MS[H<42V18?Y:_1MX4=VF+^VJ@D5W6T6
MMV0)K[1#V]YYK9O=>IM#?/&2D'<A[]N\M-.QTW9@B(UZB2^ER+:FPG]MV*X%
ME[?.&3+;$!9L&W^/76NE]4U1_MKA96O+EFF!;A:N<A?7;BO8VFD/N:O=BP4E
M!24%)04E&X91XR@YO[GEGW?L\E[9$,LMSE5GPQ[GOYVG<>_>=6>OWWKQT`_C
M-")7X\O2S5Y?B>\F9'09QDE,>WV]P<N_KMVG*0F2^);\2-[XX?"O/Q#*WS*\
MZ%>`W?T]&4E?PH0`>L43K.O6\F<RD-ZY$;9TC*])1&?.)Y.&0`#X\)6,?S_[
MNQOT%+6';>*__ST->KI"_S[[@Q/Z[=7E[;^NWTF39.I+U]_>?/IX*9WUSL__
MJ5^>G[^]?2O]S]]N/W^2U+XBW49N$'N(M>N?G[_[<B:=39)D]OK\_/'QL?^H
M]\/H_OSVZ_D/'$O%E_F?O:3T9G^4C,Z6=QM;Q%M5I9[T+-+SK<FHZ%1E>JWV
M\J7F]/--[.>;W)>;VL\;9PN+K^BS70FI928MG7PW8]+GG>Q4M4]E^"ZW)9^S
M<<LP+`;\=@8(_TCQCT]A'$O`.0E6T#0,),I!MI[I[]+S<"_5&85&6%0()15@
M'>?6!U09;O`DN;.9[\&C%S>7TFTX\X:29BE,]SB:JM%)/'PID_-"+\V`;D4W
M0?J0+#U.O.%$(C$B[\43&)FV[W:C42R-PXB2`B\B3)/L0HE91&+`"C\2/H>$
M0\<X=%\"]05`X8,CST]!LTD^,@V?&#*FT0<E+^;CPA-IC*,E@.8C;Z+8<UGG
M1"G(NERRUZKW6XS2*'L1QO?"45]ZRR<-2+)\8GPA=J=$<F/ICL);\SA%G;T"
MA*#O)).($(I;[/V0X)ED$DL$F#Q:<J\&?1;^4&6<"H<@XS$9)H@/A1K4$Y#2
M]7,0\?Y'B?P[]6`5X0:`X+KP""6F]T``9X`CI&]SF<BY;_\:EQ`)F;[,@(\S
M&L5]Z:(\8$R&0,8$A0K4?NS%%#H*""5!=K$(HO+H1J"(D[E;1N(,'>#/#+##
M42,R"R,J)&Q6?&H,6C-\C%MSV8AM-?>N$7O=^Q860B!\`+TY]S6T#-RM3K]>
M,I*VMV%7]-9]=I^L7Z`UHVRQ+<YUWGW/-!S]S%OHWF::NOSE#2CMSU1IE[]]
MA_I[E=VP1#>MQ%4]%*X+^TP9%=QRUL>D*8%?(:ZG*ZYJ4\1US5#"*32ZOJ$V
M:,U]<FU1*&T]+A2Y'"?!955V-$?6M#8<_>^4Z74D_?7/&B=5J*X#"[6L#QQ9
M%VV_N\UD"[8HIQ5,[G3>@\B4;A)"3:/C2M%OC1=R&R:N7PU]%Y%JL9T?6--K
MLHIUV$8;FF`)+F_+95TV]`%PN0TM13J]H7<U04=0LFFI3D5"TM)$F'VD&E%H
M7DO#R(MIMI!BZ<KW`'XQOU-HU/E<I/>N%_WI^BFYB&.2Q)^)BZE2HZO@*V[Z
M>,R/B05Q5U.4GJ57*8-I4U+5)C:M>00^T)I[!&X,=CP"7_<(_84?$N">.+@G
MFF`P;U]6%<><ZBD.+@]RF>\_TA"O\LV1HW?TEG+IO(`^FEWSRW*>/KO17Z"0
MR[_\_(D\$%]23_?.\R9Q]2J9D*C,GJN[F$0/U#PJ??LQF*5)B=F,B<5G37"S
M"=S\%H1;L4\7[&L"^]",E:@=>S1VB*2/Q5S["YK-6Y_._'H5IQH5@7VQ8,1V
M+PFL!=:MQGHK%^7(*N[2C2?ET@JAPH18"ZQ/%NL7/2;7#Z74/H<!><+JP[](
M(HW38-1TM;8MHL?N]V++CH[7T(IKO[K'V_];JI\MJ+`9/03'!<<%QYO+\3;I
M[P-Z5X<S1-+`&WHSUY?NPNY:(8W)W1(*[&19K\FJ88H+&+K-9+&^3Y;U;5K?
M+QI$.5AD^&/P0.)D*H+"(E`HL#YIK-OH>5V&T2R,W(30)F(D&F(_L9D[(Y',
MVGC)S"6C';PPI[CI2J[U.[AJR8:FRX8AKF/N-I?5@29;@S;40PLN"T=,L'XS
M0'18W+C(C;9W:FE]?60W"_4%'04=!1V[1\=N!,5X`PY:8RJYB33&?/V'/%^_
M>^[CL4^H-4/63%,VU3:T8Q#,W=!9=&1=MX6SV$GF"A_QU#AN:+(YT&5-;<.U
MK)UV#;O:\$504E!24+*KE-SHG'%"+T7Z_<Q9D\C%\T7QM]&M=]MX3IOUI5[<
MICOA/C<F;"^L<<%ZP?I38[TAZXHA#S31L58PN1%,[K37W<V#&T%'04=!Q^[1
ML4L'LK[GWGD^NZ]7G,H*EZ)[UJ;@N."X<"L$;T^/MYUV&;MZE",H*2@I*-E5
M2A[PH/&E>CF_)4,RO2-1@9^NTG[.JNCGO*>7!-8"ZU9CW8T(F>CP+`1=8"VP
M;G&2F.CG_$)Q(5/6+4NV6U';+7@K(OB"XX+C@N/MU-\OZEV)#L]'7*E[;0.J
MVVUI`RJ8+/8MP7K!>L'ZSJGV-AZ`B7[.(BPHL!98=\7S^G8CW8</)`I0I4GA
M'0#E)EX8-%V[M7ZC%C;:R;)>EQW%D6W%$$SN+I/%^CY9UK=I?1_0!S/%K12G
M(O&VK%NF[!AJ"R1>,'G;/J,JO7I$;T5L27!9V"V"]1LW$K:=@:RV0HVO#+^T
MO:"MF[T2!!T%'04=NT?'%XV$BTLINI)FIYJRJMBRZ8A["SK)7$W79*4503#!
M7.$C"HZO#&DKLJX/9',@>IT<V83L:C<$04E!24')KE+R@,>,XE*%EH>=A34I
M6"]8?VJL-V3=4F75$L$?P>1&,+G37F,W#QX$'04=!1V[1\<N'2B*2Q6$2]%M
M:U-P7'!<N!6"MZ?'VTZ[C%T]BA"4%)04E.PJ)>=5<O[Y__1ZTKM@)-VZ./>;
M</0D]7IS;^!/?*;?SM.X=^^ZL]?OP6/[$QVV"YH:^IFX<1J1T57PE0S3*/*"
M^S=N[,6WX#Z^\</A7W_@@+]ET]&O8-+[>S*2OH0)80"\EH:1%_<T1=442U>^
M8Y6B^9T"H/9ZQ1!O"/BI6PRB98,L8/&I\$>7H?(M".]B$CW@0!^#69K`SV$P
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M/COZDX"XL?S=`YIL1W5'A'(49S8O:@8<K`5:5IL@D1_8_RPF(^&>'%C(?S8-
M7;8,Z^@R_HOPN850[TMS.[9LM**A6Z>-6N%QM]?CKO$(.Z&C&F!4*H8\T(3'
M+3SNMJ4*[/%4>-=T`FVG=`)K+B<AP_1F."&CU"=7XV]!1("Q_R&C3V$<7P6E
M"W+HJ">7+9"1K)0ML`6U=DD&<(SF)@-8^H[)`.LF$[SP0P+<0Z=:K.7#+MT(
M#VI9[6W8(CJKS:_!N57,7EAFP6]NZ:CYBW?XQ\4TC!)44_2;2#JG'GH8)Q21
MNQRE9I"MZ]PH=HTR.SZX7B#8<01VH)DG_9G7\!V#_&O:KJ>0AU;<!D(O_9#9
MC1_T[@]Z&8APSP]S(*[)EN+(`ZL-_KE@[F;SV[+JF(*OG>,K+EK5DE7#;@%S
M.QU4ZV;$7]!1T+%)=#S@.?B!VX;`5'\1%O6+,6Y,8\G"E!6FK&"N,&4%7X4I
MVQS3H:OGPX*2@I)-H^1><A:6&K:(@37[\2O_R,/H"GPCE4U?YZ>JV6O\M*/%
M.R&2FQTX2<,P3F0IS8\\I'O7"U@\MY08&H[K362*F_O@>C[^T!N'42]VX0DW
MQE>65P;(TJ.73&#,!`=ZDD8N!I$C-P"L[Z4[DCP2$DAA0"@@\,E_(-(4,)PP
MT.C;KO1("RT`:/>!1.X]*0:$V?6^G;\249#&H>^'C_%KZ3G+?E:S2V@%IY!Q
M2AWCGI<^D5G0P+-O`:[(+.CHX:G(+&@2-T1F0:/8(3(+FA2)_=:_Z4L?0K#D
M`LS0E,([`(MFYXI([*&J[!W%D:U67$`O>+O9_)8NF-HYIK(%:[?BEM\V'@:>
M:'+;CN;<_N1;!>%V;-FVV]#:0'!YZ\YCNMB=.LU@7,8#66V%8=GIP\)NYAD)
M.@HZ-HF.*U5(:^(O(A/NI?=)39/-@24;ZJ`%^Z1@[J96KJ$=OWN5X.M!%JTM
M.T8;TAP[;=QV->M(4%)0LFF47/.<<H/N/5MT:=FZ.<]\7YVM.LTXSS;GN1@.
MHQ2P*-H1G69/'F=53Y[GB+1+*Q[;:F["G&WLF#"W[OLO_%`+P-WJ*$JDUNR2
M6K/0NY$B<)>C4L8KRX/:?=:\/V3]1$WQ>+K'[MI,[Y=BN7HTEJ]I%9U"]A;?
MUD$BIS,2Q#1O:Y%L(FRXCQI+["+MB!/4[G%6E17+E$V[[1W"FZJDKJ-P3.*8
MNCO2F'3V8*,YF0#F0+:T-D1*!8NW9?%`D<WVWVG0&D/K*IF`G2WTUF&%6H5M
M6!59B%UFL67)BB[:68B,H$X</'63CFUT,F@>54<WZ"8XR!IX%"*QIHN\-31-
M5A6Q)8L<AHYLREVEY"&S09[+#]@Z"60^?V.KU`95>38+Y&;B1N2-&Y/1M?N$
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MIR+`MMZSC:W$MST*^JWWX,%HHQ,Q([Z$0<WFTWG4#AFVWD>L<NO0]D)4>J=@
MK):-@H^44'S'/<2+8`14SCX5B%^64O\O?)B7_G4U_DJ&X7V`]9W7)/+"$;:?
M/O%XMR;UI)>C[BXQ\('6W!BXZ>P8`U_W#H,7?DB`>^+@GE!L/3_UL%8JBKJ[
M<^JO8#G(V<G[L%3:F$Q*9R6W$W#KBX_L@*7XG)^T+(M4+[EX9B6:ZJ'0W.@8
MJ"F&\<E+I@0"*=6=[@F9VT4X3E$)'[F,O+&'G2=`^.-5T9\XX87$GYS$B\2$
MXFB,Q,2-AA-ZR<*(/!`_G-'K?\@/#'<T.1UA)[R/G6VO6Z;LF*(RNWN<56T'
MKXD1G.T<9VU8LXK:AE)[P=D-M;&ARX[5]NLRFFIC?"`!B5R?FACN:.H%7IQ$
M;N(]D*Y;&?LYE]W'=72&*CM.&TK[!(NWM3L<759T87=TF<6R!B:((8S++C/9
M&IBR-6B#JEZ9>];V*NQN-O00=!1T%'3L'AU7JN+6!*/9%6CTJM_>'2;=5=H9
M9\YB1WW%8\=`5%E1;-DVM!98'H*WFYXV@/MOB*Y-W>.L!CZ_(ANB5V8'>0L:
M61_(IMD&WG;:%^QJ'RE!24%)0<FN4G)>)>>?-RZW>[E2J9U+\+2]E.#IZ[27
M*Z-)OXTOTF021HC@-_"*HU+UX;7O!O&;IW<_2#3T8G(=>4/RU0WN3[<$3W^F
MY=Q^J;M+"9ZJ*`VNP;.:U(=N?P\)<`6X;0)WE?_3"-_W`"GDJG+<'')>V"]=
MI4F<N`'J;8K#78Y-,RAV<$8L5,@=AP]\_Z6FX['XL,LZG`^AK+3@E]'T5ZJ;
M7MO:;.OHSQQY,[-&HG:-1`V;5?1MRFE(8VI-OJ1X-ZH4CNDWO.4JLRE/4U\<
MF1__)!@;K7;`O7@@D<OD.OOJ*YFZ7L"5>O;E)<P6N<,D97=\9%]_\L:E*M:?
MO:#XP+H6"D8WE]&9@BNPIIJN_,BL?+<Q7;J"H4*3GCP_.KG`UHQ;GD)UYBM)
MZ=L#J2>]DM2^/FBNK;<3EHU)O=5D6S=E1ZDA=.,.7`63MP3$Z+<BN;IM_#UZ
MLD1?Y,!T>=EJLFG9LJD*W=S)M=L&MFX56SRR!5G"*O\+;$D#CU]K?]/Z:DU7
M"F%G[E>769H#^DQL6!UFLMFW=,'?[O)7[=N"OQWFKR8KEB[KHM]+EYFL]JTV
MU#NMLCS;$\U<8F]J]C);5._;-35+PA;=KYHS=(Q[BKVLPTPV^XK@;X?YJ_5M
MT4JRP_Q59=,T94-4\':9R5K?;+LMVBK+4^\/G&66IU'+"V%Y[M?RU!1#ME2C
M!4(OF+PE(';?$99)A_EKU*8E"?YVA;^VZ8#=*99PAUEL]-4V!`<Z'`,%:]-:
M9HF:?:OF!$)8HGM5<IHB*XHXZ.DPB]6^([(M.LQ?HV\+/[+#_+553:CH;K.X
M)4MXI1W:]DYWW>R.W!SBBY>$O`MYW^:EG8Z=M@-#;-1+?"E%MC45_FO#=BVX
MO'7.D-F&L&#;^'OL6BNM;XKRUPXO6UNV3`MTLW"5N[AV6\'63GO(7>T6+2@I
M*"DH*2C9,(P:1\GYS2W_O'%7_9?K?KYS5WU]MZ[Z*AM%7=Y5_R)(O)'GIW@I
M^`T9II&7>"1^]V/HIR,R>@]F"%(D3?A-`N_<"!M#QM=`"*3.Z771STA:VT5_
M7]3<I6N^;36W:;Z];N/P!5N>#Z`WI_%XR\#=*HS[DB[AWH9=T22R?A/C^6>X
MB2FS'[_RCVPT_*9NE"V\N+D6DN_#2$HFE5Z0MY.($,D-*FTE;[P?TF<8?1*7
MOX7]A'6?/+_+2;,B46T]7-5#X0J;0*D'IJ[(9510OZZ/25,B&$)<3U=<U::(
MZYHV\2ET;*5VN13R&Q'"N9LI6J!0VAKW%H>2)\%E578T1]:T-IQA[92R<"3]
M]4\W`H<U$:KK)85:U@>.K(O^M=UFL@5;E-,*)G?Z`$^D_#4)H:;1<:7HM\8+
MN0T3UP>7N`@#2W$>!Q;;^8$UO2:K6%!HM*&;B^#RMES694,?`)?;4!O?Z0V]
MJR?-@I)M.+/?UUGK]F?T\Z?K^,CKB]&('SI_]GP2)V%`OI)A>!]@!@%"=>U&
M24"BRH'YC?>#Q<QIG/R[KOP]#>CI^0<28&![./G^,1A^_TSP%K@S*0T\]MZW
MF[=GTH@,O:GKQWC:^X?!V/C;^4;`E."_=./)M?LTA6EOPV\!$#>*O>3IDS<D
M01SN`/;W8K#OV6CQ.BBI98R>`:^,R`13,3X&[UTO^M/U4_)M%@8\RI+?[+I.
MUL(JV'JFH5N&E0&WQI1E"/$('E8CE="+^X@01`LOV@1!97_%'BQ5^OLU2!S\
MX/HE"E3`?^/Z;C`D%_'5>!<!4E6S(D([`[DMPB"H!-B[=,WL"5_#VA[=&A`K
MV$ZG84#/)3[&<4I&5P&Y!7,"/R#DB_)+8G[/8QE/>LI666;J9S>:E\Q\I#)Z
M'[^\/_M#RS';%IP*3ADAKNY@JW'9:<M:.N$32?\B4\_]?A&,OG]ZFLXF8%!]
MOPF''@&-L+8>*'&J!I02J&^]B`R3J_&81/#8=1H-)RY/TEHJ1YH-2@"@5:J`
MO+N^*<.B`5'[9D;7%?.4H'D7@R7I)F3TU8O_>@\<_8CGE:"2O\*7ZQ!0_?[9
M_>%-T^DBJ6!.LL!VI0_O<!!73KYG(+U@,R`5YV!`/J_0EP)E;`K4CQD(`1E]
M@A4$@I0%\_^%5R!OQ=T_KHU_93"L&'N_(%1Y]\>U?B@0EB8(7FO_LC];;S>;
M-M-@5^.2CKL-N1(CZTV]2O,,+*/0.\_-5@*,\_2]%\`+L"O>I+-9&('A\I7X
M*%2X9SP]OZDMAXW*JU'6BFM-608QLPOCYZW4Y3O1]_=A.***_6V4WG^_&$U!
ME.*$[9);Z/9GH-H2_OU9V=N#"P\]`='^(LG[-!C%N:6X7`K4MV1(ER<^^YT^
M#""Z,:@N-$WB[U_1^<&])S.TT?BBS*!_O/MWZH%?2!]=`S53MRS;L#/,EL&[
M?YP^!N"LQ6`F/!!?S5#I$,ZYM+T,3K:C@ZMJO3Q.1^3CYCA?@U,&H[OW5)T'
M2>3=I:BS;D-\Y2"&[;S-H:'%86:J9#5`2R"_2<$"IMO/>]B`KET/;/NOX9/K
MTXB(&P5D352>482UH"MF#>AK0%3&)0J'A`"':-"F0/IJ?#`N/!<Y60W2$MB_
MDGO8]<`^'%6=@HJI`/!EALP7`H]D]L1E&">[FRJJ,3"T>C1VAZZ$-JUSN1IG
M%MJ?(5@7GD]#<&L9F\])E9-AL&*B+<#9W"70$1K;-#8#9PFIF3]=(3BL&O"[
MEX=REKBD_+4%8S!S^3:'8`/PN80<"?3J[&N`C8_5X'T;\I&>1^`[?W)-E:B9
MSZ#R'$1K(A5O1'I6SK9`=LLP!IKCK`%Q5<)C\,*&$]`7;W&G#V>XH7^%/X-T
MO5#!2C6F:>!R%51<,==6,"UZ,FM!!72R[(,!M96Z=PRCT$TO1Z=G_&7'T38'
MBGY3.%"Y4\7CR#'WL/=&NNJ&O^G\^P)].8EW/?S9`:,;^":BRB2+@*^(62P-
MYMQ.,/N%CR2YV5#2+`H?O!'LS,G$3:2W4;\X._R'YP:RY`42^3&DARG2.(RD
MB1?#%^`JH`6&!2=2$`81>0B'-,`@A6/)E>Z!6I'K2Q'QP<,@^.70=[UIC,.-
MW0<8![Y*`"8\%W2#)\F-`;P$9T@F^%!2#Z\L/7J^+]V1#'"P2$F4N/!&\?0=
MS#X&%8G`XPDDJ$R`R4^GLUZ<3J49/[`AN4,C):$$K.A-7!^@HED&B.8=@NX&
M00J8Q*#0HR<IPK@FD@14\3!!J`$/?!;4]-0+&`E&^!`,B5""M8U9Q/C.17J?
MQHF$_.ASL7B.MV4QJ"V+IF7/FUI5/N9.+#F96#'-/#`Q.[JX#0L'@RS?!6E\
M:CC9]4ARR<:IE1?;<NAV1&$?9ZK[0Z`X/7J;TN,.,`Y"^)O<AMD!9Q&GW2BR
MN0Q&5-/97K+9]&6X%]S10P4&V>EI!N_"M.O#M&)?>/_];^%X/`4M\?V3^_UK
M.)P0X/[4@Q6\5K3K!4#<F'#6"P!UE2;?0?J8T'R_&/TOJ$;4?QLG(:R$[Q:T
M\G9G'V9VW%(S!)M@1+S7%P#R",%^[[OWZXT\!BS(;^<+;Q>#7J91A%]Z\=#U
M<4*@W=MUS]/^Z/54K:>K;(9E0Q63O0V'Z31_A+'C/7RW)IW^H;&)E@ZS;"8$
M9H-Y\'_K9LJ'69R'`;$1[?!_>XH%7U3GJ@RU.-/MTVS-"52E]X_JT/AN,>*[
M(('MXQ*^!^OI(RR9'_]-UC3P8$6HJN)HZ*DM'6IAIL+?93K_JBAX6KIC*!I8
M,NOM&/;`TC1SH%1`6C'G/'SOP4J.+H'H]V&T)ATNAD,P.M%.&TGT]?+<E?'F
M)V/N-B[S+^YT389>?OOZ\4;Z^.6R/$MUH&JW%P`O3$&1@-F/^6I\@3Y_.K/:
M0]<MP]#M(C.O?I;=(%G+V]0,;:"KUG:0L!0>?.P+2?9#&4-3K!JZU,VT#YC6
MHI&N.KI20Z*U@(H(38::@I_D_8>G4[X%54A'`+_^.B)3+YW&'X,'PG;4C6/`
M-9EUJJ;HEEX!>0M`]H[,5OD#`]56]X])BID1[AT//^]'>%5#TU2E*K[U$^T,
MSUJ"JRJ6!O^_+3S743@F<4Q38-%6VQ.1!HJ)QN!ZD^T'L/6H9<+F9^X$V`T&
M'?8G3HIEFO8BJ>9FV0V2M4AC.[;AZ!L#DDY3&AJY2B:PBX?3640F8/B#UPV.
M33@EG\*8'93=NC]VI)6N#ZPJ[S:9_$"0K[>[#&Q-WQ?D><HZ^E4?@TMWYF%-
MW6ZTM6W8308:ALJ?F6A':-:317O@&`[\MS$TF<L:8\P.@!AZ=.<NB'H;TM1K
M'JA\\_0M)C#:U8QF+`?W%\/$>]CJE+;&[G(<VZKBL#_P7@CQ;79S7;=`F-07
MP7NW&A>P+](YQ;D&IY?X5:INZ`/%*&NH?4!W+(2_4V_P.^ODN7[,5%4=S=$T
MNRM46'JPO0Q_"QQ^U6D9^FN=]W9+[I>C?%J2OX(.IR'[SV]QR]#5P`57#*UE
M^"X]S-E2[!5;4VW-Z`H5-A9Z?>#HK1/ZM1)7NB7W*PZ^3DKR5]"AD;(?QV35
M4?EZ(6?8EA2E$CV@PVXVU5J^JVDJVL`P!^M,M9\8DNZ8BFX8ZOR,]2&;]29>
M"U7#-$`5&/8&$^<U!AC,]4,L=-AC9<]J,BFZ/C`'VCRT-2`=!/*=ZCZ>B6J"
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M2B3WI,J.1XO#>FG?2TD[^U8`.YAJQW7P-B6*K5NFTRZ:;&RL;RPHJJ'I>B7Q
MZ.A$V;RKQ89(;Z(HCHGTBZX.U0)),(RU7*6F$.7PR\-2!UK5O3T$43Y$L/44
M&]$'UPMP,]H][]):!_`ELQ\<^+U8NM5\WN;AN),%VTS<ULM'4YVU7+%C`;\/
MX=LKCIC,!;/C/Z4611?)I1M%3Z#!UG.9E-4`.YIEEE7\6I/N%<ZUT@`M>X"'
M3\>$<ST-:ZKJP-:/"NAZ2=P:!GE,\P"`LJ*RC\$PPA)YH!K]=Q_%&HINV,\+
M:_W\>X)\J_[-N@(&M?TLK=<"W'?CHDOE5?05[SJH7`Y>U'3R7S=6W#6]<S2P
MD?L5:=D"CC4PR?K5E/QRU_<QF74GI);G6FFZICV#U?HPO3""&Z<::*I6*2G9
M+[KA=.HQ0QI%.^2-DX>8#?TC]EX'GO_[61*EY&QS'7N^_ZF6:<F:J;(65FYT
M%=TD6'%`=6&6<+$I.G.-GO-&RB6^/#_I'J&LI\1AH60">I$FDS!""V@C&BY-
MJ<J;RJ\QXQY`VR3;:X^@L=X4^Z"8[:B6J5NKH&*3[0C1^H1R%-/!^K)=(5JG
MW'L30MFJ:@.I5H"U4.R]&VSKD\P>F+KN.(,=8=N']4OER:@%I,YZ7'ORM2Q:
M*CKU@E,_^7RY6&V=VI:6JFIKIF-7Y679?-L!MF5WN9XQT%5U3EKV"]E6)C)Z
MH:9]#'H]`YCF#`::KFX%64SM$VSCB?=<["Y7JF+8MN54]'5UC@T@V%*`3'C`
MT;6]@+!E[UG=T'3KL#18#8-E`QOLP;H@O"4@,$./W?82C,H%^;O+A&$JY=6\
M8J[M@-J&1Y9BE"5D`Y@B\(4Q[SF_6N!C$(,ASQL)YM7X6QVIK2:C;JFJY92!
MWAZ6E\1JV4F(OE:"9=NP7B^E6E>,@::U#ZL=>7DXK%F7WJR0&+4=Z[/^Q!7>
M[EH=#V#+<OC<C+L`N+1L:;U&AS699B\(_)9;UO]O[UI[V\:QZ"]JEF]*P&*`
M=+,=%-C$09IVT/UBN+;2%<:Q,K+=3O[]DI)=4R^3HJYDQ<F7HD@<W\-S^;B\
MO`]%L%E'Z400_=OS=8)?3I%Y/UO'<UTK6&?9N+4M..[#T>7IT(49SFT1Z8_/
MU6RK16A69^H-H=/ZKX>'3TF@$T+FB_#Q:9D\1]&G*/VA)GY]-=K+Y7)7;7CR
M<*BHG#\+9";FKF"'_JE?V86Z.X6ZK%)C]^H)Z?!T>%YP*`NDF9=Y-GQXG<N"
MA=(L]G0V;'B>HP&EBI$Q\G&39)%,ZAM^SM+%^CY17VC^7@NZ239?H\T!0M<T
M39E5U&W)A@_0@?C8UW=-=S_2G\..A77)5W$]`!.U$$OT_+75)4%;W2:/US`_
M7GAPU[C0*KXS2O_*SYX8ZRY.DY^K:)&]=:FS_EK)G,=/L^4AI,N(Z+K<C*_U
M'J&RN&;AQC@.[D[8&NZLN(5-Y268G2$UMMGB/N\L\<PCY_;SI\,7:0^O#L9X
M[G\C;!OE7T[_@AC/J1D:-/I]``;WL;"3U<%_:7SY3;2Y3:,-S"MM0'#`C77C
M*AL`L>_S+26(L=-`]GK7U9=I-#**;9!#3LVDL,Z0X_73+HEP\E!3'L=K\NK"
M^*(68U5:"5C>PDHO2J.#]H^HA:?<5II><FR^F%LD^L/S7$0X$%(&9`"`/DN&
M(\&%F><Q/'V65@A$,!X(7X!)LLA:G75[KPW"@!1LGOWWMI7FYO5QDU8.W?ZX
M*G6)T!152LO#Q!M),XS/#PCX8+Q.#"(I"?E08SGTINBN!HG-"$$7F1U1^O!+
MI"`TA(6ISC_=#_`J>HC2--I'P2B]9)79H8Z\=T29:T<)=L$!/A8_LT@$S-Q"
M^QG+G;+MTUBWD-;W4P@-X%!M_<=@%T5V`.A'*Q9FX%%;>/N[4![5]W&E6Q2O
M`=[8>!#BPNY<+\@#CJ<%1(H6+B`@+XN'HN*&WS\]EAHJ+`Q96T!-AZ"';4,1
MP\A89HWGFI-,M^S<4#)N=I1RD:EVHRR^^G_)<A&EZ]RI#EYEU"80"IYG95)O
M>$"%2V4@.&.U>&IKB()W3U*K11T+I`V"K*WE&JR1.RWEUI0$N$OW#1F`DM^M
MQ7A_P[?$6[8"<#U+_XPVVJPT,@QAN@56"KX=D04`RK,>ES,HW2VOIJ'+SN<*
MVV<'JSN7((8.W86#@/:9^0QKWR+I#7-^[@,3+5BH)H0==(UP$-!>=G48(DY#
MVAOH7EI'O0MT<0O3$>DN'02UW_4<X4*?T0Z8#YVA8%Q,F!$SQ+4@P56X?]J:
M.N<$ZRC=+S5-(-G?N*WI9X%@G+A)3U;)?EKDGP'SZ;_#4BB[USP?FH3Y8/*=
M%>K00F'8$R@_#P1E%/&A:;)ZFW3EE-:@)L7/`&TD8<@Q,8NAU(AIA\-[3Q$X
M*'3#[(S$S^%-!#/=0_WQ80/"E*V*6O&1^2+[ZA*L-EXSZ>.X,!A@;KDTF'.S
M80L<L,O50JW-.0S*+!C-%65!<AWDS.'L`L[MJA8&%6@E"9U`N#UD>H$PN`.C
M`W-!S:(7S8*Z`W*;/%)*1-L#NIT][UJ47L[_VL9I5'?9[7Z($"ZP,DB-->@D
MN"M6KT:N"`L:F)V+(:"JZX#:FS?/MTJQ>NUJ5^/38UGO?MPR08\RVR@;!+-G
MLUS31/9&G#^YU3ZUP1QIDE%IVJL.$@$ANK;9QK0;Q&0>18NU;E2F:_5H^9,'
MHQI+#\XJJ\PN$$%<4QT0ZM*A.F9WMM%[P_/DH9\]E1(4R@"S>LQ.("#'X.4\
M080CQALF!L`0)@_J)XNM=KE$/47RV456(-;O;3=1U]V*<5XH97I,%`0HM\<&
M$H3<"]1=M(YTEI-.T=71TDGV,3`7B="SSZQ.>E2>+S3?%RK,&#)IZP6<SYH-
M)2/,O'3V@JRQY$-=)IE_'0B,BVEFPTX!6Z-)I/9&<3)PL%1GB:?>3.]B@(SL
M![B;+>6A>8A:I`%!<[O4A6KS)-[0-K-X%2WV50\NY_/MXW:I2WY>10_Q/.Y*
MW#NI+)!`"E9`:!,*!]+-1Z9`2A90LU1=>Y#9JSB`Z<")*&V=^3<[R/,]1T(2
M".DET2^V02)=HAYVB+;J41QSR:PB/>H+M4Y;+I=%.E;DQJ\@CP\DTRGK@`@J
MT(432B6IB*X-,CDB&DX[0(!\TS`XD06+#EIZ>T+:0*JOB`!1SX:&W(Q1KA<$
M!F:ZRW[)TH"+^2_3W:IPLF="+LRZ(GVCWMM+&6S#8FJ#F3(:"`R.V?=H$C@P
M+]*]HP'2/`XHHO#S]0AN"-UC&00('K6?UT?'2P^VX@F4WG7GG1XH;(0-H79=
M\,=\J^Y[LEK,0X1DH597[W"@=GLU7P/XW?X(;I#]7O#`[`'CC_I2-Q+YGA4E
M>/]\^,CNX2:KAI3]\R6/)LQK'KD68L)?;1#]Q`\TL,;UJV[FTWU9J6E>`=-P
MEOQVR\8][E_U'B[7Z^WC4U8%0D\^[7^XBG5PXVIQIR[-QSJX.%B$M]LTJG1Q
M.2EH^YG6C/F;'?.W-ICOH_31:;IA-:%$>4+U@F94H_ZUK@[+ZHQ9:-Y#SWC0
MC?OKB%0/O55]29;J:Y:QNHNKS>IZ]G?\N'WTVUD/%L&N)93I*AL._"A(<]W9
MJYQ9[ZGGP9DRCP$G&AV6M!S\*$CSGV@#+\[>.;N+UW]^4+><?0XV_'Z&B/6*
M`X]]!(QYSS'UH?,G#'0G0Z2O97D$^P@8ZS#%K#ZG00CSL?\F^PTSZXVKH\V4
MK#1>K>-Y!J9HG7I$L3-6*F[<'U2@.524$ZT_KG)70U8`NRBR^X-00$25G9Y1
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M=6_05>VPJE?K33MV[4Q6>^HS/66Q`B7UW/],=A_1'\Z4U5H[^$*4W4%OVK%K
M)U='3OY-K-C_M_Z^\O(I+3"M+X_E@\L6Z9N"'!3T:VWH_WW2(:WEU6.H,/]]
M:0-TTP^YX&\+J+U^LK/$)#];144-';;`RN[GNKGA\GUD/+JIV'2>2&ZVFHK)
M0Q51*\NJP6$@!1>R8E[UCWVDA/5@-#41CUT<6:^&=WASJ(%W@@2E]O>+5T-\
M+Y9.TYSG`6/6Y]S70WT/-DR3WYQSSNSI&*^&>FCSI&FS48<KK]@H9T&[X98$
M-$<PD@1+^WL\./B1,C:@/4)<O+2OAO?A[!%!`BZL>4>OAO@A[1%"$!/X;;,Y
M@4%"&"626M]B7PWU0QDDDO(`]6V0.-$.Y:FI"COFJ7D??8]7NB[(3@T@SU.\
MG#LXDK&]9-;/X/GJ-6MOL.>M2AK"2#AZT=H;\OF+]N7"?]4*'.YY3)8=>B-A
MZ47K;ZCGL_*]<R0,G5)W=]'C+-9@_J6TE,[FF^ULJ1-#B6.N+O\JKC&^.A6Q
MC?#'SVEC4#24*:B+46!TC>6;=@"U`V7JZ:4CWY0#JQQ`2^ZW6ZE7CWC3#Z1^
MP`PUO7S>SAU0Y<!88;H4$,;7.'P1NLE\@;\GR6*=]R"*=LE(GZ+TAQ*XOD\5
M!O452@Q8K78B@_H0I%8XX`?C6?H04XQJ'Q5./!RO7BX!$F&MFWZLNK%U4F*D
M/@2ERWB@NZ[3,)`\++B5+8W,P3NK,XDX"T+B#N$^C6;K;?J<?2[?REK1T!@2
MP*1$!A4U<CH`:1.;T`F();O,:5X$(2:FN[HJP!^`TZQH"^"/69IE^:EU=:>/
M)#.;S<H%LO0C5/HPJTT>DP6!RJWL+2."AP.B<FL=0P4N5"X?"M54)Z1-LXFA
MS"$]5;*<MO7T3K?X2=5WN%2Z'`7\CZLG]:?3_^ABG73?+^-E#L^Q\#YB(1E^
M?1$H4D<`O\\YXS^\XN5@_VB?'6#&'RFC*)[K_BWQ<JL^W=;*KQZB6;UBC/1D
M-V![@0$?D).EWS`D*@,JPM$-R:?&AAY/H&868R](1?8AA8@3CB7`D/[YC[^_
MI4OUG_\#4$L#!!0````(`#`X"4%.AKV#?`T``".Q```5`!P`8W)I<RTR,#$R
M,#8S,%]C86PN>&UL550)``.+F"-0BY@C4'5X"P`!!"4.```$.0$``.U=W5/C
M.!)_OZK['WS9E]V'D"\('S7<5H!ABBJ84,#<[=N4L!6B6T?*2G8@^]>?9#O$
M7[(E)X[MP-,PH&YW]Z_5:K6^OOS^-K.-!:0,$7S>ZAUT6P;$)K$0?CEON:P-
MF(E0Z_=___,?7_[5;O]Q\7!K6,1T9Q`[ADDA<*!EO")G:EQ2PM@$46@\+XT'
MM(".\4@FSBO@OPGX&X<'@X/3X4'7F#K._*S3>7U]/:"B*0M:'IADUFX''[L`
MC#/G9-Y7^P>]][_<<?DFR/OCF7'2.>GTN[V^<7HV&)X-CHW1G=_01OC/9\[#
MX"IB=MX*??3MF=H'A+YPPNZ@LVK8\EN>O3$4:?TZ6+7M=?ZXNWTTIW`&V@@S
M!V!S3278I-'U3D]/.]Y?>5.&SIA'?TM,X'A&SY7+D+80_VNOFK7%K]J]?GO0
M.WAC5HO;P#"^4&+#!S@Q/`'.G.4<GK<8FLUM(;CWNRF%D_.621%K"SMVAX.N
MH/_E`MA"O\<IY`"U#,'HQ\/-N[RFRRD$8,+ZW7;WM#WH=D2C3HRPLZD@CPYW
M,^%Q;#RY!&QZ;9-7+8$D##86[!H@^A]@N_`.`N92_Q-7T`'(UI(OF\_&8EX%
M'7;U[PA;7[&#G.4-GA`Z\]Q01UPU?AN+'7&C>QX=L#.%#C*!7=@98UPV%O$[
M<#A<X\F%RQ"&3`OT).T6+,80=_%["AE74QO75/*-A7J`"XA=3FR2%XQT94JC
M+J??;MQAMR#8)9G-"'YTB/DG[U3_!90"[-PB\(QLWKUT),SCM+&H(].D+K16
M+!'4,F`:]39$(BX/1/CEFE!/=2^%X*:80\RTNX,2NXV%ON'9U@S>\N3I'M(`
MM2D/4SJ2RGF4TU6>P+.MAW<FFQ)\45]".8]=^&4A>569EN:C^E+G<2HU)>MM
M*R?KE1[J"R21B@Q+Z&P%A,U@LHON5DQB9:X[5$'+I[78[E")?CE*]'>JQ!-\
M<UR]N4D!YJ7%\@)=(I?5%H*D;8-G0CU3C%XHS$_5@U@HH=O";,86-2\^D726
M3SS",F#FY97!/$9"5Y:-%/#,,M7V,)1HKBI?'OD6.L0",D?-KR)MM_GE_$PJ
M_OTM)G?O/%4Q22/9:I5O/(>^0S*>RHAP2.&41T2T\*)-KGPZK`*Y36";KNTU
MO.52!K(*;OH%S[#N/&Y#;$'K_;?($2R[O5[7:!OO@O*?+PEOAT7)F__$B(TL
MK[@>\#9\YL:O/S!P+<3_\IM?X.6RV\2,?-,6I65"HP8/E/#JQQ/`GKTBLLO:
M+P#,O?IY!]H.6_W&@Z;=[06UY%^"7_\<,192D0<.:'O+!*$__AP.#OM'1R?]
MX<G):?]D>-0]7%FY"EDO72IJ?IDB!VV$Y,/#X\.CX;#?[?=.^_VCD.0A#QG1
MJ!*`FBO^_,>(TR1K]D&+#G-G?JFTS=&<K>@GE,R4+!I\G^CH0J@%Z7FKWVT9
M+N,RDKGXOD@K7B%ZF3KGK5XU4(FBO.B>_)^O?[EH`6S1>4?.)9_%+'EZY$W$
M)!`JT=85VBRTD@@75U4)^3E%A/*Y8F5N<`?HGWP\X0/;(Q315LP+L_MO!L5^
M0*ZK8`#T8;V!#B8^[`&:D+LQU^X[='(B=0;)?D"MK6&`];#>6-]3.`?(^OHF
MYK20AZ^Q,X5497!6H-P/Y(LJ&CC`B:(#]*MR`,)S<&=YSQ-9;ZV8#UUSD?1R
M]Y8B+R>I*^2*69JV:LV(Z-\(L5Z1;4L`7?VYX>!EJM&,</S`9^X4F7P"&9K%
M?R?8S`S%.50-A[6(=IJQMR*T0P-)+L:I;1N.K+I.`9Z];KT!#:V8\<'#6S.8
M$IN+SL1`(G9VI&*;1Q8QY^EI=46;R(Z0/%7JYYR%[)QTVSP=-:?S%25^7N<+
MJ:(6@5():HVT8I:OJ9UFWE<1QB%]LB=SR8;[@*FB5LU(#5<%B'NP%-4'M7I,
MM'&M,2U6CE%0L!G5U>2>FUR$T]OO%\@:.C8C)"LGA>GI26V1W22A4E2U&;66
MT$Z_S(6Q6+/Z@:N(2LI"F(IJM5WM'%D6\D6Y!\BZP9=@CAP@*YU)6N\1FCH:
M*O70*D!]HMX^X65NMTPVW",H%97+SX?;U25)[LSUMIQY\[7(CJ'UAL?OT!E/
MGL";/'72X;)'#K`-S95*J]74SAV`,+2^`HH1?F$A9:_@!)E(7C[/(]PC%RBH
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M^ED&1?W<IG24DXZE:Q_-`#:HJ%8OSDNF7"N17J]/;?SI'7JF:48`$0M3T$,M
MY.CCR15B_JHD[P+W%,Z0.V.10XG2E3Q]9I^.M5W3J14]*P])\>G##4X>3)#X
MF0KIIU=M8JC\TFB[#M$KJ5]PQ.$*3B"E,/VH@[)7J3#[]+/MFDZA/%M3UXMM
MY!')8\KM8YH!+8O9I^MMUW0KUZMY,>(;0%A8<HQY=C`G#/FI0F9LRZ3Y]*-"
M%EJY2T:&7XM(%=(,4C[F.]X**7.HZY\_@0X/UHYTC5F5_-.+-C76RJ'JGKE+
MBGG^O&2#%9$4!O5SJMVMB*B:H[9;E?@`''2^D<E-16':)0,2%U&BK9]W;`AE
MTC>*VR&_,-FNPR93;BH30HM=<SL^`B]=NQ,W5G.9QA,=A]'E\Q&<9RLV:<9F
MY>0\8'W:5EA5>>85)?L`7E+(!+I%QJKNA(B'3^FU"*KCD)3!!_"4#8VA6U2L
MR8@D7BH@EBN,!3,GV?F$'\%'BAE!]UA\1?%$8JYKA`&?7!:?^J0PJ)^O[&[J
MHVH.I?.N5<>0&\9<<;7F>!(Z3J000E+I(F88GAQ7[Q4;0I@=0=1M4/;9V.1%
MLN(W/U,%?"*WR!3K'8DPH$CS4<IFBN8(L#VJPQ;P[#>TP@#)=H(/NT=&VQ`K
M^S81'/A_!%/#XVJ$V1J_!HPKO(/W7=^UP++='_+V583@(``!.U1_';]B:'D;
M[,54V,7(1'-@?R,+2+%H,'ZVT4MPB[/SKHE$W^U](-)+!L='U0?U7.S#`;MD
M0S1C(Y74"#\>UUJ+M<@7B,WE=AQ-@_6^NMBF)M"\,47;N21IPQW!<.E7X*Y=
M;#&9"V0W;BBH!91JQ@VDHP4?K$5%53RS`L*%U?Q15!R$TZ2O/](%E-K)<;_T
M!$TQ`U1[EC2:\XFS?ZOVX1\!M@R?V$A[U+0$Z;/>*8W*W.OUBCT=$>'Z6^3<
M8HF*)=\YC:K#V\?3;I]$'+.\B#^.6HKE4YX]C<O8C\OH40D14Y]++4',M)=0
MXU(.XE(&1$;:^ZDER"AY%S4NINH\JTQ1\QY(C<M\')?99V!X'+QX$?`PDJ^L
MEB"^?`OC6N23N,@!D1&A*E7&_`=48T)[S^+$A0ZX&#P0^_8.WH9/?8JU!$7D
M[ZO&I4^$,D%D<*IW=XF\R[JK+KAZ+"HJ[I%&P</G4.I`(7^!-2ZVBF/O2F35
M1UAC.A3V\YWHE?=,:UP9-;??B>@Y[[8F2GX)T?-J?D:O5/D5GW&-ZU%@>`I5
M,7?:JZ4ZJ'7K2DNOI5RAF5@NVOD%\9IJ91/5;RE,3]1DE:N`OHVY\5?H=$_)
MA$^R/`&OH:)32XCV#_T"^C9C:UZ@V".P`54-9;'&>XNVBI[U+XGI/%H>&XTW
M2%!WE%:H/V6>4"V1].GJ5G(2J/7&>4*[1*U*6[M^3;1[?_8\H6.BTJ6M8\"[
MDGF4M-.I3J3*Z&+!]$/R<GJ\N'28G'"$*(V41]>W):+T*?6XB*?):JA':7BD
M1MHS["6;43KU4;9FB=#GO;0>EUG=O"4*G7+YR=H!AG$)T]YO+T$26=TJ2YY2
MBB-QP:189DM6Z91;NDQY242X=XG+?F`*@8W^YFF?"+7!(>&\[1M;X5ROY>QO
ME$NYEGEUZE7;`%(^U:;VVW.%2,:O;X:&//@B52RXS$CD7$PZX5.E_E@^$5.^
MZ$R_O#E@XD+D8/NOV'2%K<A][.'8\+Z[H%_H/N3U1[QB<^0S?A);\37)^M?`
M5G64A6"RVK#M2Q-<TB,36M8^4K,X&O2JK\TD[)OL>'K:-",.5W'11SWPU@(S
MZ0P;:=X,WUCGV;Z!;K`#*90.RK+F^X>]EJ;-J+>/H_;(&(A26M80X?QHKJI'
M,_`3&9_(H0)'EH$7;U8_Y%1A20*JI%M#;CCY!C$W@RU.)U@SA!$?5[P1)CO=
MRJ&J']A*D*6,O07T;,:0^P`9Y`841Z:OX`+:Q+L9(1OU3)J]P5Q?RV8$[BM$
MH>F\1SUAG0>R!+:S3$=='(]0H&D2Q(HJ-6/;2K"K738`K_Y<OWY9?.#-U*D9
MO3`X.,X"523@Q5K5#\-,))+`J>C3D''3CQ7I\(GX$F_0!)C2Y"Z[.TG.GJ:/
MONGFSB=H;,<IJ%K1D2NM$/^E(Z1Y!@SR__P?4$L#!!0````(`#`X"4$.\WE*
MI14``*JH`0`5`!P`8W)I<RTR,#$R,#8S,%]D968N>&UL550)``.+F"-0BY@C
M4'5X"P`!!"4.```$.0$``.U=6W/CN+%^/U7Y#SS.R^Z#QI:=W63F9$Y*OLVZ
M2AZY9'DGR4L*)B$)&8I0`-)CG5]_`)"4*(E7"2!`BC55'EO"I?M#=Z,!-!I_
M_=O[PK7>(*$(>Y_/^A\NSBSHV=A!WNSS64![@-H(G?WM?__P7W_][U[O[]?C
MH>5@.UA`S[=L`H$/'>MU98W'UBWV/.BZ<&5-P&P&2=RJU;_XP/_U/W[\'^L&
M+U<$S>:^]=/-SUNU>KVHCVM`69NLGNCL\D,__,9%WO=/_,<K^]YB5'M4_/GY
M;.[[RT_GYS]^_/CP_DK<#YC,SB\O+J[.X])G4?'WO?(_KD1I1MK'<_'MNBAK
MR/'799/M_G(>?KDN2E%:FZQD__SOC\-G>PX7H(<\Z@//CFDI1S5%GZBH/L0V
M\,4(%5:S,DOPOWIQL1[_J->_[%WU/[Q3YXQ!;%DAR`2[<`RGE@#DD[]:PL]G
M%"V6+B=)?#8G</KYS":(LF;ZEQ>_7EWP1OYX@UT7O&(B:!W,"(1<3N@M]`%R
MZ9G%6WX9/ZRYL`/6Q`<;+\[Y-^=%U<^E$'D/$/D=N`%\A(`&I#2)K)&+WL7'
MWM5%2&U^.W)H??#>(/4K@9A610XQ-WBQP-ZSC^WO`\_Y!@@!GC]$X!6YR%\=
M@&#)!N50/[!M''@^LVOWF(@^A:%A-"RA1X7('<!"E5;KYJ.OAI%^_9Q<JN'D
MLGY.)O#=#X"KAI]UX[*,#R,'#C&E3Y!$NCH'!!Z@)H5-)2D&Q"Y+=,9<%T_1
M?)+[1?`R9TT0.WB%/0<QV\C]DC,KZBC)PKH5Y/GGK.AY5.8\M0'55*^[ZCEX
M`5!%DO=KUT@OG(+`]0\F.*ZNG&*!3&\!%Z^05*1VNZIJ2H'K5J-/5(BH8FZU
M]5LLP=8MG"(/<<-A_31$'K0>?+B@EH\W97X63G?,C[.NP(I_W^*)F1SH.=")
MN>)='^K?1>TBGS=Q\>O%GZR>=8NH[6+N7[$_MAJP-BU8/T5M_!SZL3'=+K:W
MB'6Y&XU)Z@@('*>`O@HPV<IG!L"2&[++<^CZ-/Y$F,C>13_RF_\8??PO[N8[
M@0M'TP21;W#`?9I92"7S<;YB9@C3OYZPWRBP.6=T`EXW<L)*0U>LQ91U=*X+
M-0DL#-X1S8!*6NO;^&RT84"VD6*J%Y,2:>&!$TO8QI3@A=J!CXC'"C##Q('D
M\]G&6SQ/,24;ZW0KK*GU**PIM3KS<P**U"Q\'J.)7A5"CUN.1"6,]GUW_LF_
MOD"/]0'M.7._4ZG/+"6/AB$,OL,%`@R'X6JQG#,U?\8V@OXJFZ+B.O+HN_\-
M3Z<+X'E#,,;,P@[1`OG0R2:NH()$RC!V&`*W))@-G`4S@-0/+4\.;4555$YD
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MD(DN5%H)$9VD:,]W#Z5M^RA?I#:;Q6'4UB>NQ=#Y?.:3`&X^Q)[/+,B=*YKY
M?$;AC/]2TGH]>'-F!L4=`FN*B;598'VRK(BY3S+!ZXSB2:GW,:Y6QK!&\<B#
M5WZX8OMI7E?9FO)H'<,WZ`5P#&T\\]#_0><1N9#ZV(-/8"4Z#S=$8%0PC>KJ
M;<BC?]T5W71_SRSH$R"^E^[:%E:11]W`<825`.ZZT])DEJ^K6G)OL(BW#W^C
MB!EW\?T39I;.1\"]`70>C71YH:[4J"8.&=Z0V8ZBD3J^37G\/0>O;JAL]Q#2
M)X"<-(K32FES!,=X!5Q_E6Y@L@IIH_;N/P'R5^O;;IOI.(/PG/(21YW?'J$/
ME`;0F>#-Z,+=J;.PM&XIN'OGUW@*I&!=2!NUMXA`VQ\MA5)[LQM,_5(,E*@G
M3RJ>V/J>F1\P8][]OL:/O+!G!.D=(!Y,-125FY!HJ3<3P`3OG\^D&N*B*C+G
MD?5ES5"11AZ<H`7D?_!%R7[_D'X-LG;;CFE-IB]((5N0SGDD$+.S+EYR)"/!
MO,?D$9#OD(OM&,[6$4+I#N%!#>FS/7GT9IFB_#IJM)C[%`2]!ARO";X/O$*E
M3:LAD3:";0@=RIV99$^C:29M!35D:FCL?XV8W9H)&4N=#C,*2D0I-$D#2K&-
M>(J(>P>D8I-:KOE!AZD;4`>N'-L4CIJ-2^$2M4TQJ=DPE%\"[\:GMA,/"2OI
M"*A?.J#R5^013K^V&Z>T?8"(\S^WEO.L+86(\;^TGO&<+8D(@X^MQ:!P`R0^
M1;]H+019FRDQY_H#(E1S7F(7)@:CY8YFY?V=&)>6>YZ%.TDQ#JWW.`_?F(HA
M:KFO>>!F5XQ.>SW,DCME,1#M=3A+;<K%,+37_2RU_Q?#T'(/-&//,=[=:J_S
MF;/1&3-?.D=.'"G,`UAY?K0NRK[+DV,</GKRY"B+R8\S$2JR&1J2F716IKO&
M;/@U9BW:K/S6<.DD`IT&=K?I%-RFTZ)5$B^NE;V)JO5&>K5G`G9U[)=='>/5
M+5'?2C9@@(JM&6.K&B@,89RZ'T$:T<HW5"'#AK"E7V@I2?SG-:`H]^Z7Q/:U
MJ?*:A^O-Z=-O"!*^.[0:\KVA'+M4MK(1-]6E2T/2-)1%PJB<LZ=G".H3<AW<
M)5'?)S5WAJ[8AGY>'[QEX%,!?S_7S\^M810?EY7YN#22CZO*?%S5O,;*R6)0
MS52D3@'E5,B85`<'F8]4QM,TK-UL7F:MG]O%YM4.F]TRQTCOIEOFE/$`$Z-W
M3^!_`NC9JW+N7W;-DUK@9,-@5"K2T]/_.F1;\[IF35OEU<Q>3:/XHFNM+.<\
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MB"LJK&_.01ZS&PBX#QY#)Q"*,OKA04<$VS+9>`P\9*,E<+_@-TB\Q?:UNX&?
MQ;&*#LQ#Z>5Y0S7C93#C6\IR\*G4M#XM?6,6E4]U]Y@\L[7',[<CPM243_-:
ML0WS+%)52Z21AV_B?HF8%L9H-F>R%OB4N0X.,_T9;.17T9=&EOD\;^+26IH*
M)>:\\@-V7)-FK;#E><5%<Y=Y(57*U@42YS)CLA#J0ZW2#&=,ED+E>%6<#HW)
M2J@>F.SYU)B4@\I!R)^-C4E`J!R'X^;JW7R%VJ_1GMX62'?%1\45'RT7<[7=
MQ>C45H/:=K&KA\:NZE9.52&>YF2C.$5][.*?S(I_TJWE!H3@-.+>F8`W$2N2
M:19^W34+B4H&F(+-,[39.P?E7D8NK*_-5#R"?V/"LRK1T?06OO+MHC`3^X;$
M'.-7NK81@<R5QS.IVJ59-2K!15M448N8FL5?[A1<H;Z\,_H7FKH;GQIF6Z:"
MS&>VR)+G/(/7V'/H5^Q#OE$F,H9G4U>BDOZ(X(J*4-&"&1?P6UDOUN=J!;+6
M`@Y+R*NIT;EMF99.P4,L0^.P('2N8AM:@E\/XG,[.6+IP=SHI>;@U4I,=T;`
M3`4Q(BHM?#P@P`%]\0@$+G\-<8@I?<)42,EF:Z0@RE1F#P;B-%A@XG/2^0-/
ME3'8J6T@?U\(&Y+-`'UAG@L?I,J<9K9C(,^E)5.=S&OW8X^>/DL+O3%A<0I9
MSI1^8Z+;%#)?0>AW@]>TGY.UQ:GI-MP4;;AI.<32LVMD\AG5[GEVXDU!QF$4
M"Q@'NZTRM?C/^^\M\'8LT9`%/,>*FK+6;1VEW)G[G7G4I^U`E*\F;U>66_G1
M5'1WO1I-IY`?B&:=KY>JH?58J2KRFY=^"[@RZ@2I78JB6@35T)8Z$Y6LH_M"
M5&[2E9TR^HY7*@A'"34VYABEDERE!,.W(1=?LPV683.['-,PY@]QY2P?$M\W
M;H9/X<'HI,`-40_-@E<WC;FSYE8)?2MH)HB+8)%+Z4X9C:O]]V):M\OH#_78
M$]8]\V)<,$.*[&[M)6R+0V/(WI8,4X,J&FK9F^'X'$3E,./4MUK56J,A#N$J
M$9%4`OS-"8:FV`=.ZJ>2+'8J:I3P*S0H;`0#X&8$)QS2@#S*QW"&J`\)=&X1
M@;8?K^%?F#!^#?BD-)HFB)O@B+8T)@YO2U\N8KY5,9I&A(R(N)T?TYHX-62V
M##K7J_@>?U0PR]4_NE5YXWM'?;0`/G3&B'Z_)Q`^>'R$J#]F'Z8-8D$%B92]
M+YF,0&>(WN`&+/H/"$BJ6N>7U[D)=NB4=KB^:`]3.)1O:1JB/5;AJ)$O4#+M
M:7..8RY747<SWVB/JFB7WW3JAU"UAD#4<[+3:4BWK:MP6U=+T%#E_<?C=L2&
M>HX'![:-`QYO..-QB$+E`>6AIHLE`TE<&LO2EO[%KK9L&A/;#J*YGFC/2C9H
M@,ILPC?9&$!"MCD><!V?B:V7;\B?/W@.>D,.6]X^SP&!@J$GL!*QBN6N-\GI
M1&-*U*/(OUY-N,R,IIM".=9*56>&W<&7*7?;^>O4P&=T5-:)6K$6ZF6-Z.W1
MPUD80S>\*3U'RPF^8V+@YZ?KJMR*/BLN=G`PR?7"=@OI/P=6*^1)TUEY*(TY
MP3U0E+?FC9V!EQ+S5L,Q[XF:_LZ!K836FJ(,!JY7>T0/?@#B[&TA[B(DH6$]
MU_VE(9*>`T".P)B3*.!HN#HS>.**W014D@D<@\4R?"W!<QZA/\<.=O%L59"^
MH):>]>+Z6LS=:QGNXC.H"22+?AZ<BCILAW2FG4Y&<99UB&AN]RU&.`P)U89P
MW'T[$(X5\W?,%VS\4*EF*2X@H-4HUR?)!02T"^5;[MHS1S8EAJO&?G4G"5&S
MR%+H%&B/VJH!NEKF?NW!7TT',C:+V@/-&@1DP3QNS(MNS85R1RKUOPO7("BW
MI^;=%^6,"R$[T1VU[DRY\6?*6L+E&G1,V\[XO'Z*&>H?:X>LO@E'G'>+I8M7
M$#Y#\H9LF#$[N8(6]MMHRA\4FGD\<>(3)`B+S)DE3SJE]F5`UG(Y_%ROQG")
MB<^U(,>>J^_6L"@^!9*9?IZJ"L^6A/5UQJ^9"EPCHG(8VK"3Z\&IZDS?_0U(
M(;.3\X'GW/*'=_&2NVU\:>?1@GL=96IJX^L+]"!AOJ;G#)P%,U_\C)D__EV&
MLY)U]8=0UF5,DE.7*@TP)N92K3W9NFQ41H-.$)>2^M>4A$6=M],M];3Y-7O;
MP4H<FJ'FJ%=%6*E<LID6"2L9PLZF=G8AQRX<D\NAQ-CGY;NJ5-VPX)U*$3<M
M\1CSK7(&YU5S$QM\"MDZ`]9M@9DY)1BU!:;EK+/-^RGM/!R]3#&.ET<;QTL3
MC&.Z)(A/Z2#PYYAP&7AA\(80C414SI,+/"9W=^]LI!"%3X3)E$AJ4V[IK*93
MP[RH@]G)FUU4]&38H:A*B2QVZH[$LB4'HNTS>&U2T6;@ML]+KL.GI"=YVP'_
MA`0_86;>GN$;]+XRC^6%WF+7!81.\,B#XKL):V+S>>KIW[&-R>,H[N<>!V2[
MKPF>_`CI8V7NT5L9EHYI31Y/<4_L?P%MD@A.U`;T9_1>@JOCVI/(U[HS+BQW
M/$5P@A2.>0@^0Y>16H:QXQJ4Q]E65TD0&17LDQ!@],XUI@1;Q[1FP$&[NDE*
MDN.3;6F-.4!6.&.M4]P>8;]/"J=C)@7#[Q+*!>JX><;PVX*2H3INYC+\0J!<
MK(Z9#BNFL6]`W$O[%K7=+IZI2]V]XT25J]VAYK@8M<BEA\>H$3YCXF340-J9
MXLYXE#8>BH-G0J+H*/`ITP6'%1UX3D0>5\8C@VO*-]^."2=^6BK!<`1!'4*4
MU[MA^?8.Y'"?LV^0KSV@,WB#!,S@&'(7G#]UPV8'+ED!<'E:G,L\_$V@[D3&
M9ZO*-9PAC\-Q#5P^$5?+H*B+Q'99JH0QUF"ITGIOAR;L<Y8G9K5(?F62VK0W
MD[^@J6L6;N=V:C&V)LRP[=R?-0C[HHFSG9N^]1N6M$G3\+1PQ@MWY;EQ-WE<
M@R\==-M`79A9^\+,]%PJ:%'L2#LO$4Q8#\PG3#%Y5T>;O*AM$XXBNP>E3C)+
MIO9K`]V+J)U5Z_2TRV8K\13S*_;B>Y/Q^Y8YL<=YI?7'%C<HP6X3WT$ME(#V
M/8C::LO?^;,M?4>Q>R"U>R"U,XLGH.B*P]>BH3@R2FVO%7D\I",J=N+2B,TM
MWKR))3I*^<(*^O3!"W.8R):]C$Z:AY;X\3ND7%9#+G+#0J1UT3RD]L-*'SR?
M(+;^LL7#18I$+*<_PX*62CPD.(H?=EH??&[S)/TYXQ(=-E82MXW/SM&Q^/(6
M^'#]L%8M)K`$%68G,6,+^3=FJF!HM>@$^\!-?L^387W%_C^@OTF3E8&LPO[:
MAV$H/LQ;BC[BY;*L0=U$--9"Q.>N:_44*-0R;97KNK'(_BY$*^9-M8W-[,UL
M.U"85/`&+!&3"O[I8,$73,<H_"&]&2!_7S!VZ,!SF+V"VVS2"9,/RM:&C*7H
M98)"^:K8FI%Q>X=NE14O9@V/A-;V^&K&:M;PX&5M<*4N:`T/--8M6SG+6,/#
MB*4@IVCMVKTF+7=MNONV=,OP5+@BC9#[2X><E"5G!.?'EL)9S^HR#KRXZ%"L
MMJR,@=,?EZ-1FP]93\;`M7^%47&A&0-S53)TP.2K2ZT^YN_B7AL?]ZKE$E*#
M@DR;=,?HP6.?PB&FE$T\#-M%=.,JLA?[-FCOX29>UV*5K;"V):JO#8X)898#
M-EH.<@/^`NLSY%CX"#(7SW8#!M@]$S,N5($?S<5W@/`KWAP0P4NY,$LYG6@S
M+$>2?[U*;R#'-BOMT;`+1#(E,&FJE&)H]"VB]MJM5FNB=AR_@D7^)>[B:OK.
M]#:WGM/O"N45U$;U-\"]-#^7X)TR^J\TU:"$Q78\*73&7&0JJU9;J_H4>6PT
M0SOR6O&M5FT7L-H[:7;.?HTNQMX.GEQ_8JCY?I5L=-)O6<D1(6-N6<D"K;.`
MIZ73QUQ#RAK,#-\KYSK5H2TUU8+G!D-*:MM(MTZ.%9>$4$6WL?XCJ\Y:=ILL
M1FRR:#EQ,GX/(,M>1)_S'SSFCWWR_U!+`P04````"``P.`E!04K4YGQ&``"*
MVP,`%0`<`&-R:7,M,C`Q,C`V,S!?;&%B+GAM;%54"0`#BY@C4(N8(U!U>`L`
M`00E#@``!#D!``#=?>MSY+B1Y_>+N/\!-[<1[HDH]=/S7'LW2J^Q;M4JK:0>
MKV_B8H,B41(]++),LM1=_NL/#S[`(D"`+R2J/]BCEI!`_L#,1"*12/SIW[]L
M(O2"TRQ,XC]_\^[UVV\0COTD"..G/W^SRTZ\S`_#;_[]W_[G__C3_SHY^:_3
MNVL4)/YN@^,<^2GV<AR@SV'^C,[2),O688K1XQ[=A2\X1_?).O_LD=\4_:,_
MOO[P^J?O7[]%SWF^_?G-F\^?/[].:=.L:/G:3S8G)\5@IUY&.B=D;-3WK]]5
M?_E(^%N'[(\_HQ_?_/CF_=MW[]%//W_X_N?OWJ/E1]XP"N/?'TD?B$",LS]_
M(PSZY3&-7B?I$R%\^^%-V?`;WO+G+UG8:/WY0]GVW9O_^GA][S_CC7<2QEGN
MQ7Y-1;N1T;W[Z:>?WK"_DJ99^'/&Z*\3W\O9I&OY0LH6]%\G9;,3^JN3=^]/
M/KQ[_24+OB%S@-"?TB3"=WB-&`,_Y_LM_O,W6;C91I1Q]KOG%*_E7$1I^H;2
MOXGQ$_W2=(0?3\@@?(3_7?SZ&T0;?;J[JGIA/>RR-T2`GCQORSN)O$<<O:EH
MWLS#WT]T!MY]+_)W30=N,WDXG3\U^BJ("BZ)T+G/*1-[.U-ZB],P">YS+\T'
M\=RFMR<.#TGN18.X%BDM\DNL)Q[&KT!9\,N4\)KPU>`8?\EQ'%"MY+^EG708
M)J[.U*"Q3FFWB=_H,*+6+4F;<^"G879"3?7;[S^\90CI;_[[O%A/EG%P$>=A
MOK^*UTFZ8=9Q^9CEJ>?G94>,?=Z3(=V;BD5*NDR;?'JI7W9-?M3`+EJ\\1-B
M]K?Y2<1GEI.OTV33B[&"C:0'T7]'C]$AH@:<%&?)+O5QK^\HHN@[OYPCL@`2
M2NHQX/CDT_TW_U:2(B\.$"=&`C7ZK:3_?W_BXT\+J?10V&!S0L,<6EA3OSX$
M9*(8XJJ98?_U4_+R)L`A<VOH#TQI3MZ^*]==\JL*P@/I]@!B^\]VE4#%'I7U
MP[]9$VGYP.K/2]O8^I9+,F)`1[V,O"<)WP=_M_\UI0R6G[/Q1ZO?4S)RZX-6
M;1!M9%L[N9]S$0?G9#WND,B#=G#Z*F7X4'$;C4`T6,*!6I5Y8[(.!8@VMRT#
MEV'F>]'?L)=>DM]D':A:+>'D0,'TH20<-`.1!2D/:FG@S1%MCQ@!C#QPH323
MB$9;:)F0,"Z7"J$AH%RTN-!*1F$NK,H&]T+O\%-(G<\XO_$VLN5"WLR^1'2Q
M6PJ#K(U5.5`ST!*!8HM2MT6TL=V/?T9$,/6B*[(/__(?>*\$U&H']?D5##>_
M_T$C``&0<J"2@*(Q8JT1:6Y+!LYV:=I8R]0^H[JI?4G0L5T*@ZJ=57GH9J(E
M$D7SAL-@VX?D8GD91C@](\,^):G:,!RT@C(+4F:;1J'1!,`D2,97&036%)5M
M+:\(R6:3Q/=YXO]^_^R1:5CM<GKF1`_GU.:NDPALK3"`<K!P=%!`K"):=I1+
M"J-$C'2!.#$2J,?*U-K+'AF4\K"-"1:.\NKX[5#"BE__]WU.Q)IZOJOU91A[
ML1\2=SG)PH[`>S]2N](V!!:5N3YTUB2O/U,M^:M(4;)&%3$JJ3N"\/9$<)EE
M.,\TPG;8"$:LY*R*`M1L85U49,.WPZ&LT=P',"\X?4RJH\<1W-[?7SS<PXGG
MF9<]+^.`_N?B'[OPQ8N(.F7+_,Q+TSVQW;]ZT>[01>])"R/,O8"),FY$:%WT
M>W#5=O,)$3O,8S\(Y`ODY:CL`;$N9E&6;1G+[E*740B7]W]!RYMSQ'ZX^,]/
M5[\NKR]N'NX7Z(+\=G6);B_NKE;G,Z(3,SULXCN]^.7JYN;JYI>941H8O$ED
MU*<_X)H<SC1^]-+?<>X]1O@>^[N4N!0X*W;,B@GHI(`Q@P8@1./7T=RZR=/R
MTA*BF@+5)`M4$$&IQ2@<644"Z,+Z?K(CJGB'?4S4DK!U@_-N3>@F`7)O#6`T
MG-V.]O9=7RTS;=>R($$US0(1*G"%&(,EK6C@].$VQ5LO#"Z^;'&<8;+BK?)G
MG')WOULMC"AAM*,'*%%)#,BLZXHQ3RTQ*RA10<H<$D:,.#6XZHR'A@5H"8/F
M%Z<`'NL%.E*B65=<4!6M4L"*OXDTV!#G7,@E'\PH2TAW1D1OTX3L]O+]+>&1
MI=:2?<J6!B#)`J;4V"X2*%NOA]$T\NKVLXBWD274\20Q@9R$)S:7[1<HQO,H
M0/<:-9C]!6)$//.\1G'31F%/,>YPEJ>AG^/@*GXA/U.6LALBB9W67$L%HQZ&
M8$0-T9!87P.,^&E)6$V%!#(B6A4AE-\S#,]U$C^=Y#C=H+"B0B=D#U%V!J<P
MOR1)\#F,5'CK/\.HP"%[HJR7?[,NU,V!6U^[_#.4C`YDSY[,"7L%K6E6M(61
MQD[&1=&4-K0NIQU<M*2BN;N$-[3]>8?VR3FSG5L,V(VB>H<(M#7LW!-";@4[
M]X#0<G8=>H]AQ$+QQ%]GR4[/213@-*-.>+[7I'B8D\/(:E]XHC2;TEJ7]WZ,
MM?W'FKS:;9'M(WQJR5A<5\O3J^NKAZN+>W:J?/^P.ON/OZRNSR_N[O_`CI<?
M_@9_W'3K[6F<W^R@Z;`Q[!&3G'79X5*SY:&"6)WT=(<#0;"T\ZYJ#S;UW0`.
M9E_>&.)<KXL3V4$8;8]$TS1K$%<HL#$I@*@F`'(Y>C+.O!`GW(]NS71')<UT
MT0$E["<#U6D$N`A/S[?E8(0`P"PBH2``#$MT0FC%)J2M80(4':PH=OH"Q>RA
M"NVZ,Q!#5(6$G=`"`8!>QQVPXQH##FFY.TV?2Z9Z**,6+P4DFTW(SUAH/F\2
MYV'\A&-?+:6=%$`7`/0@&FG_ZN9PN[+>42;WXDK](DD.Q8YZ1U5$@C^4L:)E
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MJC6BS5$8HX(`+)M^*/\T'?B$\._+^;<G\0\I]K)=NM<:<UE#&#E7LRR*>+N5
M=>E6L=#>?A0-RS(.,]P&E1;UGHAKM@JA5\24^TF6+]"[Q=L__K#XX>T/A<'_
M%C(W,O?"&`<77AJ3Y29;^OYNLXOH')SC=>B'ZO1(/2%4AJ0II&:2I(X*($_2
MC"5)JB0G1"4E>B70HH*X)76V%H7!N$00`6\)>A)<,L.B=\3CW*;X&<=9^(*O
M8C_9X.LDRVYPOEH_>%_4!SW]>@$[P!P"]N!8LT\7$(>=_?GK%%$>U&WT@WA'
MZ!7MZEN6%T_+PY#^`.\[3@R[N+C5@!VRCB!K+1T&%(PC#^[$ILQB4@[$HL;'
MH&#BX,9(>#@\:^#!C,")TQIIVI4^]J\@`S_7Z833)]7/N12_7JE]X&=#?2"T
M#HP8$+<T1@@E$JNS2EG%MH#MZ&YQRDH%ZH.0:DKP6*X.E"*\JR)S(.+;S9HF
M"%R%?ZW?IQR-H`A[$&*4I(B3\R`(+9?.JUHZH4>\ON:RBJ7K)Z1-`:XW*A`*
M?3EL;K_\FHX7C5@515%K*K`:74.!%!K>.LIQ2">NV(&/*?"RM2.ZT&2^4P]X
M4W@=$/DPDO\%XB3."+\)@J;@AU(`@$*OKIAM1N*(^"NJ99NTAU<$?:5LN39T
MU,@&4PEC+$V]2%PH]]TX-N)P3`Z8RI8.'"4VF5:>)?)FL(>)(@_:TT3>&$K(
M!_!=2'=QG@@GTCP\7!4ZUZ3_*5O#B+:&>5&\%4VMBW@G'Q)3&`>TFEJ`R$]9
M$H4!VS96Y!D]>5AM<<I>3N4!FN9A!0W\.U&G_@Z_X'B'=97JV\V@3J#E[#;/
MFYMM`$Z790Q(SI)Y,P>R0DTYOOCUXN;3Q3U@_N=UZ%/-RPJ.E:'5@U90D78I
ML\W`>J,)0!Q=,KXD;,Y;H:(9W`7X'MRB-1YVFT+QG/L=SC#Y^+36^3D9/TI8
M!3:Y()H0`#S@;@2A>KF]L[7=)]L-6)&5-6,T;/D5J*"$>!H@04T%\\3\$`1_
M"8ECG8:^%T7[!<J?PPP]>QG-78AV`?&<+A\N4(K#S>,NS9@']1JAJQQY49:4
MC;)F`^IAE>D0&7&X\F?BLS][Q+5ZQ#BF1/168(#(CO41/WO1FA)X]*0BCW$Z
M^C'[\0Z79B6&=K"Z'"LPATKC2,$<XVJ8X\>UJ8)%FQ'$C%UQ*VI(ZQQ^=7.H
MR&$W^\VHH;PM0,2PBQ')MI):,I:64!`XL#7HBV%U_\"K"UW\U^W%S3WH9D&^
M5!5(E.K<20-6FE8/Y*`PK9H`HBRMCAMS[ZT@@RD_,!J)X+Z5-?G!XJ-3@@$L
MJ8N)0^=%!,0RV(0Q>^<\#U]PMYIKJ8`*\)J!:=3E[2:Q7Z[7A)]VF5Q.Q<2J
M23>KPIO4]QV-QVO0N>,"&J[XKKA\)JX>N(MG[-K!;%8,V2T*1U5,JU8JBW6C
M^&E*_%1?G%!`E+8$JA2E9KI1(JK=S'YM*!4/[8)*9<OFC1L8>39GFYVXT<^#
MDNI@#DZ<;Y(X:;)>ONW4O2TWH(,1=6-`HN!KB:RK@2%'+>D2Z2J]*$B_=6`7
M/Q37ZN$O%W?HZN9L]?'BS:MB2_\MX):^?@>$P[B*R9Z-_$9YKJ]J#I4:T<U^
M,S="WA8@.:*+D9;,U,T+35B@D@)*_'LCX'\&OUSYBQ?&=.%:Q><X#5_8_N$J
M)AJ[XR_AX/PVQ;GR"K0Y.=!NMR>\QK;7D-;^_K<78^V-(R$O7"IZ>%7W@81.
MB@==>4=0U3I&`CU[)O^B]Y?1V@O+\E')&GWVTM03RM7.<SO/9.-_%/@8MEUE
M203Y++^A8_`<<++[.DG..=6]G&EWG.@ASC/,OK(O!!XPX0D)6!ZOM"CW.-=&
M20[:`,FWC-&&3(L-[,MQ>_2V[.*\&0=QJNR"*8*(_!EL:SJ"1YME3HK<[M7Z
MS,N>+Z/DLRZ%HIL$JO2)'D:S"(JZ/4`Y%!TSPS+U:6>(]>9$2CX1=LK1;9J\
MA`$.3O>?,OK^:17J7/K$5>-E(S3!P@$=@2T$`R$?K!8]>X%84@:Q*+6(3&[+
MKM#C'KVBO1&7_%M4!^GK'ET(0TX%_VQY_Q=T>;WZZSVZO%M]1*O;B[OEP]7-
M+VAY]G#U*WOC##!*N0S^OBM>*WY([C#5@##"C97N(9E&R><9"JJ,\'S3UJQ!
M//TX``6,YP(AJ1Y<#44]VFHPU/9^R9^/SRS!365:365<N+CTM_1GG\[BMI[%
M-Z]VY2S6FV6O&A;0V)WC+8$1LB-5FB6S2=(\_*?L_H`1!8SI,0`A6I".YM8-
M@9:7EA"*%`M$_A5A^B-/OA+(V7-/1`:#G4__":6>XP#R%"R!!G`32>^@GWI$
MC^EM8+(OZ5(256.@C6,GZXTMH[2E_<UB!QOM^IFT\<FCQS>*=7.8).->K`L%
M,PL`OD"D"D;:4MU^7Z$G"+O/Y#(3*=J>U?H\S/ASOL0JW:9X$^XV67W4K'R<
M?F!G<`_L#H=^^/IN_YY`GN8=RJ;TV5N^MKX2N_N6AIVJ'MD*5?9)DR6J7J&.
M=B>=`^)#G#!O-BS3*E[QO(IOWX`KMG`(&F;;)`LYT&668:7^:FC`4RG40!3Y
M$VT"R*0)%3?:3(F:D&H7)W4@-\(8#]U,/U%,M,J6%['3=$^*PFH=(EH:"9]C
M_E]ARUL\.*0O363<`5BUHIX0#PH8&5)#U#3JQ9HD#8X3HE=E%]_2?(\ZB%-T
M,W<$1^LPCT;*DUEH00(QN,)TCRW.0K5MT-S70YADG6;K\1WV<?A"3YR-9TA&
MZHH"JF%UJUZ;S@&E4S%EJFXE/:H[@%K51H"K4*1*%)"*1+Q9^B[>.5YC6C:D
M3(Z/^<LMG>[@T,Y<4;8^T+O5SZ2G:15RC.B:<]L2YH*TNA;'U@B>_"5WV`#,
MCDUX+BR!M]Z>&A4:'R:;UQV1AO;S]<;FK+LS5S2W#W2SA;.K)X>64CV;ZO5G
MRVGYJ0"G%MT[N!LJ#H`]S@0)"X>Z7T-"Q-R)$$>=``&1^`"3$FQAUOB1E%</
M=`RYE*,SUMS/G1R7,^EPKN1T.9)@:?KCD?9,&').)_E!T@3YS9T=.:6C!I`-
M=+6C%U=T5LMB7]VM.G0KD7`R^(?YS5<WOU[<NY/?3/8DA0>Q]/^Q"U/\T4M_
MQ^S*TSWV=VG7BFI("Z.HO8")NFE$:%T=>W#5C@(5M-2S+:A138YJ>JAH]"AP
MA)]G&FM/UFA3@\J4H"SJ5IKX&`?9)1',>X]M_#]Z.65KOUKWT;/^_0#IW%#`
M#?WKVXE]71S&H20ZR_OAQ:QH3RR\4_9%)=J"FIH>S4Z%^KY(B'!,6=MANSNR
MTJ>A3VP7]02,HWV'9*[$F.5PNJ/)31IW3GQD?$E2QXM3V#!&:47`=E<.G.H8
M05`<)->TS+-V9X5;K6^+.P8ON/.HU830C35,#:EKT6I3@:]2*I9,EB5BKFOB
M61+RAJY"`U&YDI77\GP)FUN<YOM;PGQ.R[N2W[*RW*:N<T<'CFS$M!`[=V-*
M:O@MF88UHWU9V<<"L5X6O-)PV9$S&[3>4(M=&JO2L"V(>4%B%387PYBC@T7N
MARW'A2L=#E-.%YYTZFBA'U)VM%`=)[P13QG(+TJH#I\M7(:Q%_L3G"UT=N24
MDAI`-E#6CEY<45HMBWV5M^KP*,X6^L,_/%NXO+I9WIQ-<+:@>#=3=+[O\%.8
MT5M@P3GQ!_Q\M5[CE#"_6@LOTA//X*^\BB2M0KE:7V79CF#$[/&"@]F9902`
MESGGF:3J*<]IN[?[]N<<O&LV>O4PB(^#RH%8O3`V%'_CGGFCY6@L+8@T*`=$
M;$20=T8!)BVM)RW@DY8(D[:+0UJW..8S%)8SY,\V0]J'3)V;(I_+55;)U>=2
MKJ2S!OB(J?E:-'HQ<]^M&N=..>Q&3><^.;7WZ8?T,*T*K2M\+FQX*$!BE^A_
M:#3EQ8MHQ.66V)0D.#P^4$Q3ORZ`W@(;`+/Q3E@/>OMOB/5FKNW34RFE2P;[
M0>AE@7@_2'(H!/0$V7BT-Q</Z/SB[.YB>7^!KFX0V]'0-V?9#Q?_^>GJU^7U
MQ<W#_82[F!MZ:HU7Z]-=%L8X4\4/-&T!=A8ZQJL]@JJA76^_FXNV*+#FU#DJ
M">;>JFO]RL$('@L"2,>NX'U5O9&F6ELE#8$<-27+#8>LU<J^XZ5@H4,BZJ;H
MMP?\)4>GY-O_#A>"ZH^@5`+`ER/3)R\N2AC51<!Y*<%;,E&E*J_6A6/H175Y
M<$V4>**^@5ZGG')B&N]93M&Q_1<PI^.ZI0^G7A9F/!^B[HC[:TE$^$B*IXZ7
M=+__Q+ITHA3]J#FAU<*B)".&@)HN9KGFF'KI,$>H41W3-9ER2<8X+CU3`FB_
M7"D,LT"-@<IZ>[4F$LVL!A,?AZB'<V+]M31U4FL%9X3N\`N.=YC>57V*62$U
MS:K<10!C&/001!57M[:NK#I66K)3$""!PHF5[#XDW*Q#GR8>\>H(8?QT2Q3(
M#W&F6Y],B8%*,_>"UBC5;$1IOW1S#[;:%P5J8E13HY+<"3L^"J!$PP##SZ+[
M*GBOYKY?KQZ`@L_]039BS^;D]D//?7F3O+"EVL`XYCQ-"I6L:LNG%&/@\A:7
M7IC^2E]>K4'H0A;=)#`*9@)#U*BN]M952,],2Y`H"6(TZ"/V*`7?;KC@*%5P
M!,ZNXNVNSWZ^9Q_`0M<'J%0*33J`$TMS[CKD="$**N+]+%RS\--";JCFA`>)
MTH2BLJ;;ONM8T902X)"Q'ZCJR-&,S.X!9!^>)"Z"/#4051V`'T].@:^5HE8_
M]S[H\'*0JJA6H7ZDSBF+=,WI0^>2NNA=:KV^`*XL5A"Z:`8,44UM!Z9[K:E9
M)_5LE])'V'5/J>KIX-Y@,@)T^-Q2)Q'(RTH&'$D?4:*5:P5")[9*K)*VP%2/
M`T\32J`S3'-0C6-)/9G]DT93GMJ'AZS8N2AOCFUUAD.3*)-K#V)JS+2.R*4'
M,KL,=#>%(P]FZDUS><)RF:3<RSDY;;VCZ82YKG6$W>JIF+O#$:UDP&[QU)-0
M%2_0F/+1O0*]=SS-9#3>1![7I?UWDZ?@MUT_JEXH^%7!6@F*COFMP`42'YVM
MBGJXL+C,,S&"J5AWF`HX^W#AI3'ACEY%8.@TRY"Z.8Q&Z]@75575UKH.=C/2
MDB%:G9Y>:*FNX%(:)Q:70R"Z9:.CO1OBTVGJE8W!!4AGA<KV3(H*\7'`Y/:%
M(54$!PX->3&UXN0D6)$EPR=;?(*,Y10:GQL:=P-\=-@3KO3TT+`/N`/$7@QV
MGB'RGLJ#M0`QGZCH#/&LT]\>6&U7!U1R*OQ57O$A>B]'PFEC>RX<4&<A2*#"
M_RE.'C.<LA<=V6%K^:9,R-PY8Y6?="A@LS##M$E-QX3CP)F7R4%TFB`QIM=A
MAQ9('),G/*#FJ"Z:*IMS2;>WVK,LBZ%$_QD'.UK:M7W,P#Z4-LF[1P=`(<;>
M$!OA1F-J^Z''GJRUD[Z+#JA,2D^+G%'5T5#=BM]7:%KQH.5G+PU8D&>U95>%
MJ='@(>4LVVWX[WHJYC2#0"OOE%,E5_`I1@`T`M.QWVDH)/%7Q$9:%-D:Q6`+
M5`V'A/&<-"HS3ET]"9XP":PH;)X@WXO\'0T/HS7U$%Y*#P%OME&RQ^3G@L"C
M#.%@PBRQ&OU%,=@R#FZ2N/R7XF`K8F.PVY+%59I_DEEC96A8A+O3-MD<&"!#
MS>J45OEM5D:UFQUG$5*GK2O'8[E:9/SZ%SP&*CFRK9F@'=1LE`6E&",.&$'P
M>6[,;4RFJ[)Y&9M;OL+XXMSB+_1G0E$Q`),$Z(IXXOY3Z#7$,ZW%<\O%$[I$
MIFQ-%B>1_39;[O+G)*5\?XH#G`H+-7TC(3O=7WS!J1]F^#8-?7Q'[ZP-<9>G
M'M@=%WJ>*=6YU=..ZH2K/0<D8_=;'+Q(C,A0/3[:408:7CE[Z(2XYH][5+*!
M&!^(,>+`N@0^V87#CY)=GN7$L+*2I?3M%-X3FQ\^L;B<P2V;078UU@7+N8SS
M,`BC';VQ6[\0>/'%CW9D"T'K-M.)W)5%3_J>P<\Q$+1EG'K*%!'$B4:9Q?)I
M7P.;"T<[5B=T+[S$B4Z:`89&#7GKCPQ:FXU&D%8Q,^5@O%RZ,!S;Q,AR-W1F
M'L)N_16'3\\Y#I9D>?">\,UN\XC3PO[WC7GVZ@O:^@P`+C<P/3J"MB&]66UO
M(-=K_A0`.I>H!)%]]FO,:C@G&ZS-^[%H,L:#%ZU"V1LJND.\O\I;-`DWP->^
MR?@>VE?\^8'\E-'2\<3R+[^$J@*[D_7N5LV<@9-C4D^G9]?.U-H9Q+=Y'9ZL
MC/F=^,I2/>(8Z#<ZRG'KU4=,[<9\WZ'L_VAUJSE!$VL7[_P8]4ODO(^&+;F&
MF2K8>;+QPOBX5>PZC/%5CC<SKE_"$$>K:*UIFEC7JOZ/4=T.F)]S3:-#(3:6
M"[6U>"HPF:CNA#T^DVDSWY@ZP&8IRV/Z=R*Q?OP$=63<#^\<.A5_+.<F.?I4
MO_2YLH46IM(D?D!%8_'QCLV5\'>@@M"'##;J/Y=_M%_NN3ERN_8L/UL!WB`P
M+CI=_$8+P"^L=K.%/\-\Y4Y7M_C."C_53H1M+)?VY/%C&(>;W:93(@_:P,BD
ME%%1*AL-K,NE9/36-R_:H-]X*R#9G()3B_+I?='+9[,-D'S*&&W(I]C`OGRV
M1V]_==X&6CXGX/2XMD6Z<,3$8QSO]J@S(#'I`$>Y3=*%)";?*KD5F#C=5S_^
M)<0ID<WG_35^(2*NWDR9$@/KC!$TJ3)T4L))N0%;G>);$8%OZ&2%N[,V..[H
MZZ;%K`]W:LYK@>IJSBL[<*+FO(8[X[<1A-\+@@NZ0YT6;J/$?K;H!QA`5WEE
M?69PWG5N+3HI@/50#4*J=>WF<#JFXJ5+HS@-XD3`>Y3^0/YSE]#D()8!G1$L
M:.FS4Y^/7OH[=<1>L3[0NV]=VM,(Z-[W5I/W[JG)^WYJ\MXA-7D_1$W>.Z@F
MW4!X\>+50?622CW>NZH>'WJKQP?WU.-#/_7XX)!Z?!BB'A\<5(]N(.W"/I5J
M?!BG&HK[Z1^3&._Y&G6YBX/:0SR`I&L,<`]<RWIU=UO9TNY]:PT;[2`H;5\X
M$(A1B(XWS*7<81@V',.:8ZB+,+2NP,ZKEQ,A`%R9RGI]5W&6I^Q+9:O/,0[8
M2]K+./BXBT,_W'K1+\D+3F/:8/48A4\>S]#-5>H]QP!`Z][D4]18)B?KW?ZJ
M.C'K'<4DA1$6B(VQX`_7LT!S-0ZJ!T+"2(MF\4F@I7ONV:IGX3%QTZ9\NJ^A
M$<#+)QS[^VFL2:^N';,C`Z;%R(+TZ-<=V]&;Z9Y6X].]:"2H]>!#'(^]&#]#
M9`Z>ZCE(:E+`1\S8X:+D<6'%['2T!WJT3`>@\5B9JK']1\JZ.6G?\6;M&^'Z
MFF8>14ER+^I2E+X0'FB'M*H;.\W.A<V#O;<\)5GMYF3NO>%YF(-N2N/4VYT=
M&>-&[W9*D\#M[*%'(W/BA=MK15)3/U+GM*,%RU!#KJUG%O5G:I"F7*MS@%Q0
M%T.(;CX&>YLF/L9!1LN77&79CKB0_%FK$K!B$36@@_&KC`&)_I66R+J?9<A1
M2]A*.EXAIJ0LWEJK-`UFAS(-IE#`Y(NJQ8MUY<^8%<;QXOT?,EX?\412'W%+
MRX8UM+&L\C5/B2&#2FCS3L^$J_(=?@HS\K5Q<!ZFV,]7ZS6F.9N?XC"7KL4:
M`H`5V`A"M>YVMK:[VAJPTKX(5-$@3H1**L3(0$K2#@$BFK.T!A5P4$G1PX)8
M@KE0:5V%D=_G``I',J5'W>3JEN!_]HJJB3(XG<T!]-:`_4IK.]K:U5DM(Y)7
M4IMJ6M+PY"Z`(\O!$"I)WI80>!'-+5FJJ7##:.G4<``=^+/(R[+5NMB4K-([
M6B.L*C16U4D[\Z((!Z?[LHYBT5!9GF1LKT`52::9C$81DG%=PI3?FX3I=BSW
MZ8FLNO00-:X*SV6\\!S]B>]O7[PP8KE#>5(KR2ZC.O,9JH;G/-/!>A6?^4I2
MQ`@68F&^NE(A[YZ69"X'J"@`#U*D<].HIES]<9#1T';ED*4PA*TU#YI^'+()
M1IRV*W(V"V(3,7=+M8>AZM#G@QKJ=9N1*JQPTA]PNJG9_AOV4NFV6MH,P"GO
M8+=RQB5M[#KA2@;:YWVDI?B)%XBU!MDE]^?Z<\7U?C:NM?[U:+:GW/*R.BBK
M]<67+?'@<?!K$A&^^65DZ0Z^JSE$J$K/?AVH4K>U'*;2,:*H5D/+F!<T2"2"
M"5'U!E'Q_E*V;3WY:BD,-7S^<0O#P#<T%>IXD>7AAFPB@KLP^_TRQ?@JIK&O
M++\COY1AT1``J*01A$HI.UO;54L#5MHR7=(@2G2R)E2H)$.4#D0WQR%)*R1A
MB22="XE65V>!`AB1*I[@O?<B+Z6[ZEV:$O@*_UW5&"@IKY/U1D:>M*7]=+P.
M-I1O(Y>M%ZAH#W7B.8A[\1@77,AOTV2-LXRPXD67V%#8E42@0J^!(A%^!064
M$G2RHQ0GD0I1,E>THA^<!HPUAGSUG%VP;C_?WJT:.B(8U3"#(JI&-X5UU3!A
M1W%#OE00@0Q<-8;#<>'=JW.\QH31YF.Q=4GVOX;Y\U4<A"]AL/.BUE/EG:7-
MIQX$^J6L*:=*_H36%",`ODPZ'?N=3TZ5PQR\?2V\(_"9C(3JH1:-ATO+X>!+
MGH^<K]/]0YC3>:\;=93\FVLP&*V<=^I$[9QG).M:.B>,=F+*-!K*G@IFXU*U
MKUN#%S]LS06=OCL<\0N(S^'V(;F(\S#O+G_8NQ<851L(5M2AGEU85XY!_+6/
MC9BDKAJ22CM"8D_H(4&\KU&%`15Q[)LDOMALHV2/,4\.2U+YPVK:U@`1;#WS
M5?A:W=1N[%K'1TM&"`$J*5!%,F]!)EW8>@B($]L@M!'K02APB2(H20!CU/*W
MYH55\W3?6IB7G[V4[#J["ZE/T3'0YFNR*6ELN$;W:G^3-1'+[8V5X'<IO37B
MADG\,\0&&%T.7;&4R1'?TBM2,O7O;`ZPF!FP7ZUF'6WM+F=:1A3B<]H6'T8$
MLIP-!=&^D+<0<HJWL^'1KFPS`CK&U6ZU9;[T+RPUZRJ^Q6F8!%.;3<4@1[8*
M=D[5)"NB=(3C61T[V)]^I5R@8K@%X@.BD-A)-N0"W6!ZD0==)ND:A_DNA;OR
M:V4RB[;HB3;&P?&:H=4NSW*/;/CCIZLX3\,X"_VNXF\SCG><QDD[@5/:*>5@
M1V>R-$AFM5["V`M4C3YCG3D+5JOO?-;WSL)J`EC]+9:N6H85DL+,)77OP*;N
M43]%CXHI*BZ<T$.SYA2]Z_HF,PT(:.QFG<*6M9ME-!AS-R.46>V=,+A;]L[F
MA%Y)S%S=1VGICM>1:[JM?\7T_AP.EN13>$^8_?&<6'M=;5_K7!RGTS=PLN?;
MLFI9.#H'<1`^RYO>DBM4L,6;(,K8W*6+K6^$AWZ!:HZ\8H[8EODDH'-45WT5
MJAV`6^+R&.X>IR^AC^73>)/$+SBC\T%G+&/U;,6_GR59?I/D?\/Y'?:3ISC\
M)U8%^68<#\:ZSCZ!HAV=;3#K%G-F).W[3N4NKQ@0J8SE`E6C<J-(C"$OX-PP
MJ71HTC)'>YRC>G0H\V=[.C_1AY:+)LVZB#Z=F)@'2'%UR6RM#I4>C]=9%G&H
ME@DV@U8BB69#'Z=_V6=:IW0J3<8].D_2')2-73AN>)#<C+JT)X>9Z(/=>=:(
M0C;\PJJFK!.'+K\D29`MXX"L([BYWF0/9-HRSZ=,TY(!<:8WA#U[@[9M@\#+
MS56OK@`MT``^.XT*ZX^53!9Z+!VR#`E]+E#1*[QUF&(2&MF+#6\)RV$>@4]4
M;8676;;;<',EJS_P,8S#S6XSM17N/3RT_;`SO9/X1SW'/AX?:1"P.?PDX3$C
M@94%*Y""+EL%4A:HX`C>'(+,>/%7TZHK7Y/U]+Z`6L]R^*_5>C:GUZ[UY&-_
MA=93!.:&]>0<?;W6LW/&B[]^Y=:S5:EN;]G[U##P%5A0HRF>S89VCG[<5M0`
MFDT[VBZ@N?\*W=`ADUXZHNKJG%^7];3G?6H8^'JMIR4/M'/TK])Z0GFA'=;S
M*W)#ATQZZ8A^M=;SG%:2P'$@*41L<=ROR%;*)G1V$RD.^G58QC8B$(-8L@%2
M]!EZ@LLFD/DO5?$WHW2A9<1X(3^MUG5"$#_LIJE"AO4$)QT+NJS@#!,GKRXX
MX4"`108G1]%9:[!'CE\])B6L1RUR55AZGP-%!Z>>R=/]'=XF:7X=QKBC_.#\
MPWX=>JR:SCE5^G#,H]=N.2"KBLYJ%W(N$&4#O&;A-#-;SVMG:<.Y!G,X'W_P
MU/5.QN\]DIN9^`-A&*;AHU/)OJ-6W)5ZA6XH[8@2C=.H[1W.,!'5YV4<G.,7
M'"5;NGLH<L.DI1U[4<(H5`]0HG88D%D7=6.>)"^L<TI$2)%`6^8I@A6%G!":
MUQ.:/;WZ!<<X]2*";1ELPCC,\I18AA=LHEF&M#"ZU0N8J%U&A-;UJP=7+3$L
M:)F"-:F=T;$IX'G]X1V;VWFMJ7`Z^2C'[&BV)FMZ#_,:K!#J+/R/N=II&/:Y
M'E<D=>K8CWS>V&^SY2Y_3E**X5,<X/2>WA[B-Y18S<G3?>,I:_9&IUG8=IY!
MH>,^<TZE/.HSQXB`,9_YX'1&?-0JS8=&]=AH1P=';/3B0B(O<,NB/`</L3,F
M'(CS#I_5]ISJUM^Y!G/IW'FJJ=,?-H\=R9$3YFE@&!\K]]-;N=*ZL4I/.9LW
MK.#S:BW4-RQN&]OXEEVC?P6ZK9_<V91=/?1Q:[\.ET5SL$`W5;5T@9VR(H%;
MV2:VIKLLW-RH`5O/$V?#M1JG`R>G/2D'1;P:)*?X*8QCTO;4(]WY/:NB0K'H
M4AU5V,^DK[P*PY\CM5HAP5LU^A)3+ZE4V*1=H(IS5+#N5F%8I[Z>=`W1S##:
MTH](47QECKE0B!?`,9>-_A4YYNK)G=TQ;P_]=3CF*EQ`CKG`SE?IF!M/=VE4
M&\7*OU+'O#TI7<N2%4>\-TM?@>,]\#/,YFCWY.>X'>M!8*T::8EIUKIY7X77
M/,VGD1KT8_"2JX.]99R'01CM:$K*/?9W:9B'F,R7'^T"'%P2PT0G>Y<7)_47
M7DHW#]DMF6,*P>Q0>9I!H`^1IYPJ^:'Q%",`'A)/QW[GH;`X#*K'0>5`B'Y`
M)`S%?-!B,)KR460?@Q__CIROT[V\@XX;/K.."*.?%B915-89A[.NN;-C:;_(
M-HWJLI0.55_0EWCDDW+C;;JOX^C)7-*O-AR]DM0TCDCZ(4/&XDH)';AW(GBY
M66<RO*PAD#>E9+GA$;5:V?=J%"RT/1-AKY6!YZKW9%OR]J4#^>@CUR5=(MQT
MW;MDD8=/SX3N#5QZV[2,S^6X.)*]-G*REIMD%^?S?(BR[Z-4K>;$3*A7O.-C
M4RJ1Z_FV`GP4J`5WSBGB#^=XXD1EU1!PUN,\3+%/^NYT.0\;P>BSG%51,9LM
MK&N8;'A)#2G>"-R[G(;;HT@&D=U:Z2J=,\=(1Y?DH9NTB1(Z5,,<4_)&-X:9
MS@"5%Z&`0V:39F5T1MEF&>GH]%0W:;,E7@&%_V;#(-=365V;MII^4JBI0D45
MT<9)YB['J<6T*?T$SG1S##Q@>QUZC[0`,G'?SW9I2DN,/M)Z$+YJ,]U%`&-U
M]!"H\2`=].!]%MW7L="2/*'Q`A7-R<I8$%CWN7OS7[(L$/T,&&+*,IP;2KFB
M+5`(J(OQ4K:-.)Y-K%4LMD(LK)TKPFS*=<DM;P\HPE7EY]/]1^QENY35B;Y,
M\3]V./;W';M!(TH8\>X!2O0"#<BL>W7&/+5$3"A9?KI'`C&JJ,'W1!4Z&;;.
M/8X1);#TZ4%)I4]-!B=].IZZI$\A>N".J@Q<=D=CSVD8/W4&?LU(W1$_%2R=
M_!W2.2&`<J8,)9"652VHP2/-(.!,],M/PXQIS=OO/[QE.D-_\]]DJ[HA&V*Z
M%5W&P5\]^JY$7GKB^P?\)=]YD<(-'M*!7?T9#I%J47]J:[HTE+6VT\KZ*&(1
MM-ACT4VU&]NC5T5/WP+ZX5\EWB#Q=U3%69QH9L!9!?AS`3@J^WD-O=FN;.9Y
MF/E10BV?T<:[DPYR$VX`J)%CH2.:Q:R8Y`B8,=9>R<+8B_V05L=E/93K68"\
M7'QVB<AEO;B=>ED(F!Q0H13"4"7;J[ABDW'Y*4X>,YR^T&L85_%VE]/*G`0P
M42FJRF=>Y.\B]N-=$D6724K?8](Y#/.-"^RSSCVA4H=WKD&A5-$2L"ZG-%FW
M%\M9UL7.S*Z!)JDP1`*<FG3N==YH,P3W7861:T.]:IEF)`Z/V/BHR0`2.$"4
M!53P8&V_L@R"D([N1:-W+AU=.;>'T<(VW,TH^W%I7Z-A<I#'7_>)CF.S\Y5,
MPL@=T,!9F'HOI#)5Q8F1[Z<['`A6MM,HZ8D@S(\IE-K0Z"@LFQ0S=M1G>IRP
ML5:"Z\9(3%Z!*:HI6^)OQ]0-!+)L`YA0?:]B/]G@ZR2C.>^%'6*9[_*[PQTZ
M/;0G`$4?![K2_F'=V#4)8WALB2+O#-'>V!6/<KUE677J"]^@'L8<$_"*=O>M
M^12<-++@,O::4K'*SU-J36M59YF5B,T*K9_C%RX(FQ7%#9DIG1!B(^E%';*+
M(WLQ-M>M;$B#K=*07@"LUW"PE>7JWX5=JS64/]GB672$UDF1C'HBR?]UYO3G
MZT6NM4ES06<;H2)GV1<ZLVR`"N,O5.PERX!0F6RD93+OWDV3U7=Z^M@RT[Z=
M,W+]&#>R`;+;#Y)JTBQP()8?=-\NSC!94H,IFZUE<[:^==:"3CM)/,;4-JW2
MRB54HG`]DF7S.]*\NFX^QYA'9\W?1.;-?=,UE6E23D'QFJV[=@G0I9OSDNR2
M;O*?6(KCZ;YN<NOMZ:^6]-BP.AM=9MENP^TFL<D?<?Z<!$F4/.TU:4)61G;I
M$NTLDZJ_5#OIL%`9%M:@=:GP9:<1.XT\\I=[_YE`RJJ;HVGH4]*/28"C><Q8
M5P(#W+0IKRP+@]-K,F*[@@'$.!"S000FF,LJL-&Q2D(_<=">YD>3::9KGI_C
MX`&GFWX/&$PSH$O/$TPYA>4M2WMS-XMJSPW!^.Y\0Y,?]XU7E1N:O%"H\@*5
M0R,Z-L3M4:L36:'-20/T:H^]-&LM"?:,5OG2??'0O6*IJ-ZX7ZWK%^[Y`_?L
M??LS;QOF7D1_VUG`;[;18,S5S)-7VBI+LS:;H9IOFEK*58R$BJ$Z'GFOQZ-9
ML_6(B`^)V)@+)(P*5`W0[@PV;#OF&V_77*J!M6&TCQG>87HUEOSY+(F9,[FC
M66OIYGTO_PN`.Y><-;"/T^W9@7\5RVX@Q&=P[Y76BELDL.N8G^G"ES)[D54^
MF]?A&J-788R.PI6]2>(7G-%9H@Y\QLK@BG^G"^5-DO\-YX=+Z&62%K^B[51[
M<MM,..SX3C[5O?SAV>88UDV><E)'>,\5&WQS3VPO+RC=<!\I+Z1E3BQ#+GC8
MB]+%IH<A`DO..M9SSOFG.*VW'HU3:)_TND"?2R/L%49X6\]=6G>]X-;W"$^0
MV/_]2J:7K"M\TCK#G9,-<61G0AW3U'!\9YJ?>;W7Z29DAK`E/X<H1BI,%YCW
M./-,R;)A/&&F7HI9X$8(W.@4:>B=-:,.VL"HO9314F\[.9Q-\0Y9.I2'\O;A
MK-6:E,6!>W`(]S!6+R;=>@9KL#$I=HJ_,G_H*B[<G/(<9.J56S?:D2WB9I,W
M>CWO-VON+>W::9IAE:]B2'Q4%,;%4B^>6Q[5LM][%AG.%_K'C!Z)%/N[3'S,
M#[`,U8L71C3SEB;A>9%POTM2:$1AAGKV`52>:@C0JG;T&(2S&8*^D%K)5R7]
M"=GUGF2D!^%^XD)>,`:D"O5(G&=)NDU2+\?L"B(-^'H1VGK$V5YP-5R@QR0.
M,I:,'B?YI'>I*<.K-<]OW:_6:TS+RIQ%7B9[\]N(`B#7W`Q$E5[>W=QN1KD)
M+^V%S^//UO-S$[+"E82(42H*35M)'!^.9U7B.;6)1YL'/NH#9>4'2DI`/J6<
M\AJ)FC]I16]#&J>4N%W%VXC`%47N?IQ&I\IS/M(S7)GUF+K4>4Y,(Q3:Z$--
MJ=*3AL-HBO8=/340+\IU1\<4)*#!LDX8![$S(_[G#J6I&%:&A*@;QPG$@_=9
ME($';"_B0!/',L5PZI%_^AA=S,WR?>ZE^<1,G^*G,([GXMLDIME75``CFZ:L
MUM$#:AP_*QBW9PSODKT7Y?L[_()C96#RL!&,P9.S6IJX;AYG,VHMI@X_>-$`
M%2T@1-201]`7K>]P1';TP2TQ8_L'HA.9Y_-[5-WW(O5D0+)J"*>2WIXXYI-G
M/>,MZ>$DB-$@@<B)ZV8J0'6(B1:<.24<_-Y3QJ0]N"5N'2!UDF>`SKH0RN$8
MRV/6J)1-NT"L#Y`3T9DP3A@I^07'9%^(_>>KV)?F#BA;`41#U,Q6\8]V$[L1
M#]7XK8];-42D)=BQO;,\:R,6_9E>H##VIXPR7N/=[W@3>F17<+W?;)^3C7>?
M^"'.]VI-TM,`Z)4ID$K+=`1V=<Z,F_9#Q`49BSV4A*B@A-7(XT.DU=<I($4E
MI(Q33EK^/(E(7_3(D:84/*68/V=G]#"#&27(.PQ]0`G/+IB0V7YEP9PGR6FR
M0(QJ:G?*A1XY/(.7$2;#YU744^I_$3BI;RU\#".<Y4F,BT2B[#KTZ0U@>11M
M8!\`-F$HT,HZ].W`KIT8QIUD[\7^*EZ&KSHJ\^4R5'0%%?>;`[!P!6=3`=Z6
M@+T,107F=$;,6G-B%?0!8L!3S2+(6Q0![`[D5XU``_D'K!X$\A4\SAW(KYE2
M!?(OY-4>+`;RU3RR^A7T8"DMF"WD,F-BG`9XT@?,O.RY4*F'Y%,<$N:S,-]S
M[4JD6UPM"80C;`:C]H"[VUMV?4V8:8L)H:HRN_,$U82HI(3Q=(>CV=9H=C6:
M:$XT>L=V+CA3.K=MOC)UB*JC,8#F:EFO=%;9TJZV:MB0W'INZ27<-:XC0:#5
MRA$02OV#S%X[QVGXXM%W=JJWJ:]BLD7>%:YM]8"8^86/<5W"^)!33$/I<4Z)
M?S;_="3@0ZFNNT/U&^="APOQ@4"'+H],/`V\'(?P[!Y]UWU=Y6C!J3GU`I9Q
M0/]S\8\=@1Q1?)U7N+M)8-34!$:IAGWXGTW--`Q+G35Z_L!^$"A`;UL/`6'"
MNSWQOV*E9#9:F9>T@Q%T)<.E=&LYG4VD9:RUG_>KVH!*[E2\6BP1X#_C8$>O
M2`A'$2]8N'E,4X-OB`0I_BPF_SS0:Y$*49]C(*#"`+--65438/:YFDU;9YF<
MUN6<8A`:*FP,(Y8"X#<OR$@GOJI),[ON-S8<H"X^D`%6:X$_R9U<35L8C>AD
MO!1J(XYGDTL5BRV/FK2C8B5*22E'GE)RI!=6+99-:&F7)U>H3F>D=R]`I1.&
M@:V*)XQ#.9N`]H?5*J`@LWUJF57<RK0GM=46]W2_S#*<J\H0&+2'D40M@%+F
MC#F?3;JZ6&W)$6W0>14?0$884T3V/1H)"5;Q':VZ0>_CGGI9F'V*D\<,IR]T
M`;^*MSM6HC/VPRAD<501M/2:_/S#`4OH3-/7$O"9YVU^_9A^HJ17*'DL\G&/
M&LHVPB0K<[^DUS0,<C]-*4'RO/J`$K*[3,ALYW29\]3CYIHSR9_'CL\@76L.
M@%.>D%]EV8Y>B*<[\LTFB5DIC(>DR"+#TJ)/>AH`M3<%4BF\CL"NJIMQTPX7
M%F0\UD$)BT(K>8(J6A#=G@"0SP%E):!H5D!:99X3$>"9^RI_QNG2]],=#H0C
MQC/BV-!`"`_'\7\H_.)>/<"XN@-`EM[K"'2S.:3]X+1>>J'4J"`7C\(A#D7&
M02E!1&H0%A^?^<<NS/?FJ2D=[8&>=-$!J%Y?,>5\-@WH8K7UI@EKZU">1Q_F
MFS5UDAB?Y.$&HU"QJLQ^,Y`^^T0VO/RG+`PP__MMDI-?A5XDY(7*%M$).G7F
M/N&`J=!<->S1HPNW$'NS:WJ##]4]HT;7J.H;B7G>#EU='#\G%U'X%++5;$]]
MQ!3[F)Y,^O64^$(6=58\FT>64>2+'+ETWW%J0:FN0C9FI2$HVTI0Q-F"S&T-
MR9?,5UO&('V1+\N-KC49T`%EJ9H"JE)1^R*9S7LP8;V55,IH4$7$GC9;(!LW
MISK+"0[!HKQ*M6#O_GCQ'B6/Q`RQ^!.Q041[%+<U0/8,0R'+$$]9?9DZ8'2[
MCX/S75J]M'2^PP])^7CG:EW65)19S[X]0%1F'@2RKM/<B]QRU>8!O+6SCUAL
MA_>">#?E6X>D(ZI%U6.V1!JABGM.A[>J9(L+BGD>1M-7<I[NXX7\XP7\XQ6/
M+0;\XV'AXY4%3@&="OH>3(J?B<TCEODJ)L8;W^!\M7[POBC<B4X*H#QZ/0AJ
M/PR:6[,7QKQ(UB&!`G$21&AHC71"9=L0#`?";Y?X#3A1DDVYH"J*IPPH2N1B
M-:*^98B<JC\TM#(/](GL%'#F*<1SOWLLCH,N,<YNO3"0+G.25A!>H)+9VM-K
M-;'LS2G&;R_Z54-$6R+:U.XVKA^_=SC#Y#OQJUD!V<9$R9;%0C#?_-!Z&%&Y
M<Z-AH<OSY1\RY&VW:?)"3#8EJX)'172)/R9]D=(?GX!JVPSY8&OZP;:DZ92:
M2#Q'GS+Z1)\&:3&UBJN*XA=>&F.IFO;N`D"'!\*L%+PGO5WM'\1<2]+J7MBS
M/!)#@<AZ4/6%>&<`QF,.N&D%"\\'2VL5YD"620P(_9"'B.<R*C0<GH:/.Y8+
MEESN8JT-D5$`FPPU"*F%:#>',P@J7C1B(Y+1M942`NOZ0"2^B(3\>TT($?W.
MZ/KZ'E[/IT!%O@]%-6VIW/*L:<6#X_2JC'R3(6T(LO7L8%G8<$I:V=YF*EF0
M[,:J,S^A,8`F]F.:GZOPT]JD:D\%=>/]7I==A-H7#YK_&L>D>^&S9WHM[2JN
M4F0^;9.XB-V6P5PI"B,Z"#WL`:A62P,BRUIJS%%;:!@I?5-=2,.BY.492'4N
M`J'(4^!:>[+7SV8^%]$FJ4R!K,)2IEGN@8S4Q)]I1\6O`%=]IRGM&#V.]G.:
MV/J"L_KTZ6]D>R%U'+K;`]@M$P"5O>IJ;-=.Z3EI9UT5)(C1B&>SB)$!6*4Q
M**(21:F["[2?#896<2=%PH%,&GI_]@AL?GC\D-11!OGUIZ[6$*%X+?-U2%[9
MU')H7L-'.^++",JL"N(QBS00L?J^`&YVM"Q#ZPI0QG&%%2YK&5;Z:/S`;U1C
MR02:22-I:>)C'&271`?$2,%JK8RD:2@@(FE&(.I(6F=SRY$T`U[:D9J"B$>9
MS@[B3U"1M"%(#GEOQ,Z0MTEV,^6CZT-HXS^,+#`XI>Y^]+Z$F]VF*F]ZO]MN
MDS1_2,2;TC)LAH0`FMP+4J701E1V];H'2RTI*FB%<KL%-5T(&A?9`=1\-F"_
MG'Y\@%'U*2"M*TA9#:E,'=C2#B;UL3%Q;.B-M2KI1J_T>AH(?]L02.UU:P@L
M^]Y&W+2]NY),N*3E@&I/AP;(RQ[+OR=^C=F4MWIE*JM?GJ)>!N4QEK^FH26!
M6*K-8-2+='=[R\NS"3-M8U]1B4^Z43I4$(*$I8>!X2D>[:?*@-;@L1]$>'V-
M.=];3CBEXBZ#(*3\>U$UKK$&F],"J')?8)5.FQ+:5>Y^7+7+8%3DPFN-+NG[
M2'R%XGLQ\FJDCIB!Z3Y=#<B"9>AU4?NNR!+66(SQ?3IS.Z/_1`PK[2#IT(7[
M'7VY'5_8H>P:WE;--"-+%AEL)MQG6^R'ZY#\RR=LA#XQ`F)"/\W43_'3+J):
M3:]D_QW[M$H]6(Z0!5$Q*.U03^%8VSA1W2>R.A%&LUN<LD,06@S67\;!>1CM
M\M;]`&,JH!I09F"J2E#]4,QBQXSXD/H4E(+>SD:,9H$8%5.[@@ZD.E1O*/3Z
M*+UZ2>\J5P>,E!2]>JP0!9S\6S@]^2L.GYX)"TL:O'C"_$QTM68@5[L\RPF;
M12UEO?H,[0Q&J\9!+Y5M&LRSZ>!@D*V:`D5'J.@)U<?GQ2FST)TC6CL]>*\`
M+RIT9J+1LWWDZI$-WZ>^3';K[6FM\Z)6H\KO*1K371IM#77#W3VFNZ:8EI@-
M\_*]C\K'\D-E_H5``5A$P#&F=5-<5/%ER:0=+)9EE1<\;WE19")-NAVOF.%]
MKV+\$&YP63VX_<8VSKB-D7OJPWL#V8*/!2]LOH=V97O;/8[/3C$M$^5(GXAV
MBJH:U'F"6J]6DT6%]PRTVYYX(FI?099,1S/`B3C&F#\5\#G,G\L[\B?5#7E"
M"WL5?B[IR,3Z1C30V*PE*TM`)-(1LYZG##[>X:<PRW&*@Z*4VWJ-:;&ETFL2
M\)-=$,&J>(2D?R\@#Y(,!2L\3M*W"]L/E0SC3U+;HNP(E?46BZZ$/4##U-'=
M.^T0Z`&3Z7$'''=2=+5`<?*ZE3A,-_I$5:%N"UK`75@=)7(;YH@R+H'TD!07
M&/I,C;XOATR3*7"M@=)UY(:9,N.RC[&B/:HL%EEEBWZ=LED#)^'7@PN/U,$B
MO6_8E9UML^R&K$`]K,$:_^4/S1:U32K;1;Y\,4LVG:D"R@A'ZK`'ARQ5-TAC
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M6J\U_=+SF*T2`/DO,\DB-LI7;:SOPR\&AFM<?P"F:XH)J(S7F,[LFJ_QG+:K
M\U?6B?[$W:X#^\4D773+2.?.F+`9IN3]Z_<_$"/VX?4/WP,;L9F^=^%7D9^X
M^W5@Q=CW%MVSC'SOF0Q9A8)ZE1<TH4G`2&TW-^+$E!+&32S9N`XA3-D44U#;
MLC&]639FXUEM2[=@J]CFD75[8-"8IU8X;72-IBKAC#F;85(^O/[I1V+/_OCZ
MN_?0]FRV3\[-%=M'LK3(`YO&7+;">Z.?G-J^>2Q:`X1HE0D^\AMNL<,O=`ML
M8,[&]`9@R\:#KPS9\*[L6K&Q?+;?<3ZP3@?.%K5?]->%/T;^R*(IKMBOR:>#
M6*WOB?'Z[O7W;X&-USQ?6C!*33<+)?RWA2-&_O9/^J%'6JUI+FA<Q2\XX]FX
MY_@Q7\8!?ZG\'ON[-*0/(RB>WAK2`<Q%C/X0R\L7P['-8J7ZLM024X&XXU6N
M,4'87;Y:\U<8E\'?=WRLCBAK5W.(,*J>_3I.JFYK.1"J8Z0=_]JQ9W&+)TIK
M(N@XWU`@Q7.=7D74LJ=V0K#S?PA[Z\*]_XR#7817ZT]QBKV(%B:X3K)L%0M&
MY('>DWG`7_)3PLGOB@5B4$\P*\4(T.62,0':V=:.8?!:A:B*7JCDUOT@VA%]
M4*FQQK#.$.T-L>ZL>[+3P7YXQK329YHSM#Y["'Y7PW_RPCAC5_2:;P)LO/1W
MG+-IR*HE&GDO7AC17YZLD_0D\\A?V;6$C9?3)GL4>#FM%D08H/D>CSC_C'',
MSB+H$.1?$?$G-TF</_-!&;6'/A]>)"P[A#,DRQ+J99+>$Z"UH\(OB^V27=;\
M+K=)QLJC5"7_-1[HI"/`&)X9)JDT2#/.SFR&:MKI:%WT;"M?/<`"U4.TS%LY
MRD)\T&3FYVTUQFW>J9K9Z$UZF3+=TGHB^#2)@^PF(>:3[(U89J]Z_V%`!'(U
MTA"*<`-20V'[HJ,1.Y(;:P4=8H2(43+QXEGTL-N3\:@>&:JX0L4RQ&'V*K8_
MD0O^QK(T9&?$CO7V)0ZH7?,3I.#T/D`G*H#U_1!&S[6[(D>4GE4)L5X9823`
M!@(7U>B7E#@1M4OQ"_$!J%O16Z&4_;BF6AK`>B4S1`J@;FIH/16/=23ZR[0K
M](IV-D^MFL$*:`[Y`(V+NFCLX\^W=79/7WM/RH1;90=TN@_\>;?&\SP.D.1>
M-.-N6':ZJT1D,1Y/-B:L1N:]CV,O#9/EEU"UYBK:`L74NQBOHN8F',\7%U>P
MV(Y\\S^CWV@#T,,9SLBGN*HF>YYLR!JE/()1MH<Z:-$`J(]3##F?\=!$S:I*
M0!9(:(U^X^V=.,Q3&TAV`*(]PM/20Q_<&0)L']?U1&;AD$X/I>MHKG,I+T[F
M`$7RH_?W)'T@HV2KM2J11;W"&5/#B&-/<*4P#D0UFRB:PVB_-T8H$2.ELDB)
M69"0DS<$$7@I-<#8N;3VH'=6%N5+[V!DD/*H7)I[2.11+-?788ROB->JW`/T
MZ\/=9;L%M,_2K40(NGR+D$8LX;0;Q/J9,H7S4_9+\H+3F.Z'5H]1^,0.Q#HN
M-F@(``Y0C2!4AZ>=K>T>G!JPTHY29J@F0@(5[.V!05!>H_O7(&BTA[\#O\Q3
MC26IJ4:G^V?8?TVZ?A.R_#6^L/"?#Y<4_ELA:UR5K=G5T*X*ZUENI^?;SZ64
MLZ=.N"<[+M@LR+X,M\Y-1Y6KRS#Y\L_T$83ZK:.++UM:;)@LCQ]9OE`8/_&:
M5VE'8:U!'8$4KQL!6:AA-Z`7VZ7L!K,H*7G&^^(/>PBO8A7=L0>TJ@Z1V"-0
M7;OIL(MK'2\?NO7B/0ICG[Y:,<_[)@:%[&;ZN.*39UCXN)OJXZ9"CU/>ZKWE
M#T<NLRSQ0_IT\F7@R:#+VP%8DBZ&*T,A:V37#J@Y:$E"T135;1%I#"/A`]CV
M:K;7@0>3O^?F;"L?;J<.R%VR]Z)\?T?KD$B/687':U/>EA@!UGC22_U)0*U9
MNGM:!ILPKFQ,U\U]#0G(]7PC&,(=_,[VMB_:&S`CN6--[_A1QX#0H28A^'WR
MJ0'-8U64^CD&Q?GR#^K=^1A-_4NR7F^\.+[V[A+_&5^'FY`8KPX][2:`T%(3
M"+6.=K6VK*%Z5MJ"@$HB=.TA1H8*.FCUG`I-'H#HY0#V.<.R:2]^OB:CD'^3
M?Y$?'KT,DW_\?U!+`P04````"``P.`E!,D\EYNDG```PO`(`%0`<`&-R:7,M
M,C`Q,C`V,S!?<')E+GAM;%54"0`#BY@C4(N8(U!U>`L``00E#@``!#D!``#M
M7=U7XSBR?[_GW/\AM_=E]H&&0$/3<V;N/0&:7LX%D@/TS.Y]F6-L)=&.8V?]
M09/]ZZ\DVXF36%^V9,F&A]VA09)553^52J6JTB__\[KP!R\@BF$8_/IA^/'H
MPP`$;NC!8/;KAS0^<&(7P@__\]__^1^__-?!P=\O'FX'7NBF"Q`D`S<"3@*\
MP0^8S`>741C'4QB!P?-J\`!?0#)X#*?)#P?])A]_\.GCR<<O9Q^/!O,D6?Y\
M>/CCQX^/$6X:YRT_NN'BX"#_V(43H\%1-_+5XX_#]5_NT/RFD/SQY\'YX?GA
M\='P>/#EYY.SGT^/!Z.[K*$/@S^?T1@#1&(0__JA]-'7Y\C_&$8SU/'HY+!H
M^"%K^?-K#+=:_S@IV@X/_WYW^^C.P<(Y@$&<.(&[Z86'J>HW_/+ERR'Y*VH:
MPY]CTO\V=)V$,)T[KP&U!?[70='L`/_J8'A\<#+\^!I['Q`/!H-?HM`'#V`Z
M(!/X.5DMP:\?8KA8^GCBY'?S"$Q__>!&,#[`?#PZ.SG"_?]RE<NY^.\H\+X&
M"4Q6-\$TC!9D]A\&>/SO#S=K,MP4#83EB(5R='#TY>#DZ!`W.A0;[[#IM"\<
M'XOE<0X0KF3FM]-1[40F"-U!,@<)=!V_]JQV1FD\Q<<$+6`LBW@\O73B^;4?
M_I#B&66`QA.[=Y(T`N/I11K#`,12<]KOJT"4,4043B(0(UJED5_9O?&D'L`+
M"%+4V0UG`92=4U7OQE.Z=F#TF^.GX`XX,1("08;,K"@#-)[89;A8A,%C$KI_
M(K7SNQ-%3I#<0N<9^D@!R<R0-U+CJ8Y<-TJ!5PP)@10#JWJKF%*8(E4=S*[#
MB)!.]F;$BB4(8NGE(#1<XTG?(#-F`6Z153(!42ZU.=*?,C.ECZ%GJ3PYS[Z<
MO)G#:,"B_`SI8[2!RUKS%1U4&T;E9\T;20]>KT#B0+\Y8-?C:)WF4-4\A]IW
MI!J,%1Q0@TZH,5G&(&UHA?QC3^`U2>7,\1J#MTB0'DI:)4%JD4H-VR(1QWJ(
M.-:XY=1`$'<H!4K2]YWG,"),&,TBP#]1Y+J0TD_!H<O'/B]T$$]63TC#QH[+
M,W_SXQ:EGRX>"<B3Q2IU,J10+CH_7G<%"^(%Q(D8KK;:JOPRW^#;_;Y"&W0]
MIJA,JKHH]46-ER`#9(Q,&:P((S!'NA"^$&W#G9_,4/F\ER7?S"V:9CY9/)PR
MUV:9)\@X`($'O/5O88*_='0T.!@4HY1_=`)OD`TY*(]))H^F[X?NUO`^]BZ'
M$8_G^#=_L"8]>HZ3"*VX8B"D*H"?C238[U!JBCFGB9<[!N['6?ARZ`%('/SX
M!S+]@Z-A[N/^"_K5>AY/:-B=>>[^^8^SDT]GGSY_.CT[.SXZ/1D>'Y^69EC&
MP"C:GJT3N<78Z,<M6.R[Y?,6ATOBKCUPY]!?"WH:A0LI!N:S"`6I"2,/1+]^
M.#OZ,$AC-,EPB8?;V*$Z)3%",_/P[*Y]9U8ABJV_=U\6?')R80R/3$BC(.D:
MQJ[C_P,XT37Z3<Q8(CLMNR\A&<(*61V;EQ4RIV'HB4FKU+9O\N*15DCLDPF)
M7:91M(6LKX%WA<R."H'1FG9?7E*4%>(RLC5E)%U#'YU4T01G8;2JD%1%J^X+
M292H0C[GYN13\F$23T(\3A,<98'#4:CB8G7JB_2D:<R%>6S$\LCF_`!F$-,4
M)/?.HDHO5C7KB\`$J%J+R-QR0Z1%CG^##J*O_POH"G&G75]D)$)6+B0C)D9!
M668'T>V+RG;=%Y(X6;F0J!O7+X>[[AT53I^=>#$1[\YPB/T[:_<4^ODR1.T"
M'.B(?HI#'WHDI#(?>Y`-/OCI>^"D'D1_^:N<RZ<,NZD3/Q/!I?'!S'&6&?:`
MG\3%;W9!F/_ZC_6$Q]-K&*")062<AS%D>(ADNF*9'I^>GA^?G7_^<G1V=GKT
MJ<GRJD_G*(X1MSD4;3>R9IDU9OAF\4E02M_#$.E3@$X'WFW&/BIIA*X7$#V'
M,2!MS<A^$H5+$"6K"5IX1$W]*X5+S,=[0$,"JXMUN!`0YCX"I"FD;Y==P\,#
M0)R"+E*YI=N.^S!PLR,O!1*<7OU`11TBZ6[IK@'C6QAZ/Z#O4Q!0_+D?HF92
M0S>[NB;3<3('4<8@[A*O;-L/:8N3QKC8Z)KL,WJ9QEX_I,N@A7'W(2?.)$P<
M/Q?F$AW;(G340^:A&<F6H@N1[4*<9_/01Y3&V(Y)5AQ#7[2[=>A0>`1HQ(/^
M&(-$,99X(;9)5':P#BV-1$S90\0I5V47)FB^8$_Q?#:N>/BZI>^`X)&JRHJL
MWGI.S2``W]?`[&!$PLY(>"]`FIB*"$:/OB-$EO0>&9_21DF'S!#%**EG?#0W
M:<V#I'3Y2S*2&!JDW,PZ0"A1%%P*^^.2'GD>S.8^<:!W$UPZ2Y@X-,<3I77_
M4"!#*.L(4I@()]U#Q@..N@^`]]6)`K17QB/731<I292X`E/H0KI_FM>Q?WBI
M23/K9-)AZ)2H)T>UK92(34;7/4C&TR?GE:9LY$;I'ZA4,(!U\NDPPO9Y*VS+
M]@\G@C0J.])4GX*-QE/D0<*4@PWZ/*U=9SSL#!KZ8XWB\D[X>([^@X'\XOCD
MP)Y<.E&T0OLJ\V@BTM>:Q<\09\69I#9I_8'&G1/]B8RL9Q\\`APOAX_\ETS_
M.*-'-V$@2U!_[D;R\@7Q`W`!@C_B`#)ZV-)G=>FF^*4IZD\\S"0"2W0.__J*
MJU4`I`I+401L&`CT["8:ZA+6GX`:$?'W0-#"(M5EV`^-7W#RK7M6XQ[<3_!(
M[(^95VQR$V>%=SBQ/7Z[L57+G(_BJBU>@*!>B7RG3AM7ZM7MNRUX"9I4&?;5
M`2V&PAF$Y=\KP<M)O'D(DTT!++S-L6;,I#5HT!_L)$X_HXY%AYV_>052S(<'
M.)LGC%Q^O#39S7L`$3Z1>K<.0T>%IXC4SUUQPU?V&UJG+!JK!T$:<R"<U@;"
MEPP(`9CA"\HM^[&%7.B=5RK*@J$G1@_K)49O?>NO;R51^GQX_.5H:"Y1NA2(
MA00PCLCD/0+H"8CR$OG5-T'\GA8N^YJBJ;@MJDE^?TZ4>Y5L1FDR1UO4OS=*
M@0Z9W1YO!"I"9/?G1FF/\ILX3L7AD;5^4]!@D-R?BR:)XF`B7=X40`3+A?7@
MYFG+Q,Z(%SEP9"W[C`E1<K5FU^@Y?5!>H1,Z>)P(5F3:?&,03@?X*P/R&8N.
M'&O2Q8\:>UT*,'T>?CXZ.C=XQ,#Q$VARDRA\@4AN%ZOO,:XWDI=S#V8C-X$O
MF5.&3:W\0#9K`3&![:]^15SHSSD$,603IDV'SJ:-=:A0)-)*K'#([@\,1MX_
MT^)%C1`_AHFV6!*\M>'`4ZA&$>GXU-L!96O<Z\\Y^IL#`\R7<7`%(OB"F(!3
M4Q#I:5:Q"R23""34'!_1[M9AL#6H[*.T$<]RY)UH\/JW'S4"B,`7893`?Q/A
MCZ=7,,Y":$:!A]BP@.DBWGI1B1I2(C_8.RBU<+!0CIV':&FAPGB9GZC'4V8Q
M,&:?=\`U851QX]EY7"'F8C\+N`+9?TOLS//4.5:B^`#OB%/&-64UB"HC+TYL
M@>)^EHHP"/>[6@>_AA@0`94@%PH7JE)M9B&>\CR7JYRHRGP7882)#/86,5>;
M+X63IN\HW`G,1YS9C]B6UG.LP=XB"FOS18^KT#@,5=HZ+?@+K8.LR>.P;KYJ
MR?FS^PZN\=W;.T"5<4U+,6^+X)?YJ!1<`3,&L@Z.^JZ`9;G0G_L19,ODZWOD
M_BN%$:@JXD&!E%!?ZU"D"`+[V*K/#BUG93L.)IMW<C#3A8\@V]VVF'9V_KF_
M&*K%B=[<F8FSM?$F]W8@U9`G.C)[+<)6'E':W)!B#&0=UO094K)<Z$]DOCA#
M&N/*.CPI`D,3E+'0U:^<\NIBB]D#P;OF`RTE1&((Z\"F0'DUIE_'>RWV8$E7
M/=->HT>$<&5.T26!*J(E2MX8>H9O%CY#A5[-9?&<O$V>)^I#RZ+N)^H`UFFA
M]GQ0<CPI+BH_=C\(#1'N`N#%UXCQ.#485\Q`BW:3%$I#%:]?5\#4W/JNQPI5
ME]WE.#(3`+H":+XNS"09>.6X80IT&#VL\X(;O-J395.QZ]572ISP"4-5H4C^
M\04Z8GCXX100Q"QL53=^AU4M#JVWN6.UD#*]SSTZ)"KISDGP;=-J/)6YS),=
MQSKLZ3.JE+!FK<8^-P6=5651=YDSGJ+?>"GF-6!&O_([=L724H\P05ZL]9@F
M2$E[.-T(Q@0H1V<G1P0F^#=_5!J/3^$M='$8[YY*$NSSQO8Y0:ZL,?'II#$J
MVJM><H_U*:+J(HUA`&+!PB5HE,'!`.?P^6&,^J-_9`/A\B3KH50@>'=^E#M"
M3ELC]U+Y;'+@A0'U_FFOH37Z5T@$6_=&8K3H+.&@J\9H#&.\.VP&$5TJQ[M+
MA8R%5\K6:`8@.HYF3I"?`#?UAK+387ENI?I/FTI$G-MZ16.;6+F-IKZ1]!."
MQ(5/=WBI_HPU6D,+O,I:IA7.=4]'/8`7$*0`6T6S`,JHJ)-=%94/-2B/9>2I
MZ5V*.%J'W@'+&%EFG[X,C\Z//A^?G0_/#7F?()K9%+KX6B#+:T)&Z01!V$4F
M*4]GB'6V3A-(BJ7"QU2?[NZMXVL'1N0R\HX4301;!4IX2_ET=RGCT09DN,'6
M>`:@OR9L,T&>&<'N8F+]5DGG)EBF,EN_U!C6K681,987;W-JN[>&2UX"9)3D
M3V\4Z:HKT<7\>7<Q9\,.R+@#)_`&^<B#S=`J3MWLV;/.X*(]E;BWV!^C+4*9
MKM:LO1IB6?NNFM#:O95'S[_GK;;SW=66#S4HCV73.WB\FH_\?D:.U[AT1&E2
M$B=F?D]K%JRT\+8.N#4)[>1JS:WYZS`B*HIZ,<]9OL.CBN6;CSV8AE&V:1Z0
MX0=;XUL3@L`KG<WI9"189\UP<C.RGM4#\'$<VF48)_%FWNLH.<Y";SBJ=4I`
M3-Q;L3H:.-`][;"YU)N`*#=CRN\[\53"WBT5'FJ`QEH;TF0T`^OFJQ,%2#'%
MQ<-+G*5/;VYBT>_.AK><J>VM6Z@\L927J!Q5W5M\E6ZH)QQP(VA1GPH[HP8_
M9>,:><2B7UZI+&HE9ZXW1AL&DG"$<$IN'84=4X+#6+>`:_NFFA#<GQ<)UNPH
M'3YH//D>A,\QB$@E2N+.*\)QL@AC8:@I_%1_X*B;*3H+Z;3EUY';BT2\.T;W
MH9ZY>1[=.?!2'%))D1SWKE-X`.N6?2VG3T-ZNV=@"OA^I)9X;0^0T67?&U?0
M!K][CHG1#R?*'J\?$U3&>(_+IAS'Z2+[G:124/$1ZQ2'O*.H!8;88-Y2;@`W
MU']=+/UP!7".R'T8%/^B\-,GWR`18GE,RK\1UTAN-O&L,:'8WH<[#$_#3.I/
MG<BJ]5WFUN[SW-_1UAB5%CW./X\O5E]?0>3"&$PBZ((')YC5TK1J/]QA>!MF
MDL[J7>UZ\N4,/#%_OE%SKM.._=(1!%G-'O13G`BWR:_\^NKZ*9(,3I?#,$^+
M.&O9&P'U'[).F<A<);3$CKY4B-BPZW<`9_,$>".DR9P9N$\7SR#*E;'L@4)B
MK)Z`K2G%RLK\[>&IQ1NM*Y`XT!?<@LXDKK3R@=_OM!3=::&S`]LKGATNHNV+
M&\9#8\K&MTX=-+P%4\P)5=N.;TDAT#6W+E;K'_\&D0J-W/GJ%KP`?_0*:=F^
M8IWM1906A#`0*<\F%MP,5QZJW(#VZ;L*%PZD%222&L->',G+E0&2VJSHBT6\
M)CK+JR&,'-X!;,_Q8+3?PU[0U)8S`SN"]/<9*<?22#E^XTAAT:_O5&0>*2?2
M2#EYXTAAT:_LB0];D-+`.$2G>7"3@`77;E;Q#7O1V+9YK8V;JBKU6WCH*VF,
MZPC\*P6!NZHX\:')B/5Z"\`39@9]][3EP+:><.4Q;8M05B\34A>6`D5P+'KH
M!K(M@HO7**ZT8FB4[G<S+CH^&EFBVR?(A@@?14&T1(U5^#\IWF_,(X$^75?1
M[+UZ&S("[-#]KKJJ^J=W80!66:'@ZS3P-D15A711&UMC+0I*9R<*2XXN'7X.
M\W[7H@S<38"8E!(E./X1`(^4A<-EI=,`NG#I^-]"A,F`/#3S[,-95L-RE-"`
MH_X#W05;2[S0X5XQ?[J@\>S[XX9)^,V&&=[JU4!38N@>@[(I%W3X<#9P/#%D
M1;TXT,>G.IR8X90K[%>PO<JBDNO?"235H$N5#T29F:3<%4(X>.D[<<QW@.RV
M[;I-7</ML<L"NO*PP(U;,^^T3"7?0Z+\4\;/YK1%L0<'Y:3;Y8&I?FZ1ZGEA
M-S<N54U+H@`%F_K^N&>R%UL63"14M.F[^"M([D\&$]7*HAQ8J.V[?PJ1(TW9
MJ\56/:-^!2*DWW!^0]69K&2&B1TUF@W7"?0T)[-`DF)M8AQ+>2U;;+\_X%2&
M>)PF<>($'M+,%5AA-^\,%MAD*'NKFN/!;3]%8RB<H[&7)\A+TA@,W],T+*@9
M=>GX;NIGA2Y#W[\.(US"@'5^U/=-*]P3G/R-EEBA^[I/^E:(5@]^CE.G;X(U
M2[XOPR#7ED6*==7-GU@_XX<0W>MK4S!>B!]Z/=^&;@J_H=,93BH?!QN+JV1H
MW8-D$J$MXY6BG46[6_.&;^L`4\*I''HGM:'W)8->`&:XFK(MX.N%.=LJFL3-
MX<:'Z"4I0/,UZ"):1+K\<?Q&,"/*C`(Y31_SS8#SF#A1TO9IBOWRBV3F>XW'
MB.HFP??Z6:**C'31;M9X0#4^1U0KC;Q83\=F5#$IV<1(^E[_O4L"E,DG81/(
MNLLP'.E")LY,:BNUL$9Z8FRGB.D-)+G>P0`NT@53KEMM[)0L8V[[LN73T\O0
MWCOGE2_J<IL^B)I+C_D<Y%JVT2TE"52FJS7R5;3%-J9=59!9[4<X4\>O;YOO
M#6"I*-DRD#.!=TGNC/^=?2#P/)C-NS$H&$-9"H^:IR$&H7H"A-2#X@',8(SV
M$>!=P0BXR7B*)@>#V?<`)I5ZGMFA2]J="_@U".1)[DH&WC8]DS1RYTY>Y[A*
M]HSF_92\+,%Z+]VDW2<4J4^BT`7`BW&]6AJVR;N6^SS$-S_CZ4T<IT[@`E+O
MO0HH:K_03VRUP"/=&2Z&O$(D5'<\S9DQCLC]P%:1]O4?X_RO--=?G:%Z!T?E
MS%`7&JLF"Y2B!Y]`M-A0]`_@1)7*K*)9[R`@1:BR&$8=3\XXY+D'\ES5JE"C
MM!0XH1Z6BE78.<&C3[>MJLIJH=-1F<<FV,>8=,6`*B!%?GZ9H1.GTC@*:C[2
MSM\ME&=U4M'.O'OI_>]\Q)2J[54\$$KQHT$:'$;X/F0\_?JZ1.<4X/T6XFB>
M+":HTEU$;VXJI$FM;XA-7R'6OAW!RH?7XARZ=5BEG+>X_7IG63>C?+TMV*X6
MOL8)7.!HW0<8_WD=`7`38']&G#R@7U8I!F8'BU4#3R%PZ;+N9D"14V;#M8D3
MC2-23LHC8:/%LT<T'PR_9V^U0EW:"[V@Y8W!I@<U3`U6<<"[2HG?G(387J7@
M*2R\21LW0^6Q37*$+B.A%L':,X9-*9$J#^3ZX;-U.:=+Q_>!=[%JXN05'[5+
MRJ>NE[<A-_2>7J5M7)J-DAOIM_`%Q`*.7W;[[B%`@*A<D*>]<D.\M:Q!U4:*
MBF3`X6=KL@'?3'JR4A-%*NOX>&B-82(9]U1LA&7#'$0XTD<F&(HU2N>14(?H
M`A=-L_5,AL-5T/<4YFR4C91CCV4I1)K$R;$)5I7,:5IKY`0UT!B[(U@*!77:
M8I?@P@(=?M2O+/2D]8Y<-TI!N62M9"KO^6XJ;S[BH#2DV0>L]TF\3",,)TYY
M)(%^:FRY?-2]SS&#VOF=3"8B"?-\8[+Q">IIT`"55[*XM,SW(PKKK:J64K2I
M"AFM+FII"`[C9`XB64RP._4`&#4(5!7?;D'9VXSN211.01P3(JZ!H)J@=.H!
M)&H0V*-*R!GQCX[O1*([QD[C_D!`A#"=A<^UF>9A&B3H^(&?""&Q>DX,/'36
M68(@)H/F9G5^K!$TV8=')Q4V>_ZIP32,LC(\!^1K@_+G-C5.\R\:L>?)1?,>
M*SC&/*^3B37\Z,Z!E^)(S*L<@5MSPT?-&2DN^SM,YC>!!U^@AYB^(67BK(A3
MNZH.D)Z/6*,SY,!0UADM,,3B\D(-:;Y8/6$U,IYN&C%J%>GYF'T8U(^H?1BW
MR%L1.!LZ+.T1@>E^`%G1OG@.ET_A5[2O)=4/+-<<Q3H`MHB%?2"J8)XJX\S7
MY4N_#X.OBZ4?K@#(/,-A5/WJ#*>U==!1(;T=3YXD]?UYD8ABBVP6XL5J;_&-
M<$G16TJM(G4#6X<[(WNF)C[2O0I*=(_`.5"@"DZ=42PT[)O*:D=7U>&*#0J+
M%LU<R;2)[P35H<OTYM8HC(9+8!.U+$FK#5(VO"V-"<GQ-Q)S>1-D8=ZJMZC*
MC_0)?2UR2'>VSI=N`KB4NWH3)!$,8NBRGCG7]KUW6#=EEIXB0<9`_<SGVS.%
M;WD8:_9T09EO0Q:JM7RPM[!NCUO*BA!9`FQE^]SO`"?R`&^$"'-F@/SQRDG`
M.K*[%7N$.XO>+@'#++2B>I.:=5'XQ!Y!]`)=4,W=^Y`\WXS8A!D9/^'`I/+?
M<?F\^S#Y!R!/U<P"^&]`L\BU?:^/6&^769HR8KNH[8MLG+6>(%QMQ4P7^70?
ML6Z,;YKJRUBKS$<^F0'Z:3S=:(2,9Z0.ZJ6SA(AU^+>C!9;L#M)Q)29M7^HH
MBK7RI'#ZO9L;]!TMXR`27?XKW&[WS"DL)(43Z#N>%;)*4_VV3MD?Y/]^0PQ=
M%S"I`K':X3L,4;6,Z$]H?E-CZC>RI`M+BN;5:"0!WI?>(BIY/-%4RLXL0K^%
MH8<K>J*=!&SO./$3XEB,&(QHQ#57@KWJ$0U'Z_<YJCDK"KQI\0B83D\0SDMH
MFI;PGH[PGHY@9=32>SK">SI"OT,K+4M',`3G]W2$]W0$5CJ"*2V;A^$S7S;>
M;F0=J-0F*D@0_1X(^IZ?\)Z?8`$*U^Z941RGB\R!@P[==R"9AU[HA[.]EW%5
M>,]DOFKAR4-=OD1K7'Q7N)7LJGJBX0X&<)$N5*MER<];H[Q;@ZA"U:V"U_TI
M:Z.?C<ZKT163??Y]Q1CF]?L%9"4;]UX&6[6\RS`G\+YJC'.[9_DWFAG9WE[#
MG,#[NC'.[??\'C8GK[#_!`1>Q0-\K7WW?9F88G*/LGQJYPVR&(C?NJ=&)VKZ
MV!L!OFXV]KGLZ!J2W,">8>."H\/WV!XUL3UJ<B?$0GP4?FMKWSC_=&+^@JA!
MI(]NOE@<(:&:"1>K![`,HP3?8C!"?W1_UCYXM@8V_4`78K;%14K5<&'#`V;P
MD)Z/]1[?0AC;AWJ+W+:G1JJ:5?&`,(/D/4<V^A5X`7ZXQ'9U'B3/C%02Z&D=
M7EL$RCY*ZS*L/S?QWT``(L='#!AY"QA`;*7AEV%%X";4]QUP6X_PUF99?ZZR
MU0B`%WJG^"O6P=BD'=L&;\W7#FY8--B.Z+<V1+4!B#QO^K.35K-6RA5FC9*I
MNT3X-R9:S:D$1)9Y@H^%/<''C3W!Q^^>8#4.N.K9D=_&HS29H^,A4H_?D2`S
MX6<Y\Z1B]L6J*`(UB9"Z?<`7)6(N81T?M4:?J/`-M\8@FYW$:GG`\@NK_Y)]
M:&P?6Z+;I'I&6^P&;L""?08P?<`:OF0?JEL"E%(H2W%7G[G88=SS_"%Z/F8?
M^CNNTV5Y;=Y-LO]<P2CP2E7>&[I1Q(?OJ-*5E;B\MT6<A7WWQM04R'V*W?+C
M:8F#.4_;4+;TKUNC?77I"FU*59*G/5L7>R&=-;FXS[V=QPRVNER`&0P"U/;"
M0<.YDN^QF)GBVUMA-C.^[\F)#9592<P&MJ?]K[^]Q6.(ISU+/E2E@O:YQU)!
MK6Q'DE-Z>RO()D;W+3>QM:W]`6#?'?KS91@0<:>.C]-^CG>6&#W'R,#,^K:L
MK&*N#=%K%!?7_X$HG(0P2![!"PCN80"^QU>A[SM1_!2.`T#^]H2&V/R^,BJR
MZ6"]<5\)!40VY58.J%-=+_I*7X51T%50<1VFT38E3^'3CXQZU.8:OHC`J\EH
M;Q!?3=A5`.S4/HU53!W]ERR<,E68RLV2>H2O`JAJ-MX;Q%4SAA7(^OS11FRM
MYX_5\5>\OY>HPPLI6U%HR2#J1<#5;,"WB*YF'"O@=?[QLX7XVII^>74@RM!O
MLI4#7[%E(`"N)J.]060U89?6IUGUA.G>!.BWX#:,XPF($*,7.8LE7U_9J]&`
M1QR@(0?9F`,RJ-FW5KXZ$3YX84+);#CQM_3F9B-O1^@8[$$_Q2E1CP!+-H$`
M0=[U4R2::[2&\'I)DSQ789<,L4A;%1^QQC$G"H#JF%IMK+`XAK8AS1>KZ@$8
ML;0:OV@=#EO`UCZ@VV9PY]!][RS8@;&\;M;AK&V1BX*.P[*^/:!2LDZKS71Z
MPXY`BB/0BMU5C-+^A!0U7(J\P&55PUN'MRYNE4:#D6GG.8HJ9\0=UQW)/O6D
M2'([CH*Z_'E7:L7Q:X&O=/5HM&QL:]29@J6I4$$QF-,?</[NX!*L2:7!A:_]
M=_YNG]82-JHJJ-$32E!A24LZ):O=B!17)9G!)?:P/H=1)H]9!$A-W8U?,O=`
M'A]]VO5`;O4<E+H:`&-I+B^@5!MX,V'\9/@%FL&?%5"5ZJW$BJ!PG64N<+L8
MT[N"Q!1+28K;>O1E18B%]H5&7L/$%:JC9%5Z=WY_H7W976AYSP'I.BCW-5(8
ML)(,&G2QP/E=S%0XK)Z5F,J0ZFVJ6KNHK(J5*454?U8F17_MWM`5=W'B.Z'9
MZ[C-T9ZF<7$%_OL06<W5?RY#H.I6BP1W:OB("6V@8/85ER^L[4YZ9&-O/FC#
M$<\BD&8172=U%%/4TY7"L4WA2O&24PBFG5->8SA1#@&X#FN0`'=^$[CT\**J
M5AT6V3:A:V=?%96"U8*,AY/=@O1/L(`.8L+M:K&<APOG,70A2%9TJ?+[]$_&
M?)IUNU4,U992P%+:!94BB96&?S<SQ/A$SP/7Z2'"![#4\6LXBO9Z=EC![*V&
MM8X1);X_?OB'<.7XR>H!1_JG54>TW0:V^0DID%X[)7:F7\0`GW2]\EI.6%YU
MGRZX=8-N"FX]_6+)Z?<8-56]3CS/'Q)\"K\'2`U%,?K`+701(6&E.<?MTB'9
MB1%42%-Q'13CMMH3^L!X6MIW*&X=2KO^6D\4@E6%VRB*F-BCUY%TK$B/8$KB
M3*`60I.F1K/+8U^3,!*K&(U-,;TFOM9JE4%2:_<I+2<%_2M%GU^_Q;NY-ZE8
M>XRV'=H_.91HRF'38`954H[+:D`$>/)3#!$MY.^3,$&_@HY?,AS$#Z=2@W8(
M"JI(UE-SKBW(O(VP%AT6F.;=^#%]]LDV!*X!B"<.]*HD5-7*-J'PUF`5#84B
M-EC"G2*7"8A<S-09KB"^-_-QD)VL<42J$P6@4FC20W1-HM($%FNI\;ZK5=RD
M:A5\3O'4GL+K-.!*MZI'EX5914\AN\;%)97+;K.-CQ$&9X3N77<!JV'7)$4A
M(Q?0B7VZ-*MG<1/'*?">PHVF`)528K7NFJA8M!1[WV>5\E)O3TZBT`7`B[.,
MBXU>&$^IFI'3HVM"Y-%3++QATS([RA?>'?1!G(0!B#>O>6(J<'1I4.WPX7;I
MFO2X!!7BL[`DY<CS8#:9-17"@A3OVS6)BE.FISAD^YX=1!Y`!U6>R)N/V34H
M-*<XA\@7*R%"TB=Q&8',@A@'X`DN`/X'?AMA_U(0Q%G!^&IPU!^M>["H3VMQ
MSFELEID/2[F"$7"3\9+@'U=CCA-NP(-`GPZA09"B0N8&XUDH.B`/N=GL;^LM
M+W=,QSE^JV./:H[1(0G7I+`X?*FMC&G\IN\1B8JP[!&1ZZ#9L%[VK6[;S^@)
M#M$L0]&T2/.)?@_B)7#A%`*/_;0MO;W1(C<L9&X7):3.7\O3Q;1Z[6DRGDX`
M&M<;>?],XP3/G5&0G=7<;'$A#GPV1=)9)%@7&4'=+V.`F#-'JN(*Z7H_7&(J
M\HW^.HSNG.A/@,V`!S"#>#?!9%1OFK4&ZM[.68O,M9'<L_V3R0Z*PF7VV2IK
M<GHR-%N=1QXD]8E<0Z1Y>7OUMWV953B*X]"%.-W^VG,J/=F5[3HD/@85A=O3
M^ABHZQ!M2`AV43H;>0L8K-40JQP\ITN'\VXH48U<DE7%+^F];;K^6SB=+IP@
MN'4>0G0BN(4+B!#+$#6[0P\%S298E<N;(V93I7JH!4'$*_:8K0AB0>T>JNE<
M^1F!;$?1GEVHP2-%D'6G(C48'2=S$(U<-TK1_*'S#'U2K.\RC3"7<PV6_:,"
MKE*]C=E2<F@O?,E2M'4E8OC.>86+='$-`R=`!J+_F"Z7890\A64>5<8*B'7L
MD(QER&+%#=0NC:$^]@K@-SD#%ZS/"WRY\OMT3:1\BOIB-]T$+R!SW574#SW;
M-9+*K0UL-*7/7X%GK#^SI!UN\>XZ`]3?26/@?IR%+X>0?"TC+_MYE[#LMZ5I
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M$E^:@HLP\.+[,`'X/I7$^=-OB`4Z6;Y74`+V!`BSKI@OK295_"U$WPBP!5Q*
M:F;4I6)WZ*9`.43I253LPZZA;[<P_&B:^@U5\1ZB+I,B"1/'MQ^3WR+$A@U3
MOJ%UC!DCC4#J.&\2;U1NK`L$-0XB[8S6&RW"*,%<P)EJTKC:Z?TFT;3#@QQ#
MS>.0S3^3M<ZB0;9%GM&(XY@"#[^%&H$Y"&+X`LH*J?!B(XMK<#!8]R<O9J&O
M!C'P\$]QZ$./Q,MM/C$(IX/-1P9.@%N6/C/`WQG\]#UP4@^'(!KR@.,'9]>3
MYKJ[*UOC`/;CT]/SXR_#L].C3_A_IO(/2'XBSVN_V\R:+(,Z?-Y?V4+D]>?U
M`*RE\!K.LREXPJ<U[QD(I,AL[2W@=I%Q'P9AD;>><3/G!@<BW'X]PTH]>JV+
MSU14[7GG)?0+)X8N3@W!KV_O5:H4[M5=='!)TU,#QC@0?@=P-D<$CG#LXPQD
M!4[&4\*#<9K$";+H$%_$\%%WL.["IB[%!9IZ=F#=,OTSSMZ#9#Q]<EXKD@"8
MK;N'"2Y)A=!5'S*-6!T@R<AC.+:VVOQQW$694DG)97G>*X\FU422-2&M,QWK
M&7\21B3+>&R>+U`)$D/GC<+O.@ZN0`1?2';J38"XF!*'$%HIDP@D>PI?MGMO
M(=2(`<49MF=VPR:T,>/L39``)&%^0.IV\]YB1HI@W5?`9X823K<9R;`[*EI:
MAXQFYH@HA;W<@':=?H(N4.L@(.6\Y/L^60!H7CZ^$@#GABP0$"#X^XCV<A63
M%XZQRNG5-WC4(;=P=NJR+@PIC/X6[%*$E=J%NQ0733>.E!X50VX(#;FBR-IL
M36,:([M<YERM6Z<'A"[%Z7?I!DP(0P?.HJ![=45L2JN^B%N$+#VF@)&UG*FL
M:DF3RD\[#3HDT:KIZ]Z:]5;A99:H9W3H^MJL2:'.=XDJ`Q5_.<13?G9B@/[Q
M_U!+`P04````"``P.`E!;'%H/?X,``#-?@``$0`<`&-R:7,M,C`Q,C`V,S`N
M>'-D550)``.+F"-0BY@C4'5X"P`!!"4.```$.0$``.U=W7/CMA%_[TS_!T9/
MR4QE67;.C3UV,C[[?/6,;&ED.4W[DH%(2$*/!!2`M*W^]5V`!,4O`:1T/BE3
MOMQ1Q&*QNS\LL(L/^O*7M\!W7C`7A-&K3O_HN.-@ZC*/T/E5)Q)=)%Q".K_\
M_->_7'[7[?[V<3QP/.9&`::AXW*,0NPYKR1<.#><"3$C'#O3E3,F+SATGM@L
M?$7P)N'O_'AT>G1^=G3L+,)P>='KO;Z^'G%)*A+*(Y<%W6[2V$<D@#E44ZV>
M'/73D@>0;T94X87S4^^GWLEQ_\0YOS@]N_APXEP_Q(3"7>``.:`@%5>=3).O
MIT>,SZ'2<;_WV\/@2=%U8L*+MRGW28Y<OM$53GN$BA!1%VMZG]`O!G)9/`5%
M4O8E^D2:_OGY>4^5=IP0\3D.'U&`Q1*Y."5W(TZ$M)%2^/CL5*+E8PG&'>/!
M+9ZAR`^O.G]$R%<&ZC@H##F91B'.$40T0Q(+1J.@6@TOY+UPM<0]H,"<N&D%
M1FO48;1;J`>=2A:M(9DA,56U=(G2KGO<[Y[V=247%#>:80V>%Z:$62@^].+"
M#G0-Q[E$E+(0A=`KU6_Y9KDD=,:2G_!"8G'!F8\G()0C'Y[']Q5"R)+>$S!3
M0(CA;+C$7+$6U]2[8<&2XP6F`CKZ`'RDXQ#OJM.`/I5(R^3A&:%$R2[U=[I.
MR@V>;QCUH#9X!SP)YA-/.>FZ08?-G'63#J*2,M.H(UMUOG^F*/((5/WALE=L
MMBA1!,T-Z<_J&1@):$9Q'\"+I'9"8JKI(M^-_"TJKB7;7"]YJ_'<$N9[^H)%
MJ,QXBT-$_`3.BO=&V,Z.SP"J6R)<GXD(ALBNDV'A?)\P:4U?:?H)FOJX;/GD
MM='P'RR&CWFT=J^T>\GB9EN?&&W=FC@U\1C[<HP>(1ZN)AQ1@5S9;&Z$L=!8
M1IOS(A`).T?Q<S(,V[&G`J`;YOMHRN(I\WK.,2Y/`18:"T`_%@'*L7/6_%I\
MZCN0T7-L8U=]EVF!L#F*T4-L0-1VC1:')"<Z[AZ?=T^/8T@^(E_FJT\+C#40
M^5?F_*)?,[](>#HQTS9]L,&230!OD%C<^>RU(C=<%YEA.MTJ#93<'<6^!<P&
MV!TB_%?D1_@!(SD0E2,`(X5E_O]0'.0D,T=Q<[+LVNG?C-)MLCBI_[^FWB<:
MDG!U3V>,!V@=%M2B-*(F74[7SC[*%968E9/AU>)EG9T@L@*=%S@DH$3%5)4O
MM\Q;_>WFK5P;/[3#H@W`1Q3"V#2<?8P$H5@O;Y;>6F*\?G'XBQG(.4JS:,U?
M[3^"0)@PRJBK':=<8`'AI`B"XB$QR')I<:C"88Q?,(WP&+ML'C>ND\_2>PL*
MI^6\4[%P,CQ:#&I':(;0S(9$W9BL1:,*C1L6!(P^A<S]`J'5/Q'GB(8#@J;$
MA\A(KP@8:2SX_+V\,"#9.8J?BL(2CD[*LH6J"JIKU^41]K25B-Y;J7AO@>2G
M(B0)"R?#H\5@`P8L@J2!SN\85SU8G7^0.[,0M68F]CJ$9I34DDX1I82G`_E*
M[$#)^8LLWQ:Y*N3N*;Q56_4CS),1;0%9A-XMVU!JP:@4$:M=>>"1CG*22XM(
M[4`@NVEL(K!L']=?J&FWDAM-.5E\-I9:P*DS_;3`[#H/%9"J26Z&;NLYJ85S
MJ\DI?X3&2&,!KMY$U<*T]>9"W[Z[T+=N+Y10LNTO./T6JBWRVL*1D#JD%NBV
MR'+;3:*FP4<.MLW%%JCJA1\M-CO&'XD!)_@MC/0^4?-J9BS[Y778V@&)'D&3
MEEJ@=P2Z*<)6:'=%MD5T1T3[32&U!3C]\@YB8W=M`YY=83UI"NN)%=;2GF1C
M6$]:6!MEAH5[+68B"WQU<\/_HW%5_B,O!([QS%'7_2[DG;>KCB#!TI?7!-6[
M!<>SJXZ\]=;5=]Q^!W6/W@)?DTC^AHN'"N.BA9*&-0O$W1*7TG5$8,*6F,O8
MM:>%UPQ"$LKJV>,!CFQ'_,U!/DC:^VK*`V)-E2^`_$ZZWZQ;>2?5?31MJCI4
MP?X[*CV0_-])77"QINKFO?*==+Y-&ZE4_+*7O4`*O_(73"]!;\9#AY8N]9JN
M&,=7F`?,58P,5>2OKJ[7E:^Z_9/N:?_H37A:QB8BK&W03`1=K[$(BI?`[M&<
MO0">)'<'>(,,E77D0W==.=?Z=]UN?2.<QWV+XKD\)UC/$#[GN5K2#.?2#/TS
M+8BZFUX;C/+EZSIB%&M5B+&5#-G+W,WD8/1Q2U&RM\.E:47MGI&M.4=H&7</
M[(<BY;6IHYB[:?%&>5T?T16D#3XTUS[587?EY9OM=-?NAM_<16,?32NII]T$
M4%D`7S66(5M/_V@LB?F3!=OCHGCM9A>B;M@V-DNF6O*\28SD@Q,J/9`S]^_F
M5>[KJ0@Y<L%+I."V-?$U-4J>KCHACV`>BL,']76."RB!_.\^Q($,L$'!"(A)
M&$GU/G,6+34A`1)HF,C[8G(.CUG%93#=$^9-%%LOXLD)FTU*FFX)%%6L1WM@
M"IIQD4N9'WTHJP=CACQ6*_Y8R$6HWW]3U4:<N1A[XHZS8(SG1(288^^6<.R&
MP]D,2UL/9Y4:B4<,)/="1#*PNF%"'BB-+?#5N18TS?8'8`$9,E_5-IO)3''9
M-+[W``5X2L+-QAM#:@<A]`*DO\4OV&=+69Z<2=:VL!'M2347`#'I5KRE4'3D
MS>4'YKR;^M\S)"QB#9*9R`"2D,LT8@>(XM3$`$5>I%$$G0G2B!%$C&DG,Y-4
M2B_''!!#K3*]I_3FT1#21=6ZJ#=X9LE-F#3K9L4>NTTW4W8LK>6.P-M2U<PD
M!G4(#?$<\Z\R#&ST=T8_!4N?K3"..Q/CX@$'4\Q3CS=15'>Q>&;S6(`(?5?I
M+5.N%*WF[)R0[MZYO/!B`>7<C::JRWZ=;O8`4\+J`?$O.+R+*,RP^N2+5L]`
ML-/48A^*TY&@V20ZP3P8SO3L_R^8*U.'J2S*:J'M]4TG%/E-/"_R8>[3[@#]
M*.,<U6Y^[?M)DC&<);>5_HN]D6I913FJYY5BR6_4V`%$HF-$YU+-MR4,+=C[
ME<F%8WWC(IFE322Y6<T%UM]4^D_00""7M<9$?+GC&-]3&4Z(<`POM?P6HOUJ
M8,]:(N0WRUA+E0XL-+3DVYZGEK21OY7RANJ'9H:(RWO=Y:-=)87MA`>FVJ8]
MVFL:$H_XT/0+?L)R([A*WVUK'Y@1ZIQ#K^[AV]3\\RD_7,I_Q3`*90`C/^\K
M5Z?>8`PF0C:_A57JL_SSF6L+<QRLND](AE:QT"N=/M_X2(CK-[).W"Q47T$I
MR!8\$LB/S,;1['NK=ZMR,KN"FFZ7A.YK:/(94_B-W06,R?FTM*IDW](.</0%
M!P2!TP]6P7(!$CPQE^!PE9?=3K=O339\EVYC1%2/^L!&@?R'*"!3>B`^1.60
M(H_02FDP(*[\/DYI:;=IO7=.P;=>[94?.TMDGK!G2M17Z>5RFQ2?I?W52K8O
M_2QK#&51"VM;!H)]>^"&3W1N\,"ZU`?F@7J_)[<I-&&)^ZQ7`.QT!]H#JT?&
M&Z;BIOA)$"_Y\/R(A?"*(#_C;^8AMA&CPUP'5%!*?+%W&ZE=#,7S-L(3ED3.
M>+T8F$8N#6OML'/30/.&LVG-:?1@O?<IFOJQ!]Z!#XX0\5)X*DH.U$-'\9H;
MDBN,9;&'=,Q6R)=Y_B?$*4XU;%QMOZM\67'EH*'^`(J<()C<+:A2JHIJWRN5
M>K`;@KWGBCJS?UA9>+"!UT*N:=_3=)OF><EH,ESI\2M5K1;M@;J77K0?0*`E
M-NSWF&GVO_$3SQ=JLIFPM;/C_`[O!HK]SCS9$SE9CQ[.<GYOH3K0OO6`WD@0
M!7>$`CE$.T_14AX'G+!L-)QND-8C/M`@"1))+BG3J*!:23O=GD.&-%,6Z^Q9
M]CHI'5WG95:R0QW7U[L_J0I&1>O3'ZK&C1(3T`W#(%]EB=WY[,EU[09*,]9X
MAAA2/"$!UCEM>44%B\<HNTJQ"X==SA.]YS&\6+Y</@_1ISQW9SN;9ZH9:ZM/
MC4M1Y?MO.>&:3A162#YA2;13YT2BN7XN3L(N"9!_"(IKH1,Y&X)<K+5_@/^-
M.1LQ<"4YU])'0O&SN)5C%Q<3!HZIRB8+&+_2]_DUQQT8['M-4DMWQR*>EW#"
M)J^Q5D!S!X/1!N5WX;!O[;5\\+^"+BNZ5&4-ZA-YVZ#_;CSV;H%41-EM/Y'Y
M(LPH(#&-P07T0,%-)MB-R;YMD!,P"Q+(#F]B`,F;]/(-!MB%P[ZU'T8P1,=K
MK=?>?Z+X[Q867-Q$LF_Y;QA?RA@3?V34$X\LQ/(/S*JI-*]%#<)]Z_(L/C.(
M^FB07_0J['"9B?:M0_4M&;D@)%=3&8]/-$-`$`<*FIWIBHVU\H&N9B3[--="
M,)?(C/W.0^D"3679MTIX-@^%X.)@>Q[-K[V`T-3&Q?'.0E:]K;''(?X?;#8+
M$*4#-&;N`@](`,R]@E9FHGWJ=-F+K[?"X_\`4$L!`AX#%`````@`,#@)00?9
M^G*_<P``0\P&`!$`&````````0```*2!`````&-R:7,M,C`Q,C`V,S`N>&UL
M550%``.+F"-0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`,#@)04Z&O8-\
M#0``([$``!4`&````````0```*2!"G0``&-R:7,M,C`Q,C`V,S!?8V%L+GAM
M;%54!0`#BY@C4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`#`X"4$.\WE*
MI14``*JH`0`5`!@```````$```"D@=6!``!C<FES+3(P,3(P-C,P7V1E9BYX
M;6Q55`4``XN8(U!U>`L``00E#@``!#D!``!02P$"'@,4````"``P.`E!04K4
MYGQ&``"*VP,`%0`8```````!````I(')EP``8W)I<RTR,#$R,#8S,%]L86(N
M>&UL550%``.+F"-0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`,#@)03)/
M)>;I)P``,+P"`!4`&````````0```*2!E-X``&-R:7,M,C`Q,C`V,S!?<')E
M+GAM;%54!0`#BY@C4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`#`X"4%L
M<6@]_@P``,U^```1`!@```````$```"D@<P&`0!C<FES+3(P,3(P-C,P+GAS
M9%54!0`#BY@C4'5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"```5%`$`
"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EO2BI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Common Stock and Warrant Liability (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Jan. 27, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockAndWarrantLiabilityTextualAbstract', window );"><strong>Common Stock and Warrant Liability (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of shares of stock available to purchase using warrants</a></td>
        <td class="nump">1,612,322<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,612,322<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_EstimatedRiskFreeInterestRate', window );">Estimated risk-free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.40%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ExpectedLivesOfWarrantsYears', window );">Expected lives of warrants, years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 7 months 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract', window );"><strong>Common Stock and Warrant Liability (Additional Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RegisteredDirectOfferingUnits', window );">Issuance of registered direct offering, units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,449,288<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit', window );">Registered direct offering, no. of common stock per units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RegisteredDirectOfferingNumberOfWarrantPerUnit', window );">Registered direct offering, no. of warrants per units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_DirectOfferingPurchasePrice', window );">Direct offering purchase price per unit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.52<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts', window );">Proceeds from registered direct offering of units, net of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 14,942,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants</a></td>
        <td class="nump">3.55<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.55<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_TermOfWarrantsYears', window );">Term of warrants, years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockIssuedDuringPeriodDueToExerciseOfWarrants', window );">Warrants exercised</a></td>
        <td class="nump">214,004<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">214,004<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
        <td class="nump">4,304,922<span></span></td>
        <td class="nump">3,426,592<span></span></td>
        <td class="nump">4,304,922<span></span></td>
        <td class="nump">3,426,592<span></span></td>
        <td class="nump">4,361,168<span></span></td>
        <td class="nump">1,604,742<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">495,341<span></span></td>
        <td class="nump">320,440<span></span></td>
        <td class="nump">487,400<span></span></td>
        <td class="nump">1,821,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RangeOfExpectedVolatilities', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75.40%<span></span></td>
        <td class="nump">80.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,174,002<span></span></td>
        <td class="nump">1,295,620<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ChangeInFairValueUponWarrantExercise', window );">Change in warrants liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (543,646)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockAndWarrantLiabilityTextualAbstract', window );"><strong>Common Stock and Warrant Liability (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_EstimatedRiskFreeInterestRate', window );">Estimated risk-free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.80%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ExpectedLivesOfWarrantsYears', window );">Expected lives of warrants, years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockAndWarrantLiabilityTextualAbstract', window );"><strong>Common Stock and Warrant Liability (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_EstimatedRiskFreeInterestRate', window );">Estimated risk-free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.10%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ExpectedLivesOfWarrantsYears', window );">Expected lives of warrants, years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CommonStockAndWarrantLiabilityTextualAbstract', window );"><strong>Common Stock and Warrant Liability (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant', window );">Value of warrant in terms of percentage of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.25<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of shares of stock available to purchase using warrants</a></td>
        <td class="nump">212,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">212,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ChangeInFairValueUponWarrantExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value upon warrant exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ChangeInFairValueUponWarrantExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CommonStockAndWarrantLiabilityAdditionalTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CommonStockAndWarrantLiabilityTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CommonStockAndWarrantLiabilityTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_DirectOfferingPurchasePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct offering purchase price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_DirectOfferingPurchasePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_EstimatedRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Estimated risk-free interest rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_EstimatedRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ExpectedLivesOfWarrantsYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected lives of warrants years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ExpectedLivesOfWarrantsYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from registered direct offering of common stock and warrants net of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RangeOfExpectedVolatilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of expected volatilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_RangeOfExpectedVolatilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registered direct offering number of common stock per unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_RegisteredDirectOfferingNumberOfCommonStockPerUnit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RegisteredDirectOfferingNumberOfWarrantPerUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registered direct offering number of warrant per unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_RegisteredDirectOfferingNumberOfWarrantPerUnit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registered direct offering unit number of common stock to warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_RegisteredDirectOfferingUnitNumberOfCommonStockToWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RegisteredDirectOfferingUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registered direct offering units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_RegisteredDirectOfferingUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockIssuedDuringPeriodDueToExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period due to exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_StockIssuedDuringPeriodDueToExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_TermOfWarrantsYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of warrants, years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_TermOfWarrantsYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 98-5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 00-27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECDAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (660,715)<span></span></td>
        <td class="num">$ (11,714,215)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">60,432<span></span></td>
        <td class="nump">45,089<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">2,030,418<span></span></td>
        <td class="nump">1,039,558<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_IssuanceOfCommonStockToLicensees', window );">Issuance of common stock to licensees</a></td>
        <td class="nump">964,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">487,400<span></span></td>
        <td class="nump">1,821,850<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Non-cash interest (income)/expense</a></td>
        <td class="num">(99,171)<span></span></td>
        <td class="nump">120,363<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Net gain on sale of assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(36,446)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(276,239)<span></span></td>
        <td class="num">(7,153)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump">468,486<span></span></td>
        <td class="nump">22,183<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(273,295)<span></span></td>
        <td class="num">(117,760)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
        <td class="nump">3,362,031<span></span></td>
        <td class="nump">2,887,684<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
        <td class="nump">2,701,316<span></span></td>
        <td class="num">(8,826,531)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
        <td class="num">(30,163,823)<span></span></td>
        <td class="num">(25,611,178)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
        <td class="nump">20,250,450<span></span></td>
        <td class="nump">32,097,814<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(33,652)<span></span></td>
        <td class="num">(246,378)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,446<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Decrease in restricted cash</a></td>
        <td class="nump">41,632<span></span></td>
        <td class="nump">219,458<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in)/ provided by investing activities</a></td>
        <td class="num">(9,905,393)<span></span></td>
        <td class="nump">6,496,162<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Company's share-based compensation plans and warrant exercises</a></td>
        <td class="nump">4,174,002<span></span></td>
        <td class="nump">1,295,620<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">4,174,002<span></span></td>
        <td class="nump">1,295,620<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(3,030,075)<span></span></td>
        <td class="num">(1,034,749)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
        <td class="nump">15,119,730<span></span></td>
        <td class="nump">7,826,549<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
        <td class="nump">$ 12,089,655<span></span></td>
        <td class="nump">$ 6,791,800<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_IssuanceOfCommonStockToLicensees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock to licensees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_IssuanceOfCommonStockToLicensees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gains (losses) included in earnings resulting from the sale or disposal of tangible assets. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfProductiveAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:FairValueMeasurementInputsDisclosureTextBlock-->
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2"><b>5.</b></font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2"><b><u>Fair Value Measurements</u> </b></font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Company discloses fair value measurements based on a framework outlined by GAAP which requires
   expanded disclosures regarding fair value measurements. GAAP also defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
   or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and
   (iv)&#160;willing to transact. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The Financial Accounting Standards Board, or FASB, Codification Topic 820,
   <i>Fair Value Measurements and Disclosures, </i>requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information
   generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The
   cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value hierarchy which requires an
   entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="94%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td width="91%">&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2"><b>Level&#160;1</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Quoted prices in active markets for identical assets or liabilities.</font></td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="2">&#160;</td>
   </tr>
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2"><b>Level 2</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
   observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="2">&#160;</td>
   </tr>
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2"><b>Level 3</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company's warrant liability was
   valued using a probability-weighted Black-Scholes model, discussed further in Note 6, and is therefore classified as Level&#160;3.</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">In
   accordance with the fair value hierarchy, the following table shows the fair value as of June 30, 2012 and December&#160;31, 2011 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the
   valuation techniques the Company used to determine their fair market value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at June&#160;30, 2012 and December&#160;31, 2011. </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="49%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted&#160;Prices&#160;in<br />Active Markets<br />(Level 1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Other<br />Observable<br />Inputs&#160;(Level&#160;2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unobservable<br />Inputs&#160;(Level&#160;3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>As of June&#160;30, 2012:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Money market funds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,832,066</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,832,066</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Municipal bonds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,145,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,145,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Investments</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate commercial paper, stock, bonds and notes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16,423,449</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16,192,698</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,616,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">24,255,515</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,337,698</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">42,593,213</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>As of December&#160;31, 2011:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Money market funds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,366,747</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,366,747</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Municipal bonds</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,375,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,375,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Investments</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">US government obligations</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,704</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,808,704</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate commercial paper, stock, bonds and notes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,365,841</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,423,300</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,789,141</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,107,588</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,232,004</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">30,339,592</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities at fair value</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><font style="font-family:times new roman" size="2">The following table rolls forward the fair value of the Company&#8217;s warrant liability, the fair
   value of which is determined by Level&#160;3 inputs for the six months ended June&#160;30, 2011 and 2012: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="85%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at December&#160;31, 2010</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,604,742</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Change in fair value </font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,821,850</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at June&#160;30, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,426,592</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at December&#160;31, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,361,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants exercised </font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(543,646</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Change in fair value </font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">487,400</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at June&#160;30, 2012</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,304,922</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19190-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 33<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 6<br><br> -Footnote 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementInputsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accrued Liabilities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CurrentAccruedLiabilitiesAbstract', window );"><strong>Accrued liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
        <td class="nump">$ 787,483<span></span></td>
        <td class="nump">$ 1,065,570<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
        <td class="nump">159,625<span></span></td>
        <td class="nump">190,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
        <td class="nump">115,518<span></span></td>
        <td class="nump">166,037<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
        <td class="nump">$ 1,062,626<span></span></td>
        <td class="nump">$ 1,422,107<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CurrentAccruedLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_CurrentAccruedLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 8<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 8<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedSalariesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>82</ContextCount>
  <ElementCount>161</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0201 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0202 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0203 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0204 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0205 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0206 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0207 - Disclosure - Common Stock and Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/CommonStockAndWarrantLiability</Role>
      <ShortName>Common Stock and Warrant Liability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0208 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0209 - Disclosure - Related Party Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/RelatedPartyTransaction</Role>
      <ShortName>Related Party Transaction</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0210 - Disclosure - Accounting for Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccountingForStockBasedCompensation</Role>
      <ShortName>Accounting for Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0211 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/IncomeLossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0505 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0506 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0508 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0510 - Disclosure - Accounting for Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationTables</Role>
      <ShortName>Accounting for Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0511 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/IncomeLossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0604 - Disclosure - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/CollaborationAgreementsDetails</Role>
      <ShortName>Collaboration Agreements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0605 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>06051 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0606 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0607 - Disclosure - Common Stock and Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/CommonStockAndWarrantLiabilityDetails</Role>
      <ShortName>Common Stock and Warrant Liability (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0608 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0609 - Disclosure - Related Party Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/role/RelatedPartyTransactionDetails</Role>
      <ShortName>Related Party Transaction (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0610 - Disclosure - Accounting for Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails</Role>
      <ShortName>Accounting for Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>06101 - Disclosure - Accounting for Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails1</Role>
      <ShortName>Accounting for Stock-Based Compensation (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>06102 - Disclosure - Accounting for Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetails2</Role>
      <ShortName>Accounting for Stock-Based Compensation (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>06103 - Disclosure - Accounting for Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/AccountingForStockBasedCompensationDetailsTextual</Role>
      <ShortName>Accounting for Stock-Based Compensation (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0611 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curis.com/2010-09-30/role/IncomeLossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element cris_RangeOfExpectedVolatilities had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>cris-20120630.xml</File>
    <File>cris-20120630.xsd</File>
    <File>cris-20120630_cal.xml</File>
    <File>cris-20120630_def.xml</File>
    <File>cris-20120630_lab.xml</File>
    <File>cris-20120630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting for Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Accounting For Stock-Based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation assumptions used to calculate fair value of employee options awarded</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note10_table1 - us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-->
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="82%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="3" align="center"><font style="font-family:times new roman" size="1"><b>Six Months Ended<br />June&#160;30,</b></font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life (years) &#8211; employees</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life (years) &#8211; directors</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">1.0-1.2%</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">2.4-2.5%</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Volatility</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">74-76%</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">73-74%</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dividends</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">None</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">None</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock', window );">Employee and non employee share based compensation expense allocation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note10_table2 - cris:ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock-->
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="58%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For&#160;the&#160;Three&#160;Months&#160;Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center">
   <p style="margin-top:0px;margin-bottom:0px" align="center"><font style="font-family:times new roman" size="1"><b>For the Six Months Ended</b></font></p>
   <p style="margin-top:0px;margin-bottom:1px" align="center"><font style="font-family:times new roman" size="1"><b>June&#160;30,</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">365,855</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">178,808</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">765,010</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">343,861</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">General and administrative expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">641,887</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">183,038</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,265,408</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">695,697</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total stock-based compensation expense</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,007,742</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">361,846</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,030,418</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,039,558</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Options outstanding and exercisable under exercise price range</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: cris-20120630_note10_table3 - us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-->
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="56%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options Outstanding</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options Exercisable</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap">
   <p style="border-bottom:1px solid #000000;width:72pt"><font style="font-family:times new roman" size="1"><b>Exercise Price Range</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Number of<br />Shares</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Remaining<br />Contractual<br />Life&#160;(in&#160;years)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise&#160;Price<br />per&#160;Share</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Number of<br />Shares</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise&#160;Price<br />per&#160;Share</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">$ 0.79 - $ 1.39</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,735,809</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.97</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.18</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,567,519</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.19</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 1.43 - &#160;&#160; 2.15</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,628,568</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.63</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.73</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,063,310</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.62</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 2.27 - &#160;&#160; 3.76</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,432,733</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.03</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.75</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,555,446</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.52</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 3.98 - &#160;&#160; 4.52</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,204,614</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7.85</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.39</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">758,445</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.13</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">&#160;&#160; 4.56 - &#160;&#160; 5.60</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">720,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.88</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.74</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">712,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.74</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,721,724</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.53</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.57</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,656,720</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.20</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule of employee and non employee share based compensation allocation of recognized period costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cris_ScheduleOfEmployeeAndNonEmployeeShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cris_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
